| 4572- | , | Mitochondrial electron transport chain, ROS generation and uncoupling |
| - | Review, | NA, | NA |
| 4384- | , | Silver nanoparticles: synthesis, properties, and therapeutic applications |
| - | Review, | Var, | NA |
| 4442- | , | Anticancer and Hepatoprotective Role of Selenium Nanoparticles against |
| - | in-vivo, | Liver, | HepG2 | - | NA, | Nor, | NA |
| 4039- | , | Association of vitamin B12 deficiency in a dementia cohort with hippocampal atrophy on MRI |
| - | Study, | AD, | NA |
| 4051- | , | Long-term association of food and nutrient intakes with cognitive and functional decline: a 13-year follow-up study of elderly French women |
| - | Study, | AD, | NA |
| 4113- | , | Post-exposure Effects of PEMF on ROS levels in H2O2-treated Glioblastoma Cell Line |
| - | in-vitro, | Nor, | U87MG |
| 2424- | 2DG, | SRF, | The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells |
| - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | HUH7 |
| 2423- | 2DG, | SRF, | 2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells |
| - | in-vitro, | HCC, | NA |
| 2435- | 2DG, | Targeting hexokinase 2 for oral cancer therapy: structure-based design and validation of lead compounds |
| - | in-vitro, | SCC, | CAL27 |
| 2434- | 2DG, | Inhibition of Key Glycolytic Enzyme Hexokinase 2 Ameliorates Psoriasiform Inflammation in vitro and in vivo |
| - | in-vitro, | PSA, | NA | - | in-vivo, | PSA, | NA |
| 2433- | 2DG, | Hexokinase inhibitor 2-deoxyglucose coordinates citrullination of vimentin and apoptosis of fibroblast-like synoviocytes by inhibiting HK2 /mTORC1-induced autophagy |
| - | in-vitro, | Arthritis, | NA | - | in-vivo, | NA, | NA |
| 2432- | 2DG, | Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth |
| - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | KP2 | - | in-vivo, | NA, | NA |
| 2327- | 2DG, | 2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents |
| - | Review, | Var, | NA |
| 2326- | 2DG, | Caloric Restriction Mimetic 2-Deoxyglucose Alleviated Inflammatory Lung Injury via Suppressing Nuclear Pyruvate Kinase M2–Signal Transducer and Activator of Transcription 3 Pathway |
| - | in-vivo, | Nor, | NA |
| 2325- | 2DG, | Research Progress of Warburg Effect in Hepatocellular Carcinoma |
| - | Review, | Var, | NA |
| 1339- | 2DG, | Cisplatin, | 2-Deoxy-d-Glucose Combined with Cisplatin Enhances Cytotoxicity via Metabolic Oxidative Stress in Human Head and Neck Cancer Cells |
| - | in-vitro, | HNSCC, | FaDu |
| 1337- | 2DG, | Rad, | 2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer |
| - | in-vivo, | NA, | NA |
| 1336- | 2DG, | 2-deoxy-D-glucose induces oxidative stress and cell killing in human neuroblastoma cells |
| - | in-vitro, | GBM, | SK-N-SH |
| 1341- | 3BP, | The HK2 Dependent “Warburg Effect” and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate |
| - | Review, | NA, | NA |
| 1340- | 3BP, | Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study |
| - | Review, | NA, | NA |
| 3453- | 5-ALA, | The heme precursor 5-aminolevulinic acid disrupts the Warburg effect in tumor cells and induces caspase-dependent apoptosis |
| - | in-vitro, | Lung, | A549 |
| 3452- | 5-ALA, | 5-ALA Is a Potent Lactate Dehydrogenase Inhibitor but Not a Substrate: Implications for Cell Glycolysis and New Avenues in 5-ALA-Mediated Anticancer Action |
| - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | LN-18 | - | in-vitro, | GBM, | U87MG |
| - | in-vitro, | CRC, | NA |
| 3538- | 5-HTP, | Oral Administration of 5-Hydroxytryptophan Restores Gut Microbiota Dysbiosis in a Mouse Model of Depression |
| - | in-vivo, | Nor, | NA |
| 3537- | 5-HTP, | 5-Hydroxytryptophan: a clinically-effective serotonin precursor |
| - | Review, | NA, | NA |
| 3940- | 5HT, | Role of serotonin in Alzheimer's disease: a new therapeutic target? |
| - | Review, | AD, | NA |
| 3941- | 5HT, | dietMed, | VitB12, | FA, | VitC | Nutrition strategies that improve cognitive function |
| - | Review, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 3973- | ACNs, | Saskatoon and wild blueberries have higher anthocyanin contents than other Manitoba berries |
| - | Analysis, | AD, | NA |
| 3972- | ACNs, | Recent Research on the Health Benefits of Blueberries and Their Anthocyanins |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3971- | ACNs, | Blueberry Supplementation Improves Memory in Older Adults |
| - | Human, | AD, | NA |
| 3969- | ACNs, | Blueberry Supplementation in Midlife for Dementia Risk Reduction |
| - | Human, | AD, | NA |
| 3968- | ACNs, | Enhanced Neuronal Activation with Blueberry Supplementation in Mild Cognitive Impairment |
| - | Human, | AD, | NA |
| 3864- | ACNs, | Anthocyanins Potentially Contribute to Defense against Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3865- | ACNs, | Consumption of anthocyanin-rich cherry juice for 12 weeks improves memory and cognition in older adults with mild-to-moderate dementia |
| - | Human, | AD, | NA |
| 4163- | ACNs, | Flav, | Dietary levels of pure flavonoids improve spatial memory performance and increase hippocampal brain-derived neurotrophic factor |
| - | in-vivo, | AD, | NA |
| 1161- | ACNs, | immuno, | Bilberry anthocyanin extracts enhance anti-PD-L1 efficiency by modulating gut microbiota |
| - | in-vivo, | Colon, | MC38 |
| 1094- | ACNs, | Anthocyanidins inhibit epithelial-mesenchymal transition through a TGF-β/Smad2 signaling pathway in glioblastoma cells: Anthocyanidins inhibit TGF-β-mediated EMT. |
| - | in-vitro, | GBM, | U87MG |
| 1- | Aco, | Acoschimperoside P, 2'-acetate: a Hedgehog signaling inhibitory constituent from Vallaris glabra |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | Pca, | DU145 |
| 147- | AG, | EGCG, | CUR, | Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | MCF-7 |
| 252- | Ajoene, | Ajoene, a Compound of Garlic, Induces Apoptosis in Human Promyeloleukemic Cells, Accompanied by Generation of Reactive Oxygen Species and Activation of Nuclear Factor κB |
| - | in-vitro, | AML, | HL-60 |
| 4- | Akk, | The Emerging Biotherapeutic Agent: Akkermansia |
| 540- | Akk, | Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy |
| - | Analysis, | NA, | NA |
| 543- | Akk, | Dynamic Changes of the Gut Microbiota and Its Functional Metagenomic Potential during the Development of Non-Small Cell Lung Cancer |
| 541- | Akk, | Akkermansia muciniphila as a Next-Generation Probiotic in Modulating Human Metabolic Homeostasis and Disease Progression: A Role Mediated by Gut-Liver-Brain Axes? |
| - | Review, | NA, | NA |
| 542- | Akk, | immuno, | Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors |
| 545- | AL, | Association and mechanism of garlic consumption with gastrointestinal cancer risk: A systematic review and meta‑analysis |
| 551- | AL, | The Influence of Heating on the Anticancer Properties of Garlic |
| - | Analysis, | NA, | NA |
| 550- | AL, | A Review on Anticancer Activities of Garlic (Allium sativum L.) |
| - | Review, | NA, | NA |
| 549- | AL, | Allicin, a naturally occurring antibiotic from garlic, specifically inhibits acetyl-CoA synthetase |
| 548- | AL, | Aged Garlic and Cancer: A Systematic Review |
| - | Review, | NA, | NA |
| 547- | AL, | Garlic and Cancer: A Critical Review of the Epidemiologic Literature |
| - | Review, | NA, | NA |
| 546- | AL, | Effects of garlic intake on cancer: a systematic review of randomized clinical trials and cohort studies |
| - | Review, | NA, | NA |
| 544- | AL, | Garlic constituents for cancer prevention and therapy: From phytochemistry to novel formulations |
| 233- | AL, | 5-FU, | Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway |
| - | in-vivo, | Liver, | NA |
| 253- | AL, | Allicin inhibits invasion and migration of breast cancer cells through the suppression of VCAM-1: Regulation of association between p65 and ER-α |
| - | in-vitro, | BC, | MDA-MB-231 |
| 234- | AL, | Allicin Induces Anti-human Liver Cancer Cells through the p53 Gene Modulating Apoptosis and Autophagy |
| - | in-vitro, | HCC, | Hep3B |
| 235- | AL, | Allicin inhibits cell growth and induces apoptosis in U87MG human glioblastoma cells through an ERK-dependent pathway |
| - | in-vitro, | GBM, | U87MG |
| 236- | AL, | Allicin: Chemistry and Biological Properties |
| - | Analysis, | NA, | NA |
| 239- | AL, | Allicin induces apoptosis in gastric cancer cells through activation of both extrinsic and intrinsic pathways |
| - | in-vitro, | GC, | SGC-7901 |
| 241- | AL, | Role of p38 MAPK activation and mitochondrial cytochrome-c release in allicin-induced apoptosis in SK-N-SH cells |
| - | in-vitro, | neuroblastoma, | SK-N-SH |
| 245- | AL, | Allicin: a promising modulator of apoptosis and survival signaling in cancer |
| - | Review, | Var, | NA |
| 246- | AL, | Allicin induces apoptosis of the MGC-803 human gastric carcinoma cell line through the p38 mitogen-activated protein kinase/caspase-3 signaling pathway |
| - | in-vitro, | GC, | MGC803 |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 248- | AL, | Allicin inhibits cell growth and induces apoptosis in U87MG human glioblastoma cells through an ERK-dependent pathway |
| - | in-vitro, | GBM, | U87MG |
| 249- | AL, | Allicin induces apoptosis of the MGC-803 human gastric carcinoma cell line through the p38 mitogen-activated protein kinase/caspase-3 signaling pathway |
| - | in-vitro, | GC, | MGC803 |
| 250- | AL, | Allicin Induces p53-Mediated Autophagy in Hep G2 Human Liver Cancer Cells |
| - | in-vitro, | Liver, | HepG2 |
| 251- | AL, | Inhibition of allicin in Eca109 and EC9706 cells via G2/M phase arrest and mitochondrial apoptosis pathway |
| - | in-vitro, | ESCC, | Eca109 | - | in-vitro, | ESCC, | EC9706 | - | in-vivo, | NA, | NA |
| 257- | AL, | Cisplatin, | Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors |
| - | in-vitro, | NSCLC, | A549 |
| 256- | AL, | doxoR, | Allicin Overcomes Doxorubicin Resistance of Breast Cancer Cells by Targeting the Nrf2 Pathway |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 255- | AL, | Allicin induces cell cycle arrest and apoptosis of breast cancer cells in vitro via modulating the p53 pathway |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 254- | AL, | Allicin and Cancer Hallmarks |
| - | Review, | Var, | NA |
| 231- | AL, | Molecular Docking Studies with Garlic Phytochemical Constituents to Inhibit the Human EGFR Protein for Lung Cancer Therapy |
| - | Analysis, | Lung, | NA |
| 232- | AL, | A Single Meal Containing Raw, Crushed Garlic Influences Expression of Immunity- and Cancer-Related Genes in Whole Blood of Humans |
| - | Human, | Nor, | NA |
| 1069- | AL, | Allicin promotes autophagy and ferroptosis in esophageal squamous cell carcinoma by activating AMPK/mTOR signaling |
| - | vitro+vivo, | ESCC, | TE1 | - | vitro+vivo, | ESCC, | KYSE-510 | - | in-vitro, | Nor, | Het-1A |
| 1023- | AL, | Allicin May Promote Reversal of T-Cell Dysfunction in Periodontitis via the PD-1 Pathway |
| - | in-vitro, | NA, | NA | - | Analysis, | NA, | NA |
| 1290- | AL, | Effect of allicin on the expression of Bcl-2 and Bax protein in LM-8 cells |
| - | in-vitro, | OS, | LM8 |
| 1916- | AL, | Allicin Bioavailability and Bioequivalence from Garlic Supplements and Garlic Foods |
| - | Review, | Nor, | NA |
| 2000- | AL, | Exploring the ROS-mediated anti-cancer potential in human triple-negative breast cancer by garlic bulb extract: A source of therapeutically active compounds |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | NA |
| 2463- | AL, | Garlic as an antithrombotic and antiplatelet aggregation agent |
| - | Review, | Nor, | NA |
| 2462- | AL, | Comparison of antiplatelet activity of garlic tablets with cardio-protective dose of aspirin in healthy volunteers: a randomized clinical trial |
| - | Trial, | Nor, | NA |
| 2770- | AL, | Allicin protects against renal ischemia–reperfusion injury by attenuating oxidative stress and apoptosis |
| - | in-vivo, | Nor, | NA | - | in-vitro, | Nor, | NRK52E |
| 2655- | AL, | Allicin and Digestive System Cancers: From Chemical Structure to Its Therapeutic Opportunities |
| - | Review, | GC, | NA |
| 2557- | AL, | Allicin, a naturally occurring antibiotic from garlic, specifically inhibits acetyl-CoA synthetase |
| - | in-vitro, | NA, | NA |
| 2558- | AL, | Allicin, an Antioxidant and Neuroprotective Agent, Ameliorates Cognitive Impairment |
| - | Review, | AD, | NA |
| 2559- | AL, | Effect of the Garlic Pill in comparison with Plavix on Platelet Aggregation and Bleeding Time |
| - | Human, | Nor, | NA |
| 2560- | AL, | Effect of garlic on platelet aggregation in humans: a study in healthy subjects and patients with coronary artery disease |
| - | ex-vivo, | Nor, | NA |
| 2645- | AL, | Allicin improves endoplasmic reticulum stress-related cognitive deficits via PERK/Nrf2 antioxidative signaling pathway |
| - | NA, | AD, | NA |
| 2646- | AL, | Anti-Cancer Potential of Homemade Fresh Garlic Extract Is Related to Increased Endoplasmic Reticulum Stress |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Melanoma, | RPMI-8226 |
| 2647- | AL, | The Mechanism in Gastric Cancer Chemoprevention by Allicin |
| - | Review, | GC, | NA |
| 2648- | AL, | Allicin Inhibits Osteosarcoma Growth by Promoting Oxidative Stress and Autophagy via the Inactivation of the lncRNA MALAT1-miR-376a-Wnt/β-Catenin Signaling Pathway |
| - | in-vitro, | OS, | SaOS2 | - | in-vivo, | OS, | NA |
| 2656- | AL, | Allicin Protects PC12 Cells Against 6-OHDA-Induced Oxidative Stress and Mitochondrial Dysfunction via Regulating Mitochondrial Dynamics |
| - | in-vitro, | Park, | PC12 |
| 2657- | AL, | Allicin pharmacology: Common molecular mechanisms against neuroinflammation and cardiovascular diseases |
| - | Review, | CardioV, | NA | - | Review, | AD, | NA |
| 2658- | AL, | The Toxic Effect Ways of Allicin on Different Cell Lines |
| - | Review, | Var, | NA |
| 2660- | AL, | Allicin: A review of its important pharmacological activities |
| - | Review, | AD, | NA | - | Review, | Var, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 2669- | AL, | Rad, | Inhibition of ICAM-1 expression by garlic component, allicin, in gamma-irradiated human vascular endothelial cells via downregulation of the JNK signaling pathway |
| - | in-vitro, | Nor, | HUVECs |
| 2668- | AL, | Allicin enhances the radiosensitivity of colorectal cancer cells via inhibition of NF-κB signaling pathway |
| - | in-vitro, | CRC, | HCT116 |
| 2667- | AL, | Allicin in Digestive System Cancer: From Biological Effects to Clinical Treatment |
| - | Review, | GC, | NA |
| 2666- | AL, | Targeting the Interplay of Autophagy and ROS for Cancer Therapy: An Updated Overview on Phytochemicals |
| - | Review, | Var, | NA |
| 2665- | AL, | Anticancerous and Antimicrobial Properties of Garlic |
| - | Review, | Var, | NA |
| 2663- | AL, | Therapeutic Effect of Allicin on Glioblastoma |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG |
| 2662- | AL, | Allicin inhibits tubular epithelial-myofibroblast transdifferentiation under high glucose conditions in vitro |
| - | in-vitro, | Nor, | HK-2 |
| 2661- | AL, | Allicin alleviates traumatic brain injury-induced neuroinflammation by enhancing PKC-δ-mediated mitophagy |
| - | in-vivo, | Nor, | NA |
| 2659- | AL, | Allicin inhibits spontaneous and TNF-α induced secretion of proinflammatory cytokines and chemokines from intestinal epithelial cells |
| - | in-vitro, | HCC, | HT29 | - | in-vitro, | HCC, | Caco-2 |
| 298- | ALA, | Rad, | Synergistic Tumoricidal Effects of Alpha-Lipoic Acid and Radiotherapy on Human Breast Cancer Cells via HMGB1 |
| - | in-vitro, | BC, | MDA-MB-231 |
| 299- | ALA, | Cisplatin, | PacT, | Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line |
| - | in-vitro, | Ovarian, | OVCAR-3 |
| 297- | ALA, | Insights on the Use of α-Lipoic Acid for Therapeutic Purposes |
| - | Review, | BC, | SkBr3 | - | Review, | neuroblastoma, | SK-N-SH | - | Review, | AD, | NA |
| 301- | ALA, | PacT, | doxoR, | Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients |
| - | Human, | BC, | NA |
| 302- | ALA, | The Antioxidant Alpha-Lipoic Acid Inhibits Proliferation and Invasion of Human Gastric Cancer Cells via Suppression of STAT3-Mediated MUC4 Gene Expression |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | BGC-823 | - | in-vitro, | GC, | MKN-28 |
| 303- | ALA, | LDN, | The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol |
| 304- | ALA, | alpha-Lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O2-*-generation |
| - | in-vitro, | Colon, | HT-29 |
| 282- | ALA, | Alpha-lipoic acid induced apoptosis of PC3 prostate cancer cells through an alteration on mitochondrial membrane depolarization and MMP-9 mRNA expression |
| - | in-vitro, | Pca, | PC3 |
| 279- | ALA, | Lipoic acid-induced oxidative stress abrogates IGF-1R maturation by inhibiting the CREB/furin axis in breast cancer cell lines |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 281- | ALA, | Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation |
| - | in-vitro, | Lung, | H460 |
| 280- | ALA, | Alpha‐lipoic acid inhibits lung cancer growth via mTOR‐mediated autophagy inhibition |
| - | in-vivo, | Lung, | A549 |
| 278- | ALA, | The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment |
| - | Review, | NA, | NA |
| 277- | ALA, | α-lipoic acid modulates prostate cancer cell growth and bone cell differentiation |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | C4-2B |
| 276- | ALA, | Alpha lipoic acid diminishes migration and invasion in hepatocellular carcinoma cells through an AMPK-p53 axis |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B |
| 274- | ALA, | LDN, | Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases |
| - | Human, | PC, | NA |
| 272- | ALA, | Evidence that α-lipoic acid inhibits NF-κB activation independent of its antioxidant function |
| - | in-vitro, | NA, | HUVECs |
| 267- | ALA, | α-Lipoic Acid Targeting PDK1/NRF2 Axis Contributes to the Apoptosis Effect of Lung Cancer Cells |
| - | vitro+vivo, | Lung, | A549 | - | vitro+vivo, | Lung, | PC9 |
| 266- | ALA, | Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death |
| - | in-vitro, | Ovarian, | IGROV1 |
| 265- | ALA, | Alpha-Lipoic Acid Reduces Cell Growth, Inhibits Autophagy, and Counteracts Prostate Cancer Cell Migration and Invasion: Evidence from In Vitro Studies |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 264- | ALA, | α-Lipoic acid induces Endoplasmic Reticulum stress-mediated apoptosis in hepatoma cells |
| - | in-vitro, | HCC, | FaO |
| 263- | ALA, | Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines |
| - | in-vitro, | SCC, | Jurkat | - | in-vitro, | SCC, | FaDu |
| 262- | ALA, | Lipoic acid decreases breast cancer cell proliferation by inhibiting IGF-1R via furin downregulation |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 261- | ALA, | The natural antioxidant alpha-lipoic acid induces p27(Kip1)-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 260- | ALA, | The effects of alpha-lipoic acid on breast of female albino rats exposed to malathion: Histopathological and immunohistochemical study |
| - | in-vivo, | BC, | NA |
| 259- | ALA, | Increased ROS generation and p53 activation in alpha-lipoic acid-induced apoptosis of hepatoma cells |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | FaO |
| 258- | ALA, | Effects of α-lipoic acid on cell proliferation and apoptosis in MDA-MB-231 human breast cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 296- | ALA, | Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo |
| - | vitro+vivo, | neuroblastoma, | SK-N-SH | - | vitro+vivo, | BC, | SkBr3 |
| 284- | ALA, | Lipoic acid a multi-level molecular inhibitor of tumorigenesis |
| - | Review, | Var, | NA |
| 285- | ALA, | HCA, | Tolerance of oral lipoid acid and hydroxycitrate combination in cancer patients: first approach of the cancer metabolism research group |
| - | Human, | Var, | NA |
| 283- | ALA, | alpha-Lipoic acid reduces matrix metalloproteinase activity in MDA-MB-231 human breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 287- | ALA, | HCA, | Lyco, | Metabolic treatment of cancer: intermediate results of a prospective case series |
| 288- | ALA, | HCA, | CAP, | Octr, | Tumor regression with a combination of drugs interfering with the tumor metabolism: efficacy of hydroxycitrate, lipoic acid and capsaicin |
| 289- | ALA, | HCA, | EA, | Cancer Metabolism: Fasting Reset, the Keto-Paradox and Drugs for Undoing |
| - | Analysis, | NA, | NA |
| 290- | ALA, | HCA, | A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results |
| - | vitro+vivo, | Melanoma, | B16-F10 |
| 291- | ALA, | HCA, | MET, | Dicl, | Metabolic therapies inhibit tumor growth in vivo and in silico |
| - | in-vivo, | Melanoma, | B16-F10 | - | in-vivo, | Lung, | LL/2 (LLC1) | - | in-vivo, | Bladder, | MBT-2 |
| 295- | ALA, | α-Lipoic acid suppresses migration and invasion via downregulation of cell surface β1-integrin expression in bladder cancer cells |
| - | in-vitro, | Bladder, | T24 |
| 1124- | ALA, | Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells |
| - | in-vitro, | Thyroid, | BCPAP | - | in-vitro, | Thyroid, | HTH-83 | - | in-vitro, | Thyroid, | CAL-62 | - | in-vitro, | Thyroid, | FTC-133 | - | in-vivo, | NA, | NA |
| 4282- | ALA, | Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial |
| - | Trial, | NA, | NA |
| 3447- | ALA, | Redox Active α-Lipoic Acid Differentially Improves Mitochondrial Dysfunction in a Cellular Model of Alzheimer and Its Control Cells |
| - | in-vitro, | AD, | SH-SY5Y |
| 3433- | ALA, | Alpha lipoic acid promotes development of hematopoietic progenitors derived from human embryonic stem cells by antagonizing ROS signals |
| 3434- | ALA, | Alpha lipoic acid modulates metabolic reprogramming in breast cancer stem cells enriched 3D spheroids by targeting phosphoinositide 3-kinase: In silico and in vitro insights |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| - | in-vitro, | BC, | MCF-7 |
| 3437- | ALA, | Revisiting the molecular mechanisms of Alpha Lipoic Acid (ALA) actions on metabolism |
| - | Review, | Var, | NA |
| 3438- | ALA, | The Potent Antioxidant Alpha Lipoic Acid |
| - | Review, | NA, | NA | - | Review, | AD, | NA |
| 3439- | ALA, | The effect of alpha lipoic acid on the developmental competence of mouse isolated preantral follicles |
| - | in-vitro, | NA, | NA |
| 3440- | ALA, | Protective effects of alpha lipoic acid (ALA) are mediated by hormetic mechanisms |
| - | Review, | AD, | NA |
| 3441- | ALA, | α-Lipoic Acid Maintains Brain Glucose Metabolism via BDNF/TrkB/HIF-1α Signaling Pathway in P301S Mice |
| - | in-vivo, | AD, | NA |
| 3442- | ALA, | α‑lipoic acid modulates prostate cancer cell growth and bone cell differentiation |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | C4-2B | - | in-vitro, | Nor, | 3T3 |
| 3443- | ALA, | Molecular and Therapeutic Insights of Alpha-Lipoic Acid as a Potential Molecule for Disease Prevention |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3444- | ALA, | Alpha-Lipoic Acid Nootropic Review: Benefits, Use, Dosage & Side Effects |
| - | Review, | NA, | NA |
| 3445- | ALA, | Rad, | The radioprotective effects of alpha-lipoic acid on radiotherapy-induced toxicities: A systematic review |
| - | Review, | Var, | NA |
| 3446- | ALA, | CUR, | The Potential Protective Effect of Curcumin and α-Lipoic Acid on N-(4-Hydroxyphenyl) Acetamide-induced Hepatotoxicity Through Downregulation of α-SMA and Collagen III Expression |
| - | in-vivo, | Nor, | NA |
| 3448- | ALA, | Alpha lipoic acid attenuates hypoxia-induced apoptosis, inflammation and mitochondrial oxidative stress via inhibition of TRPA1 channel in human glioblastoma cell line |
| 3449- | ALA, | Alpha-Lipoic Acid Downregulates IL-1β and IL-6 by DNA Hypermethylation in SK-N-BE Neuroblastoma Cells |
| - | in-vitro, | AD, | SK-N-BE |
| 3450- | ALA, | α-Lipoic Acid Inhibits Expression of IL-8 by Suppressing Activation of MAPK, Jak/Stat, and NF-κB in H. pylori-Infected Gastric Epithelial AGS Cells |
| - | in-vitro, | NA, | AGS |
| 3451- | ALA, | Alpha-lipoic acid ameliorates H2O2-induced human vein endothelial cells injury via suppression of inflammation and oxidative stress |
| - | in-vitro, | Nor, | HUVECs |
| 3454- | ALA, | Lipoic acid blocks autophagic flux and impairs cellular bioenergetics in breast cancer and reduces stemness |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 3455- | ALA, | Alpha-lipoic acid inhibits proliferation and migration of human vascular endothelial cells through downregulating HSPA12B/VEGF signaling axis |
| - | in-vitro, | Nor, | HUVECs |
| 3456- | ALA, | Renal-Protective Roles of Lipoic Acid in Kidney Disease |
| - | Review, | NA, | NA |
| 3539- | ALA, | Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential |
| - | Review, | AD, | NA |
| 3540- | ALA, | Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant? |
| - | in-vitro, | NA, | NA |
| 3284- | ALA, | Alpha-Lipoic Acid Mediates Clearance of Iron Accumulation by Regulating Iron Metabolism in a Parkinson's Disease Model Induced by 6-OHDA |
| - | vitro+vivo, | Park, | NA |
| 3283- | ALA, | Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells |
| - | in-vitro, | Nor, | NA |
| 3272- | ALA, | Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential |
| - | Review, | AD, | NA |
| 3271- | ALA, | Decrypting the potential role of α-lipoic acid in Alzheimer's disease |
| - | Review, | AD, | NA |
| 3270- | ALA, | Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis |
| - | Trial, | AD, | NA |
| 3269- | ALA, | Sulfur-containing therapeutics in the treatment of Alzheimer’s disease |
| - | NA, | AD, | NA |
| 3542- | ALA, | Chelation: Harnessing and Enhancing Heavy Metal Detoxification—A Review |
| - | Review, | Var, | NA |
| 3543- | ALA, | The Effect of Lipoic Acid Therapy on Cognitive Functioning in Patients with Alzheimer's Disease |
| - | Study, | AD, | NA |
| 3544- | ALA, | Alpha lipoic acid for dementia |
| - | Review, | AD, | NA |
| 3545- | ALA, | Potential therapeutic effects of alpha lipoic acid in memory disorders |
| - | Review, | AD, | NA |
| 3546- | ALA, | Cognitive and Mood Effect of Alpha-Lipoic Acid Supplementation in a Nonclinical Elder Sample: An Open-Label Pilot Study |
| - | Study, | AD, | NA |
| 3547- | ALA, | Potential Therapeutic Effects of Lipoic Acid on Memory Deficits Related to Aging and Neurodegeneration |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3548- | ALA, | How Alpha Linolenic Acid May Sustain Blood–Brain Barrier Integrity and Boost Brain Resilience against Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3549- | ALA, | Important roles of linoleic acid and α-linolenic acid in regulating cognitive impairment and neuropsychiatric issues in metabolic-related dementia |
| - | Review, | AD, | NA |
| 3550- | ALA, | Mitochondrial Dysfunction and Alpha-Lipoic Acid: Beneficial or Harmful in Alzheimer's Disease? |
| - | Review, | AD, | NA |
| 3551- | ALA, | Alpha lipoic acid treatment in late middle age improves cognitive function: Proteomic analysis of the protective mechanisms in the hippocampus |
| - | in-vivo, | AD, | NA |
| 3552- | ALA, | The dietary fatty acids α-linolenic acid (ALA) and linoleic acid (LA) selectively inhibit microglial nitric oxide production |
| - | in-vitro, | AD, | BV2 |
| 3541- | ALA, | Insights on alpha lipoic and dihydrolipoic acids as promising scavengers of oxidative stress and possible chelators in mercury toxicology |
| - | Review, | Var, | NA |
| 1235- | ALA, | Cisplatin, | α-Lipoic acid prevents against cisplatin cytotoxicity via activation of the NRF2/HO-1 antioxidant pathway |
| - | in-vitro, | Nor, | HEI-OC1 | - | ex-vivo, | NA, | NA |
| 4283- | ALC, | Rapid-acting antidepressant-like effects of acetyl-l-carnitine mediated by PI3K/AKT/BDNF/VGF signaling pathway in mice |
| - | in-vivo, | NA, | NA |
| 3975- | ALC, | Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease |
| - | Trial, | AD, | NA |
| 3974- | ALC, | Carnitine |
| - | Review, | AD, | NA |
| 3859- | ALC, | Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment |
| - | Review, | AD, | NA |
| 3976- | ALC, | Acetyl-L-carnitine for dementia |
| - | Review, | AD, | NA |
| 3435- | aLinA, | Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | SiHa | - | in-vitro, | Cerv, | C33A |
| 1252- | aLinA, | α-Linolenic acid induces apoptosis, inhibits the invasion and metastasis, and arrests cell cycle in human breast cancer cells by inhibiting fatty acid synthase |
| - | in-vitro, | BC, | NA |
| 1253- | aLinA, | The Antitumor Effects of α-Linolenic Acid |
| - | Review, | NA, | NA |
| 1123- | aLinA, | Linoleic acid induces an EMT-like process in mammary epithelial cells MCF10A |
| - | in-vitro, | BC, | NA | - | in-vitro, | NA, | MCF10 |
| 4512- | aLinA, | GLA, | Evening primrose oil: a comprehensive review of its bioactives, extraction, analysis, oil quality, therapeutic merits, and safety |
| - | in-vivo, | Nor, | NA |
| 4135- | Alum, | Aluminum Should Now Be Considered a Primary Etiological Factor in Alzheimer's Disease |
| - | Review, | AD, | NA |
| 4124- | Alum, | The potential influence of silica present in drinking water on Alzheimer's disease and associated disorders |
| - | Review, | AD, | NA |
| 4130- | Alum, | Silica and aluminum in drinking water and cognitive impairment in the elderly |
| - | Study, | AD, | NA |
| 4132- | Alum, | Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study |
| - | Study, | AD, | NA |
| 1440- | AMQ, | Lysosomotropism depends on glucose: a chloroquine resistance mechanism |
| - | in-vitro, | BC, | 4T1 |
| 552- | Anamu, | A critical review of the therapeutic potential of dibenzyl trisulphide isolated from Petiveria alliacea L (guinea hen weed, anamu) |
| - | Review, | NA, | NA |
| 553- | Anamu, | The anti-inflammatory and analgesic effects of a crude extract of Petiveria alliacea L. (Phytolaccaceae) |
| - | in-vivo, | NA, | NA |
| 554- | Anamu, | Petiveria alliacea extracts uses multiple mechanisms to inhibit growth of human and mouse tumoral cells |
| - | in-vitro, | NA, | 769-P |
| 1007- | And, | In vitro and in silico evaluation of Andrographis paniculata ethanolic crude extracts on fatty acid synthase expression on breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | EMT6 |
| 1009- | And, | 5-FU, | Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of β-catenin/Wnt-signaling pathways in colorectal cancer |
| - | in-vivo, | CRC, | HCT116 | - | in-vitro, | CRC, | SW480 |
| 1078- | And, | Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | HUVECs | - | in-vivo, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | MDA-MB-361 |
| 931- | And, | Effect of Andrographis Paniculata Aqueous Extract on Hyperammonemia Induced Alteration of Oxidative and Nitrosative Stress Factors in the Liver, Spleen and Kidney of Rats |
| - | in-vivo, | NA, | NA |
| 1159- | And, | Andrographolide, an Anti-Inflammatory Multitarget Drug: All Roads Lead to Cellular Metabolism |
| - | Review, | NA, | NA |
| 1158- | And, | GEM, | Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer |
| 1157- | And, | Andrographolide suppresses the migratory ability of human glioblastoma multiforme cells by targeting ERK1/2-mediated matrix metalloproteinase-2 expression |
| - | in-vitro, | GBM, | GBM8401 | - | in-vitro, | GBM, | U251 |
| 1093- | And, | Andrographolide attenuates epithelial‐mesenchymal transition induced by TGF‐β1 in alveolar epithelial cells |
| - | in-vitro, | Lung, | A549 |
| 1156- | And, | Exploring the potential of Andrographis paniculata for developing novel HDAC inhibitors: an in silico approach |
| - | Analysis, | NA, | NA |
| 1351- | And, | MEL, | Impact of Andrographolide and Melatonin Combinatorial Drug Therapy on Metastatic Colon Cancer Cells and Organoids |
| - | in-vitro, | CRC, | T84 | - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | DLD1 |
| 1294- | And, | 5-FU, | Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression |
| - | in-vitro, | CRC, | HCT116 |
| 1352- | And, | Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy |
| - | in-vitro, | AML, | K562 |
| 1350- | And, | Cisplatin, | Synergistic antitumor effect of Andrographolide and cisplatin through ROS-mediated ER stress and STAT3 inhibition in colon cancer |
| - | in-vitro, | Colon, | NA |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 1353- | And, | Andrographolide Induces Apoptosis and Cell Cycle Arrest through Inhibition of Aberrant Hedgehog Signaling Pathway in Colon Cancer Cells |
| - | in-vitro, | Colon, | HCT116 |
| 1347- | And, | Suppression of rat neutrophil reactive oxygen species production and adhesion by the diterpenoid lactone andrographolide |
| - | in-vitro, | Nor, | NA |
| 1348- | And, | Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vivo, | NA, | NA |
| 1349- | And, | Andrographolide promoted ferroptosis to repress the development of non-small cell lung cancer through activation of the mitochondrial dysfunction |
| - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | H1650 |
| 1354- | And, | Andrographolide induces protective autophagy and targeting DJ-1 triggers reactive oxygen species-induced cell death in pancreatic cancer |
| - | in-vitro, | PC, | NA | - | in-vivo, | PC, | NA |
| 4760- | antiOx, | Chemo, | Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials |
| - | Review, | Var, | NA |
| 4759- | antiOx, | Chemo, | Potential Contributions of Antioxidants to Cancer Therapy: Immunomodulation and Radiosensitization |
| - | Review, | Var, | NA |
| 4758- | antiOx, | Chemo, | Therapeutic controversies over use of antioxidant supplements during cancer treatment: a scoping review |
| - | Review, | Var, | NA |
| 4765- | antiOx, | Chemo, | Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity – Exploring the armoury of obscurity |
| - | Review, | Var, | NA |
| 4746- | antiOx, | Chemo, | VitA,RetA, | VitC, | Se | Using Supplements During Chemo: Yes or No? |
| - | Review, | Var, | NA |
| 1146- | AP, | Potential use of nanoformulated ascorbyl palmitate as a promising anticancer agent: First comparative assessment between nano and free forms |
| - | in-vivo, | Nor, | NA |
| 1095- | Api, | Apigenin inhibits epithelial-mesenchymal transition of human colon cancer cells through NF-κB/Snail signaling pathway |
| - | Analysis, | Colon, | NA |
| 1152- | Api, | Does Oral Apigenin Have Real Potential for a Therapeutic Effect in the Context of Human Gastrointestinal and Other Cancers? |
| - | Analysis, | Nor, | NA |
| 1151- | Api, | Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | 22Rv1 | - | in-vivo, | NA, | NA |
| 1150- | Api, | Apigenin inhibits the TNFα-induced expression of eNOS and MMP-9 via modulating Akt signalling through oestrogen receptor engagement |
| - | in-vitro, | Lung, | EAhy926 |
| 1149- | Api, | Apigenin inhibits colonic inflammation and tumorigenesis by suppressing STAT3-NF-κB signaling |
| - | vitro+vivo, | IBD, | NA |
| 1024- | Api, | CUR, | Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects |
| - | vitro+vivo, | Melanoma, | A375 | - | in-vitro, | Melanoma, | A2058 | - | in-vitro, | Melanoma, | RPMI-7951 |
| 1008- | Api, | Apigenin-induced lysosomal degradation of β-catenin in Wnt/β-catenin signaling |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW480 |
| 1077- | Api, | Apigenin inhibits COX-2, PGE2, and EP1 and also initiates terminal differentiation in the epidermis of tumor bearing mice |
| - | in-vivo, | NMSC, | NA |
| 983- | Api, | Apigenin acts as a partial agonist action at estrogen receptors in vivo |
| - | in-vivo, | NA, | NA |
| 958- | Api, | Apigenin suppresses tumor angiogenesis and growth via inhibiting HIF-1α expression in non-small cell lung carcinoma |
| - | in-vitro, | Lung, | NCIH1299 |
| 577- | Api, | PacT, | Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells |
| - | in-vitro, | Ovarian, | SKOV3 |
| 578- | Api, | Cisplatin, | Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Pca, | HeLa | - | in-vitro, | Lung, | H1299 |
| 581- | Api, | Cisplatin, | The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy |
| - | in-vitro, | Pca, | CD44+ |
| 583- | Api, | Cisplatin, | Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study |
| - | in-vitro, | Laryn, | HEp2 |
| 584- | Api, | Cisplatin, | Apigenin potentiates the antitumor activity of 5-FU on solid Ehrlich carcinoma: Crosstalk between apoptotic and JNK-mediated autophagic cell death platforms |
| - | in-vivo, | Var, | NA |
| 586- | Api, | 5-FU, | 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma |
| - | in-vivo, | HCC, | NA |
| 589- | Api, | 5-FU, | Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro |
| - | in-vitro, | PC, | Bxpc-3 |
| 591- | Api, | doxoR, | Polyphenols act synergistically with doxorubicin and etoposide in leukaemia cell lines |
| - | in-vitro, | AML, | Jurkat | - | in-vitro, | AML, | THP1 |
| 938- | Api, | doxoR, | Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells |
| - | vitro+vivo, | HCC, | HepG2 |
| 171- | Api, | Apigenin in cancer therapy: anti-cancer effects and mechanisms of action |
| - | Review, | Var, | NA |
| 208- | Api, | Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70–Bax interaction in prostate cancer |
| - | in-vivo, | Pca, | PC3 | - | in-vivo, | Pca, | DU145 |
| 240- | Api, | The flavonoid apigenin reduces prostate cancer CD44(+) stem cell survival and migration through PI3K/Akt/NF-κB signaling |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | CD44+ |
| 166- | Api, | Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer |
| 238- | Api, | Apigenin inhibits TGF-β-induced VEGF expression in human prostate carcinoma cells via a Smad2/3- and Src-dependent mechanism |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 237- | Api, | Apigenin blocks IKKα activation and suppresses prostate cancer progression |
| - | in-vivo, | Pca, | PC3 | - | in-vivo, | Pca, | 22Rv1 | - | in-vivo, | Pca, | LNCaP | - | in-vivo, | Pca, | DU145 |
| 210- | Api, | Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer |
| - | in-vitro, | Pca, | DU145 |
| 180- | Api, | Induction of caspase-dependent apoptosis by apigenin by inhibiting STAT3 signaling in HER2-overexpressing MDA-MB-453 breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 206- | Api, | Inhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stress |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | A549 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Lung, | H2030 | - | in-vitro, | CRC, | SW480 |
| 207- | Api, | Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells |
| - | in-vitro, | Pca, | LNCaP |
| 211- | Api, | Suppression of NF-κB and NF-κB-Regulated Gene Expression by Apigenin through IκBα and IKK Pathway in TRAMP Mice |
| - | in-vivo, | Pca, | NA |
| 242- | Api, | Apigenin inhibits proliferation and invasion, and induces apoptosis and cell cycle arrest in human melanoma cells |
| - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Melanoma, | C8161 |
| 243- | Api, | Apigenin Attenuates Melanoma Cell Migration by Inducing Anoikis through Integrin and Focal Adhesion Kinase Inhibition |
| - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Melanoma, | A2058 |
| 244- | Api, | Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma |
| - | in-vivo, | Melanoma, | B16-F10 | - | in-vivo, | Melanoma, | A375 | - | in-vivo, | Melanoma, | G361 |
| 179- | Api, | Apigenin induces caspase-dependent apoptosis by inhibiting signal transducer and activator of transcription 3 signaling in HER2-overexpressing SKBR3 breast cancer cells |
| - | in-vitro, | BC, | NA |
| 178- | Api, | Autophagy inhibition enhances apigenin-induced apoptosis in human breast cancer cells |
| - | in-vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | T47D |
| 177- | Api, | Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21WAF1/CIP1 expression |
| - | in-vitro, | BC, | MDA-MB-231 |
| 172- | Api, | Apigenin suppresses colorectal cancer cell proliferation, migration and invasion via inhibition of the Wnt/β-catenin signaling pathway |
| - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | HTC15 |
| 173- | Api, | Apigenin-induced apoptosis is enhanced by inhibition of autophagy formation in HCT116 human colon cancer cells |
| - | in-vitro, | Colon, | HCT116 |
| - | in-vitro, | BC, | BT474 |
| 175- | Api, | Apigenin up-regulates transgelin and inhibits invasion and migration of colorectal cancer through decreased phosphorylation of AKT |
| - | vitro+vivo, | CRC, | SW480 | - | vitro+vivo, | CRC, | DLD1 | - | vitro+vivo, | CRC, | LS174T |
| 174- | Api, | Downregulation of NEDD9 by apigenin suppresses migration, invasion, and metastasis of colorectal cancer cells |
| - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | DLD1 |
| 269- | Api, | Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy |
| - | in-vitro, | AML, | HL-60 | - | in-vitro, | AML, | K562 | - | in-vitro, | AML, | TF1 |
| 270- | Api, | Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo via inactivation of Akt and activation of JNK |
| - | in-vivo, | AML, | U937 |
| 273- | Api, | Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase |
| - | in-vivo, | Ovarian, | A2780S |
| 275- | Api, | Apigenin inhibits the self-renewal capacity of human ovarian cancer SKOV3‑derived sphere-forming cells |
| - | in-vitro, | Ovarian, | SKOV3 |
| 5- | Api, | Common Botanical Compounds Inhibit the Hedgehog Signaling Pathway in Prostate Cancer |
| - | in-vitro, | Pca, | NA |
| 268- | Api, | Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells |
| - | in-vitro, | AML, | HL-60 |
| 314- | Api, | Apigenin impairs oral squamous cell carcinoma growth in vitro inducing cell cycle arrest and apoptosis |
| - | in-vitro, | SCC, | HaCaT | - | in-vitro, | SCC, | SCC25 |
| 421- | Api, | Apigenin inhibits HeLa sphere-forming cells through inactivation of casein kinase 2α |
| - | vitro+vivo, | Cerv, | HeLa |
| 419- | Api, | Apigenin inhibited hypoxia induced stem cell marker expression in a head and neck squamous cell carcinoma cell line |
| - | in-vitro, | SCC, | HN30 | - | in-vitro, | SCC, | HN8 |
| 418- | Api, | Apigenin inhibits the proliferation and invasion of osteosarcoma cells by suppressing the Wnt/β-catenin signaling pathway |
| - | vitro+vivo, | OS, | U2OS | - | vitro+vivo, | OS, | MG63 |
| 416- | Api, | In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma |
| - | vitro+vivo, | NA, | NA |
| 315- | Api, | Apigenin: Selective CK2 inhibitor increases Ikaros expression and improves T cell homeostasis and function in murine pancreatic cancer |
| - | vitro+vivo, | PC, | Panc02 |
| 313- | Api, | Apigenin induces autophagic cell death in human papillary thyroid carcinoma BCPAP cells |
| - | in-vitro, | Thyroid, | BCPAP |
| 310- | Api, | Apigenin inhibits renal cell carcinoma cell proliferation |
| - | vitro+vivo, | RCC, | ACHN | - | in-vitro, | RCC, | 786-O | - | in-vitro, | RCC, | Caki-1 | - | in-vitro, | RCC, | HK-2 |
| 307- | Api, | Flavonoids inhibit angiogenic cytokine production by human glioma cells |
| - | in-vitro, | GBM, | GL-15 |
| 308- | Api, | Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U373MG |
| 311- | Api, | Apigenin inhibits the proliferation of adenoid cystic carcinoma via suppression of glucose transporter-1 |
| - | in-vitro, | ACC, | NA |
| 1301- | Api, | Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways |
| - | in-vitro, | neuroblastoma, | NA |
| 1999- | Api, | doxoR, | Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation |
| - | in-vitro, | Nor, | NRK52E | - | in-vitro, | Nor, | MPC5 | - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 1550- | Api, | Formulation and characterization of an apigenin-phospholipid phytosome (APLC) for improved solubility, in vivo bioavailability, and antioxidant potential |
| - | Analysis, | NA, | NA |
| 1537- | Api, | Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer |
| - | Review, | PC, | NA |
| 1536- | Api, | Apigenin causes necroptosis by inducing ROS accumulation, mitochondrial dysfunction, and ATP depletion in malignant mesothelioma cells |
| - | in-vitro, | MM, | MSTO-211H | - | in-vitro, | MM, | H2452 |
| 1538- | Api, | Enhancing oral bioavailability using preparations of apigenin-loaded W/O/W emulsions: In vitro and in vivo evaluations |
| - | in-vivo, | Nor, | NA |
| 1564- | Api, | Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vivo, | NA, | NA |
| 1539- | Api, | LT, | Dietary flavones counteract phorbol 12-myristate 13-acetate-induced SREBP-2 processing in hepatic cells |
| - | in-vitro, | Liver, | HepG2 |
| 1540- | Api, | Determination of Total Apigenin in Herbs by Micellar Electrokinetic Chromatography with UV Detection |
| - | Analysis, | NA, | NA |
| 1541- | Api, | EGCG, | Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence |
| - | Human, | NA, | NA |
| 1542- | Api, | Bioavailability of Apigenin from Apiin-Rich Parsley in Humans |
| - | Human, | NA, | NA |
| 1543- | Api, | Therapeutical properties of apigenin: a review on the experimental evidence and basic mechanisms |
| - | Review, | NA, | NA |
| 1544- | Api, | The flavone apigenin blocks nuclear translocation of sterol regulatory element-binding protein-2 in the hepatic cells WRL-68 |
| - | in-vitro, | Nor, | WRL68 |
| 1545- | Api, | The Potential Role of Apigenin in Cancer Prevention and Treatment |
| - | Review, | NA, | NA |
| 1546- | Api, | Apigenin in Cancer Prevention and Therapy: A Systematic Review and Meta-Analysis of Animal Models |
| - | Review, | NA, | NA |
| 1547- | Api, | Apigenin: Molecular Mechanisms and Therapeutic Potential against Cancer Spreading |
| - | Review, | NA, | NA |
| 1548- | Api, | A comprehensive view on the apigenin impact on colorectal cancer: Focusing on cellular and molecular mechanisms |
| - | Review, | Colon, | NA |
| 1549- | Api, | Chemo, | Chemoprotective and chemosensitizing effects of apigenin on cancer therapy |
| - | Review, | NA, | NA |
| 1551- | Api, | Chemotherapeutic effects of Apigenin in breast cancer: Preclinical evidence and molecular mechanisms; enhanced bioavailability by nanoparticles |
| - | Review, | NA, | NA |
| 1552- | Api, | Apigenin inhibits the growth of colorectal cancer through down-regulation of E2F1/3 by miRNA-215-5p |
| - | in-vitro, | CRC, | HCT116 |
| 1553- | Api, | Role of Apigenin in Cancer Prevention via the Induction of Apoptosis and Autophagy |
| - | Review, | NA, | NA |
| 1554- | Api, | A Review on Flavonoid Apigenin: Dietary Intake, ADME, Antimicrobial Effects, and Interactions with Human Gut Microbiota |
| - | Review, | NA, | NA |
| 1555- | Api, | USDA Database for the Flavonoid Content of Selected Foods |
| - | Analysis, | NA, | NA |
| 1565- | Api, | Apigenin-7-glucoside induces apoptosis and ROS accumulation in lung cancer cells, and inhibits PI3K/Akt/mTOR pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B | - | in-vitro, | Lung, | H1975 |
| 1556- | Api, | Dissolution and antioxidant potential of apigenin self nanoemulsifying drug delivery system (SNEDDS) for oral delivery |
| - | Analysis, | NA, | NA |
| 1557- | Api, | Preparation of apigenin nanocrystals using supercritical antisolvent process for dissolution and bioavailability enhancement |
| - | in-vitro, | Nor, | NA |
| 1558- | Api, | Preparation, characterization and antitumor activity evaluation of apigenin nanoparticles by the liquid antisolvent precipitation technique |
| - | in-vitro, | Liver, | HepG2 |
| 1559- | Api, | Dually Active Apigenin-Loaded Nanostructured Lipid Carriers for Cancer Treatment |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 1560- | Api, | Apigenin as an anticancer agent |
| - | Review, | NA, | NA |
| 1561- | Api, | Apigenin Reactivates Nrf2 Anti-oxidative Stress Signaling in Mouse Skin Epidermal JB6 P + Cells Through Epigenetics Modifications |
| - | in-vivo, | Nor, | JB6 |
| 1562- | Api, | Apigenin protects human melanocytes against oxidative damage by activation of the Nrf2 pathway |
| - | in-vitro, | Vit, | NA |
| 1563- | Api, | MET, | Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells |
| - | in-vitro, | Nor, | HDFa | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | NA, | NA |
| 2583- | Api, | Rad, | The influence of apigenin on cellular responses to radiation: From protection to sensitization |
| - | Review, | Var, | NA |
| 2584- | Api, | Chemo, | The versatility of apigenin: Especially as a chemopreventive agent for cancer |
| - | Review, | Var, | NA |
| 2585- | Api, | Apigenin inhibits the proliferation of adenoid cystic carcinoma via suppression of glucose transporter-1 |
| - | in-vitro, | ACC, | NA |
| 2586- | Api, | doxoR, | Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway |
| - | in-vitro, | HCC, | Bel-7402 |
| 2593- | Api, | Apigenin promotes apoptosis of 4T1 cells through PI3K/AKT/Nrf2 pathway and improves tumor immune microenvironment in vivo |
| - | in-vivo, | BC, | 4T1 |
| 2594- | Api, | docx, | Targeted hyaluronic acid-based lipid nanoparticle for apigenin delivery to induce Nrf2-dependent apoptosis in lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 2596- | Api, | LT, | Natural Nrf2 Inhibitors: A Review of Their Potential for Cancer Treatment |
| - | Review, | Var, | NA |
| 2637- | Api, | Apigenin Alleviates Endoplasmic Reticulum Stress-Mediated Apoptosis in INS-1 β-Cells |
| - | in-vitro, | Diabetic, | NA |
| 2632- | Api, | Apigenin inhibits migration and induces apoptosis of human endometrial carcinoma Ishikawa cells via PI3K-AKT-GSK-3β pathway and endoplasmic reticulum stress |
| - | in-vitro, | EC, | NA |
| 2664- | Api, | Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents |
| - | Review, | Var, | NA |
| 2641- | Api, | Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 2640- | Api, | Apigenin: A Promising Molecule for Cancer Prevention |
| - | Review, | Var, | NA |
| 2639- | Api, | Plant flavone apigenin: An emerging anticancer agent |
| - | Review, | Var, | NA |
| 2638- | Api, | Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death |
| - | in-vitro, | lymphoma, | PEL |
| 2636- | Api, | Apigenin unveiled: an encyclopedic review of its preclinical and clinical insights |
| - | Review, | NA, | NA |
| 2635- | Api, | CUR, | Synergistic Effect of Apigenin and Curcumin on Apoptosis, Paraptosis and Autophagy-related Cell Death in HeLa Cells |
| - | in-vitro, | Cerv, | HeLa |
| 2634- | Api, | Apigenin induces both intrinsic and extrinsic pathways of apoptosis in human colon carcinoma HCT-116 cells |
| - | in-vitro, | CRC, | HCT116 |
| 2633- | Api, | Apigenin induces ROS-dependent apoptosis and ER stress in human endometriosis cells |
| - | in-vitro, | EC, | NA |
| 2631- | Api, | Apigenin Induces Autophagy and Cell Death by Targeting EZH2 under Hypoxia Conditions in Gastric Cancer Cells |
| - | in-vivo, | GC, | NA | - | in-vitro, | GC, | AGS |
| 2317- | Api, | Apigenin intervenes in liver fibrosis by regulating PKM2-HIF-1α mediated oxidative stress |
| - | in-vivo, | Nor, | NA |
| 2299- | Api, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2314- | Api, | Apigenin Restrains Colon Cancer Cell Proliferation via Targeted Blocking of Pyruvate Kinase M2-Dependent Glycolysis |
| - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Colon, | HT29 | - | in-vitro, | Colon, | DLD1 |
| 2316- | Api, | The interaction between apigenin and PKM2 restrains progression of colorectal cancer |
| - | in-vitro, | CRC, | LS174T | - | in-vitro, | CRC, | HCT8 | - | in-vivo, | CRC, | NA |
| 2318- | Api, | Apigenin as a multifaceted antifibrotic agent: Therapeutic potential across organ systems |
| - | Review, | Nor, | NA |
| 2319- | Api, | Apigenin sensitizes radiotherapy of mouse subcutaneous glioma through attenuations of cell stemness and DNA damage repair by inhibiting NF-κB/HIF-1α-mediated glycolysis |
| - | in-vitro, | GBM, | NA |
| 3882- | Api, | Enhancing Amyloid-β Clearance May Improve Brain Function in Alzheimer Disease |
| - | Review, | AD, | NA |
| 3885- | Api, | Anti-Inflammatory and Neuroprotective Effect of Apigenin: Studies in the GFAP-IL6 Mouse Model of Chronic Neuroinflammation |
| - | in-vivo, | AD, | NA |
| 3883- | Api, | New approach to clearing toxic waste from brain |
| - | Review, | AD, | NA |
| 3884- | Api, | Neuroprotective, Anti-Amyloidogenic and Neurotrophic Effects of Apigenin in an Alzheimer’s Disease Mouse Model |
| - | in-vivo, | AD, | NA |
| 3886- | Api, | Neuroprotective effects of apigenin against inflammation, neuronal excitability and apoptosis in an induced pluripotent stem cell model of Alzheimer’s disease |
| - | in-vitro, | AD, | NA |
| 3887- | Api, | The flavonoid apigenin protects brain neurovascular coupling against amyloid-β₂₅₋₃₅-induced toxicity in mice |
| - | in-vivo, | AD, | NA |
| 4280- | Api, | Protective effects of apigenin in neurodegeneration: An update on the potential mechanisms |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4279- | Api, | The Beneficial Role of Apigenin against Cognitive and Neurobehavioural Dysfunction: A Systematic Review of Preclinical Investigations |
| - | Review, | NA, | NA |
| 4281- | Api, | The neurotrophic activities of brain‐derived neurotrophic factor are potentiated by binding with apigenin, a common flavone in vegetables, in stimulating the receptor signaling |
| - | in-vitro, | AD, | SH-SY5Y |
| 3817- | Aroma, | Therapeutic potential of aromatic plant extracts in Alzheimer's disease: Comprehensive review of their underlying mechanisms |
| - | Review, | AD, | NA |
| 3818- | Aroma, | The effect of inhaled aromatherapy on cognitive function in patients with cognitive impairment: A systematic review and meta-analysis |
| - | Review, | AD, | NA |
| 3819- | Aroma, | Aromatherapy improves cognitive dysfunction in senescence-accelerated mouse prone 8 by reducing the level of amyloid beta and tau phosphorylation |
| - | Human, | AD, | NA | - | in-vitro, | AD, | NA |
| 3820- | Aroma, | Effectiveness and Safety of Aromatherapy in Managing Behavioral and Psychological Symptoms of Dementia: A Mixed-Methods Systematic Review |
| - | Review, | AD, | NA |
| 3821- | Aroma, | Neuroprotective and Anti-Aging Potentials of Essential Oils from Aromatic and Medicinal Plants |
| - | Review, | AD, | NA |
| 3822- | Aroma, | Aromatherapy in the treatment of Alzheimer's disease: A systematic review |
| - | Review, | AD, | NA |
| 3823- | Aroma, | Aromatherapy in dementia |
| - | Review, | AD, | NA |
| - | Human, | AD, | NA |
| 3825- | Aroma, | The effects of lemon balm (Melissa officinalis L.) on depression and anxiety in clinical trials: A systematic review and meta-analysis |
| - | Review, | AD, | NA |
| - | Human, | AD, | NA |
| 3827- | Aroma, | A medicinal herb, Melissa officinalis L. ameliorates depressive-like behavior of rats in the forced swimming test via regulating the serotonergic neurotransmitter |
| - | in-vivo, | NA, | NA |
| 4278- | ART/DHA, | Artemisinin Ameliorates the Neurotoxic Effect of 3-Nitropropionic Acid: A Possible Involvement of the ERK/BDNF/Nrf2/HO-1 Signaling Pathway |
| - | in-vivo, | NA, | NA |
| 3394- | ART/DHA, | Anticancer activities and mechanisms of heat-clearing and detoxicating traditional Chinese herbal medicine |
| 3393- | ART/DHA, | Artemisinin-derived artemisitene blocks ROS-mediated NLRP3 inflammasome and alleviates ulcerative colitis |
| - | in-vivo, | Col, | NA |
| 3395- | ART/DHA, | Artesunate Induces Ferroptosis in Hepatic Stellate Cells and Alleviates Liver Fibrosis via the ROCK1/ATF3 Axis |
| - | in-vitro, | NA, | HSC-T6 |
| 3396- | ART/DHA, | Progress on the study of the anticancer effects of artesunate |
| - | Review, | Var, | NA |
| 3345- | ART/DHA, | Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK/ATF4/HSPA5 pathway in glioma cells |
| - | in-vitro, | GBM, | NA |
| 3382- | ART/DHA, | Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge? |
| - | Review, | Var, | NA |
| 3383- | ART/DHA, | Dihydroartemisinin: A Potential Natural Anticancer Drug |
| - | Review, | Var, | NA |
| 3384- | ART/DHA, | Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response‑induced upregulation of CHAC1 expression |
| - | in-vitro, | Liver, | Hep3B | - | in-vitro, | Liver, | HUH7 | - | in-vitro, | Liver, | HepG2 |
| 3392- | ART/DHA, | Artemisinin inhibits inflammatory response via regulating NF-κB and MAPK signaling pathways |
| - | in-vitro, | Nor, | Hep3B | - | in-vivo, | NA, | NA |
| 3391- | ART/DHA, | Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug |
| - | Review, | Var, | NA |
| 3390- | ART/DHA, | Ferroptosis: The Silver Lining of Cancer Therapy |
| 3389- | ART/DHA, | Emerging mechanisms and applications of ferroptosis in the treatment of resistant cancers |
| - | Review, | Var, | NA |
| 3385- | ART/DHA, | Interaction of artemisinin protects the activity of antioxidant enzyme catalase: A biophysical study |
| - | Study, | NA, | NA |
| 3386- | ART/DHA, | Effects of Caffeine-Artemisinin Combination on Liver Function and Oxidative Stress in Selected Organs in 7,12-Dimethylbenzanthracene-Treated Rats |
| - | in-vivo, | Nor, | NA |
| 3387- | ART/DHA, | Ferroptosis: A New Research Direction of Artemisinin and Its Derivatives in Anti-Cancer Treatment |
| - | Review, | Var, | NA |
| 3388- | ART/DHA, | Keap1 Cystenine 151 as a Potential Target for Artemisitene-Induced Nrf2 Activation |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | GP-293 | - | in-vitro, | BC, | MDA-MB-231 |
| 3665- | ART/DHA, | Artemisinin B Improves Learning and Memory Impairment in AD Dementia Mice by Suppressing Neuroinflammation |
| - | Review, | AD, | NA |
| 3666- | ART/DHA, | Artemisinin Attenuates Amyloid-Induced Brain Inflammation and Memory Impairments by Modulating TLR4/NF-κB Signaling |
| - | NA, | AD, | NA |
| 3667- | ART/DHA, | Artemisinin improves neurocognitive deficits associated with sepsis by activating the AMPK axis in microglia |
| - | Review, | Sepsis, | NA |
| 2320- | ART/DHA, | Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 by Suppressing PKM2 and GLUT1 Mediated Aerobic Glycolysis |
| - | in-vitro, | AML, | K562 | - | in-vitro, | Liver, | HepG2 |
| 2321- | ART/DHA, | Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma |
| - | in-vitro, | ESCC, | Eca109 | - | in-vitro, | ESCC, | EC9706 |
| 2322- | ART/DHA, | Dihydroartemisinin Regulates Self-Renewal of Human Melanoma-Initiating Cells by Targeting PKM2/LDHARelated Glycolysis |
| - | in-vitro, | Melanoma, | NA |
| 2323- | ART/DHA, | Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2 |
| - | in-vitro, | ESCC, | Eca109 | - | in-vitro, | ESCC, | EC9706 |
| 2324- | ART/DHA, | Research Progress of Warburg Effect in Hepatocellular Carcinoma |
| - | Review, | Var, | NA |
| 2570- | ART/DHA, | Discovery, mechanisms of action and combination therapy of artemisinin |
| - | Review, | Nor, | NA |
| 2582- | ART/DHA, | 5-ALA, | Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal Cancer Activity |
| - | in-vivo, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT116 |
| 2581- | ART/DHA, | PB, | Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells |
| - | in-vitro, | AML, | NA |
| 2580- | ART/DHA, | VitC, | Effects of Antioxidants and Pro-oxidants on Cytotoxicity of Dihydroartemisinin to Molt-4 Human Leukemia Cells |
| - | in-vitro, | AML, | NA |
| 2578- | ART/DHA, | RES, | Synergic effects of artemisinin and resveratrol in cancer cells |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Cerv, | HeLa |
| 2577- | ART/DHA, | Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives |
| - | Review, | Var, | NA |
| 2576- | ART/DHA, | AL, | The Synergistic Anticancer Effect of Artesunate Combined with Allicin in Osteosarcoma Cell Line in Vitro and in Vivo |
| - | in-vitro, | OS, | MG63 | - | in-vivo, | NA, | NA |
| 2575- | ART/DHA, | docx, | Artemisia santolinifolia-Mediated Chemosensitization via Activation of Distinct Cell Death Modes and Suppression of STAT3/Survivin-Signaling Pathways in NSCLC |
| - | in-vitro, | Lung, | H23 |
| 2573- | ART/DHA, | Cell death mechanisms induced by synergistic effects of halofuginone and artemisinin in colorectal cancer cells |
| - | in-vitro, | CRC, | HCT116 |
| 2572- | ART/DHA, | SRF, | Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax |
| - | in-vitro, | AML, | NA |
| 2571- | ART/DHA, | Cancer combination therapies with artemisinin-type drugs |
| - | Review, | Var, | NA |
| 2574- | ART/DHA, | Artemisinin: A Promising Adjunct for Cancer Therapy |
| - | Review, | Var, | NA |
| 2569- | ART/DHA, | A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction |
| - | Human, | Nor, | NA |
| 957- | ART/DHA, | Artemisinin inhibits the development of esophageal cancer by targeting HIF-1α to reduce glycolysis levels |
| - | in-vitro, | ESCC, | KYSE150 | - | in-vitro, | ESCC, | KYSE170 |
| 1074- | ART/DHA, | Artemisinin attenuates lipopolysaccharide-stimulated proinflammatory responses by inhibiting NF-κB pathway in microglia cells |
| - | in-vitro, | Nor, | BV2 |
| 1075- | ART/DHA, | Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-β signaling in breast cancer |
| - | in-vitro, | Nor, | L929 |
| 1076- | ART/DHA, | The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer |
| - | Review, | NA, | NA |
| 985- | ART/DHA, | Artemisinin suppresses aerobic glycolysis in thyroid cancer cells by downregulating HIF-1a, which is increased by the XIST/miR-93/HIF-1a pathway |
| - | in-vitro, | Thyroid, | TPC-1 | - | Human, | NA, | NA |
| 1079- | ART/DHA, | Artesunate inhibits the growth and induces apoptosis of human gastric cancer cells by downregulating COX-2 |
| - | in-vitro, | GC, | BGC-823 | - | in-vitro, | GC, | HGC27 | - | in-vitro, | GC, | MGC803 |
| 976- | ART/DHA, | Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 1026- | ART/DHA, | Artemisinin improves the efficiency of anti-PD-L1 therapy in T-cell lymphoma |
| - | in-vitro, | AML, | THP1 |
| 1147- | ART/DHA, | Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1 |
| - | vitro+vivo, | Ovarian, | HO-8910 | - | vitro+vivo, | Nor, | HUVECs |
| 1099- | ART/DHA, | Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway |
| - | in-vitro, | NA, | NA |
| 563- | ART/DHA, | Artesunate down-regulates immunosuppression from colorectal cancer Colon26 and RKO cells in vitro by decreasing transforming growth factor β1 and interleukin-10 |
| - | in-vitro, | Colon, | colon26 | - | in-vitro, | CRC, | RKO |
| 555- | ART/DHA, | Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action |
| - | Review, | NA, | NA |
| 556- | ART/DHA, | Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing |
| - | Review, | NA, | NA |
| 557- | ART/DHA, | Artemisinin and Its Derivatives in Cancer Care |
| - | Review, | Var, | NA |
| 558- | ART/DHA, | Artemisinin and Its Synthetic Derivatives as a Possible Therapy for Cancer |
| - | Review, | NA, | NA |
| 560- | ART/DHA, | Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo |
| - | in-vivo, | NA, | NA |
| 576- | ART/DHA, | Profiling of Multiple Targets of Artemisinin Activated by Hemin in Cancer Cell Proteome |
| - | Analysis, | NA, | NA |
| 575- | ART/DHA, | Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition |
| - | in-vitro, | GBM, | U87MG |
| 574- | ART/DHA, | Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway |
| 573- | ART/DHA, | Artesunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model |
| - | vitro+vivo, | NA, | NA |
| 572- | ART/DHA, | High-throughput screening identifies artesunate as selective inhibitor of cancer stemness: Involvement of mitochondrial metabolism |
| 571- | ART/DHA, | TMZ, | Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence |
| - | vitro+vivo, | GBM, | A172 | - | vitro+vivo, | GBM, | U87MG |
| 570- | ART/DHA, | Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling |
| - | vitro+vivo, | NSCLC, | A549 | - | vitro+vivo, | NSCLC, | H1299 |
| 569- | ART/DHA, | Dihydroartemisinin exhibits anti-glioma stem cell activity through inhibiting p-AKT and activating caspase-3 |
| - | in-vitro, | GBM, | NA |
| 568- | ART/DHA, | Mechanism-Guided Design and Synthesis of a Mitochondria-Targeting Artemisinin Analogue with Enhanced Anticancer Activity |
| - | in-vitro, | NA, | MDA-MB-231 | - | in-vitro, | NA, | HeLa | - | in-vitro, | NA, | SkBr3 | - | in-vitro, | NA, | HCT116 |
| 567- | ART/DHA, | An Untargeted Proteomics and Systems-based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells |
| - | in-vitro, | Lung, | BEAS-2B |
| 566- | ART/DHA, | 2DG, | Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | PC9 |
| 565- | ART/DHA, | Artesunate as an Anti-Cancer Agent Targets Stat-3 and Favorably Suppresses Hepatocellular Carcinoma |
| 564- | ART/DHA, | Cisplatin, | Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling |
| - | in-vitro, | NA, | HN30 |
| 562- | ART/DHA, | Artesunate exerts an anti-immunosuppressive effect on cervical cancer by inhibiting PGE2 production and Foxp3 expression |
| - | in-vivo, | NA, | HeLa |
| 561- | ART/DHA, | Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo |
| - | in-vivo, | NA, | NA |
| 559- | ART/DHA, | Artemisinin and its derivatives: a promising cancer therapy |
| - | Review, | NA, | NA |
| 1027- | AS, | Astragalus polysaccharide (APS) attenuated PD-L1-mediated immunosuppression via the miR-133a-3p/MSN axis in HCC |
| - | vitro+vivo, | HCC, | SMMC-7721 cell |
| 1000- | AS, | 5-FU, | Characterization and anti-tumor bioactivity of astragalus polysaccharides by immunomodulation |
| - | vitro+vivo, | BC, | 4T1 |
| 1097- | AS, | Astragalus Inhibits Epithelial-to-Mesenchymal Transition of Peritoneal Mesothelial Cells by Down-Regulating β-Catenin |
| - | in-vitro, | Nor, | HMrSV5 | - | in-vivo, | NA, | NA |
| 944- | AS, | Astragalus saponins inhibit cell growth, aerobic glycolysis and attenuate the inflammatory response in a DSS-induced colitis model |
| - | vitro+vivo, | CRC, | NA |
| 1335- | AS, | Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | SkBr3 |
| 1295- | AS, | Cisplatin, | Chemosensitizing Effect of Astragalus Polysaccharides on Nasopharyngeal Carcinoma Cells by Inducing Apoptosis and Modulating Expression of Bax/Bcl-2 Ratio and Caspases |
| - | in-vivo, | Laryn, | NA |
| 1338- | AS, | The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method |
| - | in-vitro, | BC, | NA |
| 1333- | AS, | Astragalus polysaccharide inhibits breast cancer cell migration and invasion by regulating epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway |
| - | in-vitro, | BC, | NA |
| 1334- | AS, | Astragalus membranaceus: A Review of Its Antitumor Effects on Non-Small Cell Lung Cancer |
| - | Review, | NA, | NA |
| 1304- | ASA, | Aspirin Inhibits Colorectal Cancer via the TIGIT-BCL2-BAX pathway in T Cells |
| - | in-vitro, | CRC, | NA | - | in-vivo, | NA, | NA |
| 1096- | ASA, | Aspirin inhibit platelet-induced epithelial-to-mesenchymal transition of circulating tumor cells (Review) |
| - | Review, | NA, | NA |
| 1028- | ASA, | Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development |
| - | vitro+vivo, | Ovarian, | NA |
| 2461- | ASA, | Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis |
| - | Review, | NA, | NA |
| 2388- | Ash, | Withaferin A decreases glycolytic reprogramming in breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-453 |
| 3178- | Ash, | Withaferin A Inhibits Neutrophil Adhesion, Migration, and Respiratory Burst and Promotes Timely Neutrophil Apoptosis |
| - | Review, | Nor, | NA |
| 3179- | Ash, | Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells |
| - | in-vitro, | RCC, | Caki-1 |
| 3154- | Ash, | Pharmacokinetics and bioequivalence of Withania somnifera (Ashwagandha) extracts – A double blind, crossover study in healthy adults |
| 3155- | Ash, | Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera |
| - | Review, | Var, | NA |
| 3156- | Ash, | Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug |
| - | Review, | Var, | NA |
| 3157- | Ash, | Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass |
| - | in-vivo, | Ovarian, | A2780S |
| 3158- | Ash, | Natural products triptolide, celastrol, and withaferin A inhibit the chaperone activity of peroxiredoxin I |
| - | Study, | NA, | NA |
| 3159- | Ash, | Neuroprotective effects of Withania somnifera in the SH-SY5Y Parkinson cell model |
| - | in-vitro, | Park, | SH-SY5Y |
| 3160- | Ash, | Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal |
| - | Review, | Var, | NA |
| 3161- | Ash, | Withaferin A inhibits ferroptosis and protects against intracerebral hemorrhage |
| - | in-vivo, | Stroke, | NA |
| 3162- | Ash, | Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A |
| - | Review, | Var, | NA |
| 3163- | Ash, | Rad, | Withaferin A, a steroidal lactone, selectively protects normal lymphocytes against ionizing radiation induced apoptosis and genotoxicity via activation of ERK/Nrf-2/HO-1 axis |
| 3164- | Ash, | Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3 |
| 3165- | Ash, | Inhibitory effect of withaferin A on Helicobacter pylori‑induced IL‑8 production and NF‑κB activation in gastric epithelial cells |
| - | in-vitro, | Nor, | NA |
| 3167- | Ash, | Withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo |
| - | in-vitro, | MM, | H226 |
| 3177- | Ash, | Emerging Role of Hypoxia-Inducible Factors (HIFs) in Modulating Autophagy: Perspectives on Cancer Therapy |
| - | Review, | Var, | NA |
| 3176- | Ash, | Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I-DNA complex |
| - | in-vitro, | NA, | NA |
| 3175- | Ash, | SFN, | Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 3174- | Ash, | Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | HUH7 |
| 3173- | Ash, | Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma |
| - | in-vitro, | neuroblastoma, | NA |
| 3171- | Ash, | Unlocking the epigenetic code: new insights into triple-negative breast cancer |
| - | Review, | BC, | NA |
| 3170- | Ash, | Withaferin A protects against hyperuricemia induced kidney injury and its possible mechanisms |
| - | in-vitro, | Nor, | NRK52E | - | in-vivo, | NA, | NA |
| 3169- | Ash, | Withaferin A blocks formation of IFN-γ-induced metastatic cancer stem cells through inhibition of the CXCR4/CXCL12 pathway in the UP-LN1 carcinoma cell model |
| - | in-vitro, | GC, | NA |
| 3168- | Ash, | Withaferin A targeting both cancer stem cells and metastatic cancer stem cells in the UP-LN1 carcinoma cell model |
| - | in-vitro, | Var, | NA |
| 3166- | Ash, | Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives |
| - | Review, | Var, | NA |
| 3172- | Ash, | Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | HL7702 |
| 1181- | Ash, | Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 1180- | Ash, | Withaferin A Inhibits Liver Cancer Tumorigenesis by Suppressing Aerobic Glycolysis through the p53/IDH1/HIF-1α Signaling Axis |
| - | in-vitro, | Liver, | HepG2 |
| 1179- | Ash, | Withaferin-A Inhibits Colon Cancer Cell Growth by Blocking STAT3 Transcriptional Activity |
| - | in-vitro, | CRC, | HCT116 | - | in-vivo, | NA, | NA |
| 1178- | Ash, | Withaferin A suppresses the expression of vascular endothelial growth factor in Ehrlich ascites tumor cells via Sp1 transcription factor |
| - | in-vitro, | Nor, | HUVECs | - | in-vivo, | NA, | NA |
| 1177- | Ash, | Withaferin A downregulates COX-2/NF-κB signaling and modulates MMP-2/9 in experimental endometriosis |
| - | in-vivo, | EC, | NA |
| 1176- | Ash, | Metabolic Alterations in Mammary Cancer Prevention by Withaferin A in a Clinically Relevant Mouse Model |
| - | in-vivo, | NA, | NA |
| 1174- | Ash, | Withaferin A Suppresses Estrogen Receptor-α Expression in Human Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | T47D |
| 1173- | Ash, | Withaferin A inhibits proliferation of human endometrial cancer cells via transforming growth factor-β (TGF-β) signalling |
| - | in-vitro, | EC, | K1 | - | in-vitro, | Nor, | THESCs |
| 1172- | Ash, | Withaferin A Inhibits Fatty Acid Synthesis in Rat Mammary Tumors |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 1142- | Ash, | Ashwagandha-Induced Programmed Cell Death in the Treatment of Breast Cancer |
| - | Review, | BC, | MCF-7 | - | NA, | BC, | MDA-MB-231 | - | NA, | Nor, | HMEC |
| 3675- | Ash, | Ashwagandha (Withania somnifera) Reverses β-Amyloid1-42 Induced Toxicity in Human Neuronal Cells: Implications in HIV-Associated Neurocognitive Disorders (HAND) |
| 3674- | Ash, | Ashwagandha in brain disorders: A review of recent developments |
| - | Review, | NA, | NA |
| 3673- | Ash, | An overview on ashwagandha: a Rasayana (rejuvenator) of Ayurveda |
| - | Review, | NA, | NA |
| 3672- | Ash, | Critical review of the Withania somnifera (L.) Dunal: ethnobotany, pharmacological efficacy, and commercialization significance in Africa |
| - | Review, | NA, | NA |
| 3671- | Ash, | Withania somnifera showed neuroprotective effect and increase longevity in Drosophila Alzheimer’s disease model |
| - | in-vivo, | AD, | NA |
| 3670- | Ash, | Neurodegenerative diseases and Withania somnifera (L.): An update |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3669- | Ash, | Withanamides in Withania somnifera fruit protect PC-12 cells from beta-amyloid responsible for Alzheimer's diseas |
| - | in-vitro, | AD, | PC12 |
| 3668- | Ash, | Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver |
| - | NA, | AD, | NA |
| 3676- | Ash, | Effect of Withania somnifera (Ashwagandha) root extract on amelioration of oxidative stress and autoantibodies production in collagen-induced arthritic rats |
| - | in-vivo, | Arthritis, | NA |
| 3685- | Ash, | Withania somnifera as a Potential Anxiolytic and Anti-inflammatory Candidate Against Systemic Lipopolysaccharide-Induced Neuroinflammation |
| - | in-vivo, | NA, | NA |
| 3686- | Ash, | Adaptogenic and Anxiolytic Effects of Ashwagandha Root Extract in Healthy Adults: A Double-blind, Randomized, Placebo-controlled Clinical Study |
| - | Study, | NA, | NA |
| 3688- | Ash, | Withaferin A Suppresses Beta Amyloid in APP Expressing Cells: Studies for Tat and Cocaine Associated Neurological Dysfunctions |
| - | NA, | AD, | SH-SY5Y |
| 3687- | Ash, | Role of Withaferin A and Its Derivatives in the Management of Alzheimer’s Disease: Recent Trends and Future Perspectives |
| - | Review, | AD, | NA |
| 3689- | Ash, | Ashwagandha attenuates TNF-α- and LPS-induced NF-κB activation and CCL2 and CCL5 gene expression in NRK-52E cells |
| - | in-vitro, | NA, | NRK52E |
| 1370- | Ash, | Withaferin A induces mitochondrial-dependent apoptosis in non-small cell lung cancer cells via generation of reactive oxygen species |
| - | in-vitro, | Lung, | A549 |
| 1367- | Ash, | An anti-cancerous protein fraction from Withania somnifera induces ROS-dependent mitochondria-mediated apoptosis in human MDA-MB-231 breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 1366- | Ash, | Selective Killing of Cancer Cells by Ashwagandha Leaf Extract and Its Component Withanone Involves ROS Signaling |
| - | in-vitro, | BC, | MCF-7 |
| 1365- | Ash, | Withaferin A Induces Oxidative Stress-Mediated Apoptosis and DNA Damage in Oral Cancer Cells |
| - | in-vitro, | Oral, | Ca9-22 | - | in-vitro, | Oral, | CAL27 |
| 1364- | Ash, | Withaferin a Triggers Apoptosis and DNA Damage in Bladder Cancer J82 Cells through Oxidative Stress |
| - | in-vitro, | Bladder, | J82 |
| 1363- | Ash, | doxoR, | Withaferin A Synergizes the Therapeutic Effect of Doxorubicin through ROS-Mediated Autophagy in Ovarian Cancer |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | CaOV3 | - | in-vivo, | NA, | NA |
| 1362- | Ash, | GEM, | Synergistic Inhibition of Pancreatic Cancer Cell Growth and Migration by Gemcitabine and Withaferin A |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Hs766t |
| - | in-vitro, | Liver, | HUH7 | - | in-vivo, | Liver, | HUH7 |
| 1360- | Ash, | immuno, | Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer |
| - | in-vitro, | Lung, | H1650 | - | in-vitro, | Lung, | A549 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 1359- | Ash, | Withaferin A Induces ROS-Mediated Paraptosis in Human Breast Cancer Cell-Lines MCF-7 and MDA-MB-231 |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 1358- | Ash, | Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms |
| - | Review, | Var, | NA |
| 1368- | Ash, | Cisplatin, | Withania somnifera Root Extract Enhances Chemotherapy through ‘Priming’ |
| - | in-vitro, | Colon, | HT-29 | - | in-vitro, | BC, | MDA-MB-231 |
| 1369- | Ash, | Withaferin A inhibits cell proliferation of U266B1 and IM-9 human myeloma cells by inducing intrinsic apoptosis |
| - | in-vitro, | Melanoma, | U266 |
| 1357- | Ash, | Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | GL26 |
| 1356- | Ash, | Withaferin A induces apoptosis by ROS-dependent mitochondrial dysfunction in human colorectal cancer cells |
| - | in-vitro, | CRC, | HCT116 |
| 1355- | Ash, | Withaferin A-Induced Apoptosis in Human Breast Cancer Cells Is Mediated by Reactive Oxygen Species |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HMEC |
| 1372- | Ash, | Withaferin-A Induces Apoptosis in Osteosarcoma U2OS Cell Line via Generation of ROS and Disruption of Mitochondrial Membrane Potential |
| - | in-vitro, | OS, | U2OS |
| 1373- | Ash, | Endoplasmic reticulum stress mediates withaferin A-induced apoptosis in human renal carcinoma cells |
| - | in-vitro, | Kidney, | Caki-1 |
| 1433- | Ash, | SFN, | A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| - | in-vitro, | AML, | HL-60 |
| 2003- | Ash, | Withaferin A Induces Cell Death Selectively in Androgen-Independent Prostate Cancer Cells but Not in Normal Fibroblast Cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Nor, | TIG-1 | - | in-vitro, | PC, | LNCaP |
| 2002- | Ash, | Ancient medicine, modern use: Withania somnifera and its potential role in integrative oncology |
| - | Review, | Var, | NA |
| 2001- | Ash, | Withania somnifera: from prevention to treatment of cancer |
| - | Review, | Var, | NA |
| 4303- | Ash, | Ashwagandha (Withania somnifera)—Current Research on the Health-Promoting Activities: A Narrative Review |
| - | Review, | AD, | NA |
| 4660- | Ash, | Withaferin A Alone and in Combination with Cisplatin Suppresses Growth and Metastasis of Ovarian Cancer by Targeting Putative Cancer Stem Cells |
| - | in-vitro, | Ovarian, | NA |
| 4677- | Ash, | Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells |
| - | vitro+vivo, | Ovarian, | NA |
| 4678- | Ash, | Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer |
| - | vitro+vivo, | NSCLC, | H1975 |
| 4679- | Ash, | Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell |
| - | in-vitro, | NA, | NA |
| 4821- | ASTX, | Astaxanthin Reduces Stemness Markers in BT20 and T47D Breast Cancer Stem Cells by Inhibiting Expression of Pontin and Mutant p53 |
| - | in-vitro, | BC, | SkBr3 | - | in-vitro, | BC, | BT20 | - | in-vitro, | BC, | T47D |
| 4804- | ASTX, | Astaxanthin in cancer therapy and prevention (Review) |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4805- | ASTX, | Astaxanthin promotes apoptosis by suppressing growth signaling pathways in HT-29 colorectal cancer cells |
| - | in-vitro, | Colon, | HT29 |
| 4806- | ASTX, | Astaxanthin's Impact on Colorectal Cancer: Examining Apoptosis, Antioxidant Enzymes, and Gene Expression |
| - | in-vitro, | CRC, | HCT116 |
| 4807- | ASTX, | An overview of the anticancer activity of astaxanthin and the associated cellular and molecular mechanisms |
| - | Review, | Var, | NA |
| 4808- | ASTX, | Anti-Tumor Effects of Astaxanthin by Inhibition of the Expression of STAT3 in Prostate Cancer |
| - | in-vitro, | Pca, | DU145 | - | in-vivo, | NA, | NA |
| 4809- | ASTX, | Astaxanthin Inhibits Proliferation of Human Gastric Cancer Cell Lines by Interrupting Cell Cycle Progression |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | MKN45 |
| 4810- | ASTX, | Effects of Astaxanthin on the Proliferation and Migration of Breast Cancer Cells In Vitro |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 4820- | ASTX, | Astaxanthin suppresses the malignant behaviors of nasopharyngeal carcinoma cells by blocking PI3K/AKT and NF-κB pathways via miR-29a-3p |
| - | in-vitro, | NPC, | NA |
| 4819- | ASTX, | Astaxanthin Induces Apoptosis in MCF-7 Cells through a p53-Dependent Pathway |
| - | in-vitro, | BC, | MCF-7 |
| 4818- | ASTX, | MEL, | Effect of astaxanthin and melatonin on cell viability and DNA damage in human breast cancer cell lines |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | T47D | - | in-vitro, | Nor, | MCF10 |
| 4817- | ASTX, | Low Dose Astaxanthin Treatments Trigger the Hormesis of Human Astroglioma Cells by Up-Regulating the Cyclin-Dependent Kinase and Down-Regulated the Tumor Suppressor Protein P53 |
| - | in-vitro, | GBM, | U251 |
| 4816- | ASTX, | Potent carotenoid astaxanthin expands the anti-cancer activity of cisplatin in human prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 4815- | ASTX, | The Promising Effects of Astaxanthin on Lung Diseases |
| - | Review, | Var, | NA |
| 4814- | ASTX, | Chemopreventive and therapeutic efficacy of astaxanthin against cancer: A comprehensive review |
| - | Review, | Var, | NA |
| 4812- | ASTX, | Astaxanthin suppresses the metastasis of colon cancer by inhibiting the MYC-mediated downregulation of microRNA-29a-3p and microRNA-200a |
| - | in-vitro, | CRC, | HCT116 |
| 4813- | ASTX, | Astaxanthin Prevents Oxidative Damage and Cell Apoptosis Under Oxidative Stress Involving the Restoration of Mitochondrial Function |
| - | in-vitro, | AD, | NA |
| 4811- | ASTX, | Astaxanthin reduces MMP expressions, suppresses cancer cell migrations, and triggers apoptotic caspases of in vitro and in vivo models in melanoma |
| - | vitro+vivo, | Melanoma, | A375 | - | vitro+vivo, | Melanoma, | A2058 |
| 4823- | ASTX, | Astaxanthin increases radiosensitivity in esophageal squamous cell carcinoma through inducing apoptosis and G2/M arrest |
| - | in-vitro, | ESCC, | NA |
| 4824- | ASTX, | Rad, | Astaxanthin protects the radiation-induced lung injury in C57BL/6 female mice |
| - | in-vivo, | Nor, | NA |
| 4825- | ASTX, | In vivo protective efficacy of astaxanthin against ionizing radiation-induced DNA damage |
| - | in-vivo, | Nor, | NA |
| 4822- | ASTX, | Rad, | Astaxanthin Synergizes with Ionizing Radiation (IR) in Oral Squamous Cell Carcinoma (OSCC) |
| 1900- | Aur, | Potential Anticancer Activity of Auranofin |
| - | Review, | Var, | NA |
| 1302- | AV, | Quantitative measurement of Bax and Bcl2 genes and protein expression in MCF7 cell-line when treated by Aloe Vera extract |
| - | in-vitro, | BC, | MCF-7 |
| 875- | B-Gluc, | Chemistry, physico-chemistry and applications linked to biological activities of β-glucans |
| - | Review, | NA, | NA |
| 876- | B-Gluc, | Clinical and Physiological Perspectives of β-Glucans: The Past, Present, and Future |
| - | Review, | NA, | NA |
| 874- | B-Gluc, | Potential promising anticancer applications of β-glucans: a review |
| - | Review, | NA, | NA |
| 1224- | BA, | Intratumor microbiome-derived butyrate promotes lung cancer metastasis |
| - | in-vivo, | Lung, | NA |
| 1098- | BA, | Baicalein inhibits fibronectin-induced epithelial–mesenchymal transition by decreasing activation and upregulation of calpain-2 |
| - | in-vitro, | Nor, | MCF10 | - | in-vivo, | NA, | NA |
| 6- | Ba, | Common Botanical Compounds Inhibit the Hedgehog Signaling Pathway in Prostate Cancer |
| - | in-vitro, | Pca, | NA |
| 1029- | Ba, | BA, | Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells |
| - | vitro+vivo, | HCC, | NA |
| - | in-vivo, | BC, | 4T1 |
| 999- | Ba, | Baicalin Inhibits EMT through PDK1/AKT Signaling in Human Nonsmall Cell Lung Cancer |
| - | in-vitro, | Lung, | H460 |
| 1032- | BA, | Gut microbiome-derived butyrate inhibits the immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages in gastric cancer |
| - | in-vivo, | GC, | AGS |
| 996- | Ba, | Tam, | Baicalein resensitizes tamoxifen‐resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia‐inducible factor‐1α |
| 1080- | BA, | Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition |
| - | in-vitro, | CRC, | HT-29 |
| 1288- | Ba, | The Traditional Chinese Medicine Baicalein Potently Inhibits Gastric Cancer Cells |
| - | in-vitro, | GC, | SGC-7901 |
| 1535- | Ba, | Baicalein May Act as a Caloric Restriction Mimetic Candidate to Improve the Antioxidant Profile in a Natural Rodent Model of Aging |
| - | in-vivo, | Nor, | NA |
| 1533- | Ba, | Baicalein, as a Prooxidant, Triggers Mitochondrial Apoptosis in MCF-7 Human Breast Cancer Cells Through Mobilization of Intracellular Copper and Reactive Oxygen Species Generation |
| - | in-vitro, | BrCC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 1519- | Ba, | Baicalein inhibits KB oral cancer cells by inducing apoptosis via modulation of ROS |
| - | in-vitro, | Oral, | KB |
| 1520- | Ba, | Baicalein Induces G2/M Cell Cycle Arrest Associated with ROS Generation and CHK2 Activation in Highly Invasive Human Ovarian Cancer Cells |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | TOV-21G |
| 1521- | Ba, | Baicalein induces apoptosis via ROS-dependent activation of caspases in human bladder cancer 5637 cells |
| - | in-vitro, | Bladder, | 5637 |
| 1522- | Ba, | Baicalein reduces lipopolysaccharide-induced inflammation via suppressing JAK/STATs activation and ROS production |
| - | in-vitro, | Nor, | RAW264.7 |
| 1523- | Ba, | Baicalein induces human osteosarcoma cell line MG-63 apoptosis via ROS-induced BNIP3 expression |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | Nor, | hFOB1.19 |
| 1524- | Ba, | Baicalein Induces Caspase‐dependent Apoptosis Associated with the Generation of ROS and the Activation of AMPK in Human Lung Carcinoma A549 Cells |
| - | in-vitro, | Lung, | A549 |
| - | in-vitro, | Lung, | H1975 | - | in-vivo, | Lung, | NA |
| 1527- | Ba, | Baicalein Alleviates Arsenic-induced Oxidative Stress through Activation of the Keap1/Nrf2 Signalling Pathway in Normal Human Liver Cells |
| - | in-vitro, | Nor, | MIHA |
| 1528- | Ba, | Inhibiting reactive oxygen species-dependent autophagy enhanced baicalein-induced apoptosis in oral squamous cell carcinoma |
| - | in-vitro, | OS, | CAL27 |
| 1529- | Ba, | Studies on the Inhibitory Mechanisms of Baicalein in B16F10 Melanoma Cell Proliferation |
| - | in-vitro, | Melanoma, | B16-F10 |
| 1530- | Ba, | Baicalein Decreases Hydrogen Peroxide‐Induced Damage to NG108‐15 Cells via Upregulation of Nrf2 |
| - | in-vitro, | Nor, | NG108-15 |
| 1531- | Ba, | Proteomic analysis of the effects of baicalein on colorectal cancer cells |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | CRC, | SW48 |
| 1532- | Ba, | Baicalein as Promising Anticancer Agent: A Comprehensive Analysis on Molecular Mechanisms and Therapeutic Perspectives |
| - | Review, | NA, | NA |
| 1526- | Ba, | Baicalein induces apoptosis through ROS-mediated mitochondrial dysfunction pathway in HL-60 cells |
| - | in-vitro, | AML, | HL-60 |
| 2047- | BA, | Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells |
| - | in-vitro, | CRC, | T24 | - | in-vitro, | Nor, | SV-HUC-1 | - | in-vitro, | Bladder, | 5637 | - | in-vivo, | NA, | NA |
| 2050- | BA, | The Role of Sodium Phenylbutyrate in Modifying the Methylome of Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 |
| 2597- | Ba, | Baicalein – An Intriguing Therapeutic Phytochemical in Pancreatic Cancer |
| - | Review, | PC, | NA |
| 2613- | Ba, | Hepatoprotective Effect of Baicalein Against Acetaminophen-Induced Acute Liver Injury in Mice |
| - | in-vivo, | Nor, | NA |
| 2598- | Ba, | Baicalein inhibits melanogenesis through activation of the ERK signaling pathway |
| - | in-vitro, | Melanoma, | B16-F10 |
| 2599- | Ba, | Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 2600- | Ba, | Baicalein Induces Apoptosis and Autophagy via Endoplasmic Reticulum Stress in Hepatocellular Carcinoma Cells |
| - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | Bel-7402 |
| 2601- | Ba, | Cardioprotective effects of baicalein on heart failure via modulation of Ca2 + handling proteins in vivo and in vitro |
| - | in-vitro, | Nor, | NA | - | in-vivo, | Nor, | NA |
| 2602- | Ba, | Downregulation of ZFX is associated with inhibition of prostate cancer progression by baicalein |
| - | in-vitro, | Pca, | NA | - | in-vivo, | Pca, | NA |
| 2603- | Ba, | Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 2604- | Ba, | BA, | Comparison of metabolic pharmacokinetics of baicalin and baicalein in rats |
| - | in-vivo, | Nor, | NA |
| 2605- | Ba, | BA, | Potential therapeutic effects of baicalin and baicalein |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA | - | Review, | IBD, | NA | - | Review, | Arthritis, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2606- | Ba, | Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma |
| - | Review, | HCC, | NA |
| 2607- | Ba, | SIL, | Baicalein Enhances the Oral Bioavailability and Hepatoprotective Effects of Silybin Through the Inhibition of Efflux Transporters BCRP and MRP2 |
| - | in-vivo, | Nor, | NA |
| 2608- | Ba, | Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity |
| - | in-vitro, | HCC, | Bel-7402 |
| 2609- | Ba, | Baicalein: unveiling the multifaceted marvel of hepatoprotection and beyond |
| - | Review, | NA, | NA |
| 2610- | Ba, | Hepatoprotective effects of baicalein against CCl4-induced acute liver injury in mice |
| - | in-vivo, | Nor, | NA |
| 2611- | Ba, | Baicalein as a potent neuroprotective agent: A review |
| - | Review, | Nor, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2612- | Ba, | MF, | The effect of a static magnetic field and baicalin or baicalein interactions on amelanotic melanoma cell cultures (C32) |
| - | in-vitro, | Melanoma, | NA |
| 2619- | Ba, | Tumor cell membrane-coated continuous electrochemical sensor for GLUT1 inhibitor screening |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | BC, | MGC803 | - | in-vitro, | Lung, | A549 |
| 2622- | Ba, | Cisplatin, | Rad, | Natural Baicalein-Rich Fraction as Radiosensitizer in Combination with Bismuth Oxide Nanoparticles and Cisplatin for Clinical Radiotherapy |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 2623- | Ba, | Activation of the Nrf2/HO-1 signaling pathway contributes to the protective effects of baicalein against oxidative stress-induced DNA damage and apoptosis in HEI193 Schwann cells |
| - | in-vitro, | Nor, | HEI193 |
| 2624- | Ba, | Baicalein inhibition of hydrogen peroxide-induced apoptosis via ROS-dependent heme oxygenase 1 gene expression |
| - | in-vitro, | Nor, | RAW264.7 |
| 2625- | Ba, | LT, | Baicalein and luteolin inhibit ischemia/reperfusion-induced ferroptosis in rat cardiomyocyte |
| - | in-vivo, | Stroke, | NA |
| 2626- | Ba, | Molecular targets and therapeutic potential of baicalein: a review |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 2627- | Ba, | Cisplatin, | Baicalein, a Bioflavonoid, Prevents Cisplatin-Induced Acute Kidney Injury by Up-Regulating Antioxidant Defenses and Down-Regulating the MAPKs and NF-κB Pathways |
| 2620- | Ba, | Natural compounds targeting glycolysis as promising therapeutics for gastric cancer: A review |
| - | Review, | GC, | NA |
| 2630- | Ba, | Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice |
| - | in-vivo, | Nor, | NA |
| 2618- | Ba, | Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer |
| - | in-vitro, | Lung, | H1299 | - | in-vivo, | Lung, | A549 |
| 2617- | Ba, | Potential of baicalein in the prevention and treatment of cancer: A scientometric analyses based review |
| - | Review, | Var, | NA |
| 2616- | Ba, | The Role of HK2 in Tumorigenesis and Development: Potential for Targeted Therapy with Natural Products |
| - | Review, | Var, | NA |
| 2615- | Ba, | The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways |
| - | Review, | Var, | NA |
| 2628- | Ba, | Cisplatin, | Baicalein alleviates cisplatin-induced acute kidney injury by inhibiting ALOX12-dependent ferroptosis |
| - | in-vitro, | Nor, | HK-2 |
| 2629- | Ba, | Baicalein, a Component of Scutellaria baicalensis, Attenuates Kidney Injury Induced by Myocardial Ischemia and Reperfusion |
| - | in-vivo, | Nor, | NA |
| 2614- | Ba, | Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders |
| - | Review, | NA, | NA |
| 2295- | Ba, | 5-FU, | Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway |
| - | in-vitro, | GC, | AGS |
| 2289- | Ba, | Rad, | Baicalein Inhibits the Progression and Promotes Radiosensitivity of Esophageal Squamous Cell Carcinoma by Targeting HIF-1A |
| - | in-vitro, | ESCC, | KYSE150 |
| 2290- | Ba, | Research Progress of Scutellaria baicalensis in the Treatment of Gastrointestinal Cancer |
| - | Review, | GI, | NA |
| 2291- | Ba, | BA, | Baicalein and Baicalin Promote Melanoma Apoptosis and Senescence via Metabolic Inhibition |
| - | in-vitro, | Melanoma, | SK-MEL-28 | - | in-vitro, | Melanoma, | A375 |
| 2292- | Ba, | BA, | Baicalin and baicalein in modulating tumor microenvironment for cancer treatment: A comprehensive review with future perspectives |
| - | Review, | Var, | NA |
| 2293- | Ba, | Baicalein suppresses inflammation and attenuates acute lung injury by inhibiting glycolysis via HIF‑1α signaling |
| - | in-vitro, | Nor, | MH-S | - | in-vivo, | NA, | NA |
| 2294- | Ba, | Baicalein attenuates cardiac hypertrophy in mice via suppressing oxidative stress and activating autophagy in cardiomyocytes |
| - | in-vivo, | Nor, | NA |
| 2296- | Ba, | The most recent progress of baicalein in its anti-neoplastic effects and mechanisms |
| - | Review, | Var, | NA |
| 2298- | Ba, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2297- | Ba, | Significance of flavonoids targeting PI3K/Akt/HIF-1α signaling pathway in therapy-resistant cancer cells – A potential contribution to the predictive, preventive, and personalized medicine |
| - | Review, | Var, | NA |
| 2389- | BA, | Baicalin alleviates lipid accumulation in adipocytes via inducing metabolic reprogramming and targeting Adenosine A1 receptor |
| - | in-vitro, | Obesity, | 3T3 |
| 2391- | Ba, | Scutellaria baicalensis and its flavonoids in the treatment of digestive system tumors |
| - | Review, | GC, | NA |
| 2473- | BA, | Baicalin Inhibits EMT through PDK1/AKT Signaling in Human Nonsmall Cell Lung Cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B | - | in-vitro, | Lung, | H460 |
| 2474- | Ba, | Anticancer properties of baicalein: a review |
| - | Review, | Var, | NA | - | in-vitro, | Nor, | BV2 |
| 2475- | Ba, | Baicalein triggers ferroptosis in colorectal cancer cells via blocking the JAK2/STAT3/GPX4 axis |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | DLD1 | - | in-vivo, | NA, | NA |
| 2477- | Ba, | Baicalein induces apoptosis via a mitochondrial-dependent caspase activation pathway in T24 bladder cancer cells |
| - | in-vitro, | CRC, | T24 |
| 2483- | Ba, | Baicalein and 12/15-Lipoxygenase in the Ischemic Brain |
| - | in-vivo, | Stroke, | NA |
| 2482- | Ba, | Modulation of Neuroinflammation in Poststroke Rehabilitation: The Role of 12/15-Lipoxygenase Inhibition and Baicalein |
| - | Review, | Stroke, | NA |
| 2481- | Ba, | Rad, | Radiotherapy Increases 12-LOX and CCL5 Levels in Esophageal Cancer Cells and Promotes Cancer Metastasis via THP-1-Derived Macrophages |
| - | in-vitro, | ESCC, | Eca109 | - | in-vitro, | ESCC, | KYSE150 |
| 2480- | Ba, | Inhibition of 12/15 lipoxygenase by baicalein reduces myocardial ischemia/reperfusion injury via modulation of multiple signaling pathways |
| - | in-vivo, | Stroke, | NA |
| 2479- | Ba, | Baicalein Overcomes Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance via Two Different Cell-Specific Pathways in Cancer Cells but not in Normal Cells |
| - | in-vitro, | HCC, | SW480 | - | in-vitro, | Pca, | PC3 |
| 2478- | Ba, | The role of Ca2+ in baicalein-induced apoptosis in human breast MDA-MB-231 cancer cells through mitochondria- and caspase-3-dependent pathway |
| - | in-vitro, | BC, | MDA-MB-231 |
| 2476- | Ba, | Baicalein Induces Caspase-dependent Apoptosis Associated with the Generation of ROS and the Activation of AMPK in Human Lung Carcinoma A549 Cells |
| - | in-vitro, | Lung, | A549 |
| 2769- | Ba, | Rad, | Baicalein ameliorates ionizing radiation-induced injuries by rebalancing gut microbiota and inhibiting apoptosis |
| - | in-vivo, | Nor, | NA |
| 4276- | BA, | Baicalin Attenuates Oxygen–Glucose Deprivation/Reoxygenation–Induced Injury by Modulating the BDNF-TrkB/PI3K/Akt and MAPK/Erk1/2 Signaling Axes in Neuron–Astrocyte Cocultures |
| - | in-vivo, | Stroke, | NA |
| 4304- | Ba, | Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation |
| - | in-vitro, | AD, | NA |
| 4305- | Ba, | Study on the Molecular Mechanism of Baicalin Phosphorylation of Tau Protein Content in a Cell Model of Intervention Cognitive Impairment |
| - | in-vitro, | NA, | SH-SY5Y |
| 1242- | BBM, | Berbamine Exerts Anti-Inflammatory Effects via Inhibition of NF-κB and MAPK Signaling Pathways |
| - | in-vivo, | Nor, | NA |
| 1299- | BBR, | Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review |
| - | Review, | NA, | NA |
| 2023- | BBR, | Berberine Induces Caspase-Independent Cell Death in Colon Tumor Cells through Activation of Apoptosis-Inducing Factor |
| - | in-vitro, | Colon, | NA | - | in-vitro, | Nor, | YAMC |
| 2022- | BBR, | GoldNP, | Rad, | Berberine-loaded Janus gold mesoporous silica nanocarriers for chemo/radio/photothermal therapy of liver cancer and radiation-induced injury inhibition |
| - | in-vitro, | Liver, | SMMC-7721 cell | - | in-vitro, | Nor, | HL7702 |
| 2021- | BBR, | Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways |
| - | Review, | NA, | NA |
| 1390- | BBR, | Rad, | Berberine Inhibited Radioresistant Effects and Enhanced Anti-Tumor Effects in the Irradiated-Human Prostate Cancer Cells |
| - | in-vitro, | Pca, | PC3 |
| 1398- | BBR, | Berberine inhibits the progression of renal cell carcinoma cells by regulating reactive oxygen species generation and inducing DNA damage |
| - | in-vitro, | Kidney, | NA |
| 1392- | BBR, | Based on network pharmacology and experimental validation, berberine can inhibit the progression of gastric cancer by modulating oxidative stress |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | MKN45 |
| 1393- | BBR, | EPI, | Berberine promotes antiproliferative effects of epirubicin in T24 bladder cancer cells by enhancing apoptosis and cell cycle arrest |
| - | in-vitro, | Bladder, | T24 |
| 1394- | BBR, | DL, | Synergistic Inhibitory Effect of Berberine and d-Limonene on Human Gastric Carcinoma Cell Line MGC803 |
| - | in-vitro, | GC, | MGC803 |
| 1395- | BBR, | Analysis of the mechanism of berberine against stomach carcinoma based on network pharmacology and experimental validation |
| - | in-vitro, | GC, | NA |
| 1396- | BBR, | Berberine induced down-regulation of matrix metalloproteinase-1, -2 and -9 in human gastric cancer cells (SNU-5) in vitro |
| - | in-vitro, | GC, | SNU1041 | - | in-vitro, | GC, | SNU5 |
| 1397- | BBR, | Chemo, | Effects of Coptis extract combined with chemotherapeutic agents on ROS production, multidrug resistance, and cell growth in A549 human lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 1399- | BBR, | Rad, | Radiotherapy Enhancing and Radioprotective Properties of Berberine: A Systematic Review |
| - | Review, | NA, | NA |
| 1400- | BBR, | Set9, NF-κB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells |
| - | in-vitro, | Melanoma, | U266 |
| 1401- | BBR, | Berberine induces apoptosis in glioblastoma multiforme U87MG cells via oxidative stress and independent of AMPK activity |
| - | in-vitro, | GBM, | U87MG |
| 1402- | BBR, | Berberine-induced apoptosis in human glioblastoma T98G cells is mediated by endoplasmic reticulum stress accompanying reactive oxygen species and mitochondrial dysfunction |
| - | in-vitro, | GBM, | T98G |
| 1404- | BBR, | Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation |
| - | in-vitro, | Pca, | PC3 |
| 1405- | BBR, | Chit, | Chitosan/alginate nanogel potentiate berberine uptake and enhance oxidative stress mediated apoptotic cell death in HepG2 cells |
| - | in-vitro, | Liver, | HepG2 |
| 1374- | BBR, | PDT, | Berberine associated photodynamic therapy promotes autophagy and apoptosis via ROS generation in renal carcinoma cells |
| - | in-vitro, | RCC, | 786-O | - | in-vitro, | RCC, | HK-2 |
| 1387- | BBR, | Antitumor Activity of Berberine by Activating Autophagy and Apoptosis in CAL-62 and BHT-101 Anaplastic Thyroid Carcinoma Cell Lines |
| - | in-vitro, | Thyroid, | CAL-62 |
| 1386- | BBR, | Berberine-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species generation and mitochondrial-related apoptotic pathway |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 1385- | BBR, | 5-FU, | Low-Dose Berberine Attenuates the Anti-Breast Cancer Activity of Chemotherapeutic Agents via Induction of Autophagy and Antioxidation |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 1384- | BBR, | Berberine induces apoptosis via ROS generation in PANC-1 and MIA-PaCa2 pancreatic cell lines |
| - | in-vitro, | PC, | PANC1 |
| 1382- | BBR, | Berberine increases the expression of cytokines and proteins linked to apoptosis in human melanoma cells |
| - | in-vitro, | Melanoma, | SK-MEL-28 |
| 1381- | BBR, | Rad, | Berberine enhances the sensitivity of radiotherapy in ovarian cancer cell line (SKOV-3) |
| - | in-vitro, | Ovarian, | SKOV3 |
| 1389- | BBR, | Lap, | Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS |
| - | in-vitro, | BC, | BT474 | - | in-vitro, | BC, | AU-565 |
| 1380- | BBR, | doxoR, | treatment with ROS scavenger N-acetylcysteine (NAC) and JNK inhibitor SP600125 could partially attenuate apoptosis and DNA damage triggered by DCZ0358. |
| - | in-vivo, | Nor, | NA |
| 1379- | BBR, | Berberine derivative DCZ0358 induce oxidative damage by ROS-mediated JNK signaling in DLBCL cells |
| - | in-vitro, | lymphoma, | NA |
| 1378- | BBR, | Berberine induces non-small cell lung cancer apoptosis via the activation of the ROS/ASK1/JNK pathway |
| - | in-vitro, | Lung, | NA |
| 1377- | BBR, | Berberine inhibits autophagy and promotes apoptosis of fibroblast-like synovial cells from rheumatoid arthritis patients through the ROS/mTOR signaling pathway |
| - | in-vitro, | Arthritis, | NA |
| 1375- | BBR, | 13-[CH2CO-Cys-(Bzl)-OBzl]-Berberine: Exploring The Correlation Of Anti-Tumor Efficacy With ROS And Apoptosis Protein |
| - | in-vitro, | CRC, | HCT8 | - | in-vivo, | NA, | NA |
| 1376- | BBR, | immuno, | Berberine sensitizes immune checkpoint blockade therapy in melanoma by NQO1 inhibition and ROS activation |
| - | in-vivo, | Melanoma, | NA |
| 4300- | BBR, | Effect of berberine on cognitive function and β-amyloid precursor protein in Alzheimer’s disease models: a systematic review and meta-analysis |
| - | Review, | AD, | NA |
| 4340- | BBR, | Agonist-dependent differential effects of berberine in human platelet aggregation |
| - | Human, | NA, | NA |
| - | in-vivo, | AD, | NA |
| 4298- | BBR, | Berberine mitigates cognitive decline in an Alzheimer’s Disease Mouse Model by targeting both tau hyperphosphorylation and autophagic clearance |
| - | in-vivo, | AD, | NA |
| 4658- | BBR, | Berberine Suppresses Stemness and Tumorigenicity of Colorectal Cancer Stem-Like Cells by Inhibiting m6A Methylation |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 |
| 1030- | BBR, | Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5 |
| - | in-vitro, | Lung, | H460 |
| 1010- | BBR, | Berberine binds RXRα to suppress β-catenin signaling in colon cancer cells |
| - | vitro+vivo, | CRC, | NA |
| 956- | BBR, | Berberine inhibits HIF-1alpha expression via enhanced proteolysis |
| - | in-vitro, | Nor, | HUVECs | - | in-vitro, | GC, | SCM1 |
| 7- | BBR, | Berberine, a natural compound, suppresses Hedgehog signaling pathway activity and cancer growth |
| - | vitro+vivo, | MB, | NA |
| 940- | BBR, | Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression |
| - | vitro+vivo, | PC, | PANC1 | - | in-vivo, | PC, | MIA PaCa-2 |
| 932- | BBR, | The short-term effects of berberine in the liver: Narrow margins between benefits and toxicity |
| - | in-vivo, | Nor, | NA |
| 1102- | BBR, | Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells |
| - | in-vitro, | Melanoma, | B16-BL6 |
| 1092- | BBR, | Berberine as a Potential Anticancer Agent: A Comprehensive Review |
| - | Review, | NA, | NA |
| 2706- | BBR, | Berberine Inhibits Growth of Liver Cancer Cells by Suppressing Glutamine Uptake |
| - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | Bel-7402 | - | in-vivo, | NA, | NA |
| 2696- | BBR, | Berberine regulates proliferation, collagen synthesis and cytokine secretion of cardiac fibroblasts via AMPK-mTOR-p70S6K signaling pathway |
| - | in-vivo, | Nor, | NA |
| 2697- | BBR, | Structural exploration of common pharmacophore based berberine derivatives as novel histone deacetylase inhibitor targeting HDACs enzymes |
| - | Analysis, | Var, | NA |
| 2698- | BBR, | A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine |
| - | Analysis, | BC, | MDA-MB-231 |
| 2699- | BBR, | Plant Isoquinoline Alkaloid Berberine Exhibits Chromatin Remodeling by Modulation of Histone Deacetylase To Induce Growth Arrest and Apoptosis in the A549 Cell Line |
| - | in-vitro, | Lung, | A549 |
| 2700- | BBR, | Cell-specific pattern of berberine pleiotropic effects on different human cell lines |
| - | in-vitro, | GBM, | U343 | - | in-vitro, | GBM, | MIA PaCa-2 | - | in-vitro, | Nor, | HDFa |
| 2701- | BBR, | Berberine Inhibits KLF4 Promoter Methylation and Ferroptosis to Ameliorate Diabetic Nephropathy in Mice |
| - | in-vivo, | Diabetic, | NA |
| 2702- | BBR, | The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1 |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1975 |
| 2703- | BBR, | CUR, | SFN, | UA, | GamB | Naturally occurring anti-cancer agents targeting EZH2 |
| - | Review, | Var, | NA |
| 2704- | BBR, | Inhibitory Effect of Berberine on Zeste Homolog 2 (Ezh2) Enhancement in Human Esophageal Cell Lines |
| - | in-vitro, | ESCC, | KYSE450 |
| 2705- | BBR, | Mechanism underlying berberine's effects on HSP70/TNFα under heat stress: Correlation with the TATA boxes |
| - | in-vivo, | Nor, | NA | - | in-vitro, | Nor, | PC12 |
| 2672- | BBR, | The anti-aging mechanism of Berberine associated with metabolic control |
| - | Review, | Var, | NA |
| 2707- | BBR, | Berberine exerts its antineoplastic effects by reversing the Warburg effect via downregulation of the Akt/mTOR/GLUT1 signaling pathway |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 |
| 2708- | BBR, | Berberine decelerates glucose metabolism via suppression of mTOR‑dependent HIF‑1α protein synthesis in colon cancer cells |
| - | in-vitro, | CRC, | HCT116 |
| 2709- | BBR, | Berberine inhibits the glycolysis and proliferation of hepatocellular carcinoma cells by down-regulating HIF-1α |
| - | in-vitro, | HCC, | HepG2 |
| 2710- | BBR, | Berberine inhibits the Warburg effect through TET3/miR-145/HK2 pathways in ovarian cancer cells |
| - | in-vitro, | Ovarian, | SKOV3 |
| 2711- | BBR, | Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 2712- | BBR, | Suppression of colon cancer growth by berberine mediated by the intestinal microbiota and the suppression of DNA methyltransferases (DNMTs) |
| - | in-vitro, | Colon, | HT29 | - | in-vivo, | NA, | NA |
| 2713- | BBR, | Berberine improved the microbiota in lung tissue of colon cancer and reversed the bronchial epithelial cell changes caused by cancer cells |
| - | in-vitro, | Nor, | BEAS-2B |
| 2714- | BBR, | Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer |
| 2715- | BBR, | Rad, | Berberine Can Amplify Cytotoxic Effect of Radiotherapy by Targeting Cancer Stem Cells |
| - | in-vitro, | BC, | MCF-7 |
| - | in-vivo, | Diabetic, | NA |
| 2694- | BBR, | Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells |
| - | in-vitro, | BC, | NA |
| 2673- | BBR, | Therapeutic potential and recent delivery systems of berberine: A wonder molecule |
| - | Review, | Var, | NA |
| 2674- | BBR, | Berberine: A novel therapeutic strategy for cancer |
| - | Review, | Var, | NA | - | Review, | IBD, | NA |
| 2675- | BBR, | The therapeutic effects of berberine against different diseases: A review on the involvement of the endoplasmic reticulum stress |
| - | Review, | Var, | NA |
| 2676- | BBR, | Berberine protects rat heart from ischemia/reperfusion injury via activating JAK2/STAT3 signaling and attenuating endoplasmic reticulum stress |
| - | in-vivo, | Nor, | NA | - | in-vivo, | CardioV, | NA |
| 2677- | BBR, | Liposome-Encapsulated Berberine Alleviates Liver Injury in Type 2 Diabetes via Promoting AMPK/mTOR-Mediated Autophagy and Reducing ER Stress: Morphometric and Immunohistochemical Scoring |
| - | in-vivo, | Diabetic, | NA |
| 2678- | BBR, | Berberine as a Potential Agent for the Treatment of Colorectal Cancer |
| - | Review, | CRC, | NA |
| 2679- | BBR, | Berberine Improves Behavioral and Cognitive Deficits in a Mouse Model of Alzheimer’s Disease via Regulation of β-Amyloid Production and Endoplasmic Reticulum Stress |
| - | in-vivo, | AD, | NA |
| 2680- | BBR, | PDT, | Photodynamic therapy-triggered nuclear translocation of berberine from mitochondria leads to liver cancer cell death |
| - | in-vitro, | Liver, | HUH7 |
| 2681- | BBR, | PDT, | Berberine-photodynamic induced apoptosis by activating endoplasmic reticulum stress-autophagy pathway involving CHOP in human malignant melanoma cells |
| - | in-vitro, | Melanoma, | NA |
| 2682- | BBR, | Berberine Inhibited Growth and Migration of Human Colon Cancer Cell Lines by Increasing Phosphatase and Tensin and Inhibiting Aquaporins 1, 3 and 5 Expressions |
| - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | HCT116 |
| 2684- | BBR, | Berberine is a Novel Mitochondrial Calcium Uniporter Inhibitor that Disrupts MCU‐EMRE Assembly |
| - | in-vivo, | Nor, | NA |
| 2685- | BBR, | Berberine induces neuronal differentiation through inhibition of cancer stemness and epithelial-mesenchymal transition in neuroblastoma cells |
| - | in-vitro, | neuroblastoma, | NA |
| 2686- | BBR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Nor, | NA |
| - | Trial, | BC, | NA |
| 2689- | BBR, | Berberine protects against glutamate-induced oxidative stress and apoptosis in PC12 and N2a cells |
| - | in-vitro, | Nor, | PC12 | - | in-vitro, | AD, | NA | - | in-vitro, | Stroke, | NA |
| 2690- | BBR, | Berberine Differentially Modulates the Activities of ERK, p38 MAPK, and JNK to Suppress Th17 and Th1 T Cell Differentiation in Type 1 Diabetic Mice |
| - | in-vivo, | Diabetic, | NA |
| 2691- | BBR, | Berberine induces FasL-related apoptosis through p38 activation in KB human oral cancer cells |
| - | in-vitro, | Oral, | KB |
| 2692- | BBR, | Berberine affects osteosarcoma via downregulating the caspase-1/IL-1β signaling axis |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | OS, | SaOS2 | - | in-vivo, | NA, | NA |
| 2693- | BBR, | Antitumor Effects of Berberine on Gliomas via Inactivation of Caspase-1-Mediated IL-1β and IL-18 Release |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG |
| 2683- | BBR, | Berberine reduces endoplasmic reticulum stress and improves insulin signal transduction in Hep G2 cells |
| - | in-vitro, | Liver, | HepG2 |
| 2670- | BBR, | Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases |
| - | Review, | Var, | NA |
| 2335- | BBR, | Chemoproteomics reveals berberine directly binds to PKM2 to inhibit the progression of colorectal cancer |
| - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT116 | - | in-vivo, | NA, | NA |
| 2337- | BBR, | Berberine Inhibited the Proliferation of Cancer Cells by Suppressing the Activity of Tumor Pyruvate Kinase M2 |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Cerv, | HeLa |
| 2336- | BBR, | Berberine Targets PKM2 to Activate the t-PA-Induced Fibrinolytic System and Improves Thrombosis |
| - | in-vivo, | Nor, | NA |
| 4275- | BBR, | Pharmacological effects of berberine on mood disorders |
| - | Review, | NA, | NA |
| 4274- | BBR, | Berberine exerts antidepressant effects in vivo and in vitro through the PI3K/AKT/CREB/BDNF signaling pathway |
| - | in-vivo, | NA, | NA |
| 3684- | BBR, | Neuroprotective effects of berberine in animal models of Alzheimer’s disease: a systematic review of pre-clinical studies |
| - | Review, | AD, | NA |
| 3678- | BBR, | Network pharmacology study on the mechanism of berberine in Alzheimer’s disease model |
| - | Review, | AD, | NA |
| 3677- | BBR, | Berberine: A Potential Multipotent Natural Product to Combat Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3633- | BBR, | LT, | Croc, | QC, | Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy |
| - | Review, | AD, | NA |
| 3679- | BBR, | Berberine alleviates Alzheimer's disease by activating autophagy and inhibiting ferroptosis through the JNK-p38MAPK signaling pathway |
| - | in-vivo, | AD, | NA |
| 3680- | BBR, | Network pharmacology reveals that Berberine may function against Alzheimer’s disease via the AKT signaling pathway |
| - | in-vivo, | AD, | NA |
| 3681- | BBR, | The efficacy and mechanism of berberine in improving aging-related cognitive dysfunction: A study based on network pharmacology |
| - | in-vivo, | AD, | NA |
| 3682- | BBR, | Berberine Improves Cognitive Impairment by Simultaneously Impacting Cerebral Blood Flow and β-Amyloid Accumulation in an APP/tau/PS1 Mouse Model of Alzheimer’s Disease |
| - | in-vitro, | AD, | NA |
| 3683- | BBR, | Characterization of the anti-AChE potential and alkaloids in Rhizoma Coptidis from different Coptis species combined with spectrum-effect relationship and molecular docking |
| - | NA, | AD, | NA |
| 3754- | BBR, | CUR, | EGCG, | Hup, | Traditional Chinese medicinal herbs as potential AChE inhibitors for anti-Alzheimer’s disease: A review |
| 3749- | BBR, | Anti-Alzheimer and Antioxidant Activities of Coptidis Rhizoma Alkaloids |
| - | Review, | AD, | NA |
| 3833- | BBR, | Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 1031- | BCA, | Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer |
| - | vitro+vivo, | CRC, | HCT116 | - | vitro+vivo, | CRC, | SW-620 |
| 1473- | BCA, | SFN, | An Insight on Synergistic Anti-cancer Efficacy of Biochanin A and Sulforaphane Combination Against Breast Cancer |
| - | in-vitro, | BC, | MCF-7 |
| 1285- | BetA, | Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells |
| - | in-vitro, | Var, | NA |
| 1305- | BetA, | Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells |
| - | in-vitro, | UEC, | NA |
| 943- | BetA, | Betulinic acid suppresses breast cancer aerobic glycolysis via caveolin-1/NF-κB/c-Myc pathway |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| - | in-vivo, | NA, | NA |
| 2754- | BetA, | Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors |
| - | in-vitro, | Pca, | LNCaP |
| 2753- | BetA, | Betulinic acid induces apoptosis by regulating PI3K/Akt signaling and mitochondrial pathways in human cervical cancer cells |
| - | in-vitro, | Cerv, | HeLa |
| 2752- | BetA, | Betulinic acid: a natural product with anticancer activity |
| - | Review, | Var, | NA |
| 2751- | BetA, | Betulinic acid inhibits proliferation and triggers apoptosis in human breast cancer cells by modulating ER (α/β) and p53 |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 2750- | BetA, | GEM, | Betulinic acid, a major therapeutic triterpene of Celastrus orbiculatus Thunb., acts as a chemosensitizer of gemcitabine by promoting Chk1 degradation |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | Lung, | H1299 |
| 2749- | BetA, | Anti-Inflammatory Activities of Betulinic Acid: A Review |
| - | Review, | Nor, | NA |
| 2748- | BetA, | Betulinic Acid: Recent Advances in Chemical Modifications, Effective Delivery, and Molecular Mechanisms of a Promising Anticancer Therapy |
| - | Review, | Var, | NA |
| 2747- | BetA, | Betulinic acid, a natural compound with potent anticancer effects |
| - | Review, | Var, | NA |
| 2746- | BetA, | Betulinic acid induces apoptosis and inhibits metastasis of human colorectal cancer cells in vitro and in vivo |
| - | in-vitro, | CRC, | HCT116 | - | in-vivo, | CRC, | NA |
| 2745- | BetA, | Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors |
| - | in-vitro, | CRC, | RKO | - | in-vitro, | CRC, | SW480 | - | in-vivo, | NA, | NA |
| 2744- | BetA, | Betulin and betulinic acid: triterpenoids derivatives with a powerful biological potential |
| - | Review, | Var, | NA |
| 2743- | BetA, | Betulinic acid and the pharmacological effects of tumor suppression |
| - | Review, | Var, | NA |
| 2742- | BetA, | Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | BC, | 4T1 | - | in-vitro, | BC, | MCF-7 |
| 2755- | BetA, | Cytotoxic Potential of Betulinic Acid Fatty Esters and Their Liposomal Formulations: Targeting Breast, Colon, and Lung Cancer Cell Lines |
| - | in-vitro, | Colon, | HT29 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | H460 |
| 2756- | BetA, | Betulinic acid inhibits growth of hepatoma cells through activating the NCOA4-mediated ferritinophagy pathway |
| - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | H1299 |
| 2757- | BetA, | Betulinic Acid Inhibits Glioma Progression by Inducing Ferroptosis Through the PI3K/Akt and NRF2/HO-1 Pathways |
| - | in-vitro, | GBM, | U251 |
| 2758- | BetA, | Betulinic Acid Attenuates Oxidative Stress in the Thymus Induced by Acute Exposure to T-2 Toxin via Regulation of the MAPK/Nrf2 Signaling Pathway |
| - | in-vivo, | Nor, | NA |
| 2759- | BetA, | Chemopreventive and Chemotherapeutic Potential of Betulin and Betulinic Acid: Mechanistic Insights From In Vitro, In Vivo and Clinical Studies |
| - | Review, | Var, | NA |
| 2760- | BetA, | A Review on Preparation of Betulinic Acid and Its Biological Activities |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA |
| 2761- | BetA, | Betulinic acid increases lifespan and stress resistance via insulin/IGF-1 signaling pathway in Caenorhabditis elegans |
| - | in-vivo, | Nor, | NA |
| 2762- | BetA, | Targeting Effect of Betulinic Acid Liposome Modified by Hyaluronic Acid on Hepatoma Cells In Vitro |
| - | in-vitro, | Liver, | HepG2 |
| 2763- | BetA, | Betulinic Acid Inhibits the Stemness of Gastric Cancer Cells by Regulating the GRP78-TGF-β1 Signaling Pathway and Macrophage Polarization |
| - | in-vitro, | GC, | NA |
| 2764- | BetA, | In silico profiling of histone deacetylase inhibitory activity of compounds isolated from Cajanus cajan |
| - | Analysis, | Var, | NA |
| 2765- | BetA, | Unveiling Betulinic Acid as a Potent CDK4 Inhibitor for Cancer Therapeutics |
| - | in-vitro, | Lung, | A549 |
| 2766- | BetA, | Role of natural secondary metabolites as HIF-1 inhibitors in cancer therapy |
| - | Review, | Var, | NA |
| 2771- | BetA, | Cardioprotective Effect of Betulinic Acid on Myocardial Ischemia Reperfusion Injury in Rats |
| - | in-vivo, | Nor, | NA | - | in-vivo, | Stroke, | NA |
| 2740- | BetA, | Effects and mechanisms of fatty acid metabolism-mediated glycolysis regulated by betulinic acid-loaded nanoliposomes in colorectal cancer |
| - | in-vitro, | CRC, | HCT116 |
| 2716- | BetA, | Cellular and molecular mechanisms underlying the potential of betulinic acid in cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2741- | BetA, | Betulinic acid triggers apoptosis and inhibits migration and invasion of gastric cancer cells by impairing EMT progress |
| - | in-vitro, | GC, | SNU16 | - | in-vitro, | GC, | NCI-N87 | - | in-vivo, | NA, | NA |
| 2717- | BetA, | Betulinic Acid Induces ROS-Dependent Apoptosis and S-Phase Arrest by Inhibiting the NF-κB Pathway in Human Multiple Myeloma |
| - | in-vitro, | Melanoma, | U266 | - | in-vivo, | Melanoma, | NA | - | in-vitro, | Melanoma, | RPMI-8226 |
| 2718- | BetA, | The anti-cancer effect of betulinic acid in u937 human leukemia cells is mediated through ROS-dependent cell cycle arrest and apoptosis |
| - | in-vitro, | AML, | U937 |
| 2719- | BetA, | Betulinic Acid Restricts Human Bladder Cancer Cell Proliferation In Vitro by Inducing Caspase-Dependent Cell Death and Cell Cycle Arrest, and Decreasing Metastatic Potential |
| - | in-vitro, | CRC, | T24 | - | in-vitro, | Bladder, | UMUC3 | - | in-vitro, | Bladder, | 5637 |
| 2720- | BetA, | Betulinic acid induces apoptosis of HeLa cells via ROS-dependent ER stress and autophagy in vitro and in vivo |
| - | in-vitro, | Cerv, | HeLa |
| 2721- | BetA, | Proteomic Investigation into Betulinic Acid-Induced Apoptosis of Human Cervical Cancer HeLa Cells |
| - | in-vitro, | Cerv, | HeLa |
| 2722- | BetA, | Betulinic Acid for Cancer Treatment and Prevention |
| - | Review, | Var, | NA |
| 2723- | BetA, | Betulinic acid and oleanolic acid modulate CD81 expression and induce apoptosis in triple-negative breast cancer cells through ROS generation |
| - | in-vitro, | BC, | MDA-MB-231 |
| 2724- | BetA, | Down-regulation of NOX4 by betulinic acid protects against cerebral ischemia-reperfusion in mice |
| - | in-vivo, | Nor, | NA | - | in-vivo, | Stroke, | NA |
| 2725- | BetA, | Betulinic acid protects against renal damage by attenuation of oxidative stress and inflammation via Nrf2 signaling pathway in T-2 toxin-induced mice |
| - | in-vivo, | Nor, | NA |
| 2726- | BetA, | Betulinic acid induces DNA damage and apoptosis in SiHa cells |
| - | in-vitro, | Cerv, | SiHa |
| 2727- | BetA, | Betulinic acid in the treatment of breast cancer: Application and mechanism progress |
| - | Review, | BC, | NA |
| 2729- | BetA, | Betulinic acid in the treatment of tumour diseases: Application and research progress |
| - | Review, | Var, | NA |
| 2739- | BetA, | Glycolytic Switch in Response to Betulinic Acid in Non-Cancer Cells |
| - | in-vitro, | Nor, | HUVECs | - | in-vitro, | Nor, | MEF |
| 2738- | BetA, | Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | NA, | NA |
| 2737- | BetA, | Multiple molecular targets in breast cancer therapy by betulinic acid |
| - | Review, | Var, | NA |
| - | Review, | Var, | NA |
| 2735- | BetA, | Betulinic acid as apoptosis activator: Molecular mechanisms, mathematical modeling and chemical modifications |
| - | Review, | Var, | NA |
| 2734- | BetA, | Betulinic Acid Modulates the Expression of HSPA and Activates Apoptosis in Two Cell Lines of Human Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW480 |
| 2733- | BetA, | Betulinic Acid Inhibits Cell Proliferation in Human Oral Squamous Cell Carcinoma via Modulating ROS-Regulated p53 Signaling |
| - | in-vitro, | Oral, | KB | - | in-vivo, | NA, | NA |
| 2732- | BetA, | Chemo, | Betulinic acid chemosensitizes breast cancer by triggering ER stress-mediated apoptosis by directly targeting GRP78 |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 2731- | BetA, | Betulinic Acid for Glioblastoma Treatment: Reality, Challenges and Perspectives |
| - | Review, | GBM, | NA | - | Review, | Park, | NA | - | Review, | AD, | NA |
| 2730- | BetA, | Betulinic acid induces autophagy-dependent apoptosis via Bmi-1/ROS/AMPK-mTOR-ULK1 axis in human bladder cancer cells |
| - | in-vitro, | Bladder, | T24 |
| 2728- | BetA, | Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy |
| - | in-vitro, | Var, | NA |
| 1566- | betaCar, | Lyco, | Antioxidant and pro-oxidant effects of lycopene in comparison with beta-carotene on oxidant-induced damage in Hs68 cells |
| - | in-vitro, | Nor, | HS68 |
| 3986- | betaCar, | VitC, | Editorial: Impact of Diet on Learning, Memory and Cognition |
| - | Review, | AD, | NA |
| 3987- | betaCar, | Lyco, | Carotenoid bioavailability is higher from salads ingested with full-fat than with fat-reduced salad dressings as measured with electrochemical detection |
| - | Trial, | AD, | NA |
| 3988- | betaCar, | Lut, | Zeax, | Effects of egg consumption on carotenoid absorption from co-consumed, raw vegetables |
| - | Trial, | AD, | NA |
| 3989- | betaCar, | Dietary factors that affect the bioavailability of carotenoids |
| 4061- | betaCar, | VitB12, | VitB6, | FA, | VitB3 | Revisiting the Role of Vitamins and Minerals in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4078- | betaCar, | VitC, | VitB6, | Impact of Diet on Learning, Memory and Cognition |
| - | Review, | AD, | NA |
| 4080- | betaCar, | Vitamin A and Alzheimer's disease |
| - | Review, | AD, | NA |
| 4081- | betaCar, | Vitamin A supplementation and risk of skeletal fracture |
| - | Study, | NA, | NA |
| 4082- | betaCar, | Marginal vitamin A deficiency facilitates Alzheimer's pathogenesis |
| - | Study, | AD, | NA |
| 4083- | betaCar, | Significance of vitamin A to brain function, behavior and learning |
| - | Review, | AD, | NA |
| 2502- | Bical, | Complete Response of Metastatic Androgen Receptor–Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature |
| - | Case Report, | BC, | NA |
| 1250- | Bif, | Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12 |
| - | in-vitro, | SCC, | NA |
| 3698- | BM, | Bacopa monniera prevents from aluminium neurotoxicity in the cerebral cortex of rat brain |
| - | in-vivo, | AD, | NA |
| 3697- | BM, | Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies |
| - | Review, | AD, | NA |
| 3696- | BM, | Discovery of Molecular Networks of Neuroprotection Conferred by Brahmi Extract in Aβ42-Induced Toxicity Model of Drosophila melanogaster Using a Quantitative Proteomic Approach |
| - | in-vivo, | NA, | NA |
| 3690- | BM, | Neurocognitive Effect of Nootropic Drug Brahmi (Bacopa monnieri) in Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3691- | BM, | Effects of a Standardized Bacopa monnieri Extract on Cognitive Performance, Anxiety, and Depression in the Elderly: A Randomized, Double-Blind, Placebo-Controlled Trial |
| - | Study, | Nor, | NA |
| 3692- | BM, | Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer's disease |
| - | Review, | AD, | NA |
| 3693- | BM, | Bacopa monnieri prevents colchicine-induced dementia by anti-inflammatory action |
| - | in-vivo, | AD, | NA |
| 3694- | BM, | Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials |
| - | Review, | AD, | NA |
| 3695- | BM, | Bacopa monnieri (L.) wettst. Extract protects against glutamate toxicity and increases the longevity of Caenorhabditis elegans |
| - | in-vitro, | AD, | HT22 |
| 4277- | BM, | Reversion of BDNF, Akt and CREB in Hippocampus of Chronic Unpredictable Stress Induced Rats: Effects of Phytochemical, Bacopa Monnieri |
| - | in-vivo, | NA, | NA |
| 4272- | Bor, | Neuroprotective properties of borax against aluminum hydroxide-induced neurotoxicity: Possible role of Nrf-2/BDNF/AChE pathways in fish brain |
| 4271- | Bor, | Effects of Boron on Learning and Behavioral Disorders in Rat Autism Model Induced by Intracerebroventricular Propionic Acid |
| - | in-vivo, | NA, | NA |
| 3785- | Bor, | Discovery of boron-containing compounds as Aβ aggregation inhibitors and antioxidants for the treatment of Alzheimer's disease |
| - | Analysis, | AD, | NA |
| 3786- | Bor, | New and potential boron-containing compounds for treatment of Alzheimer's disease and cancers |
| - | Analysis, | AD, | NA | - | Analysis, | Var, | NA |
| 3518- | Bor, | Boron Report |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3513- | Bor, | Boric Acid Activation of eIF2α and Nrf2 Is PERK Dependent: a Mechanism that Explains How Boron Prevents DNA Damage and Enhances Antioxidant Status |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Nor, | MEF |
| 3517- | Bor, | Se, | The protective effects of selenium and boron on cyclophosphamide-induced hepatic oxidative stress, inflammation, and apoptosis in rats |
| - | in-vivo, | Nor, | NA |
| 3516- | Bor, | Boron in wound healing: a comprehensive investigation of its diverse mechanisms |
| - | Review, | Wounds, | NA |
| 3515- | Bor, | EVIDENCE THAT BORON DOWN-REGULATES INFLAMMATION THROUGH THE NF-(KAPPA)B PATHWAY |
| - | in-vitro, | Nor, | NA |
| 3514- | Bor, | CUR, | Effects of Curcumin and Boric Acid Against Neurodegenerative Damage Induced by Amyloid Beta |
| - | in-vivo, | AD, | NA |
| 3512- | Bor, | Activation of the EIF2α/ATF4 and ATF6 Pathways in DU-145 Cells by Boric Acid at the Concentration Reported in Men at the US Mean Boron Intake |
| - | in-vitro, | Pca, | DU145 |
| 3511- | Bor, | Boron |
| - | Review, | NA, | NA |
| 3510- | Bor, | Boron Affects the Development of the Kidney Through Modulation of Apoptosis, Antioxidant Capacity, and Nrf2 Pathway in the African Ostrich Chicks |
| - | in-vivo, | Nor, | NA |
| 3509- | Bor, | Boron and Prostate Cancer a Model for Understanding Boron Biology |
| - | NA, | Pca, | NA |
| 3508- | Bor, | The Effect of Boron on the UPR in Prostate Cancer Cells is Biphasic |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 3507- | Bor, | Boron inhibits apoptosis in hyperapoptosis condition: Acts by stabilizing the mitochondrial membrane and inhibiting matrix remodeling |
| 3506- | Bor, | Boron Chemistry for Medical Applications |
| - | Review, | NA, | NA |
| 3505- | Bor, | Mineral requirements for mitochondrial function: A connection to redox balance and cellular differentiation |
| - | Review, | NA, | NA |
| 3504- | Bor, | Boron Contents of German Mineral and Medicinal Waters and Their Bioavailability in Drosophila melanogaster and Humans |
| - | Review, | NA, | NA |
| 3503- | Bor, | Chemical disposition of boron in animals and humans |
| - | Review, | NA, | NA |
| 3502- | Bor, | Plasma boron concentrations in the general population: a cross-sectional analysis of cardio-metabolic and dietary correlates |
| - | Review, | NA, | NA |
| 3520- | Bor, | Effect of boron element on photoaging in rats |
| - | in-vivo, | NA, | NA |
| 3521- | Bor, | A new hope for obesity management: Boron inhibits adipogenesis in progenitor cells through the Wnt/β-catenin pathway |
| - | in-vitro, | Obesity, | 3T3 |
| 3522- | Bor, | The Boron Advantage: The Evolution and Diversification of Boron’s Applications in Medicinal Chemistry |
| - | Review, | Var, | NA |
| 3523- | Bor, | Design, Synthesis, and Biological Activity of Boronic Acid-Based Histone Deacetylase Inhibitors |
| - | in-vitro, | Var, | NA |
| 3524- | Bor, | Boric Acid Alleviates Lipopolysaccharide-Induced Acute Lung Injury in Mice |
| 3525- | Bor, | Synthesis of DNA-Boron Cluster Composites and Assembly into Functional Nanoparticles with Dual, Anti-EGFR, and Anti-c-MYC Oncogene Silencing Activity |
| - | in-vitro, | PC, | PANC1 |
| 3527- | Bor, | The potential role of borophene as a radiosensitizer in boron neutron capture therapy (BNCT) and particle therapy (PT) |
| - | NA, | Var, | NA |
| 3519- | Bor, | Boron-Based Inhibitors of the NLRP3 Inflammasome |
| - | Review, | NA, | NA |
| 726- | Bor, | Redox Mechanisms Underlying the Cytostatic Effects of Boric Acid on Cancer Cells—An Issue Still Open |
| - | Review, | NA, | NA |
| 718- | Bor, | Boric Acid Exhibits Anticancer Properties in Human Endometrial Cancer Ishikawa Cells |
| - | in-vitro, | NA, | NA |
| 719- | Bor, | Boric Acid Affects Cell Proliferation, Apoptosis, and Oxidative Stress in ALL Cells |
| - | in-vitro, | Var, | NA |
| 720- | Bor, | High Concentrations of Boric Acid Trigger Concentration-Dependent Oxidative Stress, Apoptotic Pathways and Morphological Alterations in DU-145 Human Prostate Cancer Cell Line |
| - | in-vitro, | Pca, | DU145 |
| 721- | Bor, | Polymers Based on Phenyl Boric Acid in Tumor-Targeted Therapy |
| - | Analysis, | NA, | NA |
| 722- | Bor, | Boric acid as a promising agent in the treatment of ovarian cancer: Molecular mechanisms |
| - | in-vitro, | Ovarian, | MDAH-2774 |
| 723- | Bor, | Boric acid suppresses cell proliferation by TNF signaling pathway mediated apoptosis in SW-480 human colon cancer line |
| - | in-vitro, | Colon, | SW480 |
| 724- | Bor, | Does Boric Acid Inhibit Cell Proliferation on MCF-7 and MDA-MB-231 Cells in Monolayer and Spheroid Cultures by Using Apoptosis Pathways? |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 725- | Bor, | Boric acid exert anti-cancer effect in poorly differentiated hepatocellular carcinoma cells via inhibition of AKT signaling pathway |
| - | in-vitro, | HCC, | NA |
| 717- | Bor, | PacT, | Boric acid as a protector against paclitaxel genotoxicity |
| - | in-vitro, | NA, | NA |
| 727- | Bor, | RSL3, | erastin, | Enhancement of ferroptosis by boric acid and its potential use as chemosensitizer in anticancer chemotherapy |
| - | in-vitro, | Liver, | HepG2 |
| 728- | Bor, | Boric Acid and Borax Protect Human Lymphocytes from Oxidative Stress and Genotoxicity Induced by 3-Monochloropropane-1,2-diol |
| 729- | Bor, | Promising potential of boron compounds against Glioblastoma: In Vitro antioxidant, anti-inflammatory and anticancer studies |
| - | in-vitro, | GBM, | U87MG | - | in-vivo, | Nor, | HaCaT |
| 730- | Bor, | Cisplatin, | The Effect of Boric Acid and Borax on Oxidative Stress, Inflammation, ER Stress and Apoptosis in Cisplatin Toxication and Nephrotoxicity Developing as a Result of Toxication |
| - | in-vivo, | NA, | NA |
| 731- | Bor, | Protective Effect of Boric Acid Against Ochratoxin A-Induced Toxic Effects in Human Embryonal Kidney Cells (HEK293): A Study on Cytotoxic, Genotoxic, Oxidative, and Apoptotic Effects |
| - | in-vitro, | Nor, | HEK293 |
| 732- | Bor, | Boron's neurophysiological effects and tumoricidal activity on glioblastoma cells with implications for clinical treatment |
| 733- | Bor, | The analysis of boric acid effect on epithelial-mesenchymal transition of CD133 + CD117 + lung cancer stem cells |
| - | in-vitro, | Lung, | NA |
| 734- | Bor, | Boric Acid Affects the Expression of DNA Double-Strand Break Repair Factors in A549 Cells and A549 Cancer Stem Cells: An In Vitro Study |
| - | in-vitro, | Lung, | A549 |
| 709- | Bor, | Cellular changes in boric acid-treated DU-145 prostate cancer cells |
| - | in-vitro, | Pca, | DU145 |
| 701- | Bor, | Dietary boron intake and prostate cancer risk |
| - | Analysis, | NA, | NA |
| 702- | Bor, | GEN, | SeMet, | Rad, | Evaluation of ecological and in vitro effects of boron on prostate cancer risk (United States) |
| - | Analysis, | NA, | NA |
| 703- | Bor, | Boron intake and prostate cancer risk |
| - | Analysis, | NA, | NA |
| 704- | Bor, | Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid |
| - | in-vitro, | Pca, | NA |
| 705- | Bor, | Boric acid inhibits human prostate cancer cell proliferation |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 706- | Bor, | Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice |
| - | in-vivo, | Pca, | LNCaP |
| 707- | Bor, | Cytotoxic and apoptotic effects of boron compounds on leukemia cell line |
| - | in-vitro, | AML, | HL-60 |
| 708- | Bor, | Boron containing compounds as protease inhibitors |
| 735- | Bor, | Boric Acid Alters the Expression of DNA Double Break Repair Genes in MCF-7-Derived Breast Cancer Stem Cells |
| - | in-vitro, | BC, | NA |
| 710- | Bor, | Boric acid inhibits stored Ca2+ release in DU-145 prostate cancer cells |
| - | in-vitro, | Pca, | DU145 |
| 711- | Bor, | Receptor Activated Ca2+ Release Is Inhibited by Boric Acid in Prostate Cancer Cells |
| - | in-vitro, | Pca, | DU145 |
| 712- | Bor, | Boron concentrations in selected foods from borate-producing regions in Turkey |
| - | Analysis, | NA, | NA |
| 713- | Bor, | Effects of dietary boron on cervical cytopathology and on micronucleus frequency in exfoliated buccal cells |
| - | Analysis, | NA, | NA |
| 714- | Bor, | Dietary Boron and Hormone Replacement Therapy as Risk Factors for Lung Cancer in Women |
| - | Analysis, | NA, | NA |
| 715- | Bor, | Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1alpha inhibitors |
| - | in-vitro, | Pca, | HeLa |
| 716- | Bor, | Sugar-borate esters--potential chemical agents in prostate cancer chemoprevention |
| 761- | Bor, | Prevalence of Prostate Cancer in High Boron-Exposed Population: A Community-Based Study |
| - | Study, | BPH, | NA |
| 753- | Bor, | Boron Intake and decreased risk of mortality in kidney transplant recipients |
| 754- | Bor, | HRT, | Dietary Boron and Hormone Replacement Therapy as Risk Factors for Lung Cancer in Women |
| - | Analysis, | NA, | NA |
| 755- | Bor, | https://aacrjournals.org/cancerres/article/67/9_Supplement/4220/535557/Boric-acid-induces-apoptosis-in-both-prostate-and |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | PC, | PC3 |
| 756- | Bor, | Evaluation of Boric Acid Treatment on microRNA‐127‐5p and Metastasis Genes Orchestration of Breast Cancer Stem Cells |
| - | in-vitro, | BC, | MCF-7 |
| 757- | Bor, | Phenylboronic acid is a more potent inhibitor than boric acid of key signaling networks involved in cancer cell migration |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Nor, | RWPE-1 |
| 758- | Bor, | Comparative effects of daily and weekly boron supplementation on plasma steroid hormones and proinflammatory cytokines |
| - | Human, | NA, | NA |
| 759- | Bor, | The nutritional and metabolic effects of boron in humans and animals |
| - | in-vivo, | NA, | NA |
| 760- | Bor, | Therapeutic Efficacy of Boric Acid Treatment on Brain Tissue and Cognitive Functions in Rats with Experimental Alzheimer’s Disease |
| - | in-vivo, | AD, | NA |
| 752- | Bor, | The Potential Role of Boron in the Modulation of Gut Microbiota Composition: An In Vivo Pilot Study |
| 762- | Bor, | Mechanism of boric acid cytotoxicity in breast cancer cell lines |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | ZR-75-1 |
| 763- | Bor, | Investigation of The Apoptotic and Antiproliferative Effects of Boron on CCL-233 Human Colon Cancer Cells |
| - | in-vitro, | Colon, | CCl233 |
| 764- | Bor, | Effect of Tumor Microenvironment on Selective Uptake of Boric Acid in HepG2 Human Hepatoma Cells |
| - | in-vitro, | Liver, | HepG2 |
| 765- | Bor, | High concentrations of boric acid induce autophagy in cancer cell lines |
| 766- | Bor, | In vitro effects of boric acid on human liver hepatoma cell line (HepG2) at the half-maximal inhibitory concentration |
| - | in-vitro, | Liver, | HepG2 |
| 767- | Bor, | Boric acid induces cytoplasmic stress granule formation, eIF2α phosphorylation, and ATF4 in prostate DU-145 cells |
| - | in-vitro, | Pca, | DU145 |
| 768- | Bor, | In vitro and in vivo antitumour effects of phenylboronic acid against mouse mammary adenocarcinoma 4T1 and squamous carcinoma SCCVII cells |
| - | in-vitro, | BC, | 4T1 |
| 744- | Bor, | Borax affects cellular viability by inducing ER stress in hepatocellular carcinoma cells by targeting SLC12A5 |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | HL7702 |
| 736- | Bor, | Evaluation of Boric Acid Treatment on microRNA-127-5p and Metastasis Genes Orchestration of Breast Cancer Stem Cells |
| - | in-vitro, | BC, | MCF-7 |
| 737- | Bor, | Boric Acid Activation of eIF2α and Nrf2 Is PERK Dependent: a Mechanism that Explains How Boron Prevents DNA Damage and Enhances Antioxidant Statu |
| - | in-vitro, | Pca, | DU145 |
| 738- | Bor, | Borax induces ferroptosis of glioblastoma by targeting HSPA5/NRF2/GPx4/GSH pathways |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | A172 | - | in-vitro, | Nor, | SVGp12 |
| 739- | Bor, | Borax regulates iron chaperone- and autophagy-mediated ferroptosis pathway in glioblastoma cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | Nor, | HMC3 |
| 740- | Bor, | Anti-cancer effect of boron derivatives on small-cell lung cancer |
| - | in-vitro, | Lung, | DMS114 | - | in-vitro, | Nor, | MRC-5 |
| 741- | Bor, | Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 742- | Bor, | In Vitro Effects of Boric Acid on Cell Cycle, Apoptosis, and miRNAs in Medullary Thyroid Cancer Cells |
| - | in-vitro, | Thyroid, | NA |
| 743- | Bor, | Boric Acid (Boron) Attenuates AOM-Induced Colorectal Cancer in Rats by Augmentation of Apoptotic and Antioxidant Mechanisms |
| - | in-vitro, | CRC, | NA |
| 700- | Bor, | Diadenosine phosphates and S-adenosylmethionine: novel boron binding biomolecules detected by capillary electrophoresis |
| - | Analysis, | NA, | NA |
| 745- | Bor, | Investigation of cytotoxic antiproliferative and antiapoptotic effects of nanosized boron phosphate filled sodium alginate composite on glioblastoma cancer cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | Nor, | L929 | - | in-vitro, | GBM, | T98G |
| 746- | Bor, | Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope |
| - | Review, | NA, | NA |
| 747- | Bor, | Growing Evidence for Human Health Benefits of Boron |
| - | Review, | NA, | NA |
| 748- | Bor, | A Study on the Anticarcinogenic Effects of Calcium Fructoborate |
| - | in-vitro, | BC, | MDA-MB-231 |
| 749- | Bor, | Comparative effects of boric acid and calcium fructoborate on breast cancer cells |
| 750- | Bor, | Calcium fructoborate regulate colon cancer (Caco-2) cytotoxicity through modulation of apoptosis |
| - | in-vitro, | CRC, | Caco-2 |
| 751- | Bor, | 5-FU, | Cytotoxic and Apoptotic Effects of the Combination of Borax (Sodium Tetraborate) and 5-Fluorouracil on DLD-1 Human Colorectal Adenocarcinoma Cell Line |
| - | in-vitro, | CRC, | DLD1 |
| 699- | Bor, | Boric Acid Alleviates Gastric Ulcer by Regulating Oxidative Stress and Inflammation-Related Multiple Signaling Pathways |
| - | in-vivo, | NA, | NA |
| 698- | Bor, | Boron deprivation decreases liver S-adenosylmethionine and spermidine and increases plasma homocysteine and cysteine in rats |
| - | in-vitro, | NA, | NA |
| 697- | Bor, | Boron-containing compounds as preventive and chemotherapeutic agents for cancer |
| - | Review, | NA, | NA |
| 696- | Bor, | Nothing Boring About Boron |
| - | Review, | Var, | NA |
| 4624- | Bor, | VitD3, | Boron as a Medicinal Ingredient in Oral Natural Health Products |
| - | Review, | Pca, | NA |
| 4623- | Bor, | Proteomic insights into the anti-cancer mechanisms of boron-based compounds in prostate cancer |
| - | Review, | Pca, | NA |
| 4622- | Bor, | Boron Level in the Prostate of the Normal Human: A Systematic Review |
| - | Review, | BPH, | NA |
| 4621- | Bor, | Boron |
| - | Review, | BPH, | NA |
| 4620- | Bor, | BTZ, | Boron Compounds in the Breast Cancer Cells Chemoprevention and Chemotherapy |
| - | Review, | Var, | NA | - | Review, | Arthritis, | NA | - | Review, | Pca, | NA |
| 4619- | Bor, | Using Boron Supplementation in Cancer Prevention and Treatment: A Review Article |
| - | Review, | Var, | NA |
| 4625- | Bor, | Boron and Inflammation |
| - | Review, | Arthritis, | NA | - | Review, | ostP, | NA |
| 1185- | Bos, | The journey of boswellic acids from synthesis to pharmacological activities |
| - | Review, | NA, | NA |
| 1169- | Bos, | Boswellic Acid Inhibits Growth and Metastasis of Human Colorectal Cancer in Orthotopic Mouse Model By Downregulating Inflammatory, Proliferative, Invasive, and Angiogenic Biomarkers |
| - | in-vivo, | CRC, | NA |
| 1248- | Bos, | The anti-proliferative effects of a frankincense extract in a window of opportunity phase ia clinical trial for patients with breast cancer |
| - | Trial, | BC, | NA |
| 1425- | Bos, | Protective Effect of Boswellic Acids against Doxorubicin-Induced Hepatotoxicity: Impact on Nrf2/HO-1 Defense Pathway |
| - | in-vivo, | Nor, | NA |
| 1419- | Bos, | Enhanced Bioavailability of Boswellic Acid by Piper longum: A Computational and Pharmacokinetic Study |
| - | in-vivo, | Nor, | NA |
| 1417- | Bos, | Potential complementary and/or synergistic effects of curcumin and boswellic acids for management of osteoarthritis |
| - | Review, | Arthritis, | NA |
| - | in-vitro, | Pca, | DU145 |
| 1416- | Bos, | Anti-cancer properties of boswellic acids: mechanism of action as anti-cancerous agent |
| - | Review, | NA, | NA |
| 1420- | Bos, | Acetyl-11-keto-β-boswellic acid inhibits proliferation and induces apoptosis of gastric cancer cells through the phosphatase and tensin homolog /Akt/ cyclooxygenase-2 signaling pathway |
| - | vitro+vivo, | GC, | BGC-823 |
| 1421- | Bos, | Coupling of boswellic acid-induced Ca2+ mobilisation and MAPK activation to lipid metabolism and peroxide formation in human leucocytes |
| - | in-vitro, | AML, | HL-60 | - | in-vitro, | Nor, | NA |
| 1422- | Bos, | Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family |
| - | in-vitro, | CRC, | NA | - | in-vivo, | NA, | NA |
| 1423- | Bos, | Acetyl-11-keto-β-Boswellic Acid Suppresses Invasion of Pancreatic Cancer Cells Through The Downregulation of CXCR4 Chemokine Receptor Expression |
| - | in-vitro, | Melanoma, | U266 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | SkBr3 | - | in-vitro, | PC, | PANC1 |
| 1424- | Bos, | Boswellia sacra essential oil induces tumor cell-specific apoptosis and suppresses tumor aggressiveness in cultured human breast cancer cells |
| - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 1426- | Bos, | CUR, | Chemo, | Novel evidence for curcumin and boswellic acid induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer |
| - | in-vivo, | CRC, | NA | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | RKO | - | in-vitro, | CRC, | SW480 | - | in-vitro, | RCC, | SW-620 | - | in-vitro, | RCC, | HT-29 | - | in-vitro, | CRC, | Caco-2 |
| 1427- | Bos, | Acetyl-keto-β-boswellic acid inhibits cellular proliferation through a p21-dependent pathway in colon cancer cells |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | LS174T |
| 1451- | Bos, | Phytochemical Analysis and Anti-cancer Investigation of Boswellia serrata Bioactive Constituents In Vitro |
| - | in-vitro, | CRC, | HepG2 | - | in-vitro, | CRC, | HCT116 |
| 1449- | Bos, | Chemo, | Anti-proliferative, Pro-apoptotic, and Chemosensitizing Potential of 3-Acetyl-11-keto-β-boswellic Acid (AKBA) Against Prostate Cancer Cells |
| - | in-vitro, | Pca, | PC3 |
| 1448- | Bos, | A triterpenediol from Boswellia serrata induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells |
| - | in-vitro, | AML, | HL-60 |
| 1447- | Bos, | Boswellia carterii n-hexane extract suppresses breast cancer growth via induction of ferroptosis by downregulated GPX4 and upregulated transferrin |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vivo, | BC, | 4T1 | - | in-vitro, | Nor, | MCF10 |
| 2024- | Bos, | Antiproliferative and cell cycle arrest potentials of 3-O-acetyl-11-keto-β-boswellic acid against MCF-7 cells in vitro |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 4270- | Bos, | Boswellic acids ameliorate neurodegeneration induced by AlCl3: the implication of Wnt/β-catenin pathway |
| - | in-vivo, | AD, | NA |
| 4269- | Bos, | Boswellia serrata gum resin aqueous extract upregulatesBDNF but not CREB expression in adult male rat hippocampus |
| - | in-vivo, | NA, | NA |
| 3868- | Bos, | Enhanced absorption of boswellic acids by a lecithin delivery form (Phytosome(®)) of Boswellia extract |
| 3867- | Bos, | Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers |
| - | Human, | Nor, | NA |
| 3866- | Bos, | Mechanistic role of boswellic acids in Alzheimer's disease: Emphasis on anti-inflammatory properties |
| - | Review, | AD, | NA |
| 2779- | Bos, | Identification of a natural inhibitor of methionine adenosyltransferase 2A regulating one-carbon metabolism in keratinocytes |
| - | in-vitro, | Nor, | HaCaT | - | in-vitro, | PSA, | NA |
| 2767- | Bos, | The potential role of boswellic acids in cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2778- | Bos, | Development, Analytical Characterization, and Bioactivity Evaluation of Boswellia serrata Extract-Layered Double Hydroxide Hybrid Composites |
| - | in-vitro, | Nor, | NA |
| 2777- | Bos, | Boswellia serrata Preserves Intestinal Epithelial Barrier from Oxidative and Inflammatory Damage |
| - | in-vitro, | IBD, | NA |
| 2776- | Bos, | Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities |
| - | Review, | Var, | NA |
| 2775- | Bos, | The journey of boswellic acids from synthesis to pharmacological activities |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | PSA, | NA |
| 2773- | Bos, | Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer |
| - | Review, | Var, | NA |
| 2772- | Bos, | Mechanistic role of boswellic acids in Alzheimer’s disease: Emphasis on anti-inflammatory properties |
| - | Review, | AD, | NA |
| 2774- | Bos, | Boswellia ovalifoliolata abrogates ROS mediated NF-κB activation, causes apoptosis and chemosensitization in Triple Negative Breast Cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-453 |
| 2768- | Bos, | Boswellic acids as promising agents for the management of brain diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2399- | CA, | EA, | Polyphenol-rich diet mediates interplay between macrophage-neutrophil and gut microbiota to alleviate intestinal inflammation |
| - | Review, | Col, | NA |
| 3032- | CA, | Carnosic Acid Induces Apoptosis Through Reactive Oxygen Species-mediated Endoplasmic Reticulum Stress Induction in Human Renal Carcinoma Caki Cells |
| - | in-vitro, | Kidney, | Caki-1 |
| 1230- | CA, | Caff, | Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | Human, | NA, | NA |
| 1297- | CA, | Caffeic Acid Phenethyl Ester (CAPE) Induced Apoptosis in Serous Ovarian Cancer OV7 Cells by Deregulation of BCL2/BAX Genes |
| - | in-vitro, | Ovarian, | OV7 |
| 1646- | CA, | Caffeic acid: a brief overview of its presence, metabolism, and bioactivity |
| - | Review, | Nor, | NA |
| 1650- | CA, | Adjuvant Properties of Caffeic Acid in Cancer Treatment |
| - | Review, | Var, | NA |
| 1651- | CA, | PBG, | Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer |
| - | Review, | Var, | NA |
| 1652- | CA, | Caffeic Acid and Diseases—Mechanisms of Action |
| - | Review, | Var, | NA |
| - | in-vitro, | Cerv, | SiHa |
| 4342- | CA, | Antiplatelet effects of caffeic acid due to Ca(2+) mobilizationinhibition via cAMP-dependent inositol-1, 4, 5-trisphosphate receptor phosphorylation |
| - | in-vitro, | NA, | NA |
| 1101- | CA, | Tras, | Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2+ breast cancer cells |
| - | in-vitro, | BC, | NA |
| 1207- | CA, | PacT, | Caffeine inhibits the anticancer activity of paclitaxel via down-regulation of α-tubulin acetylation |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Cerv, | HeLa |
| 1011- | CA, | Dihydrocaffeic acid improves IL-1β-induced inflammation and cartilage degradation via inhibiting NF-κB and MAPK signalling pathways |
| - | in-vivo, | NA, | NA |
| 145- | CA, | CUR, | The anti-cancer effects of carotenoids and other phytonutrients resides in their combined activity |
| - | in-vitro, | NA, | NA |
| 4265- | CA, | Potential applications of nanomedicine for treating Parkinson's disease |
| - | Review, | Park, | NA |
| 4263- | CA, | Neuroprotective Effects of Carnosic Acid: Insight into Its Mechanisms of Action |
| - | Review, | AD, | NA |
| 4264- | CA, | Carnosic Acid Mitigates Depression-Like Behavior in Ovariectomized Mice via Activation of Nrf2HO-1 Pathway |
| - | in-vivo, | NA, | NA |
| - | Analysis, | AD, | NA |
| 3791- | CA, | Caffeic Acid and Diseases—Mechanisms of Action |
| - | Review, | AD, | NA |
| - | Study, | AD, | NA |
| 4267- | Caff, | Caffeine‐mediated BDNF release regulates long‐term synaptic plasticity through activation of IRS2 signaling |
| - | in-vivo, | NA, | NA |
| 4161- | Caff, | Chronic caffeine prevents changes in inhibitory avoidance memory and hippocampal BDNF immunocontent in middle-aged rats |
| - | in-vivo, | AD, | NA |
| 4268- | Caff, | Modulatory effect of coffee fruit extract on plasma levels of brain-derived neurotrophic factor in healthy subjects |
| - | Study, | NA, | NA |
| 1653- | Caff, | Higher Caffeinated Coffee Intake Is Associated with Reduced Malignant Melanoma Risk: A Meta-Analysis Study |
| - | Review, | Melanoma, | NA |
| 1205- | Caff, | immuno, | Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody |
| - | in-vivo, | Melanoma, | B16-F10 |
| 1206- | Caff, | Caffeine inhibits TGFβ activation in epithelial cells, interrupts fibroblast responses to TGFβ, and reduces established fibrosis in ex vivo precision-cut lung slices |
| - | in-vitro, | NA, | NA | - | ex-vivo, | NA, | NA |
| 4266- | CAP, | Capsaicin effects on brain-derived neurotrophic factor in rat dorsal root ganglia and spinal cord |
| - | in-vivo, | NA, | NA |
| 3855- | CAP, | Capsaicin consumption reduces brain amyloid-beta generation and attenuates Alzheimer’s disease-type pathology and cognitive deficits in APP/PS1 mice |
| - | in-vivo, | AD, | NA |
| 3854- | CAP, | Capsaicin consumption reduces brain amyloid-beta generation and attenuates Alzheimer’s disease-type pathology and cognitive deficits in APP/PS1 mice |
| - | in-vivo, | AD, | NA |
| 2347- | CAP, | Capsaicin ameliorates inflammation in a TRPV1-independent mechanism by inhibiting PKM2-LDHA-mediated Warburg effect in sepsis |
| - | in-vivo, | Nor, | NA | - | in-vitro, | Nor, | RAW264.7 |
| 2348- | CAP, | Recent advances in analysis of capsaicin and its effects on metabolic pathways by mass spectrometry |
| - | Analysis, | Nor, | NA |
| 2349- | CAP, | The TRPV1-PKM2-SREBP1 axis maintains microglial lipid homeostasis in Alzheimer’s disease |
| - | in-vivo, | AD, | NA |
| 2394- | CAP, | Capsaicin acts as a novel NRF2 agonist to suppress ethanol induced gastric mucosa oxidative damage by directly disrupting the KEAP1-NRF2 interaction |
| - | in-vitro, | Nor, | GES-1 |
| 2652- | CAP, | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| - | Review, | Var, | NA |
| 1265- | CAP, | Capsaicin shapes gut microbiota and pre-metastatic niche to facilitate cancer metastasis to liver |
| - | in-vivo, | CRC, | NA |
| 1264- | CAP, | Capsaicin modulates proliferation, migration, and activation of hepatic stellate cells |
| - | in-vitro, | HCC, | NA |
| 1263- | CAP, | Capsaicin inhibits the migration and invasion via the AMPK/NF-κB signaling pathway in esophagus sequamous cell carcinoma by decreasing matrix metalloproteinase-9 expression |
| - | in-vitro, | ESCC, | Eca109 |
| 1262- | CAP, | Capsaicin Inhibits Proliferation and Induces Apoptosis in Breast Cancer by Down-Regulating FBI-1-Mediated NF-κB Pathway |
| - | vitro+vivo, | BC, | NA |
| 1261- | CAP, | Capsaicin inhibits glycolysis in esophageal squamous cell carcinoma by regulating hexokinase‑2 expression |
| - | in-vitro, | ESCC, | KYSE150 |
| 1260- | CAP, | Capsaicin inhibits in vitro and in vivo angiogenesis |
| - | vitro+vivo, | NA, | NA |
| 1259- | CAP, | Capsaicin inhibits HIF-1α accumulation through suppression of mitochondrial respiration in lung cancer cells |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | H2009 |
| 2013- | CAP, | Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vivo, | NA, | NA |
| 2014- | CAP, | Role of Mitochondrial Electron Transport Chain Complexes in Capsaicin Mediated Oxidative Stress Leading to Apoptosis in Pancreatic Cancer Cells |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | Nor, | HPDE-6 | - | in-vivo, | PC, | AsPC-1 |
| 2015- | CAP, | CUR, | urea, | Anti-cancer Activity of Sustained Release Capsaicin Formulations |
| - | Review, | Var, | NA |
| 2016- | CAP, | Capsaicin binds the N-terminus of Hsp90, induces lysosomal degradation of Hsp70, and enhances the anti-tumor effects of 17-AAG (Tanespimycin) |
| 2017- | CAP, | Spice Up Your Kidney: A Review on the Effects of Capsaicin in Renal Physiology and Disease |
| - | Review, | Var, | NA |
| 2018- | CAP, | MF, | Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma |
| - | Review, | HCC, | NA |
| 2019- | CAP, | Capsaicin: A Two-Decade Systematic Review of Global Research Output and Recent Advances Against Human Cancer |
| - | Review, | Var, | NA |
| 2012- | CAP, | Capsaicin induces cytotoxicity in human osteosarcoma MG63 cells through TRPV1-dependent and -independent pathways |
| - | NA, | OS, | MG63 |
| 2020- | CAP, | Capsaicinoids and Their Effects on Cancer: The “Double-Edged Sword” Postulate from the Molecular Scale |
| - | Review, | Var, | NA |
| 1517- | CAP, | Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1) |
| - | in-vitro, | Bladder, | TSGH8301 | - | in-vitro, | CRC, | T24 |
| 1518- | CAP, | Capsaicin-mediated tNOX (ENOX2) up-regulation enhances cell proliferation and migration in vitro and in vivo |
| - | in-vitro, | CRC, | HCT116 |
| 1287- | CAR, | Carvacrol induces apoptosis in human breast cancer cells via Bcl-2/CytC signaling pathway |
| - | in-vitro, | BC, | HCC1937 |
| - | in-vitro, | Kidney, | HK-2 |
| 1082- | CAR, | Carvacrol, a component of thyme oil, activates PPARα and γ and suppresses COX-2 expression |
| - | in-vitro, | lymphoma, | U937 |
| 3881- | Carno, | The Therapeutic Potential of Carnosine/Anserine Supplementation against Cognitive Decline: A Systematic Review with Meta-Analysis |
| - | Review, | AD, | NA |
| 3877- | Carno, | Carnosine, diabetes and Alzheimer's disease |
| - | Review, | AD, | NA |
| 3880- | Carno, | EFFECT OF ANSERINE/CARNOSINE SUPPLEMENTATION ON THE PREVENTION OF ALZHEIMER'S DISEASE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT |
| - | Trial, | AD, | NA |
| 3879- | Carno, | Daily Carnosine and Anserine Supplementation Alters Verbal Episodic Memory and Resting State Network Connectivity in Healthy Elderly Adults |
| - | Human, | AD, | NA |
| 3878- | Carno, | Safety and Efficacy Evaluation of Carnosine, An Endogenous Neuroprotective Agent for Ischemic Stroke |
| - | in-vivo, | Stroke, | NA |
| 3876- | Carno, | Ex, | Swimming exercise versus L-carnosine supplementation for Alzheimer’s dementia in rats: implication of circulating and hippocampal FNDC5/irisin |
| - | in-vivo, | AD, | NA |
| - | in-vitro, | AD, | NA |
| 3873- | Carno, | Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice |
| - | in-vivo, | AD, | NA |
| 3872- | Carno, | Carnosine Protects Macrophages against the Toxicity of Aβ1-42 Oligomers by Decreasing Oxidative Stress |
| - | in-vitro, | AD, | NA |
| 3874- | Carno, | Effects of zinc and carnosine on aggregation kinetics of Amyloid-β40 peptide |
| - | Review, | AD, | NA |
| 3871- | Carno, | Unveiling the Hidden Therapeutic Potential of Carnosine, a Molecule with a Multimodal Mechanism of Action: A Position Paper |
| - | Review, | NA, | NA |
| 3870- | Carno, | Could carnosine or related structures suppress Alzheimer's disease? |
| - | Review, | AD, | NA |
| 3869- | Carno, | Carnosine, Small but Mighty—Prospect of Use as Functional Ingredient for Functional Food Formulation |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 939- | Catechins, | 5-FU, | Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil |
| - | vitro+vivo, | GC, | SNU620 |
| 603- | Catechins, | Catechins induce oxidative damage to cellular and isolated DNA through the generation of reactive oxygen species |
| - | in-vitro, | NA, | HL-60 |
| 18- | CBC/D, | Cynanbungeigenin C and D, a pair of novel epimers from Cynanchum bungei, suppress hedgehog pathway-dependent medulloblastoma by blocking signaling at the level of Gli |
| - | vitro+vivo, | MB, | NA |
| 17- | CBC/D, | CBC-1 as a Cynanbungeigenin C derivative inhibits the growth of colorectal cancer through targeting Hedgehog pathway component GLI 1 |
| - | in-vivo, | CRC, | NA |
| 1199- | CBD, | Cannabidiol improves muscular lipid profile by affecting the expression of fatty acid transporters and inhibiting de novo lipogenesis |
| - | in-vivo, | Obesity, | NA |
| 1103- | CBD, | Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway |
| - | vitro+vivo, | NA, | NA |
| 1081- | CBDA, | Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 1054- | CEL, | Celecoxib inhibited activation of NF-κB and expression of NF-κB P65 protein in HepG2 cells |
| - | in-vitro, | Liver, | HepG2 |
| 955- | CEL, | Celecoxib Down-Regulates the Hypoxia-Induced Expression of HIF-1α and VEGF Through the PI3K/AKT Pathway in Retinal Pigment Epithelial Cells |
| - | in-vitro, | RPE, | D407 |
| 1105- | CEL, | Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis |
| - | in-vitro, | BC, | NA |
| 2653- | Cela, | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| - | Review, | Var, | NA |
| 2392- | Cela, | The role of natural products targeting macrophage polarization in sepsis-induced lung injury |
| - | Review, | Sepsis, | NA |
| 2393- | Cela, | Celastrol mitigates inflammation in sepsis by inhibiting the PKM2-dependent Warburg effect |
| - | in-vivo, | Sepsis, | NA | - | in-vitro, | Nor, | RAW264.7 |
| 2398- | CGA, | Polyphenol-rich diet mediates interplay between macrophage-neutrophil and gut microbiota to alleviate intestinal inflammation |
| - | in-vivo, | Col, | NA |
| 1298- | CGA, | Chlorogenic acid regulates apoptosis and stem cell marker-related gene expression in A549 human lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 1244- | CGA, | immuno, | Cancer Differentiation Inducer Chlorogenic Acid Suppresses PD-L1 Expression and Boosts Antitumor Immunity of PD-1 Antibody |
| - | in-vivo, | NA, | NA |
| 1106- | CGA, | Chlorogenic Acid Inhibits Epithelial-Mesenchymal Transition and Invasion of Breast Cancer by Down-Regulating LRP6 |
| - | vitro+vivo, | BC, | MCF-7 |
| 954- | CGA, | Chlorogenic acid inhibits hypoxia-induced angiogenesis via down-regulation of the HIF-1α/AKT pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 1083- | CGA, | In Silico Insight the Prediction of Chlorogenic Acid in Coffee through Cyclooxygenase-2 (COX2) Interaction |
| - | Analysis, | NA, | NA |
| 2175- | Chemo, | VitB12, | FA, | Systemic Chemotherapy Interferes in Homocysteine Metabolism in Breast Cancer Patients |
| - | Study, | BC, | NA |
| 4490- | Chit, | FA, | Chitosan Nanoparticle-Based Drug Delivery Systems: Advances, Challenges, and Future Perspectives |
| - | Review, | NA, | NA |
| 4493- | Chit, | Selenate, | Se, | A novel synthetic chitosan selenate (CS) induces apoptosis in A549 lung cancer cells via the Fas/FasL pathway |
| - | in-vitro, | Lung, | A549 |
| 4489- | Chit, | Se, | Inhibiting Metastasis and Improving Chemosensitivity via Chitosan-Coated Selenium Nanoparticles for Brain Cancer Therapy |
| - | in-vitro, | GBM, | U87MG |
| 4487- | Chit, | PreB, | Unravelling the Role of Chitin and Chitosan in Prebiotic Activity and Correlation With Cancer: A Narrative Review |
| - | Review, | NA, | NA |
| 4482- | Chit, | Hyaluronic acid-coated chitosan nanoparticles induce ROS-mediated tumor cell apoptosis and enhance antitumor efficiency by targeted drug delivery via CD44 |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HepG2 |
| 4481- | Chit, | Antioxidant Properties and Redox-Modulating Activity of Chitosan and Its Derivatives: Biomaterials with Application in Cancer Therapy |
| - | Review, | Var, | NA |
| 4479- | Chit, | Chitosan nanoparticles triggered the induction of ROS-mediated cytoprotective autophagy in cancer cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | HCC, | SMMC-7721 cell |
| 4478- | Chit, | Chitosan promotes ROS-mediated apoptosis and S phase cell cycle arrest in triple-negative breast cancer cells: evidence for intercalative interaction with genomic DNA |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D |
| 4477- | Chit, | Recent Advances in Chitosan and its Derivatives in Cancer Treatment |
| - | Review, | NA, | NA |
| 4476- | Chit, | Chitosan decreases total cholesterol in women: a randomized, double-blind, placebo-controlled trial |
| - | Trial, | NA, | NA |
| 4475- | Chit, | Cholesterol-lowering properties and safety of chitosan |
| - | Review, | Nor, | NA |
| 428- | Chit, | docx, | CUR, | Chitosan-based nanoparticle co-delivery of docetaxel and curcumin ameliorates anti-tumor chemoimmunotherapy in lung cancer |
| - | vitro+vivo, | Lung, | H460 | - | vitro+vivo, | Lung, | H1299 | - | vitro+vivo, | Lung, | A549 | - | vitro+vivo, | Lung, | PC9 |
| 4262- | Chol, | Choline up-regulates BDNF and down-regulates TrkB neurotrophin receptor in rat cortical cell culture |
| - | in-vitro, | NA, | NA |
| 4261- | Chol, | VitB12, | FA, | VitB2, | B-Vitamin and Choline Supplementation Changes the Ischemic Brain |
| - | Study, | Stroke, | NA |
| 3701- | Chol, | Lifelong choline supplementation ameliorates Alzheimer's disease pathology and associated cognitive deficits by attenuating microglia activation |
| - | in-vivo, | AD, | NA |
| 3699- | Chol, | Association of dietary cholesterol and egg intakes with the risk of incident dementia or Alzheimer disease: the Kuopio Ischaemic Heart Disease Risk Factor Study |
| - | Study, | AD, | NA |
| 3700- | Chol, | Eggs and Health Special Issue |
| - | Review, | Nor, | NA |
| 3705- | Chol, | LEC, | Effects of consumption of choline and lecithin on neurological and cardiovascular systems |
| - | Review, | AD, | NA |
| 3702- | Chol, | Alzheimer's Disease: Targeting the Cholinergic System |
| - | NA, | AD, | NA |
| 3704- | Chol, | Acetylcholine, aging, and Alzheimer's disease |
| - | Review, | AD, | NA |
| 3703- | Chol, | Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities |
| - | Human, | AD, | NA |
| - | in-vivo, | NA, | NA |
| 3258- | CHr, | PBG, | Chrysin Induced Cell Apoptosis and Inhibited Invasion Through Regulation of TET1 Expression in Gastric Cancer Cells |
| - | in-vitro, | GC, | MKN45 |
| 953- | CHr, | Inhibition of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor by Chrysin in a Rat Model of Choroidal Neovascularization |
| - | in-vivo, | NA, | NA |
| 1033- | CHr, | Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression |
| - | vitro+vivo, | HCC, | NA |
| - | in-vitro, | BC, | NA |
| 1145- | CHr, | Chrysin inhibits propagation of HeLa cells by attenuating cell survival and inducing apoptotic pathways |
| - | in-vitro, | Cerv, | HeLa |
| 1144- | CHr, | 8-bromo-7-methoxychrysin-induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | Nor, | HL7702 |
| 1143- | CHr, | Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2 |
| - | in-vitro, | HCC, | HepG2 | - | in-vivo, | NA, | NA | - | in-vitro, | HCC, | HepG3 | - | in-vitro, | HCC, | HUH7 |
| 1249- | CHr, | Chrysin as an Anti-Cancer Agent Exerts Selective Toxicity by Directly Inhibiting Mitochondrial Complex II and V in CLL B-lymphocytes |
| - | in-vitro, | CLL, | NA |
| 2591- | CHr, | doxoR, | Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway |
| - | in-vitro, | HCC, | Bel-7402 |
| 2590- | CHr, | Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the ERK/Nrf2 signaling pathway |
| - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG |
| 2794- | CHr, | An updated review on the versatile role of chrysin in neurological diseases: Chemistry, pharmacology, and drug delivery approaches |
| - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 2795- | CHr, | Combination of chrysin and cisplatin promotes the apoptosis of Hep G2 cells by up-regulating p53 |
| - | in-vitro, | Liver, | HepG2 |
| 2796- | CHr, | Chemopreventive effect of chrysin, a dietary flavone against benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice |
| - | in-vivo, | Lung, | NA |
| 2797- | CHr, | A flavonoid chrysin suppresses hypoxic survival and metastatic growth of mouse breast cancer cells |
| - | in-vivo, | BC, | NA | - | in-vitro, | BC, | 4T1 |
| 2798- | CHr, | Chrysin: a histone deacetylase 8 inhibitor with anticancer activity and a suitable candidate for the standardization of Chinese propolis |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 2799- | CHr, | Chrysin suppresses renal carcinogenesis via amelioration of hyperproliferation, oxidative stress and inflammation: plausible role of NF-κB |
| - | in-vivo, | RCC, | NA |
| 2800- | CHr, | Chrysin Activates Notch1 Signaling and Suppresses Tumor Growth of Anaplastic Thyroid Carcinoma In vitro and In vivo |
| - | in-vitro, | Thyroid, | NA |
| 2801- | CHr, | AMP-activated protein kinase (AMPK) activation is involved in chrysin-induced growth inhibition and apoptosis in cultured A549 lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 2802- | CHr, | Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis |
| - | in-vitro, | Pca, | DU145 | - | in-vivo, | Pca, | NA |
| 2803- | CHr, | 5-FU, | Potentiating activities of chrysin in the therapeutic efficacy of 5-fluorouracil in gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 2804- | CHr, | Rad, | Gamma-Irradiated Chrysin Improves Anticancer Activity in HT-29 Colon Cancer Cells Through Mitochondria-Related Pathway |
| - | in-vitro, | CRC, | HT29 |
| 2781- | CHr, | PBG, | Chrysin a promising anticancer agent: recent perspectives |
| - | Review, | Var, | NA |
| 2805- | CHr, | Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC) |
| - | in-vitro, | ESCC, | KYSE150 | - | in-vivo, | ESCC, | NA |
| 2807- | CHr, | Evidence-based mechanistic role of chrysin towards protection of cardiac hypertrophy and fibrosis in rats |
| - | in-vivo, | Nor, | NA |
| 2806- | CHr, | Se, | Selenium-containing chrysin and quercetin derivatives: attractive scaffolds for cancer therapy |
| - | in-vitro, | Var, | NA |
| 2792- | CHr, | Chrysin induces death of prostate cancer cells by inducing ROS and ER stress |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 2793- | CHr, | Chrysin Inhibits TAMs-Mediated Autophagy Activation via CDK1/ULK1 Pathway and Reverses TAMs-Mediated Growth-Promoting Effects in Non-Small Cell Lung Cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H157 | - | in-vivo, | NA, | NA |
| 2780- | CHr, | Anti-cancer Activity of Chrysin in Cancer Therapy: a Systematic Review |
| - | Review, | Var, | NA |
| 2782- | CHr, | Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
| 2783- | CHr, | Apoptotic Effects of Chrysin in Human Cancer Cell Lines |
| - | Review, | Var, | NA |
| 2784- | CHr, | Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review) |
| - | Review, | Var, | NA |
| 2785- | CHr, | Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin |
| - | Review, | Var, | NA |
| 2786- | CHr, | Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives |
| - | Review, | Var, | NA |
| 2787- | CHr, | Network pharmacology unveils the intricate molecular landscape of Chrysin in breast cancer therapeutics |
| - | Analysis, | Var, | MCF-7 |
| 2788- | CHr, | Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action |
| - | Review, | Var, | NA |
| 2789- | CHr, | Anticancer Activity of Ether Derivatives of Chrysin |
| - | Review, | Var, | NA |
| 2790- | CHr, | Chrysin: Pharmacological and therapeutic properties |
| - | Review, | Var, | NA |
| 2791- | CHr, | Chrysin attenuates progression of ovarian cancer cells by regulating signaling cascades and mitochondrial dysfunction |
| - | in-vitro, | Ovarian, | OV90 |
| 1274- | Cin, | Cinnamon bark extract suppresses metastatic dissemination of cancer cells through inhibition of glycolytic metabolism |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 1567- | Cin, | Cinnamon: Mystic powers of a minute ingredient |
| - | Review, | Var, | NA |
| 1568- | Cin, | Can Cinnamon be the Silver Bullet for Cancer? |
| - | Review, | NA, | NA |
| 3894- | Cin, | Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis |
| - | in-vitro, | AD, | NA |
| 3893- | Cin, | Cinnamon extract inhibits tau aggregation associated with Alzheimer's disease in vitro |
| - | Review, | AD, | NA |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 3891- | Cin, | Identification of potential targets of cinnamon for treatment against Alzheimer's disease-related GABAergic synaptic dysfunction using network pharmacology |
| - | Analysis, | AD, | NA |
| 3890- | Cin, | The Therapeutic Roles of Cinnamaldehyde against Cardiovascular Diseases |
| - | Review, | NA, | NA |
| 3889- | Cin, | Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models |
| - | in-vivo, | AD, | NA |
| 3888- | Cin, | Cinnamon, a promising prospect towards Alzheimer's disease |
| - | NA, | AD, | NA |
| 4259- | Cin, | The Potential of Cinnamon as Anti-Depressant |
| - | Review, | NA, | NA |
| 952- | Cin, | Cinnamon Extract Reduces VEGF Expression Via Suppressing HIF-1α Gene Expression and Inhibits Tumor Growth in Mice |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | GBM, | U251 | - | in-vivo, | Ovarian, | SKOV3 |
| 1055- | Cin, | Cinnamon extract induces tumor cell death through inhibition of NFκB and AP1 |
| - | vitro+vivo, | Melanoma, | NA | - | vitro+vivo, | CRC, | NA | - | vitro+vivo, | lymphoma, | NA |
| 2315- | Citrate, | Why and how citrate may sensitize malignant tumors to immunotherapy |
| - | Review, | Var, | NA |
| 1588- | Citrate, | ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism |
| - | Review, | NA, | NA |
| 1576- | Citrate, | Targeting citrate as a novel therapeutic strategy in cancer treatment |
| - | Review, | Var, | NA |
| 1587- | Citrate, | ATP citrate lyase: A central metabolic enzyme in cancer |
| - | Review, | NA, | NA |
| 1574- | Citrate, | Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Melanoma, | WM983B | - | in-vivo, | NA, | NA |
| 1586- | Citrate, | Extracellular Citrate Is a Trojan Horse for Cancer Cells |
| - | in-vitro, | Liver, | HepG2 |
| 1577- | Citrate, | Citric acid promotes SPARC release in pancreatic cancer cells and inhibits the progression of pancreatic tumors in mice on a high-fat diet |
| - | in-vivo, | PC, | NA | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | PATU-8988 | - | in-vitro, | PC, | MIA PaCa-2 |
| 1578- | Citrate, | Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update |
| - | Review, | Var, | NA |
| 1579- | Citrate, | Effect of Food Additive Citric Acid on The Growth of Human Esophageal Carcinoma Cell Line EC109 |
| - | in-vitro, | ESCC, | Eca109 |
| 1580- | Citrate, | Citrate activates autophagic death of prostate cancer cells via downregulation CaMKII/AKT/mTOR pathway |
| - | in-vitro, | Pca, | PC3 | - | in-vivo, | PC, | NA | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | WPMY-1 |
| 1581- | Citrate, | Hypothesis proved. . .citric acid (citrate) does improve cancer:A case of a patient suffering from medullary thyroid cancer |
| - | Case Report, | Thyroid, | NA |
| 1582- | Citrate, | Clinical report: A patient with primary peritoneal mesothelioma that has improved after taking citric acid orally |
| - | Case Report, | PerC, | NA |
| 1583- | Citrate, | Extracellular citrate and metabolic adaptations of cancer cells |
| - | Review, | NA, | NA |
| 1584- | Citrate, | Anticancer effects of high-dose extracellular citrate treatment in pancreatic cancer cells under different glucose concentrations |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 |
| 1585- | Citrate, | Sodium citrate targeting Ca2+/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Nor, | HEK293 |
| 1591- | Citrate, | The biological significance of cancer: mitochondria as a cause of cancer and the inhibition of glycolysis with citrate as a cancer treatment |
| - | Analysis, | NA, | NA |
| 1592- | Citrate, | Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | IGROV1 |
| 1593- | Citrate, | Citrate Induces Apoptotic Cell Death: A Promising Way to Treat Gastric Carcinoma? |
| - | in-vitro, | GC, | BGC-823 | - | in-vitro, | GC, | SGC-7901 |
| 4258- | CoQ10, | Neuroprotective effects of coenzyme Q10-loaded exosomes obtained from adipose-derived stem cells in a rat model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 4257- | CoQ10, | Dietary intake of coenzyme Q10 reduces oxidative stress in patients with acute ischemic stroke: a double-blind, randomized placebo-controlled study |
| - | Trial, | Stroke, | NA |
| 3995- | CoQ10, | Effects of Coenzyme Q10 on TNF-alpha secretion in human and murine monocytic cell lines |
| - | in-vitro, | NA, | NA |
| 3993- | CoQ10, | Coenzyme Q10 Decreases Amyloid Pathology and Improves Behavior in a Transgenic Mouse Model of Alzheimer’s Disease |
| - | Review, | Park, | NA | - | Review, | AD, | NA |
| 3994- | CoQ10, | Se, | Coenzyme Q10 Supplementation in Aging and Disease |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3996- | CoQ10, | Coenzyme Q10 decreases TNF-alpha and IL-2 secretion by human peripheral blood mononuclear cells |
| - | in-vitro, | Nor, | NA |
| 3997- | CoQ10, | Coenzyme Q and Its Role in the Dietary Therapy against Aging |
| - | Review, | AD, | NA |
| 3992- | CoQ10, | Coenzyme Q10 |
| - | Review, | AD, | NA |
| 3991- | CoQ10, | Evaluation of Coenzyme Q as an Antioxidant Strategy for Alzheimer’s Disease |
| - | in-vivo, | AD, | NA |
| 3990- | CoQ10, | Serum levels of coenzyme Q10 in patients with Alzheimer's disease |
| - | Study, | AD, | NA |
| 4761- | CoQ10, | Elevated levels of mitochondrial CoQ10 induce ROS-mediated apoptosis in pancreatic cancer |
| - | in-vitro, | PC, | NA | - | in-vivo, | PC, | NA |
| 4776- | CoQ10, | Antitumor properties of Coenzyme Q0 against human ovarian carcinoma cells via induction of ROS-mediated apoptosis and cytoprotective autophagy |
| - | vitro+vivo, | Ovarian, | SKOV3 |
| 4775- | CoQ10, | Chemo, | Chemotherapy induces an increase in coenzyme Q10 levels in cancer cell lines |
| - | in-vitro, | Var, | NA |
| 4773- | CoQ10, | Coenzyme Q10 inhibits the activation of pancreatic stellate cells through PI3K/AKT/mTOR signaling pathway |
| - | in-vitro, | Nor, | NA |
| 4772- | CoQ10, | The anti-tumor activities of coenzyme Q0 through ROS-mediated autophagic cell death in human triple-negative breast cells |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MDA-MB-231 |
| 4771- | CoQ10, | Coenzyme Q10 Protects Astrocytes from ROS-Induced Damage through Inhibition of Mitochondria-Mediated Cell Death Pathway |
| - | Review, | Var, | NA |
| 4770- | CoQ10, | VitK2, | Cancer cell stiffening via CoQ10 and UBIAD1 regulates ECM signaling and ferroptosis in breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 |
| 4769- | CoQ10, | CoQ10 Is Key for Cellular Energy and Cancer Support |
| - | Review, | Var, | NA |
| 4768- | CoQ10, | Role of coenzymes in cancer metabolism |
| - | Review, | Var, | NA |
| 4767- | CoQ10, | Efficacy of Coenzyme Q10 for Improved Tolerability of Cancer Treatments: A Systematic Review |
| - | Review, | Var, | NA |
| 4766- | CoQ10, | Activities of Vitamin Q10in Animal Models and a Serious Deficiency in Patients with Cancer |
| - | Review, | Var, | NA |
| 4764- | CoQ10, | VitE, | Auxiliary effect of trolox on coenzyme Q10 restricts angiogenesis and proliferation of retinoblastoma cells via the ERK/Akt pathway |
| - | in-vitro, | RPE, | Y79 | - | in-vitro, | Nor, | ARPE-19 | - | in-vivo, | NA, | NA |
| 4763- | CoQ10, | Chemo, | doxoR, | Effect of Coenzyme Q10 on Doxorubicin Cytotoxicity in Breast Cancer Cell Cultures |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 |
| 4762- | CoQ10, | The role of coenzyme Q10 as a preventive and therapeutic agent for the treatment of cancers |
| - | Review, | Var, | NA |
| 16- | CP, | Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis |
| - | in-vitro, | GC, | SGC-7901 |
| 945- | Croc, | Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Cerv, | HeLa |
| 4158- | Croc, | Antidepressant effects of crocin and its effects on transcript and protein levels of CREB, BDNF, and VGF in rat hippocampus |
| - | in-vivo, | AD, | NA |
| 4208- | Croc, | Antidepressant Effect of Crocus sativus Aqueous Extract and its Effect on CREB, BDNF, and VGF Transcript and Protein Levels in Rat Hippocampus |
| - | in-vivo, | NA, | NA |
| 3832- | Croc, | Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3625- | Croc, | Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial |
| - | Trial, | AD, | NA |
| 3626- | Croc, | Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial |
| - | Trial, | AD, | NA |
| 3627- | Croc, | The effects of Crocus sativus (saffron) and its constituents on nervous system: A review |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3628- | Croc, | VitE, | CUR, | Vitamin E, Turmeric and Saffron in Treatment of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3629- | Croc, | Studying saffron nanopowder (Crocus Sativus L.) on the temporal memory of rats suffering Parkinson's disease |
| - | in-vivo, | Park, | NA |
| 3630- | Croc, | Crocin Improves Cognitive Behavior in Rats with Alzheimer's Disease by Regulating Endoplasmic Reticulum Stress and Apoptosis |
| - | in-vivo, | AD, | NA |
| 3631- | Croc, | Investigation of the neuroprotective effects of crocin via antioxidant activities in HT22 cells and in mice with Alzheimer's disease |
| - | in-vitro, | AD, | HT22 | - | in-vivo, | AD, | NA |
| 3634- | Croc, | A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease |
| - | Trial, | AD, | NA |
| 3635- | Croc, | A Review of Potential Efficacy of Saffron (Crocus sativus L.) in Cognitive Dysfunction and Seizures |
| - | Review, | NA, | NA |
| 3636- | Croc, | Saffron as a source of novel acetylcholinesterase inhibitors: molecular docking and in vitro enzymatic studies |
| - | in-vitro, | AD, | NA |
| 3637- | Croc, | Investigation of the neuroprotective action of saffron (Crocus sativus L.) in aluminum-exposed adult mice through behavioral and neurobiochemical assessment |
| - | NA, | AD, | NA |
| 3624- | Croc, | Crocus Sativus L. (Saffron) in Alzheimer's Disease Treatment: Bioactive Effects on Cognitive Impairment |
| - | Review, | AD, | NA |
| 1595- | Cu, | The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy |
| - | Review, | NA, | NA |
| 1596- | Cu, | CDT, | Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review |
| - | Review, | NA, | NA |
| 1597- | Cu, | Anticancer potency of copper(II) complexes of thiosemicarbazones |
| - | Review, | NA, | NA |
| 1598- | Cu, | Targeting copper in cancer therapy: 'Copper That Cancer' |
| - | Review, | NA, | NA |
| 1599- | Cu, | Copper in tumors and the use of copper-based compounds in cancer treatment |
| - | Review, | NA, | NA |
| 1600- | Cu, | Cu(II) complex that synergistically potentiates cytotoxicity and an antitumor immune response by targeting cellular redox homeostasis |
| - | Review, | NA, | NA |
| 1601- | Cu, | The copper (II) complex of salicylate phenanthroline induces immunogenic cell death of colorectal cancer cells through inducing endoplasmic reticulum stress |
| - | in-vitro, | CRC, | NA |
| 1602- | Cu, | A simultaneously GSH-depleted bimetallic Cu(ii) complex for enhanced chemodynamic cancer therapy† |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | 4T1 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HepG2 |
| 1603- | Cu, | BP, | SDT, | Glutathione Depletion-Induced ROS/NO Generation for Cascade Breast Cancer Therapy and Enhanced Anti-Tumor Immune Response |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 1604- | Cu, | Targeting copper metabolism: a promising strategy for cancer treatment |
| - | Review, | NA, | NA |
| 1642- | Cu, | HCAs, | Copper-assisted anticancer activity of hydroxycinnamic acid terpyridine conjugates on triple-negative breast cancer |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | Nor, | L929 |
| 1572- | Cu, | Recent Advances in Cancer Therapeutic Copper-Based Nanomaterials for Antitumor Therapy |
| - | Review, | NA, | NA |
| 1571- | Cu, | Copper in cancer: From pathogenesis to therapy |
| - | Review, | NA, | NA |
| 1570- | Cu, | Development of copper nanoparticles and their prospective uses as antioxidants, antimicrobials, anticancer agents in the pharmaceutical sector |
| - | Review, | NA, | NA |
| 1569- | Cu, | Copper Nanoparticles as Therapeutic Anticancer Agents |
| - | Review, | NA, | NA |
| 1639- | Cu, | HCAs, | Green synthesis of copper oxide nanoparticles using sinapic acid: an underpinning step towards antiangiogenic therapy for breast cancer |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 1590- | Cuc, | ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism |
| - | Review, | NA, | NA |
| 1609- | CUR, | EA, | Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells |
| - | in-vitro, | Cerv, | NA |
| 1616- | CUR, | EA, | Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid |
| - | in-vitro, | Nor, | NA |
| 1510- | CUR, | Chemo, | Combination therapy in combating cancer |
| - | Review, | NA, | NA |
| 1809- | CUR, | Oxy, | Long-term stabilisation of myeloma with curcumin |
| - | Case Report, | Melanoma, | NA |
| 1792- | CUR, | LEC, | Chondroprotective effect of curcumin and lecithin complex in human chondrocytes stimulated by IL-1β via an anti-inflammatory mechanism |
| - | in-vitro, | Arthritis, | RAW264.7 | - | NA, | NA, | HCC-38 |
| 1487- | CUR, | Relationship and interactions of curcumin with radiation therapy |
| - | Review, | Var, | NA |
| 1486- | CUR, | Curcumin and lung cancer--a review |
| - | Review, | Lung, | NA |
| 1485- | CUR, | Chemo, | Rad, | Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs |
| - | Review, | Var, | NA |
| 1408- | CUR, | Antiproliferative and ROS Regulation Activity of Photoluminescent Curcumin-Derived Nanodots |
| - | in-vitro, | Lung, | A549 |
| 1411- | CUR, | Cisplatin, | Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects |
| - | Review, | Var, | NA |
| 1410- | CUR, | Curcumin induces ferroptosis and apoptosis in osteosarcoma cells by regulating Nrf2/GPX4 signaling pathway |
| - | vitro+vivo, | OS, | MG63 |
| 1409- | CUR, | Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma |
| - | in-vivo, | CCA, | Walker256 |
| 1383- | CUR, | BBR, | RES, | Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases |
| - | Review, | NA, | NA |
| 1418- | CUR, | Potential complementary and/or synergistic effects of curcumin and boswellic acids for management of osteoarthritis |
| - | Review, | Arthritis, | NA |
| 1488- | CUR, | Anti-Cancer and Radio-Sensitizing Effects of Curcumin in Nasopharyngeal Carcinoma |
| 1505- | CUR, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
| - | Review, | NA, | NA |
| 1977- | CUR, | Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | A549 |
| 1982- | CUR, | Inhibition of thioredoxin reductase by curcumin analogs |
| - | in-vitro, | NA, | NA |
| 1978- | CUR, | Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells |
| - | in-vitro, | Cerv, | HeLa |
| 1979- | CUR, | Rad, | Dimethoxycurcumin, a metabolically stable analogue of curcumin enhances the radiosensitivity of cancer cells: Possible involvement of ROS and thioredoxin reductase |
| - | in-vitro, | Lung, | A549 |
| 1980- | CUR, | Rad, | Thioredoxin reductase-1 (TxnRd1) mediates curcumin-induced radiosensitization of squamous carcinoma cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Laryn, | FaDu |
| 1981- | CUR, | Mitochondrial targeted curcumin exhibits anticancer effects through disruption of mitochondrial redox and modulation of TrxR2 activity |
| - | in-vitro, | Lung, | NA |
| 3586- | CUR, | PI, | Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers |
| - | in-vivo, | NA, | NA |
| 3574- | CUR, | The effect of curcumin (turmeric) on Alzheimer's disease: An overview |
| - | Review, | AD, | NA |
| 3575- | CUR, | The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse |
| - | in-vivo, | AD, | NA |
| 3576- | CUR, | Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3577- | CUR, | Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study |
| - | Trial, | AD, | NA |
| 3578- | CUR, | SIL, | Curcumin, but not its degradation products, in combination with silibinin is primarily responsible for the inhibition of colon cancer cell proliferation |
| - | in-vitro, | CRC, | DLD1 |
| 3579- | CUR, | SNP, | Metal–Curcumin Complexes in Therapeutics: An Approach to Enhance Pharmacological Effects of Curcumin |
| - | Review, | NA, | NA |
| 3580- | CUR, | Curcumin Acts as Post-protective Effects on Rat Hippocampal Synaptosomes in a Neuronal Model of Aluminum-Induced Toxicity |
| - | in-vivo, | AD, | NA |
| 3581- | CUR, | Curcumin Attenuated Neurotoxicity in Sporadic Animal Model of Alzheimer's Disease |
| - | NA, | AD, | NA |
| 3582- | CUR, | PI, | Therapeutic and Preventive Effects of Piperine and its Combination with Curcumin as a Bioenhancer Against Aluminum-Induced Damage in the Astrocyte Cells |
| 3583- | CUR, | Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers |
| - | Review, | Arthritis, | NA |
| 3584- | CUR, | Curcumin in Health and Diseases: Alzheimer’s Disease and Curcumin Analogues, Derivatives, and Hybrids |
| 3585- | CUR, | Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer |
| - | Study, | NA, | NA |
| 3590- | CUR, | The Holy Grail of Curcumin and its Efficacy in Various Diseases: Is Bioavailability Truly a Big Concern? |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3588- | CUR, | The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies |
| - | Review, | AD, | NA |
| 3856- | CUR, | Curcumin induces IL-6 receptor shedding via the ADAM10 proteinase |
| - | in-vitro, | AD, | NA |
| 3857- | CUR, | Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment |
| - | Review, | AD, | NA |
| 3860- | CUR, | Curcumin Ameliorates Memory Decline via Inhibiting BACE1 Expression and β-Amyloid Pathology in 5×FAD Transgenic Mice |
| - | in-vivo, | AD, | NA |
| 3861- | CUR, | Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment? |
| - | Review, | Var, | NA |
| 3862- | CUR, | RES, | The metalloproteinase ADAM10: A useful therapeutic target? |
| - | Review, | AD, | NA |
| 3760- | CUR, | GI, | CAP, | RosA, | PI | Extending the lore of curcumin as dipteran Butyrylcholine esterase (BChE) inhibitor: A holistic molecular interplay assessment |
| 3793- | CUR, | Curcumin Downregulates GSK3 and Cdk5 in Scopolamine-Induced Alzheimer’s Disease Rats Abrogating Aβ40/42 and Tau Hyperphosphorylation |
| - | in-vivo, | AD, | NA |
| 3794- | CUR, | Curcumin hybrid molecules for the treatment of Alzheimer's disease: Structure and pharmacological activities |
| - | Review, | AD, | NA |
| 3795- | CUR, | Curcumin: A Golden Approach to Healthy Aging: A Systematic Review of the Evidence |
| - | Review, | AD, | NA |
| 3797- | CUR, | Curcumin reverses cognitive deficits through promoting neurogenesis and synapse plasticity via the upregulation of PSD95 and BDNF in mice |
| - | in-vitro, | NA, | NA |
| 3748- | CUR, | RES, | Hup, | Riv, | Gala | Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease |
| - | Review, | AD, | NA |
| - | in-vitro, | AD, | SH-SY5Y |
| 3751- | CUR, | Gala, | A Novel Galantamine-Curcumin Hybrid as a Potential Multi-Target Agent against Neurodegenerative Disorders |
| - | in-vivo, | AD, | NA |
| 3752- | CUR, | Revealing the molecular interplay of curcumin as Culex pipiens Acetylcholine esterase 1 (AChE1) inhibitor |
| - | in-vivo, | AD, | NA |
| 3753- | CUR, | Gala, | A Novel Galantamine–Curcumin Hybrid Inhibits Butyrylcholinesterase: A Molecular Dynamics Study |
| - | Study, | AD, | NA |
| 3831- | CUR, | Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4171- | CUR, | Curcumin produces neuroprotective effects via activating brain-derived neurotrophic factor/TrkB-dependent MAPK and PI-3K cascades in rodent cortical neurons |
| - | in-vivo, | NA, | NA |
| 4175- | CUR, | Effects of curcumin on learning and memory deficits, BDNF, and ERK protein expression in rats exposed to chronic unpredictable stress |
| - | in-vivo, | NA, | NA |
| - | in-vivo, | AD, | NA |
| 2312- | CUR, | Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy |
| - | Review, | Var, | NA |
| 2308- | CUR, | Counteracting Action of Curcumin on High Glucose-Induced Chemoresistance in Hepatic Carcinoma Cells |
| - | in-vitro, | Liver, | HepG2 |
| 2305- | CUR, | Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN |
| - | in-vitro, | BC, | MCF-7 |
| 2304- | CUR, | Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | HEK293 |
| 2307- | CUR, | Cell-Type Specific Metabolic Response of Cancer Cells to Curcumin |
| - | in-vitro, | Colon, | HT29 | - | in-vitro, | Laryn, | FaDu |
| 2980- | CUR, | Inhibition of NF B and Pancreatic Cancer Cell and Tumor Growth by Curcumin Is Dependent on Specificity Protein Down-regulation |
| - | in-vivo, | PC, | NA |
| 2979- | CUR, | GB, | Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death |
| - | in-vitro, | Lung, | H157 | - | in-vitro, | Lung, | H1299 |
| 2978- | CUR, | N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells |
| - | in-vitro, | Lung, | A549 |
| 2977- | CUR, | Curcumin Down-Regulates Toll-Like Receptor-2 Gene Expression and Function in Human Cystic Fibrosis Bronchial Epithelial Cells |
| - | in-vitro, | CF, | NA |
| 2976- | CUR, | Curcumin suppresses the proliferation of oral squamous cell carcinoma through a specificity protein 1/nuclear factor‑κB‑dependent pathway |
| - | in-vitro, | Oral, | HSC3 | - | in-vitro, | HNSCC, | CAL33 |
| 2975- | CUR, | Curcumin inhibits proliferation, migration and neointimal formation of vascular smooth muscle via activating miR-22 |
| - | in-vivo, | Nor, | NA |
| 2974- | CUR, | Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT15 | - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | SW-620 | - | in-vivo, | NA, | NA |
| 2821- | CUR, | Antioxidant curcumin induces oxidative stress to kill tumor cells (Review) |
| - | Review, | Var, | NA |
| 2822- | CUR, | Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies |
| - | Analysis, | Nor, | NA |
| 2823- | CUR, | Binding of curcumin with glyoxalase I: Molecular docking, molecular dynamics simulations, and kinetics analysis |
| - | Study, | Nor, | NA |
| 2820- | CUR, | Hepatoprotective Effect of Curcumin on Hepatocellular Carcinoma Through Autophagic and Apoptic Pathways |
| - | in-vitro, | HCC, | HepG2 |
| 2819- | CUR, | Chemo, | Curcumin as a hepatoprotective agent against chemotherapy-induced liver injury |
| - | Review, | Var, | NA |
| 2818- | CUR, | Novel Insight to Neuroprotective Potential of Curcumin: A Mechanistic Review of Possible Involvement of Mitochondrial Biogenesis and PI3/Akt/ GSK3 or PI3/Akt/CREB/BDNF Signaling Pathways |
| - | Review, | AD, | NA |
| 2817- | CUR, | Neuroprotection by curcumin: A review on brain delivery strategies |
| - | Review, | Nor, | NA |
| 2816- | CUR, | NEUROPROTECTIVE EFFECTS OF CURCUMIN |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2815- | CUR, | Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin |
| 2814- | CUR, | Curcumin in Cancer and Inflammation: An In-Depth Exploration of Molecular Interactions, Therapeutic Potentials, and the Role in Disease Management |
| - | Review, | Var, | NA |
| 2813- | CUR, | Oxidative Metabolites of Curcumin Poison Human Type II Topoisomerases |
| - | Review, | NA, | NA |
| 2812- | CUR, | Curcumin Induces High Levels of Topoisomerase I− and II−DNA Complexes in K562 Leukemia Cells |
| - | in-vitro, | AML, | K562 |
| 2811- | CUR, | Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study |
| - | Human, | Pca, | NA |
| 2810- | CUR, | Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials |
| - | Review, | Nor, | NA |
| 2809- | CUR, | Comparative absorption of curcumin formulations |
| - | in-vivo, | Nor, | NA |
| 2808- | CUR, | Iron chelation by curcumin suppresses both curcumin-induced autophagy and cell death together with iron overload neoplastic transformation |
| - | in-vitro, | Liver, | HUH7 |
| 2688- | CUR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2466- | CUR, | Regulatory Effects of Curcumin on Platelets: An Update and Future Directions |
| - | Review, | Nor, | NA |
| 2654- | CUR, | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| - | Review, | Var, | NA |
| 2579- | CUR, | ART/DHA, | Curcumin-Artemisinin Combination Therapy for Malaria |
| - | in-vivo, | NA, | NA |
| 4707- | CUR, | The Potential Role of Curcumin as a Regulator of microRNA in Colorectal Cancer: A Systematic Review |
| - | Review, | Var, | NA |
| 4708- | CUR, | Molecular mechanisms underlying curcumin-mediated microRNA regulation in carcinogenesis; Focused on gastrointestinal cancers |
| - | Review, | GC, | NA |
| 4709- | CUR, | Curcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways |
| - | Review, | Var, | NA |
| 4710- | CUR, | Curcumin inhibits migration and invasion of non-small cell lung cancer cells through up-regulation of miR-206 and suppression of PI3K/AKT/mTOR signaling pathway |
| - | in-vitro, | Lung, | A549 |
| 4672- | CUR, | An old spice with new tricks: Curcumin targets adenoma and colorectal cancer stem-like cells associated with poor survival outcomes |
| - | vitro+vivo, | CRC, | HCT116 |
| 4651- | CUR, | Targeting cancer stem cells by curcumin and clinical applications |
| - | Review, | Var, | NA |
| 4671- | CUR, | Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy |
| - | in-vitro, | CRC, | NA |
| 4656- | CUR, | EGCG, | Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 4655- | CUR, | Inhibition of Cancer Stem-like Cells by Curcumin and Other Polyphenol Derivatives in MDA-MB-231 TNBC Cells |
| - | in-vitro, | BC, | NA |
| 4654- | CUR, | Stem Cell Therapy: Curcumin Does the Trick |
| - | Review, | Var, | NA |
| 4653- | CUR, | Curcumin: a promising agent targeting cancer stem cells |
| - | Review, | Var, | NA |
| 4652- | CUR, | Anticancer effect of curcumin on breast cancer and stem cells |
| - | Review, | BC, | NA |
| 4650- | CUR, | Curcumin and cancer stem cells: curcumin has asymmetrical effects on cancer and normal stem cells |
| - | Review, | Var, | NA |
| 4674- | CUR, | Curcumin Shows Promise in Targeting Colorectal Cancer Stem-like Cells: Mechanistic Insights and Clinical Implications |
| - | Review, | CRC, | NA |
| 4673- | CUR, | Curcumin and colorectal cancer: An update and current perspective on this natural medicine |
| - | Review, | CRC, | NA |
| 4676- | CUR, | Curcumin suppresses stem-like traits of lung cancer cells via inhibiting the JAK2/STAT3 signaling pathway |
| - | vitro+vivo, | Lung, | H460 |
| 4675- | CUR, | Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines |
| - | in-vitro, | NSCLC, | A549 |
| 4831- | CUR, | The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatin-induced ototoxicity |
| - | in-vitro, | NA, | NA |
| 4830- | CUR, | Curcumin and Its Derivatives Induce Apoptosis in Human Cancer Cells by Mobilizing and Redox Cycling Genomic Copper Ions |
| - | in-vitro, | Var, | NA |
| 4829- | CUR, | Dual Action of Curcumin as an Anti- and Pro-Oxidant from a Biophysical Perspective |
| - | Review, | Var, | NA |
| 4828- | CUR, | Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane) |
| - | Review, | Var, | NA |
| 4826- | CUR, | The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management |
| - | Review, | Var, | NA |
| - | in-vitro, | NA, | NA |
| 872- | CUR, | RES, | New Insights into Curcumin- and Resveratrol-Mediated Anti-Cancer Effects |
| - | in-vitro, | BC, | TUBO | - | in-vitro, | BC, | SALTO |
| 933- | CUR, | EP, | Effective electrochemotherapy with curcumin in MDA-MB-231-human, triple negative breast cancer cells: A global proteomics study |
| - | in-vitro, | BC, | NA |
| 155- | CUR, | Osteopontin and MMP9: Associations with VEGF Expression/Secretion and Angiogenesis in PC3 Prostate Cancer Cells |
| - | in-vitro, | Pca, | PC3 |
| 154- | CUR, | Curcumin inhibits expression of inhibitor of DNA binding 1 in PC3 cells and xenografts |
| - | vitro+vivo, | Pca, | PC3 |
| 157- | CUR, | Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulating the expression of IkappaBalpha, c-Jun and androgen receptor |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 153- | CUR, | Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in Vivo |
| - | in-vivo, | Pca, | C4-2B |
| 152- | CUR, | Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer |
| - | in-vivo, | Pca, | NA |
| 151- | CUR, | Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | LNCaP |
| 146- | CUR, | EGCG, | Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 131- | CUR, | Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer |
| - | vitro+vivo, | Pca, | LNCaP | - | vitro+vivo, | Pca, | 22Rv1 |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | NA, | DU145 | - | in-vitro, | NA, | LNCaP |
| 143- | CUR, | Nonautophagic cytoplasmic vacuolation death induction in human PC-3M prostate cancer by curcumin through reactive oxygen species -mediated endoplasmic reticulum stress |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 141- | CUR, | Effect of curcumin on Bcl-2 and Bax expression in nude mice prostate cancer |
| - | in-vivo, | Pca, | PC3 |
| 140- | CUR, | Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling |
| - | in-vitro, | Pca, | PC3 |
| 137- | CUR, | Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling |
| - | in-vitro, | Pca, | DU145 |
| 136- | CUR, | docx, | Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 135- | CUR, | Curcumin induces apoptosis and protective autophagy in castration-resistant prostate cancer cells through iron chelation |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 134- | CUR, | RES, | MEL, | SIL, | Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 133- | CUR, | Curcumin inhibits prostate cancer by targeting PGK1 in the FOXD3/miR-143 axis |
| - | in-vitro, | Pca, | NA |
| 132- | CUR, | Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 142- | CUR, | Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts |
| - | in-vivo, | Pca, | LNCaP |
| 170- | CUR, | Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis |
| - | vitro+vivo, | Pca, | PC3 |
| 183- | CUR, | Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 182- | CUR, | RES, | GI, | Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | LAPC-4 |
| 181- | CUR, | The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo |
| - | vitro+vivo, | Pca, | DU145 |
| 9- | CUR, | Curcumin Suppresses Malignant Glioma Cells Growth and Induces Apoptosis by Inhibition of SHH/GLI1 Signaling Pathway in Vitro and Vivo |
| - | vitro+vivo, | MG, | U87MG | - | vitro+vivo, | MG, | T98G |
| 10- | CUR, | Curcumin Suppresses Lung Cancer Stem Cells via Inhibiting Wnt/β-catenin and Sonic Hedgehog Pathways |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 11- | CUR, | Curcumin inhibits hypoxia-induced epithelial‑mesenchymal transition in pancreatic cancer cells via suppression of the hedgehog signaling pathway |
| - | in-vitro, | PC, | PANC1 |
| 12- | CUR, | Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells |
| - | in-vitro, | MB, | DAOY |
| 13- | CUR, | Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action |
| - | Review, | BC, | NA |
| 14- | CUR, | Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 Pathway |
| - | vitro+vivo, | Pca, | PC3 |
| 15- | CUR, | UA, | Effects of curcumin and ursolic acid in prostate cancer: A systematic review |
| 158- | CUR, | Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis |
| - | vitro+vivo, | Pca, | LNCaP |
| 169- | CUR, | Curcumin inhibits the expression of vascular endothelial growth factor and androgen-independent prostate cancer cell line PC-3 in vitro |
| - | in-vitro, | Pca, | PC3 |
| 168- | CUR, | Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism |
| - | in-vitro, | Pca, | PC3 |
| 167- | CUR, | Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria |
| - | in-vitro, | Pca, | PC3 |
| 165- | CUR, | Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP |
| 164- | CUR, | Anti-tumor activity of curcumin against androgen-independent prostate cancer cells via inhibition of NF-κB and AP-1 pathway in vitro |
| - | in-vitro, | Pca, | PC3 |
| 163- | CUR, | Epigenetic CpG Demethylation of the Promoter and Reactivation of the Expression of Neurog1 by Curcumin in Prostate LNCaP Cells |
| - | in-vitro, | Pca, | LNCaP |
| 162- | CUR, | EGCG, | SFN, | Shattering the underpinnings of neoplastic architecture in LNCap: synergistic potential of nutraceuticals in dampening PDGFR/EGFR signaling and cellular proliferation |
| - | in-vitro, | Pca, | LNCaP |
| 161- | CUR, | MeSA, | Enhanced apoptotic effects by the combination of curcumin and methylseleninic acid: potential role of Mcl-1 and FAK |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Pca, | DU145 |
| 160- | CUR, | Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2 |
| 159- | CUR, | Crosstalk from survival to necrotic death coexists in DU-145 cells by curcumin treatment |
| - | in-vitro, | Pca, | DU145 |
| 129- | CUR, | Curcumin suppressed the prostate cancer by inhibiting JNK pathways via epigenetic regulation |
| - | vitro+vivo, | Pca, | LNCaP |
| 130- | CUR, | Maspin Enhances the Anticancer Activity of Curcumin in Hormone-refractory Prostate Cancer Cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 117- | CUR, | Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells |
| - | in-vivo, | Pca, | RM-1 | - | in-vivo, | Pca, | DU145 |
| 118- | CUR, | Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 120- | CUR, | A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation |
| - | Human, | Pca, | NA |
| 121- | CUR, | Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational Study |
| - | in-vivo, | Pca, | NA |
| 122- | CUR, | isoFl, | Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen |
| - | Human, | Pca, | LNCaP |
| 123- | CUR, | Synthesis of novel 4-Boc-piperidone chalcones and evaluation of their cytotoxic activity against highly-metastatic cancer cells |
| - | in-vitro, | Colon, | LoVo | - | in-vitro, | Colon, | COLO205 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | 22Rv1 |
| 124- | CUR, | Curcumin-Gene Expression Response in Hormone Dependent and Independent Metastatic Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 125- | CUR, | Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway |
| - | in-vitro, | adrenal, | H295R |
| 126- | CUR, | Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 127- | CUR, | The chromatin remodeling protein BRG1 links ELOVL3 trans-activation to prostate cancer metastasis |
| - | in-vitro, | Pca, | NA |
| 128- | CUR, | RES, | Evaluation of biophysical as well as biochemical potential of curcumin and resveratrol during prostate cancer |
| - | in-vivo, | Pca, | NA |
| 1108- | CUR, | Curcumin: a potent agent to reverse epithelial-to-mesenchymal transition |
| - | Review, | NA, | NA |
| 430- | CUR, | Curcumin suppresses tumor growth of gemcitabine-resistant non-small cell lung cancer by regulating lncRNA-MEG3 and PTEN signaling |
| - | vitro+vivo, | Lung, | A549 |
| 424- | CUR, | Curcumin inhibits autocrine growth hormone-mediated invasion and metastasis by targeting NF-κB signaling and polyamine metabolism in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 425- | CUR, | Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells |
| - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 404- | CUR, | Curcumin induces ferroptosis in non-small-cell lung cancer via activating autophagy |
| - | vitro+vivo, | Lung, | A549 | - | vitro+vivo, | Lung, | H1299 |
| 426- | CUR, | Use of cancer chemopreventive phytochemicals as antineoplastic agents |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | CAL51 |
| 438- | CUR, | Curcumin Reduces Colorectal Cancer Cell Proliferation and Migration and Slows In Vivo Growth of Liver Metastases in Rats |
| - | vitro+vivo, | CRC, | CC531 |
| 427- | CUR, | Curcumin suppresses the malignancy of non-small cell lung cancer by modulating the circ-PRKCA/miR-384/ITGB1 pathway |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | vitro+vivo, | Lung, | A549 |
| 429- | CUR, | TAp63α Is Involved in Tobacco Smoke-Induced Lung Cancer EMT and the Anti-cancer Activity of Curcumin via miR-19 Transcriptional Suppression |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | A549 |
| 431- | CUR, | Curcumin suppresses the stemness of non-small cell lung cancer cells via promoting the nuclear-cytoplasm translocation of TAZ |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 432- | CUR, | Curcumin-Induced Global Profiling of Transcriptomes in Small Cell Lung Cancer Cells |
| - | in-vitro, | Lung, | H446 |
| 433- | CUR, | Curcumin Inhibits the Migration and Invasion of Non-Small-Cell Lung Cancer Cells Through Radiation-Induced Suppression of Epithelial-Mesenchymal Transition and Soluble E-Cadherin Expression |
| - | in-vitro, | Lung, | A549 |
| 434- | CUR, | Curcumin induces apoptosis in lung cancer cells by 14-3-3 protein-mediated activation of Bad |
| - | in-vitro, | Lung, | A549 |
| 435- | CUR, | Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway |
| - | in-vitro, | Lung, | A549 |
| 437- | CUR, | Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids |
| - | vitro+vivo, | CRC, | TCO1 | - | vitro+vivo, | CRC, | TCO2 |
| 439- | CUR, | Curcumin suppresses LGR5(+) colorectal cancer stem cells by inducing autophagy and via repressing TFAP2A-mediated ECM pathway |
| - | in-vitro, | CRC, | LGR5 |
| 436- | CUR, | Integrated microRNA and gene expression profiling reveals the crucial miRNAs in curcumin anti‐lung cancer cell invasion |
| - | in-vitro, | Lung, | A549 |
| 423- | CUR, | Inhibition of TLR4/TRIF/IRF3 Signaling Pathway by Curcumin in Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 422- | CUR, | Curcumin induces re-expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines |
| - | in-vitro, | BC, | HCC-38 | - | in-vitro, | BC, | T47D |
| 420- | CUR, | Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 417- | CUR, | Curcumin inhibits the growth of triple‐negative breast cancer cells by silencing EZH2 and restoring DLC1 expression |
| - | vitro+vivo, | BC, | MCF-7 | - | vitro+vivo, | BC, | MDA-MB-231 | - | vitro+vivo, | BC, | MDA-MB-468 |
| 415- | CUR, | Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 414- | CUR, | Transcriptome Investigation and In Vitro Verification of Curcumin-Induced HO-1 as a Feature of Ferroptosis in Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 413- | CUR, | Curcumin attenuates lncRNA H19-induced epithelial-mesenchymal transition in tamoxifen-resistant breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 412- | CUR, | Curcumin and Its New Derivatives: Correlation between Cytotoxicity against Breast Cancer Cell Lines, Degradation of PTP1B Phosphatase and ROS Generation |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 411- | CUR, | Curcumin inhibits the invasion and metastasis of triple negative breast cancer via Hedgehog/Gli1 signaling pathway |
| - | in-vitro, | BC, | MDA-MB-231 |
| 410- | CUR, | Nrf2 depletion enhanced curcumin therapy effect in gastric cancer by inducing the excessive accumulation of ROS |
| - | vitro+vivo, | GC, | AGS | - | vitro+vivo, | GC, | HGC27 |
| 409- | CUR, | Curcumin Inhibits Glyoxalase 1—A Possible Link to Its Anti-Inflammatory and Anti-Tumor Activity |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | BC, | MDA-MB-231 |
| 408- | CUR, | Cytotoxic, chemosensitizing and radiosensitizing effects of curcumin based on thioredoxin system inhibition in breast cancer cells: 2D vs. 3D cell culture system |
| - | in-vitro, | BC, | MCF-7 |
| 407- | CUR, | Curcumin inhibited growth of human melanoma A375 cells via inciting oxidative stress |
| - | in-vitro, | Melanoma, | A375 |
| 406- | CUR, | Effect of curcumin on normal and tumor cells: Role of glutathione and bcl-2 |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Hepat, | HepG2 |
| 405- | CUR, | 5-FU, | Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis |
| - | vitro+vivo, | CRC, | HCT116 |
| 477- | CUR, | Curcumin induces G2/M arrest and triggers autophagy, ROS generation and cell senescence in cervical cancer cells |
| - | in-vitro, | Cerv, | SiHa |
| 468- | CUR, | 5-FU, | Gut microbiota enhances the chemosensitivity of hepatocellular carcinoma to 5-fluorouracil in vivo by increasing curcumin bioavailability |
| - | vitro+vivo, | Liver, | HepG2 | - | vitro+vivo, | Liver, | 402 | - | vitro+vivo, | Liver, | Bel7 |
| 459- | CUR, | Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells |
| - | in-vitro, | Bladder, | T24 | - | in-vitro, | Bladder, | RT4 |
| 460- | CUR, | Curcumin Suppresses microRNA-7641-Mediated Regulation of p16 Expression in Bladder Cancer |
| - | in-vitro, | Bladder, | T24 | - | in-vitro, | Bladder, | TCCSUP | - | in-vitro, | Bladder, | J82 |
| 461- | CUR, | Curcumin inhibits prostate cancer progression by regulating the miR-30a-5p/PCLAF axis |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 462- | CUR, | Curcumin promotes cancer-associated fibroblasts apoptosis via ROS-mediated endoplasmic reticulum stress |
| - | in-vitro, | Pca, | PC3 |
| 463- | CUR, | Curcumin induces autophagic cell death in human thyroid cancer cells |
| - | in-vitro, | Thyroid, | K1 | - | in-vitro, | Thyroid, | FTC-133 | - | in-vitro, | Thyroid, | BCPAP | - | in-vitro, | Thyroid, | 8505C |
| 464- | CUR, | Curcumin inhibits the viability, migration and invasion of papillary thyroid cancer cells by regulating the miR-301a-3p/STAT3 axis |
| - | in-vitro, | Thyroid, | BCPAP | - | in-vitro, | Thyroid, | TPC-1 |
| 465- | CUR, | Curcumin inhibits the growth of liver cancer by impairing myeloid-derived suppressor cells in murine tumor tissues |
| - | vitro+vivo, | Liver, | HepG2 | - | vitro+vivo, | Liver, | HUH7 | - | vitro+vivo, | Liver, | MHCC-97H |
| 466- | CUR, | Curcumin circumvent lactate-induced chemoresistance in hepatic cancer cells through modulation of hydroxycarboxylic acid receptor-1 |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | HuT78 |
| 467- | CUR, | Curcumin inhibits liver cancer by inhibiting DAMP molecule HSP70 and TLR4 signaling |
| - | in-vitro, | Liver, | HepG2 |
| 458- | CUR, | Curcumin suppresses gastric cancer by inhibiting gastrin‐mediated acid secretion |
| - | vitro+vivo, | GC, | SGC-7901 |
| 469- | CUR, | The inhibitory effect of curcumin via fascin suppression through JAK/STAT3 pathway on metastasis and recurrence of ovary cancer cells |
| - | in-vitro, | Ovarian, | SKOV3 |
| 470- | CUR, | Regulation of carcinogenesis and modulation through Wnt/β-catenin signaling by curcumin in an ovarian cancer cell line |
| - | in-vitro, | Ovarian, | SKOV3 |
| 471- | CUR, | Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | A2780S |
| 472- | CUR, | Curcumin inhibits ovarian cancer progression by regulating circ-PLEKHM3/miR-320a/SMG1 axis |
| - | vitro+vivo, | Ovarian, | SKOV3 | - | vitro+vivo, | Ovarian, | A2780S |
| 473- | CUR, | Curcumin inhibits epithelial-mesenchymal transition in oral cancer cells via c-Met blockade |
| - | in-vitro, | Oral, | HSC4 | - | in-vitro, | Oral, | Ca9-22 |
| 474- | CUR, | Modification of radiosensitivity by Curcumin in human pancreatic cancer cell lines |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 |
| 475- | CUR, | Curcumin induces apoptotic cell death in human pancreatic cancer cells via the miR-340/XIAP signaling pathway |
| - | in-vitro, | PC, | PANC1 |
| 476- | CUR, | The effects of curcumin on proliferation, apoptosis, invasion, and NEDD4 expression in pancreatic cancer |
| - | in-vitro, | PC, | PATU-8988 | - | in-vitro, | PC, | PANC1 |
| 449- | CUR, | Curcumin Suppresses the Colon Cancer Proliferation by Inhibiting Wnt/β-Catenin Pathways via miR-130a |
| - | vitro+vivo, | CRC, | SW480 |
| 441- | CUR, | Curcumin Regulates ERCC1 Expression and Enhances Oxaliplatin Sensitivity in Resistant Colorectal Cancer Cells through Its Effects on miR-409-3p |
| - | in-vitro, | CRC, | HCT116 |
| 442- | CUR, | 5-FU, | Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress |
| - | in-vitro, | CRC, | HCT116 |
| 443- | CUR, | Reduced Caudal Type Homeobox 2 (CDX2) Promoter Methylation Is Associated with Curcumin’s Suppressive Effects on Epithelial-Mesenchymal Transition in Colorectal Cancer Cells |
| - | in-vitro, | CRC, | SW480 |
| 444- | CUR, | Cisplatin, | LncRNA KCNQ1OT1 is a key factor in the reversal effect of curcumin on cisplatin resistance in the colorectal cancer cells |
| - | vitro+vivo, | CRC, | HCT8 |
| 445- | CUR, | Curcumin Regulates the Progression of Colorectal Cancer via LncRNA NBR2/AMPK Pathway |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT8 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | SW-620 |
| - | in-vitro, | CRC, | SW480 |
| 447- | CUR, | OXA, | Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway |
| - | vitro+vivo, | CRC, | HCT116 |
| 448- | CUR, | Heat shock protein 27 influences the anti-cancer effect of curcumin in colon cancer cells through ROS production and autophagy activation |
| - | in-vitro, | CRC, | HT-29 |
| 440- | CUR, | Curcumin Reverses NNMT-Induced 5-Fluorouracil Resistance via Increasing ROS and Cell Cycle Arrest in Colorectal Cancer Cells |
| - | vitro+vivo, | CRC, | SW480 | - | vitro+vivo, | CRC, | HT-29 |
| 450- | CUR, | Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44 |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT8 |
| 451- | CUR, | The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer |
| - | vitro+vivo, | HNSCC, | SCC15 | - | vitro+vivo, | HNSCC, | SNU1076 | - | vitro+vivo, | HNSCC, | SNU1041 |
| 452- | CUR, | Curcumin downregulates the PI3K-AKT-mTOR pathway and inhibits growth and progression in head and neck cancer cells |
| - | vitro+vivo, | HNSCC, | SCC9 | - | vitro+vivo, | HNSCC, | FaDu | - | vitro+vivo, | HNSCC, | HaCaT |
| 453- | CUR, | Cellular uptake and apoptotic properties of gemini curcumin in gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 454- | CUR, | Curcumin-Induced DNA Demethylation in Human Gastric Cancer Cells Is Mediated by the DNA-Damage Response Pathway |
| - | in-vitro, | GC, | MGC803 |
| 455- | CUR, | Curcumin Affects Gastric Cancer Cell Migration, Invasion and Cytoskeletal Remodeling Through Gli1-β-Catenin |
| - | in-vitro, | GC, | SGC-7901 |
| 456- | CUR, | Curcumin Promoted miR-34a Expression and Suppressed Proliferation of Gastric Cancer Cells |
| - | vitro+vivo, | GC, | SGC-7901 |
| 457- | CUR, | Curcumin regulates proliferation, autophagy, and apoptosis in gastric cancer cells by affecting PI3K and P53 signaling |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | BGC-823 |
| 1006- | CUR, | The effect of Curcuma longa extract and its active component (curcumin) on gene expression profiles of lipid metabolism pathway in liver cancer cell line (HepG2) |
| - | in-vitro, | Liver, | HepG2 |
| 990- | CUR, | Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 |
| 1034- | CUR, | immuno, | Enhanced anti‐tumor effects of the PD‐1 blockade combined with a highly absorptive form of curcumin targeting STAT3 |
| - | in-vivo, | NA, | NA |
| 479- | CUR, | Curcumin Has Anti-Proliferative and Pro-Apoptotic Effects on Tongue Cancer in vitro: A Study with Bioinformatics Analysis and in vitro Experiments |
| - | in-vitro, | Tong, | CAL27 |
| 478- | CUR, | Curcumin decreases epithelial‑mesenchymal transition by a Pirin‑dependent mechanism in cervical cancer cells |
| - | in-vitro, | Cerv, | SiHa |
| 480- | CUR, | Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells |
| - | in-vitro, | GBM, | SNB19 |
| 481- | CUR, | CHr, | Api, | Flavonoid-induced glutathione depletion: Potential implications for cancer treatment |
| - | in-vitro, | Liver, | A549 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | AML, | HL-60 |
| 482- | CUR, | PDT, | The Antitumor Effect of Curcumin in Urothelial Cancer Cells Is Enhanced by Light Exposure In Vitro |
| - | in-vitro, | Bladder, | RT112 | - | in-vitro, | Bladder, | UMUC3 |
| 483- | CUR, | PDT, | Visible light and/or UVA offer a strong amplification of the anti-tumor effect of curcumin |
| - | in-vivo, | NA, | A431 |
| 484- | CUR, | PDT, | Low concentrations of curcumin induce growth arrest and apoptosis in skin keratinocytes only in combination with UVA or visible light |
| - | in-vitro, | Melanoma, | NA |
| 485- | CUR, | PDT, | Red Light Combined with Blue Light Irradiation Regulates Proliferation and Apoptosis in Skin Keratinocytes in Combination with Low Concentrations of Curcumin |
| - | in-vitro, | Melanoma, | NA |
| - | Analysis, | GBM, | NA |
| 4333- | Cyste, | Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription |
| - | vitro+vivo, | AD, | NA |
| 4331- | Cyste, | Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase |
| - | in-vivo, | HD, | NA | - | NA, | AD, | NA |
| 4332- | Cyste, | Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases |
| - | in-vivo, | Park, | NA | - | in-vivo, | HD, | NA |
| 1871- | DAP, | Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth |
| - | in-vitro, | AML, | U937 | - | in-vivo, | AML, | NA |
| 1876- | DCA, | Chemo, | In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines |
| - | in-vivo, | Lung, | H727 |
| 1889- | DCA, | A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth |
| - | Review, | Var, | NA |
| 1887- | DCA, | GSTZ1 expression and chloride concentrations modulate sensitivity of cancer cells to dichloroacetate |
| - | in-vitro, | Var, | NA |
| 1885- | DCA, | Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | HT-29 |
| 1883- | DCA, | In vivo metabolic response of glucose to dichloroacetate in humans |
| - | Analysis, | Var, | NA |
| 1882- | DCA, | Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer |
| - | Analysis, | NA, | NA |
| 1881- | DCA, | Chemo, | Co-treatment of dichloroacetate, omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: in vivo experiments and a case report |
| - | in-vitro, | NA, | HT1080 | - | in-vitro, | NA, | WI38 | - | Case Report, | Var, | NA |
| 1880- | DCA, | A Novel Form of Dichloroacetate Therapy for Patients With Advanced Cancer: A Report of 3 Cases |
| - | Case Report, | Var, | NA |
| 1879- | DCA, | Long-term stabilization of metastatic melanoma with sodium dichloroacetate |
| - | Case Report, | Melanoma, | NA |
| 1878- | DCA, | 5-FU, | Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal Cancer |
| - | in-vitro, | CRC, | LS174T | - | in-vitro, | CRC, | LoVo | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | HT-29 |
| 1877- | DCA, | Non-Hodgkin′s Lymphoma Reversal with Dichloroacetate |
| - | Case Report, | lymphoma, | NA |
| 1884- | DCA, | Sal, | Dichloroacetate and Salinomycin Exert a Synergistic Cytotoxic Effect in Colorectal Cancer Cell Lines |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | CRC, | HCT116 |
| 1875- | DCA, | Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells |
| - | in-vitro, | neuroblastoma, | NA | - | in-vivo, | NA, | NA |
| 1874- | DCA, | Dichloroacetate induces apoptosis of epithelial ovarian cancer cells through a mechanism involving modulation of oxidative stress |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | MDAH-2774 |
| 1873- | DCA, | Dual-targeting of aberrant glucose metabolism in glioblastoma |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 1872- | DCA, | Dichloroacetate, a selective mitochondria-targeting drug for oral squamous cell carcinoma: a metabolic perspective of treatment |
| - | in-vitro, | Oral, | HSC2 | - | in-vitro, | Oral, | HSC3 |
| 1870- | DCA, | Rad, | Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation |
| - | in-vitro, | Pca, | PC3 |
| 1864- | DCA, | MET, | Dichloroacetate Enhances Apoptotic Cell Death via Oxidative Damage and Attenuates Lactate Production in Metformin-Treated Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vitro, | Nor, | MCF10 |
| 1865- | DCA, | Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo |
| - | in-vivo, | BC, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D |
| 1866- | DCA, | MET, | BTZ, | Targeting metabolic pathways alleviates bortezomib-induced neuropathic pain without compromising anticancer efficacy in a sex-specific manner |
| - | in-vivo, | NA, | NA |
| 1867- | DCA, | Chemo, | Sensitization of breast cancer cells to paclitaxel by dichloroacetate through inhibiting autophagy |
| - | in-vivo, | BC, | NA | - | in-vitro, | BC, | NA |
| 1868- | DCA, | MET, | Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy |
| - | Case Report, | NA, | NA |
| 1869- | DCA, | Dichloroacetate induces autophagy in colorectal cancer cells and tumours |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | CRC, | HT-29 |
| 1445- | Deg, | Deguelin--an inhibitor to tumor lymphangiogenesis and lymphatic metastasis by downregulation of vascular endothelial cell growth factor-D in lung tumor model |
| - | in-vivo, | lymphoma, | NA | - | in-vitro, | lymphoma, | NA |
| 1444- | Deg, | Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer |
| - | in-vitro, | GC, | MKN-28 |
| 1443- | Deg, | Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | BC, | BT549 |
| 1442- | Deg, | Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention |
| - | Review, | Var, | NA |
| 1446- | Deg, | Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells |
| - | in-vitro, | BC, | 4T1 |
| 19- | Deg, | Deguelin inhibits proliferation and migration of human pancreatic cancer cells in vitro targeting hedgehog pathway |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | PANC1 |
| 4456- | DFE, | Induction of apoptosis and cell cycle arrest by ethyl acetate fraction of Phoenix dactylifera L. (Ajwa dates) in prostate cancer cells |
| - | in-vitro, | Pca, | PC3 |
| 4455- | DFE, | Ajwa Date (Phoenix dactylifera L.) Extract Inhibits Human Breast Adenocarcinoma (MCF7) Cells In Vitro by Inducing Apoptosis and Cell Cycle Arrest |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | 3T3 |
| 4454- | DFE, | Cytostatic and Anti-tumor Potential of Ajwa Date Pulp against Human Hepatocellular Carcinoma HepG2 Cells |
| - | in-vitro, | Liver, | HepG2 |
| 4177- | DHA, | Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats |
| - | in-vivo, | NA, | NA |
| 4178- | DHA, | The salutary effects of DHA dietary supplementation on cognition, neuroplasticity, and membrane homeostasis after brain trauma |
| - | in-vivo, | NA, | NA |
| 1183- | DHA, | Docosahexaenoic acid inhibited the Wnt/β-catenin pathway and suppressed breast cancer cells in vitro and in vivo |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | MCF-7 | - | in-vivo, | BC, | NA |
| 1109- | DHA, | DHA inhibits Gremlin-1-induced epithelial-to-mesenchymal transition via ERK suppression in human breast cancer cells |
| - | in-vitro, | BC, | NA |
| 1184- | DHA, | Syndecan-1-Dependent Suppression of PDK1/Akt/Bad Signaling by Docosahexaenoic Acid Induces Apoptosis in Prostate Cancer |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | NA, | NA |
| 1035- | DHA, | Docosahexaenoic acid reverses PD-L1-mediated immune suppression by accelerating its ubiquitin-proteasome degradation |
| - | vitro+vivo, | NA, | NA |
| 951- | DHA, | Docosahexaenoic Acid Attenuates Breast Cancer Cell Metabolism and the Warburg Phenotype by Targeting Bioenergetic Function |
| - | in-vitro, | BC, | BT474 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 1085- | DHA, | EPA, | DHA and EPA Down-regulate COX-2 Expression through Suppression of NF-kappaB Activity in LPS-treated Human Umbilical Vein Endothelial Cells |
| - | in-vitro, | Nor, | HUVECs |
| 1886- | Dicl, | Regulation of colonic epithelial butyrate transport: Focus on colorectal cancer |
| - | Review, | CRC, | NA |
| 2169- | dietF, | Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy |
| - | Case Report, | Ovarian, | NA |
| 2152- | dietFMD, | Prolonged Nightly Fasting and Breast Cancer Prognosis |
| - | Analysis, | BC, | NA |
| 1848- | dietFMD, | Chemo, | Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial |
| - | Trial, | BC, | NA |
| - | Trial, | NA, | NA |
| 1854- | dietFMD, | How Far Are We from Prescribing Fasting as Anticancer Medicine? |
| - | Review, | Var, | NA |
| 1853- | dietFMD, | Impact of Fasting on Patients With Cancer: An Integrative Review |
| - | Review, | Var, | NA |
| 1852- | dietFMD, | Chemo, | Starvation Based Differential Chemotherapy: A Novel Approach for Cancer Treatment |
| - | Review, | Var, | NA |
| 1851- | dietFMD, | Chemo, | Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | neuroblastoma, | SH-SY5Y |
| 1850- | dietFMD, | Fasting-mimicking diet remodels gut microbiota and suppresses colorectal cancer progression |
| - | in-vivo, | CRC, | NA |
| 1849- | dietFMD, | The emerging role of fasting-mimicking diets in cancer treatment |
| - | Review, | Var, | NA |
| 1857- | dietFMD, | Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 1847- | dietFMD, | VitC, | Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers |
| - | in-vitro, | PC, | PANC1 |
| 1846- | dietFMD, | VitC, | A fasting-mimicking diet and vitamin C: turning anti-aging strategies against cancer |
| - | Study, | Var, | NA |
| 1845- | dietFMD, | Fasting and fasting mimicking diets in cancer prevention and therapy |
| - | Review, | Var, | NA |
| 1841- | dietFMD, | Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer |
| - | Trial, | Var, | NA |
| 1842- | dietFMD, | Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment |
| - | Trial, | Var, | NA |
| 1843- | dietFMD, | BTZ, | Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia |
| - | in-vivo, | CLL, | NA |
| 1844- | dietFMD, | Unlocking the Potential: Caloric Restriction, Caloric Restriction Mimetics, and Their Impact on Cancer Prevention and Treatment |
| - | Review, | NA, | NA |
| 1856- | dietFMD, | immuno, | Targeting the Gut Microbiome to Improve Immunotherapy Outcomes: A Review |
| - | Review, | Var, | NA |
| 1858- | dietFMD, | Chemo, | Effect of short-term fasting on the cisplatin activity in human oral squamous cell carcinoma cell line HN5 and chemotherapy side effects |
| - | in-vitro, | HNSCC, | HN5 |
| 1859- | dietFMD, | Chemo, | Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | Melanoma, | B16-BL6 |
| 1860- | dietFMD, | Chemo, | Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape |
| - | in-vitro, | BC, | SUM159 | - | in-vitro, | BC, | 4T1 |
| 1861- | dietFMD, | Chemo, | Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models |
| - | in-vitro, | Colon, | CT26 | - | in-vivo, | NA, | NA |
| 1862- | dietFMD, | Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial |
| - | Trial, | Var, | NA |
| 1863- | dietFMD, | Chemo, | Effect of fasting on cancer: A narrative review of scientific evidence |
| - | Review, | Var, | NA |
| 2352- | dietFMD, | Glucose restriction reverses the Warburg effect and modulates PKM2 and mTOR expression in breast cancer cell lines |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 1810- | dietKeto, | Oxy, | The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer |
| - | in-vivo, | Var, | NA |
| 4256- | dietMed, | Association between Mediterranean dietary pattern with sleep duration, sleep quality and brain derived neurotrophic factor (BDNF) in Iranian adults |
| - | Study, | Nor, | NA |
| 2264- | dietMet, | Methionine restriction for cancer therapy: From preclinical studies to clinical trials |
| - | Review, | Var, | NA |
| 2265- | dietMet, | Cysteine supplementation reverses methionine restriction effects on rat adiposity: significance of stearoyl-coenzyme A desaturase |
| - | in-vivo, | Nor, | NA |
| 2266- | dietMet, | Cysteine dietary supplementation reverses the decrease in mitochondrial ROS production at complex I induced by methionine restriction |
| - | in-vivo, | Nor, | NA |
| 2267- | dietMet, | Role of amino acids in regulation of ROS balance in cancer |
| - | Review, | Var, | NA |
| 2268- | dietMet, | Methionine dependency and cancer treatment |
| - | Review, | Var, | NA |
| 2269- | dietMet, | Mechanisms of Increased In Vivo Insulin Sensitivity by Dietary Methionine Restriction in Mice |
| - | in-vivo, | Nor, | NA |
| 2270- | dietMet, | Methionine-restricted diet inhibits growth of MCF10AT1-derived mammary tumors by increasing cell cycle inhibitors in athymic nude mice |
| - | in-vivo, | Var, | NA |
| 2271- | dietMet, | A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension |
| - | Review, | Nor, | NA |
| 2272- | dietMet, | Methionine restriction - Association with redox homeostasis and implications on aging and diseases |
| - | Review, | Nor, | NA |
| 2273- | dietMet, | Methionine and cystine double deprivation stress suppresses glioma proliferation via inducing ROS/autophagy |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vivo, | NA, | NA |
| 2263- | dietMet, | Methionine Restriction and Cancer Biology |
| - | Review, | Var, | NA |
| 1893- | dietMet, | Clinical Studies of Methionine-Restricted Diets for Cancer Patients |
| - | Review, | Var, | NA |
| 1894- | dietMet, | Long term methionine restriction: Influence on gut microbiome and metabolic characteristics |
| - | in-vivo, | Nor, | NA |
| 1895- | dietMet, | Altering Diet Enhances Response to Cancer Treatments in Mice |
| - | Review, | Var, | NA |
| 1896- | dietMet, | Dietary methionine links nutrition and metabolism to the efficacy of cancer therapies |
| - | in-vivo, | CRC, | NA |
| 1897- | dietMet, | Methionine metabolism in health and cancer: a nexus of diet and precision medicine |
| - | Review, | Var, | NA |
| 2170- | dietMet, | Low Protein Intake is Associated with a Major Reduction in IGF-1, Cancer, and Overall Mortality in the 65 and Younger but Not Older Population |
| - | Study, | Var, | NA |
| - | Trial, | Colon, | NA |
| 2155- | dietP, | Transepithelial Anti-Neuroblastoma Response to Kale among Four Vegetable Juices Using In Vitro Model Co-Culture System |
| - | in-vivo, | neuroblastoma, | Caco-2 | - | NA, | NA, | SH-SY5Y |
| 2156- | dietP, | Phytochemical-rich vegetable and fruit juice alleviates oral mucositis during concurrent chemoradiotherapy in patients with locally advanced head and neck cancer |
| - | Human, | HNSCC, | NA |
| 2157- | dietP, | Plant-Based Diets and Disease Progression in Men With Prostate Cancer |
| - | Study, | Pca, | NA |
| 2158- | dietP, | Association of Animal and Plant Protein Intake With All-Cause and Cause-Specific Mortality in a Japanese Cohort |
| - | Human, | Nor, | NA |
| 2159- | dietP, | Postdiagnostic Fruit and Vegetable Consumption and Breast Cancer Survival: Prospective Analyses in the Nurses' Health Studies |
| - | Human, | BC, | NA |
| 2160- | dietP, | Dietary proteins and protein sources and risk of death: the Kuopio Ischaemic Heart Disease Risk Factor Study |
| - | Trial, | Heart, | NA |
| 2161- | dietP, | Plant-Based Diets and Cancer Prognosis: a Review of Recent Research |
| - | Review, | NA, | NA |
| 2162- | dietP, | Effect of low-fat diet on breast cancer survival: a meta-analysis |
| - | Analysis, | BC, | NA |
| 2163- | dietP, | SFN, | Intake of Cruciferous Vegetables Modifies Bladder Cancer Survival |
| - | Human, | Bladder, | NA |
| 2165- | dietP, | SFN, | Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects—results from the POUDER pilot study |
| - | Trial, | PC, | NA |
| 1626- | dietSTF, | dietFMD, | When less may be more: calorie restriction and response to cancer therapy |
| - | Review, | Var, | NA |
| 4159- | dietSTF, | 2DG, | CRMs, | Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms |
| - | Review, | AD, | NA |
| 4180- | dietSTF, | Brain-derived neurotrophic factor, but not body weight, correlated with a reduction in depression scale scores in men with metabolic syndrome: a prospective weight-reduction study |
| - | Human, | Obesity, | NA |
| 3707- | dietSTF, | Intermittent fasting protects against the deterioration of cognitive function, energy metabolism and dyslipidemia in Alzheimer’s disease-induced estrogen deficient rats |
| - | in-vivo, | AD, | NA |
| 3709- | dietSTF, | Intermittent Fasting Protects against Alzheimer’s Disease Possible through Restoring Aquaporin-4 Polarity |
| - | in-vitro, | AD, | NA |
| 3708- | dietSTF, | Fasting as a Therapy in Neurological Disease |
| 3756- | EA, | Acetylcholinesterase and monoamine oxidase-B inhibitory activities by ellagic acid derivatives isolated from Castanopsis cuspidata var. sieboldii |
| - | Analysis, | AD, | NA |
| 4255- | EA, | Effects of nutritional interventions on BDNF concentrations in humans: a systematic review |
| - | Review, | NA, | NA |
| 4254- | EA, | Chronic administration of ellagic acid improved the cognition in middle-aged overweight men |
| - | Human, | Obesity, | NA |
| - | Human, | MS, | NA | - | NA, | IBD, | NA |
| 4252- | EA, | Effect of ellagic acid on BDNF/PI3K/AKT-mediated signaling pathways in mouse models of depression |
| - | in-vivo, | NA, | NA |
| 1608- | EA, | Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 1621- | EA, | The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art |
| - | Review, | Var, | NA |
| 1610- | EA, | Anticancer Effect of Pomegranate Peel Polyphenols against Cervical Cancer |
| - | Review, | Cerv, | NA |
| 1611- | EA, | Targeting Myeloperoxidase Activity and Neutrophil ROS Production to Modulate Redox Process: Effect of Ellagic Acid and Analogues |
| - | in-vitro, | Mal, | NA |
| 1612- | EA, | Negative Effect of Ellagic Acid on Cytosolic pH Regulation and Glycolytic Flux in Human Endometrial Cancer Cell |
| - | in-vitro, | EC, | NA |
| 1613- | EA, | Ellagitannins in Cancer Chemoprevention and Therapy |
| - | Review, | Var, | NA |
| 1614- | EA, | Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice |
| - | Human, | Nor, | NA |
| 1615- | EA, | Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers |
| - | Human, | Nor, | NA |
| 1617- | EA, | CUR, | The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin |
| - | in-vitro, | Nor, | NA |
| 1618- | EA, | A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action |
| - | Review, | BC, | NA |
| 1619- | EA, | CUR, | Antimutagenic Effect of the Ellagic Acid and Curcumin Combinations |
| - | in-vitro, | Nor, | NA |
| 1607- | EA, | Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions |
| - | Review, | GC, | NA |
| 1606- | EA, | Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells |
| - | in-vitro, | Colon, | HCT15 |
| 1605- | EA, | Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence |
| - | Review, | Var, | NA |
| 1620- | EA, | Rad, | Radiosensitizing effect of ellagic acid on growth of Hepatocellular carcinoma cells: an in vitro study |
| - | in-vitro, | Liver, | HepG2 |
| 1037- | EA, | Unripe Black Raspberry (Rubus coreanus Miquel) Extract and Its Constitute, Ellagic Acid Induces T Cell Activation and Antitumor Immunity by Blocking PD-1/PD-L1 Interaction |
| - | in-vivo, | CRC, | NA |
| 27- | EA, | Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice |
| - | in-vivo, | PC, | NA |
| 1110- | EA, | GEM, | Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters |
| - | vitro+vivo, | Bladder, | NA |
| 4341- | EA, | Novel Bioactivity of Ellagic Acid in Inhibiting Human Platelet Activation |
| - | in-vitro, | NA, | NA |
| 4832- | EA, | Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid |
| 2402- | EA, | Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase |
| - | in-vitro, | NA, | NA |
| 1111- | EDM, | Evodiamine exerts inhibitory roles in non‑small cell lung cancer cell A549 and its sub‑population of stem‑like cells |
| - | in-vitro, | Lung, | A549 |
| 1022- | EDM, | Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis |
| - | in-vivo, | Lung, | H1975 | - | in-vitro, | Lung, | H1650 |
| - | in-vitro, | HCC, | NA | - | in-vivo, | NA, | NA |
| 1036- | EGCG, | Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | LU99 |
| 1056- | EGCG, | EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression |
| - | vitro+vivo, | BC, | E0771 |
| 1071- | EGCG, | Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase |
| - | in-vitro, | Nor, | NA |
| 1072- | EGCG, | Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways |
| - | in-vitro, | Thyroid, | 8505C |
| 1012- | EGCG, | Inhibition of beta-catenin/Tcf activity by white tea, green tea, and epigallocatechin-3-gallate (EGCG): minor contribution of H(2)O(2) at physiologically relevant EGCG concentrations |
| - | in-vitro, | Nor, | HEK293 |
| 937- | EGCG, | Metabolic Consequences of LDHA inhibition by Epigallocatechin Gallate and Oxamate in MIA PaCa-2 Pancreatic Cancer Cells |
| - | in-vitro, | Pca, | MIA PaCa-2 |
| 936- | EGCG, | Bioactivity-Guided Identification and Cell Signaling Technology to Delineate the Lactate Dehydrogenase A Inhibition Effects of Spatholobus suberectus on Breast Cancer |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 26- | EGCG, | QC, | docx, | Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy |
| - | vitro+vivo, | Pca, | PC3 |
| 25- | EGCG, | QC, | Quercetin Increased the Antiproliferative Activity of Green Tea Polyphenol (-)-Epigallocatechin Gallate in Prostate Cancer Cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP |
| 24- | EGCG, | GEN, | QC, | Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin |
| - | in-vitro, | Pca, | 22Rv1 |
| 23- | EGCG, | (-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells |
| - | in-vitro, | Chon, | SW1353 | - | in-vitro, | Chon, | CRL-7891 |
| 22- | EGCG, | Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics |
| - | in-vitro, | PC, | CD133+ | - | in-vitro, | PC, | CD44+ | - | in-vitro, | PC, | CD24+ | - | in-vitro, | PC, | ESA+ |
| 21- | EGCG, | Tea polyphenols EGCG and TF restrict tongue and liver carcinogenesis simultaneously induced by N-nitrosodiethylamine in mice |
| - | in-vivo, | Liver, | NA |
| 20- | EGCG, | Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer |
| - | in-vivo, | Liver, | NA | - | in-vivo, | Tong, | NA |
| 651- | EGCG, | Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications |
| 665- | EGCG, | Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway |
| - | in-vitro, | NA, | H1299 |
| 652- | EGCG, | VitK2, | CUR, | Case Report of Unexpectedly Long Survival of Patient With Chronic Lymphocytic Leukemia: Why Integrative Methods Matter |
| - | Case Report, | CLL, | NA |
| 653- | EGCG, | Phase 2 Trial of Daily, Oral Polyphenon E in Patients with Asymptomatic, Rai Stage 0-II Chronic Lymphocytic Leukemia(CLL) |
| - | Trial, | CLL, | NA |
| 654- | EGCG, | MNPs, | MF, | Characterization of mesenchymal stem cells with augmented internalization of magnetic nanoparticles: The implication of therapeutic potential |
| - | in-vitro, | Var, | NA |
| 655- | EGCG, | A new molecular mechanism underlying the EGCG-mediated autophagic modulation of AFP in HepG2 cells |
| - | in-vitro, | HCC, | HepG2 |
| 657- | EGCG, | MNPs, | MF, | Interaction of poly-l-lysine coating and heparan sulfate proteoglycan on magnetic nanoparticle uptake by tumor cells |
| - | in-vitro, | GBM, | U87MG |
| 658- | EGCG, | MNPs, | MF, | Laminin Receptor-Mediated Nanoparticle Uptake by Tumor Cells: Interplay of Epigallocatechin Gallate and Magnetic Force at Nano-Bio Interface |
| - | in-vitro, | GBM, | LN229 |
| 659- | EGCG, | MNPs, | MF, | Augmented cellular uptake of nanoparticles using tea catechins: effect of surface modification on nanoparticle-cell interaction |
| - | in-vivo, | Nor, | NA |
| 660- | EGCG, | FA, | Epigallocatechin-3-gallate Delivered in Nanoparticles Increases Cytotoxicity in Three Breast Carcinoma Cell Lines |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 661- | EGCG, | GoldNP, | Epigallocatechin-3-Gallate-Loaded Gold Nanoparticles: Preparation and Evaluation of Anticancer Efficacy in Ehrlich Tumor-Bearing Mice |
| - | vitro+vivo, | NA, | NA |
| 662- | EGCG, | Advanced Nanovehicles-Enabled Delivery Systems of Epigallocatechin Gallate for Cancer Therapy |
| - | Review, | Var, | NA |
| 663- | EGCG, | EGCG-coated silver nanoparticles self-assemble with selenium nanowires for treatment of drug-resistant bacterial infections by generating ROS and disrupting biofilms |
| - | in-vitro, | NA, | NA |
| 664- | EGCG, | SNP, | Epigallocatechin-3-gallate-capped Ag nanoparticles: preparation and characterization |
| - | Analysis, | NA, | NA |
| 666- | EGCG, | The Role of EGCG in Breast Cancer Prevention and Therapy |
| - | Review, | NA, | NA |
| 650- | EGCG, | Cellular thiol status-dependent inhibition of tumor cell growth via modulation of retinoblastoma protein phosphorylation by (-)-epigallocatechin |
| - | in-vitro, | NA, | NA |
| 649- | EGCG, | CUR, | PI, | Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets |
| - | Review, | Var, | NA |
| 648- | EGCG, | Bioavailability of Epigallocatechin Gallate Administered With Different Nutritional Strategies in Healthy Volunteers |
| - | Human, | Nor, | NA |
| 647- | EGCG, | Food Inhibits the Oral Bioavailability of the Major Green Tea Antioxidant Epigallocatechin Gallate in Humans |
| - | Human, | Nor, | NA |
| 646- | EGCG, | PI, | Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice |
| - | in-vivo, | Nor, | NA |
| 645- | EGCG, | The Effect of Ultrasound, Oxygen and Sunlight on the Stability of (−)-Epigallocatechin Gallate |
| - | Analysis, | NA, | NA |
| 644- | EGCG, | Citrate, | Simple Approach to Enhance Green Tea Epigallocatechin Gallate Stability in Aqueous Solutions and Bioavailability: Experimental and Theoretical Characterizations |
| - | Analysis, | Nor, | NA |
| 643- | EGCG, | New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate |
| - | Analysis, | NA, | NA |
| 642- | EGCG, | Prooxidant Effects of Epigallocatechin-3-Gallate in Health Benefits and Potential Adverse Effect |
| 641- | EGCG, | Se, | Antioxidant effects of green tea |
| 640- | EGCG, | Epigallocatechin Gallate (EGCG) Is the Most Effective Cancer Chemopreventive Polyphenol in Green Tea |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Colon, | SW480 |
| 639- | EGCG, | Immunomodulatory Effects of Green Tea Catechins and Their Ring Fission Metabolites in a Tumor Microenvironment Perspective |
| - | Review, | NA, | NA |
| 638- | EGCG, | MushCha, | MushReishi, | A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea |
| - | Case Report, | AML, | NA |
| 637- | EGCG, | CAP, | Cancer prevention trial of a synergistic mixture of green tea concentrate plus Capsicum (CAPSOL-T) in a random population of subjects ages 40-84 |
| - | Human, | NA, | NA |
| 667- | EGCG, | Anti-cancer effect of EGCG and its mechanisms |
| - | Review, | NA, | NA |
| 695- | EGCG, | TFdiG, | The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention |
| - | in-vitro, | NA, | HL-60 |
| 694- | EGCG, | Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways |
| - | in-vitro, | BC, | MCF-7 |
| 693- | EGCG, | CAP, | Phen, | Metabolite modulation of HeLa cell response to ENOX2 inhibitors EGCG and phenoxodiol |
| - | in-vitro, | Cerv, | HeLa |
| 692- | EGCG, | EGCG: The antioxidant powerhouse in lung cancer management and chemotherapy enhancement |
| - | Review, | NA, | NA |
| 691- | EGCG, | Preclinical Pharmacological Activities of Epigallocatechin-3-gallate in Signaling Pathways: An Update on Cancer |
| - | Review, | NA, | NA |
| 690- | EGCG, | Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer |
| - | in-vitro, | Pca, | NA |
| 689- | EGCG, | EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down regulation of NF-κB and MMP-9 |
| - | vitro+vivo, | Bladder, | SW780 |
| - | in-vitro, | PC, | NA |
| 687- | EGCG, | Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 686- | EGCG, | Prevention effect of EGCG in rat's lung cancer induced by benzopyrene |
| - | in-vivo, | Lung, | NA |
| 685- | EGCG, | CUR, | SFN, | RES, | GEN | The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein |
| - | Analysis, | NA, | NA |
| 684- | EGCG, | Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation |
| - | in-vitro, | CRC, | NA |
| 683- | EGCG, | Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy |
| - | Review, | NA, | NA |
| 682- | EGCG, | Suppressive Effects of EGCG on Cervical Cancer |
| - | Review, | NA, | NA |
| 681- | EGCG, | Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models |
| - | vitro+vivo, | BC, | NA |
| 680- | EGCG, | Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea |
| - | Review, | NA, | NA |
| 679- | EGCG, | 5-FU, | Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer |
| - | in-vitro, | CRC, | NA |
| 678- | EGCG, | Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: from Early Investigations to Current Focus on Human Cancer Stem Cells |
| 677- | EGCG, | Induction of Endoplasmic Reticulum Stress Pathway by Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Activation of PERK/p-eIF2 α /ATF4 and IRE1 α |
| - | in-vitro, | CRC, | HT-29 |
| 676- | EGCG, | Chemo, | The Potential of Epigallocatechin Gallate (EGCG) in Targeting Autophagy for Cancer Treatment: A Narrative Review |
| - | Review, | NA, | NA |
| 675- | EGCG, | When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy |
| - | Review, | Var, | NA |
| 674- | EGCG, | Biocompatible and biodegradable nanoparticles for enhancement of anti-cancer activities of phytochemicals |
| - | Review, | Var, | NA |
| 673- | EGCG, | Iron Chelation Properties of Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Analysis on Tfr/Fth Regulations and Molecular Docking |
| - | in-vitro, | CRC, | HT-29 |
| 672- | EGCG, | Molecular Targets of Epigallocatechin—Gallate (EGCG): A Special Focus on Signal Transduction and Cancer |
| - | Review, | NA, | NA |
| 671- | EGCG, | The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer |
| 670- | EGCG, | Epigallocatechin-3-gallate and its nanoformulation in cervical cancer therapy: the role of genes, MicroRNA and DNA methylation patterns |
| - | Review, | NA, | NA |
| 669- | EGCG, | Epigallocatechin-3-gallate and cancer: focus on the role of microRNAs |
| - | Review, | NA, | NA |
| 668- | EGCG, | The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment |
| - | Review, | BC, | MCF-7 | - | Review, | BC, | MDA-MB-231 |
| 2468- | EGCG, | Green tea epigallocatechin-3-gallate inhibits platelet signalling pathways triggered by both proteolytic and non-proteolytic agonists |
| - | in-vitro, | Nor, | NA |
| - | in-vitro, | Nor, | HSC-T6 |
| 2459- | EGCG, | Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2‑mediated glycolysis |
| - | in-vitro, | Tong, | Tca8113 | - | in-vitro, | Tong, | TSCCa |
| 2501- | EGCG, | A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea |
| - | Case Report, | AML, | NA |
| 2458- | EGCG, | QC, | Identification of plant-based hexokinase 2 inhibitors: combined molecular docking and dynamics simulation studies |
| - | Analysis, | Nor, | NA |
| 2395- | EGCG, | EGCG inhibits diabetic nephrophathy through up regulation of PKM2 |
| - | Study, | Diabetic, | NA |
| 2561- | EGCG, | ASA, | Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment |
| - | ex-vivo, | Nor, | NA |
| - | Trial, | NA, | NA |
| 2563- | EGCG, | Cardioprotective effect of epigallocatechin gallate in myocardial ischemia/reperfusion injury and myocardial infarction: a meta-analysis in preclinical animal studies |
| - | Review, | NA, | NA |
| 3210- | EGCG, | Protective effect of epigallocatechin-3-gallate (EGCG) via Nrf2 pathway against oxalate-induced epithelial mesenchymal transition (EMT) of renal tubular cells |
| - | in-vitro, | Nor, | NA |
| 3209- | EGCG, | Epigallocatechin gallate upregulates NRF2 to prevent diabetic nephropathy via disabling KEAP1 |
| - | in-vitro, | Diabetic, | NA |
| 3208- | EGCG, | Induction of Endoplasmic Reticulum Stress Pathway by Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Activation of PERK/p-eIF2α/ATF4 and IRE1α |
| - | in-vitro, | Colon, | HT29 | - | in-vitro, | Nor, | 3T3 |
| 3207- | EGCG, | EGCG Enhances the Chemosensitivity of Colorectal Cancer to Irinotecan through GRP78-MediatedEndoplasmic Reticulum Stress |
| - | in-vitro, | CRC, | RKO | - | in-vitro, | CRC, | HCT116 |
| 3206- | EGCG, | Insights on the involvement of (-)-epigallocatechin gallate in ER stress-mediated apoptosis in age-related macular degeneration |
| - | Review, | AMD, | NA |
| 3205- | EGCG, | The Role of Epigallocatechin-3-Gallate in Autophagy and Endoplasmic Reticulum Stress (ERS)-Induced Apoptosis of Human Diseas |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3204- | EGCG, | The Role of ER Stress and the Unfolded Protein Response in Cancer |
| - | Review, | Var, | NA |
| 3203- | EGCG, | (-)- Epigallocatechin-3-gallate induces GRP78 accumulation in the ER and shifts mesothelioma constitutive UPR into proapoptotic ER stress |
| - | NA, | MM, | NA |
| 3202- | EGCG, | Epigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | HCC, | QGY-7703 |
| 3201- | EGCG, | Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential |
| - | Review, | NA, | NA |
| 3211- | EGCG, | Antioxidation Function of EGCG by Activating Nrf2/HO-1 Pathway in Mice with Coronary Heart Disease |
| - | in-vivo, | NA, | NA |
| 3238- | EGCG, | Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications |
| - | Review, | Var, | NA |
| 3229- | EGCG, | Epigallocatechin-3-gallate (EGCG) Alters Histone Acetylation and Methylation and Impacts Chromatin Architecture Profile in Human Endothelial Cells |
| - | in-vitro, | Nor, | HMEC | - | in-vitro, | Nor, | HUVECs |
| 3230- | EGCG, | Green Tea Polyphenol Epigallocatechin 3-Gallate, Contributes to the Degradation of DNMT3A and HDAC3 in HCT 116 Human Colon Cancer Cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 |
| 3231- | EGCG, | Epigallocatechin-3-gallate restores mitochondrial homeostasis impairment by inhibiting HDAC1-mediated NRF1 histone deacetylation in cardiac hypertrophy |
| - | in-vitro, | Nor, | NA |
| 3232- | EGCG, | (−)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer׳s disease model mice by upregulating neprilysin expression |
| - | in-vivo, | AD, | NA |
| 3233- | EGCG, | Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways |
| - | in-vitro, | Cerv, | HeLa |
| 3234- | EGCG, | Rad, | EGCG, a tea polyphenol, as a potential mitigator of hematopoietic radiation injury in mice |
| - | in-vivo, | Nor, | NA |
| 3235- | EGCG, | (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells |
| - | in-vivo, | Cerv, | HeLa |
| 3236- | EGCG, | BA, | Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate |
| - | in-vitro, | Colon, | RKO | - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Colon, | HT29 |
| 3237- | EGCG, | (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression |
| - | in-vivo, | AD, | NA |
| 3212- | EGCG, | EGCG maintained Nrf2-mediated redox homeostasis and minimized etoposide resistance in lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | Lung, | NCIH23 |
| 3239- | EGCG, | (−)-Epigallocatechin Gallate, A Major Constituent of Green Tea, Poisons Human Type II Topoisomerases |
| - | in-vitro, | AML, | K562 |
| 3241- | EGCG, | Epigallocatechin gallate triggers apoptosis by suppressing de novo lipogenesis in colorectal carcinoma cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | HUH7 |
| 3242- | EGCG, | Epigallocatechin gallate has pleiotropic effects on transmembrane signaling by altering the embedding of transmembrane domains |
| 3243- | EGCG, | (−)-Epigallocatechin-3-Gallate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt/β-Catenin Pathway |
| 3244- | EGCG, | Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells |
| 3245- | EGCG, | (−)-Epigallocatechin-3-gallate protects PC12 cells against corticosterone-induced neurotoxicity via the hedgehog signaling pathway |
| - | in-vitro, | Nor, | PC12 |
| 3246- | EGCG, | Epigallocatechin gallate suppresses hepatic cholesterol synthesis by targeting SREBP-2 through SIRT1/FOXO1 signaling pathway |
| - | in-vitro, | Nor, | NA |
| 3227- | EGCG, | Epigallocatechin-3-gallate treatment to promote neuroprotection and functional recovery after nervous system injury |
| - | NA, | Nor, | NA |
| 3213- | EGCG, | Rad, | Epigallocatechin-3-gallate Enhances Radiation Sensitivity in Colorectal Cancer Cells Through Nrf2 Activation and Autophagy |
| - | in-vitro, | CRC, | HCT116 |
| 3214- | EGCG, | EGCG-induced selective death of cancer cells through autophagy-dependent regulation of the p62-mediated antioxidant survival pathway |
| - | in-vitro, | Nor, | MRC-5 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | CRC, | HCT116 |
| 3215- | EGCG, | Epigallocatechin gallate modulates ferroptosis through downregulation of tsRNA-13502 in non-small cell lung cancer |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H1299 |
| 3216- | EGCG, | Epigallocatechin-3-gallate suppresses hemin-aggravated colon carcinogenesis through Nrf2-inhibited mitochondrial reactive oxygen species accumulation |
| - | NA, | Colon, | Caco-2 |
| 3217- | EGCG, | Epigallocatechin-3-gallate promotes angiogenesis via up-regulation of Nfr2 signaling pathway in a mouse model of ischemic stroke |
| - | in-vivo, | Stroke, | NA |
| 3218- | EGCG, | Comparative efficacy of epigallocatechin-3-gallate against H2O2-induced ROS in cervical cancer biopsies and HeLa cell lines |
| - | in-vitro, | Cerv, | HeLa |
| 3219- | EGCG, | Nano-chemotherapeutic efficacy of (−) -epigallocatechin 3-gallate mediating apoptosis in A549 cells: Involvement of reactive oxygen species mediated Nrf2/Keap1signaling |
| - | in-vitro, | Lung, | A549 |
| 3220- | EGCG, | Dual Roles of Nrf2 in Cancer |
| - | in-vitro, | Lung, | A549 |
| 3221- | EGCG, | EGCG upregulates phase-2 detoxifying and antioxidant enzymes via the Nrf2 signaling pathway in human breast epithelial cells |
| - | in-vitro, | Nor, | MCF10 |
| 3222- | EGCG, | Epigallocatechin gallate and mitochondria—A story of life and death |
| - | Review, | Nor, | NA |
| 3223- | EGCG, | The Effects of Green Tea Catechins in Hematological Malignancies |
| - | Review, | AML, | NA |
| 3224- | EGCG, | Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis |
| - | in-vitro, | Nor, | NA |
| 3225- | EGCG, | Epigallocatechin‐3‐Gallate Ameliorates Diabetic Kidney Disease by Inhibiting the TXNIP/NLRP3/IL‐1β Signaling Pathway |
| - | in-vitro, | Nor, | NA | - | in-vivo, | Nor, | NA |
| 3226- | EGCG, | Epigallocatechin-3-gallate, a green-tea polyphenol, suppresses Rho signaling in TWNT-4 human hepatic stellate cells |
| - | in-vitro, | Nor, | NA |
| 3228- | EGCG, | Targeting fibrotic signaling pathways by EGCG as a therapeutic strategy for uterine fibroids |
| 2993- | EGCG, | Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP |
| 2992- | EGCG, | Effects of Epigallocatechin-3-Gallate on Matrix Metalloproteinases in Terms of Its Anticancer Activity |
| - | Review, | Var, | NA |
| 2994- | EGCG, | Nano-Engineered Epigallocatechin Gallate (EGCG) Delivery Systems: Overcoming Bioavailability Barriers to Unlock Clinical Potential in Cancer Therapy |
| - | Review, | Var, | NA |
| 2309- | EGCG, | Chemo, | Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Nor, | HPNE | - | in-vitro, | PC, | PANC1 | - | in-vivo, | NA, | NA |
| 2310- | EGCG, | Epigallocatechin-3-gallate downregulates PDHA1 interfering the metabolic pathways in human herpesvirus 8 harboring primary effusion lymphoma cells |
| - | in-vitro, | lymphoma, | PEL |
| 2302- | EGCG, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 4152- | EGCG, | Green tea catechins potentiate the neuritogenic action of brain-derived neurotrophic factor: role of 67-kDa laminin receptor and hydrogen peroxide |
| - | in-vitro, | AD, | NA |
| 3594- | EGCG, | Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and NF-kappaB in HMC-1 cells |
| - | in-vitro, | AD, | HMC1 |
| 3593- | EGCG, | Epigallocatechin Gallate (EGCG) |
| - | Review, | AD, | NA |
| 3592- | EGCG, | (-)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3591- | EGCG, | Epigallocatechin-3-Gallate Provides Protection Against Alzheimer's Disease-Induced Learning and Memory Impairments in Rats |
| - | in-vivo, | AD, | NA |
| 3428- | EGCG, | Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex |
| - | Review, | Var, | NA |
| 1514- | EGCG, | Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | MCF10 |
| 1515- | EGCG, | Phen, | Reciprocal Relationship Between Cytosolic NADH and ENOX2 Inhibition Triggers Sphingolipid-Induced Apoptosis in HeLa Cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | BT20 |
| 1516- | EGCG, | Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential |
| - | Review, | NA, | NA |
| 1303- | EGCG, | (-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation |
| - | in-vitro, | EC, | NA |
| 1503- | EGCG, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
| - | Review, | NA, | NA |
| - | in-vitro, | GBM, | U87MG |
| 1975- | EGCG, | Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate |
| - | in-vitro, | Cerv, | HeLa |
| 1974- | EGCG, | Protective Effect of Epigallocatechin-3-Gallate in Hydrogen Peroxide-Induced Oxidative Damage in Chicken Lymphocytes |
| - | in-vitro, | Nor, | NA |
| 4681- | EGCG, | Epigallocatechin-3-Gallate Prevents the Acquisition of a Cancer Stem Cell Phenotype in Ovarian Cancer Tumorspheres through the Inhibition of Src/JAK/STAT3 Signaling |
| - | in-vitro, | Ovarian, | ES-2 |
| 4682- | EGCG, | Human cancer stem cells are a target for cancer prevention using (−)-epigallocatechin gallate |
| - | Review, | Var, | NA |
| 4683- | EGCG, | Epigallocatechin-3-gallate inhibits self-renewal ability of lung cancer stem-like cells through inhibition of CLOCK |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vivo, | Lung, | A549 |
| 4684- | EGCG, | EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells |
| - | in-vivo, | NSCLC, | A549 |
| 4685- | EGCG, | Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines |
| - | in-vitro, | NPC, | TW01 | - | in-vitro, | NPC, | TW06 |
| 4680- | EGCG, | The Potential of Epigallocatechin Gallate in Targeting Cancer Stem Cells: A Comprehensive Review |
| - | Review, | Var, | NA |
| 4291- | EGCG, | Structure-based discovery of small molecules that disaggregate Alzheimer’s disease tissue derived tau fibrils in vitro |
| - | in-vitro, | AD, | NA |
| 4290- | EGCG, | EGCG impedes human Tau aggregation and interacts with Tau |
| - | in-vitro, | AD, | NA |
| 3830- | EMD, | Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 988- | EMD, | Emodin Induced Necroptosis and Inhibited Glycolysis in the Renal Cancer Cells by Enhancing ROS |
| - | in-vitro, | RCC, | NA |
| 950- | EMD, | Emodin Decreases Hepatic Hypoxia-Inducible Factor-1[Formula: see text] by Inhibiting its Biosynthesis |
| - | in-vivo, | NA, | NA | - | in-vitro, | Liver, | HepG2 |
| 2345- | EMD, | Emodin ameliorates antioxidant capacity and exerts neuroprotective effect via PKM2-mediated Nrf2 transactivation |
| - | in-vitro, | AD, | PC12 |
| 2422- | EMD, | Anti-Cancer Effects of Emodin on HepG2 Cells as Revealed by 1H NMR Based Metabolic Profiling |
| - | in-vitro, | HCC, | HepG2 |
| 1319- | EMD, | Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF‑κB and its upstream TLR4 signaling |
| - | in-vitro, | Thyroid, | TPC-1 | - | in-vitro, | Thyroid, | IHH4 |
| 1318- | EMD, | Aloe-emodin Induces Apoptosis in Human Liver HL-7702 Cells through Fas Death Pathway and the Mitochondrial Pathway by Generating Reactive Oxygen Species |
| - | in-vitro, | Nor, | HL7702 |
| 1320- | EMD, | SRF, | Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism |
| - | vitro+vivo, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | HUH7 | - | vitro+vivo, | Hepat, | SK-HEP-1 |
| 1321- | EMD, | Antitumor effects of emodin on LS1034 human colon cancer cells in vitro and in vivo: roles of apoptotic cell death and LS1034 tumor xenografts model |
| - | in-vitro, | CRC, | LS1034 | - | in-vivo, | NA, | NA |
| 1322- | EMD, | The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers |
| - | Review, | Var, | NA |
| 1247- | EMD, | Emodin exerts antitumor effects in ovarian cancer cell lines by preventing the development of cancer stem cells via epithelial mesenchymal transition |
| - | vitro+vivo, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | A2780S |
| 1246- | EMD, | Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell formation |
| - | in-vivo, | BC, | NA |
| 1323- | EMD, | Anticancer action of naturally occurring emodin for the controlling of cervical cancer |
| - | Review, | Cerv, | NA |
| 1245- | EMD, | Emodin Exhibits Strong Cytotoxic Effect in Cervical Cancer Cells by Activating Intrinsic Pathway of Apoptosis |
| - | in-vitro, | Cerv, | HeLa |
| 1324- | EMD, | Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin |
| - | Review, | Var, | NA |
| 1325- | EMD, | PacT, | Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo |
| - | vitro+vivo, | Lung, | A549 |
| 1326- | EMD, | Emodin induces a reactive oxygen species-dependent and ATM-p53-Bax mediated cytotoxicity in lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 1327- | EMD, | Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway |
| - | in-vitro, | Lung, | A549 |
| 1328- | EMD, | Emodin induces apoptosis of human tongue squamous cancer SCC-4 cells through reactive oxygen species and mitochondria-dependent pathways |
| - | in-vitro, | Tong, | SCC4 |
| 1332- | EMD, | Induction of Apoptosis in HepaRG Cell Line by Aloe-Emodin through Generation of Reactive Oxygen Species and the Mitochondrial Pathway |
| - | in-vivo, | Nor, | HepaRG |
| 1296- | EMD, | Emodin inhibits LOVO colorectal cancer cell proliferation via the regulation of the Bcl-2/Bax ratio and cytochrome c |
| - | in-vitro, | CRC, | LoVo |
| 1329- | EMD, | Aloe-emodin induces cell death through S-phase arrest and caspase-dependent pathways in human tongue squamous cancer SCC-4 cells |
| - | in-vitro, | Tong, | SCC4 |
| 1330- | EMD, | Aloe emodin-induced apoptosis in t-HSC/Cl-6 cells involves a mitochondria-mediated pathway |
| - | in-vitro, | NA, | NA |
| 1331- | EMD, | Aloe-emodin induces apoptosis of human nasopharyngeal carcinoma cells via caspase-8-mediated activation of the mitochondrial death pathway |
| - | in-vitro, | NPC, | NA |
| 3460- | EP, | Picosecond pulsed electric fields induce apoptosis in HeLa cells via the endoplasmic reticulum stress and caspase-dependent signaling pathways |
| - | in-vitro, | Cerv, | HeLa |
| 2204- | erastin, | Regulation of ferroptotic cancer cell death by GPX4 |
| - | in-vitro, | fibroS, | HT1080 |
| 2455- | erastin, | Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments |
| - | in-vitro, | Cerv, | HeLa |
| 975- | Est, | Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism |
| - | vitro+vivo, | UEC, | NA |
| 4144- | Ex, | Exploring the impact of exercise-induced BDNF on neuroplasticity in neurodegenerative and neuropsychiatric conditions |
| - | Review, | AD, | NA |
| 4143- | Ex, | Brain-Derived Neurotrophic Factor: A Connecting Link Between Nutrition, Lifestyle, and Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4145- | Ex, | Effects of different physical activities on brain-derived neurotrophic factor: A systematic review and bayesian network meta-analysis |
| - | Review, | AD, | NA |
| 4155- | Ex, | Prior regular exercise reverses the decreased effects of sleep deprivation on brain-derived neurotrophic factor levels in the hippocampus of ovariectomized female rats |
| - | in-vivo, | AD, | NA |
| 4174- | Ex, | Exercise-Mediated Neurogenesis in the Hippocampus via BDNF |
| - | Review, | NA, | NA |
| 4141- | Ex, | Effects of exercise on brain-derived neurotrophic factor in Alzheimer's disease models: A systematic review and meta-analysis |
| - | Review, | AD, | NA |
| 4142- | Ex, | Mechanisms of the Beneficial Effects of Exercise on Brain-Derived Neurotrophic Factor Expression in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4137- | Ex, | The impact of exercise on patients with dementia |
| - | Trial, | AD, | NA |
| 4138- | Ex, | Relationship Between Exercise and Alzheimer’s Disease: A Narrative Literature Review |
| - | Review, | AD, | NA |
| 4139- | Ex, | Impact of physical exercise on the regulation of brain-derived neurotrophic factor in people with neurodegenerative diseases |
| - | Review, | AD, | NA |
| 4140- | Ex, | Experimental and clinical evidence of physical exercise on BDNF and cognitive function: A comprehensive review from molecular basis to therapy |
| - | Review, | AD, | NA |
| 3985- | Ex, | The combined effect of physical activity and fruit and vegetable intake on decreasing cognitive decline in older Taiwanese adults |
| - | Study, | AD, | NA |
| 2143- | Ex, | The association between physical activity and bladder cancer: systematic review and meta-analysis |
| - | Review, | Bladder, | NA |
| 2144- | Ex, | Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies |
| - | Analysis, | NA, | NA |
| 2145- | Ex, | Leisure time physical activity and cancer risk: evaluation of the WHO's recommendation based on 126 high-quality epidemiological studies |
| - | Analysis, | Var, | NA |
| 2146- | Ex, | A systematic review and meta-analysis of physical activity and endometrial cancer risk |
| - | Review, | Endo, | NA |
| 2147- | Ex, | The association between physical activity and gastroesophageal cancer: systematic review and meta-analysis |
| - | Review, | GC, | NA |
| 2148- | Ex, | Effects of Exercise on Cancer Treatment Efficacy: A Systematic Review of Preclinical and Clinical Studies |
| - | Review, | Var, | NA |
| 2149- | Ex, | Physical activity and exercise training in cancer patients |
| - | Analysis, | Var, | NA |
| 2150- | Ex, | Roles and molecular mechanisms of physical exercise in cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2151- | Ex, | The effects of physical activity on overall survival among advanced cancer patients: a systematic review and meta-analysis |
| - | Review, | Var, | NA |
| 2153- | Ex, | The Impact of Exercise on Cancer Mortality, Recurrence, and Treatment-Related Adverse Effects |
| - | Review, | Var, | NA |
| 1038- | F, | immuno, | Fucoidan enhances the anti-tumor effect of anti-PD-1 immunotherapy by regulating gut microbiota. |
| - | in-vivo, | BC, | NA |
| 1039- | F, | Anti-Proliferative and Pro-Apoptotic vLMW Fucoidan Formulas Decrease PD-L1 Surface Expression in EBV Latency III and DLBCL Tumoral B-Cells by Decreasing Actin Network |
| - | in-vitro, | NA, | NA |
| 1114- | F, | The Potential Effect of Fucoidan on Inhibiting Epithelial-to-Mesenchymal Transition, Proliferation, and Increase in Apoptosis for Endometriosis Treatment: In Vivo and In Vitro Study |
| - | vitro+vivo, | NA, | NA |
| 1155- | F, | The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations |
| - | Review, | NA, | NA |
| 948- | F, | Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia |
| - | vitro+vivo, | Bladder, | T24 | - | in-vitro, | Nor, | HUVECs |
| 1112- | FA, | Ferulic acid exerts antitumor activity and inhibits metastasis in breast cancer cells by regulating epithelial to mesenchymal transition |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | BC, | NA |
| 2173- | FA, | VitB12, | Elevated serum homocysteine levels associated with poor recurrence-free and overall survival in patients with colorectal cancer |
| - | Study, | CRC, | NA |
| 2176- | FA, | VitB12, | Hyperhomocysteinemia and Cancer: The Role of Natural Products and Nutritional Interventions |
| - | Review, | Var, | NA |
| 2174- | FA, | VitB12, |
| - | Analysis, | Var, | NA |
| 1289- | FA, | Cytotoxic and Apoptotic Effects of Ferulic Acid on Renal Carcinoma Cell Line (ACHN) |
| - | in-vitro, | RCC, | NA |
| 1656- | FA, | Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling |
| - | Review, | Var, | NA |
| 1655- | FA, | Ferulic acid inhibiting colon cancer cells at different Duke’s stages |
| - | in-vitro, | Colon, | SW480 | - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Colon, | HCT116 |
| 1654- | FA, | Molecular mechanism of ferulic acid and its derivatives in tumor progression |
| - | Review, | Var, | NA |
| 1622- | FA, | Folate and Its Impact on Cancer Risk |
| - | Review, | NA, | NA |
| 1623- | FA, | Folic acid: friend or foe in cancer therapy |
| - | Review, | Var, | NA |
| 4059- | FA, | Dietary B Vitamins and a 10-Year Risk of Dementia in Older Persons |
| - | Study, | AD, | NA |
| 4076- | FA, | VitE, | VitB6, | Reduced risk of Alzheimer’s disease with high folate intake: The Baltimore Longitudinal Study of Aging |
| - | Study, | AD, | NA |
| 4075- | FA, | Folic acid, ageing, depression, and dementia |
| - | Review, | AD, | NA |
| 4044- | FA, | Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial |
| - | Trial, | AD, | NA |
| 4074- | FA, | VitB12, | Associations between Alzheimer's disease and blood homocysteine, vitamin B12, and folate: a case-control study |
| - | Trial, | AD, | NA |
| 4073- | FA, | The importance of folic acid deficiency in the pathogenesis of vascular, mixed and Alzheimer's disease dementia |
| - | Study, | AD, | NA |
| 4072- | FA, | Folic acid with or without vitamin B12 for cognition and dementia |
| - | Review, | AD, | NA |
| 4071- | FA, | Folate and Alzheimer: when time matters |
| - | Review, | AD, | NA |
| 4070- | FA, | Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial |
| - | Trial, | AD, | NA |
| 4069- | FA, | Folate, folic acid and 5-methyltetrahydrofolate are not the same thing |
| - | Review, | AD, | NA |
| 4068- | FA, | Hyperhomocysteinemia in Alzheimer's disease: the hen and the egg? |
| - | in-vivo, | AD, | NA |
| 4064- | FA, | VitB6, | VitB12, | High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial |
| - | Trial, | AD, | NA |
| 3783- | FA, | Design, Synthesis, and Biological Evaluation of Ferulic Acid-Piperazine Derivatives Targeting Pathological Hallmarks of Alzheimer’s Disease |
| - | NA, | AD, | NA |
| 3782- | FA, | Ferulic acid ameliorates bisphenol A (BPA)-induced Alzheimer’s disease-like pathology through Akt-ERK crosstalk pathway in male rats |
| - | in-vivo, | AD, | NA |
| 3781- | FA, | Therapeutic potential of ferulic acid and its derivatives in Alzheimer’s disease—A systematic review |
| - | Review, | AD, | NA |
| 3710- | FA, | Therapeutic Potential of Ferulic Acid in Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3711- | FA, | A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease |
| - | Review, | AD, | NA |
| 3712- | FA, | Ferulic Acid: A Hope for Alzheimer’s Disease Therapy from Plants |
| - | Review, | AD, | NA |
| 3713- | FA, | Protective Effect of Ferulic Acid on Acetylcholinesterase and Amyloid Beta Peptide Plaque Formation in Alzheimer’s Disease: An In Vitro Study |
| - | Review, | AD, | NA |
| 3714- | FA, | Recent Advances in the Neuroprotective Properties of Ferulic Acid in Alzheimer's Disease: A Narrative Review |
| - | Review, | AD, | NA |
| 3715- | FA, | CUR, | PS, | The Additive Effects of Low Dose Intake of Ferulic Acid, Phosphatidylserine and Curcumin, Not Alone, Improve Cognitive Function in APPswe/PS1dE9 Transgenic Mice |
| - | in-vivo, | AD, | NA |
| 3716- | FA, | Ferulic Acid as a Protective Antioxidant of Human Intestinal Epithelial Cells |
| - | in-vitro, | IBD, | NA | - | in-vivo, | NA, | NA |
| 3717- | FA, | Neuroprotective Properties of Ferulic Acid in Preclinical Models of Alzheimer's Disease: A Systematic Literature Review |
| - | Review, | AD, | NA |
| 3718- | FA, | Therapeutic potential of ferulic acid and its derivatives in Alzheimer's disease-A systematic review |
| - | Review, | AD, | NA |
| 3780- | FA, | Ferulic Acid: A Natural Antioxidant with Application Towards Neuroprotection Against Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3779- | FA, | A review on ferulic acid and analogs based scaffolds for the management of Alzheimer’s disease |
| - | Review, | AD, | NA |
| 3778- | FA, | Recent Advances in the Neuroprotective Properties of Ferulic Acid in Alzheimer’s Disease: A Narrative Review |
| - | Review, | AD, | NA |
| 4251- | FA, | Antidepressant-Like Effect of Ferulic Acid via Promotion of Energy Metabolism Activity |
| - | in-vivo, | NA, | NA |
| 4249- | FA, | Folic acid supplementation during pregnancy prevents cognitive impairments and BDNF imbalance in the hippocampus of the offspring after neonatal hypoxia-ischemia |
| - | in-vivo, | NA, | NA |
| 2497- | Fenb, | In vitro anti-tubulin effects of mebendazole and fenbendazole on canine glioma cells |
| - | in-vitro, | GBM, | NA |
| 2496- | Fenb, | Impairment of the Ubiquitin-Proteasome Pathway by Methyl N-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H460 |
| 2495- | Fenb, | Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells |
| - | in-vitro, | Melanoma, | A375 |
| 2494- | Fenb, | Oral Fenbendazole for Cancer Therapy in Humans and Animals |
| - | Review, | Var, | NA |
| 2499- | Fenb, | VitE, | Effects of fenbendazole and vitamin E succinate on the growth and survival of prostate cancer cells |
| - | in-vitro, | Pca, | PC3 |
| 2498- | Fenb, | Unexpected Antitumorigenic Effect of Fenbendazole when Combined with Supplementary Vitamins |
| - | in-vivo, | lymphoma, | NA |
| 1915- | Fer, | Vascular Imaging With Ferumoxytol as a Contrast Agent |
| - | Analysis, | Var, | NA |
| 1914- | Fer, | VitC, | TMZ, | Rad, | Pharmacologic Ascorbate and Ferumoxytol Combined with Temozolomide and Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma |
| - | Trial, | GBM, | NA |
| 1113- | FIS, | Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 949- | FIS, | ATAGJ, | Cisplatin, | Ai-Tong-An-Gao-Ji and Fisetin Inhibit Tumor Cell Growth in Rat CIBP Models by Inhibiting the AKT/HIF-1α Signaling Pathway |
| - | in-vivo, | BC, | Walker256 | - | in-vitro, | BC, | Walker256 |
| 2844- | FIS, | Fisetin, a dietary flavonoid induces apoptosis via modulating the MAPK and PI3K/Akt signalling pathways in human osteosarcoma (U-2 OS) cells |
| - | in-vitro, | OS, | U2OS |
| 2850- | FIS, | Fisetin regulates TPA-induced breast Cancer cell invasion by suppressing matrix metalloproteinase-9 activation via the PKC/ROS/MAPK pathways |
| - | in-vitro, | BC, | MCF-7 |
| 2845- | FIS, | Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy |
| - | Review, | Var, | NA |
| 2846- | FIS, | Fisetin protects against cardiac cell death through reduction of ROS production and caspases activity |
| - | in-vitro, | Nor, | NA |
| 2847- | FIS, | Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells |
| - | in-vitro, | CCA, | NA |
| 2848- | FIS, | Fisetin alleviates cellular senescence through PTEN mediated inhibition of PKCδ-NOX1 pathway in vascular smooth muscle cells |
| - | in-vitro, | Nor, | NA |
| 2849- | FIS, | Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells |
| - | in-vitro, | Melanoma, | U266 |
| 2851- | FIS, | Apoptosis induction in breast cancer cell lines by the dietary flavonoid fisetin |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | SkBr3 | - | in-vitro, | Nor, | NA |
| 2852- | FIS, | A comprehensive view on the fisetin impact on colorectal cancer in animal models: Focusing on cellular and molecular mechanisms |
| - | Review, | CRC, | NA |
| 2853- | FIS, | Fisetin Inhibits Cell Proliferation and Induces Apoptosis via JAK/STAT3 Signaling Pathways in Human Thyroid TPC 1 Cancer Cells |
| - | in-vitro, | Thyroid, | TPC-1 |
| 2854- | FIS, | New Perspectives for Fisetin |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA |
| 2855- | FIS, | Fisetin Induces Apoptosis Through p53-Mediated Up-Regulation of DR5 Expression in Human Renal Carcinoma Caki Cells |
| - | in-vitro, | RCC, | Caki-1 |
| 2856- | FIS, | N -acetyl- L -cysteine enhances fisetin-induced cytotoxicity via induction of ROS-independent apoptosis in human colonic cancer cells |
| - | in-vitro, | Colon, | COLO205 |
| 2857- | FIS, | A review on the chemotherapeutic potential of fisetin: In vitro evidences |
| - | Review, | Var, | NA |
| 2858- | FIS, | Fisetin inhibits cell migration via inducing HO-1 and reducing MMPs expression in breast cancer cell lines |
| - | in-vitro, | BC, | 4T1 |
| 2859- | FIS, | The Natural Flavonoid Fisetin Inhibits Cellular Proliferation of Hepatic, Colorectal, and Pancreatic Cancer Cells through Modulation of Multiple Signaling Pathways |
| - | in-vitro, | Liver, | HepG2 | - | NA, | Colon, | Caco-2 |
| 2860- | FIS, | Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | Nor, | hTERT-HPNE | - | in-vivo, | NA, | NA |
| 2861- | FIS, | The neuroprotective effects of fisetin, a natural flavonoid in neurodegenerative diseases: Focus on the role of oxidative stress |
| - | Review, | Nor, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
| 2862- | FIS, | Fisetin averts oxidative stress in pancreatic tissues of streptozotocin-induced diabetic rat |
| - | in-vivo, | Diabetic, | NA |
| 2842- | FIS, | Fisetin inhibits cellular proliferation and induces mitochondria-dependent apoptosis in human gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 2824- | FIS, | Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics |
| - | Review, | Var, | NA |
| 2825- | FIS, | Exploring the molecular targets of dietary flavonoid fisetin in cancer |
| - | Review, | Var, | NA |
| 2826- | FIS, | Fisetin induces apoptosis in breast cancer MDA-MB-453 cells through degradation of HER2/neu and via the PI3K/Akt pathway |
| - | in-vitro, | BC, | MDA-MB-453 |
| 2827- | FIS, | The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment |
| - | Review, | Var, | NA |
| 2828- | FIS, | Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review |
| - | Review, | Var, | NA |
| 2829- | FIS, | Fisetin: An anticancer perspective |
| - | Review, | Var, | NA |
| 2830- | FIS, | Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent |
| - | Review, | Var, | NA |
| 2831- | FIS, | Fisetin as a chemoprotective and chemotherapeutic agent: mechanistic insights and future directions in cancer therapy |
| - | Review, | Var, | NA |
| 2832- | FIS, | Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies |
| - | Review, | Var, | NA |
| 2833- | FIS, | SNP, | Glucose-capped fisetin silver nanoparticles induced cytotoxicity and ferroptosis in breast cancer cells: A molecular perspective |
| - | in-vitro, | BC, | MDA-MB-231 |
| 2838- | FIS, | Fisetin induces apoptosis in colorectal cancer cells by suppressing autophagy and down-regulating nuclear factor erythroid 2-related factor 2 (Nrf2) |
| 2839- | FIS, | Dietary flavonoid fisetin for cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2840- | FIS, | Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells |
| - | NA, | CCA, | NA |
| 2841- | FIS, | Fisetin, an Anti-Inflammatory Agent, Overcomes Radioresistance by Activating the PERK-ATF4-CHOP Axis in Liver Cancer |
| - | in-vitro, | Nor, | RAW264.7 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | Hep3B | - | in-vitro, | Liver, | HUH7 |
| 2843- | FIS, | Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential |
| - | Review, | Var, | NA |
| 2313- | Flav, | Flavonoids against the Warburg phenotype—concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism |
| - | Review, | Var, | NA |
| 2642- | Flav, | QC, | Api, | KaempF, | MCT | In Vitro–In Vivo Study of the Impact of Excipient Emulsions on the Bioavailability and Antioxidant Activity of Flavonoids: Influence of the Carrier Oil Type |
| - | in-vitro, | Nor, | NA | - | in-vivo, | Nor, | NA |
| 2401- | Flav, | In vitro effects of some flavonoids and phenolic acids on human pyruvate kinase isoenzyme M2 |
| - | in-vitro, | Nor, | NA |
| 4250- | Flav, | Dietary Flavonoids Interaction with CREB-BDNF Pathway: An Unconventional Approach for Comprehensive Management of Epilepsy |
| - | Review, | NA, | NA |
| 4063- | Flav, | VitB12, | VitB6, | Homocysteine and Dementia: An International Consensus Statement |
| - | Review, | AD, | NA |
| 4060- | Flav, | Vitamin Supplementation and Dementia: A Systematic Review |
| - | Review, | AD, | NA |
| 4107- | FLS, | Ex, | Combined effects of aerobic exercise and 40-Hz light flicker exposure on early cognitive impairments in Alzheimer's disease of 3×Tg mice |
| - | in-vivo, | AD, | NA |
| 4108- | FLS, | Improvement of olfactory function in AD mice mediated by immune responses under 40 Hz light flickering |
| - | in-vivo, | AD, | NA |
| 4121- | FLS, | Sensory-Evoked 40-Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer’s Disease Patients |
| - | Trial, | AD, | NA |
| 4018- | FulvicA, | Fe, | Inhibitory Impacts of Fulvic Acid-Coated Iron Oxide Nanoparticles on the Amyloid Fibril Aggregations |
| - | in-vivo, | AD, | NA |
| 4016- | FulvicA, | Shilajit: A Natural Phytocomplex with Potential Procognitive Activity |
| - | Review, | AD, | NA |
| 4019- | FulvicA, | Can nutraceuticals prevent Alzheimer's disease? Potential therapeutic role of a formulation containing shilajit and complex B vitamins |
| - | Review, | AD, | NA |
| 4020- | FulvicA, | Natural products as a rich source of tau-targeting drugs for Alzheimer’s disease |
| - | in-vitro, | AD, | NA |
| 4021- | FulvicA, | Scaling the Andean Shilajit: A Novel Neuroprotective Agent for Alzheimer’s Disease |
| - | in-vitro, | AD, | NA |
| 4022- | FulvicA, | Chemo, | Shilajit potentiates the effect of chemotherapeutic drugs and mitigates metastasis induced liver and kidney damages in osteosarcoma rats |
| - | in-vivo, | OS, | NA |
| 4017- | FulvicA, | Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer's disease |
| - | NA, | AD, | NA |
| 4030- | FulvicA, | Therapeutic Potential of Fulvic Acid in Chronic Inflammatory Diseases and Diabetes |
| - | Review, | NA, | NA |
| 4029- | FulvicA, | Chemo, | Shilajit mitigates chemotherapeutic drug-induced testicular toxicity: Study on testicular germ cell dynamics, steroidogenesis modulation, and Nrf-2/Keap-1 signaling |
| - | in-vivo, | Var, | NA |
| 4028- | FulvicA, | Mineral pitch induces apoptosis and inhibits proliferation via modulating reactive oxygen species in hepatic cancer cells |
| - | in-vitro, | Liver, | HUH7 |
| 4027- | FulvicA, | Mummy Induces Apoptosis Through Inhibiting of Epithelial-Mesenchymal Transition (EMT) in Human Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 4026- | FulvicA, | Shilajitin Cancer Treatment: Probable Mode of Action |
| - | Review, | Var, | NA |
| 4025- | FulvicA, | Mumio (Shilajit) as a potential chemotherapeutic for the urinary bladder cancer treatment |
| - | in-vitro, | Bladder, | T24 | - | Review, | AD, | NA |
| 4024- | FulvicA, | ANTI-CARCINOGENIC ACTIVITY OF SHILAJIT REGARDING TO APOPTOSIS ASSAY IN CANCER CELLS: A SYSTEMATIC REVIEW OF IN-VITRO STUDIES |
| - | Review, | Var, | NA |
| - | in-vitro, | Oral, | NA |
| 1773- | GA, | Impact of Gallic Acid on Gut Health: Focus on the Gut Microbiome, Immune Response, and Mechanisms of Action |
| - | Review, | Var, | NA |
| 1300- | GA, | PacT, | carbop, | Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line |
| - | in-vitro, | BC, | MCF-7 |
| 1283- | GA, | immuno, | Gallic acid induces T-helper-1-like Treg cells and strengthens immune checkpoint blockade efficacy |
| - | vitro+vivo, | CRC, | NA |
| 1624- | GA, | Anticancer Effect of Pomegranate Peel Polyphenols against Cervical Cancer |
| - | in-vitro, | Cerv, | NA |
| 1065- | GA, | Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression |
| - | vitro+vivo, | Pca, | NA |
| 1086- | GA, | Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation |
| - | in-vitro, | AML, | K562 |
| 987- | GA, | Targeting Aerobic Glycolysis: Gallic Acid as Promising Anticancer Drug |
| - | in-vitro, | GBM, | AMGM | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | BC, | MCF-7 |
| 997- | GA, | The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H292 | - | in-vitro, | Nor, | HUVECs |
| 1115- | GA, | Gallic acid alleviates gastric precancerous lesions through inhibition of epithelial mesenchymal transition via Wnt/β-catenin signaling pathway |
| - | in-vivo, | GC, | GES-1 |
| 1091- | GA, | Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | HTB-35 |
| 947- | GA, | Gallic acid, a phenolic compound, exerts anti-angiogenic effects via the PTEN/AKT/HIF-1α/VEGF signaling pathway in ovarian cancer cells |
| - | in-vitro, | Ovarian, | OVCAR-3 | - | in-vitro, | Melanoma, | A2780S | - | in-vitro, | Nor, | IOSE364 | - | Human, | NA, | NA |
| 3719- | GABA, | Treatment Options in Alzheimer´s Disease: The GABA Story |
| - | Review, | AD, | NA |
| 3720- | GABA, | Effects of Oral Gamma-Aminobutyric Acid (GABA) Administration on Stress and Sleep in Humans: A Systematic Review |
| - | Review, | AD, | NA |
| 4248- | Gala, | Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement |
| - | Review, | NA, | NA |
| 935- | Gallo, | Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 934- | Gallo, | Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase |
| - | Analysis, | NA, | NA |
| 2426- | GamB, | Anti-cancer natural products isolated from chinese medicinal herbs |
| - | Review, | Var, | NA |
| - | in-vitro, | Lung, | A549 |
| 1973- | GamB, | Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain |
| - | in-vitro, | Liver, | SMMC-7721 cell |
| 1972- | GamB, | doxoR, | Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression |
| - | in-vitro, | BC, | NA |
| 1971- | GamB, | Gambogic acid triggers vacuolization-associated cell death in cancer cells via disruption of thiol proteostasis |
| - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vivo, | NA, | NA |
| 1970- | GamB, | Gambogic acid-induced autophagy in nonsmall cell lung cancer NCI-H441 cells through a reactive oxygen species pathway |
| - | NA, | Lung, | NCI-H441 |
| 1969- | GamB, | Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 1967- | GamB, | Gambogic acid induces apoptotic cell death in T98G glioma cells |
| - | in-vitro, | GBM, | T98G |
| 2060- | GamB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 1954- | GamB, | Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase |
| - | in-vitro, | HCC, | SMMC-7721 cell |
| 1955- | GamB, | Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer |
| - | in-vitro, | Pca, | NA |
| 1956- | GamB, | Gambogic Acid Inhibits Malignant Melanoma Cell Proliferation Through Mitochondrial p66shc/ROS-p53/Bax-Mediated Apoptosis |
| - | in-vitro, | Melanoma, | A375 |
| 1957- | GamB, | Nanoscale Features of Gambogic Acid Induced ROS-Dependent Apoptosis in Esophageal Cancer Cells Imaged by Atomic Force Microscopy |
| - | in-vitro, | ESCC, | EC9706 |
| 1958- | GamB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| - | in-vitro, | Pca, | NA | - | in-vivo, | NA, | NA |
| 1959- | GamB, | Gambogic acid induces GSDME dependent pyroptotic signaling pathway via ROS/P53/Mitochondria/Caspase-3 in ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA | - | in-vivo, | NA, | NA |
| 1961- | GamB, | Effects of gambogic acid on the activation of caspase-3 and downregulation of SIRT1 in RPMI-8226 multiple myeloma cells via the accumulation of ROS |
| - | in-vitro, | Melanoma, | RPMI-8226 |
| 1962- | GamB, | HCQ, | Gambogic acid induces autophagy and combines synergistically with chloroquine to suppress pancreatic cancer by increasing the accumulation of reactive oxygen species |
| - | in-vitro, | PC, | NA |
| 1963- | GamB, | Gambogic acid exhibits promising anticancer activity by inhibiting the pentose phosphate pathway in lung cancer mouse model |
| - | in-vitro, | Lung, | NA |
| 1964- | GamB, | Gambogic acid suppresses the pentose phosphate pathway by covalently inhibiting 6PGD protein in cancer cells |
| - | in-vitro, | NA, | NA |
| 1965- | GamB, | doxoR, | Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis |
| - | in-vitro, | Ovarian, | SKOV3 |
| 1966- | GamB, | Cisplatin, | Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | NCIH1299 |
| 1960- | GamB, | Vem, | Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | AML, | K562 |
| 1636- | GAR, | Dangerous dietary supplements: Garcinia cambogia-associated hepatic failure requiring transplantation |
| - | Case Report, | Obesity, | NA |
| 1632- | GAR, | Garcinia Cambogia, Either Alone or in Combination with Green Tea Causes Moderate to Severe Liver Injury |
| - | Human, | LiverDam, | NA |
| 808- | GAR, | CUR, | Synergistic effect of garcinol and curcumin on antiproliferative and apoptotic activity in pancreatic cancer cells |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | PANC1 |
| 832- | GAR, | Rad, | Garcinol, a Histone Acetyltransferase Inhibitor, Radiosensitizes Cancer Cells by Inhibiting Non-Homologous End Joining |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | NA, | HeLa |
| 831- | GAR, | CUR, | Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells |
| - | in-vitro, | AML, | HL-60 |
| 830- | GAR, | Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 817- | GAR, | Garcinol inhibits esophageal cancer metastasis by suppressing the p300 and TGF-β1 signaling pathways |
| - | vitro+vivo, | SCC, | KYSE150 | - | vitro+vivo, | SCC, | KYSE450 |
| 826- | GAR, | Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo |
| - | vitro+vivo, | HCC, | HepG2 | - | vitro+vivo, | Liver, | HUH7 |
| 825- | GAR, | Garcinol-induced apoptosis in prostate and pancreatic cancer cells is mediated by NF- kappaB signaling |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | Bxpc-3 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | C4-2B |
| 824- | GAR, | Garcinol A Novel Inhibitor of Platelet Activation and Apoptosis |
| - | in-vitro, | NA, | NA |
| 823- | GAR, | Garcinol Potentiates TRAIL-Induced Apoptosis through Modulation of Death Receptors and Antiapoptotic Proteins |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 | - | in-vitro, | CRC, | HCT116 |
| 822- | GAR, | Garcinol, a Polyisoprenylated Benzophenone Modulates Multiple Proinflammatory Signaling Cascades Leading to the Suppression of Growth and Survival of Head and Neck Carcinoma |
| - | vitro+vivo, | HNSCC, | NA |
| 821- | GAR, | Garcinol inhibits cell growth in hepatocellular carcinoma Hep3B cells through induction of ROS-dependent apoptosis |
| - | in-vitro, | Liver, | Hep3B |
| 820- | GAR, | Garcinol in gastrointestinal cancer prevention: recent advances and future prospects |
| - | Review, | NA, | NA |
| 819- | GAR, | Enhanced Hsa-miR-181d/p-STAT3 and Hsa-miR-181d/p-STAT5A Ratios Mediate the Anticancer Effect of Garcinol in STAT3/5A-Addicted Glioblastoma |
| - | in-vivo, | GBM, | U87MG | - | in-vitro, | GBM, | GBM |
| 818- | GAR, | GB, | Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs |
| - | in-vitro, | Lung, | A549 |
| 828- | GAR, | Cisplatin, | Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells |
| - | in-vitro, | Ovarian, | OVCAR-3 |
| 816- | GAR, | Garcinol downregulates Notch1 signaling via modulating miR-200c and suppresses oncogenic properties of PANC-1 cancer stem-like cells |
| - | in-vitro, | PC, | PANC1 |
| 815- | GAR, | Garcinol from Garcinia indica Downregulates Cancer Stem-like Cell Biomarker ALDH1A1 in Nonsmall Cell Lung Cancer A549 Cells through DDIT3 Activation |
| - | vitro+vivo, | Lung, | A549 |
| 814- | GAR, | PacT, | Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-κB/Twist1 signaling pathways in a mouse 4T1 breast tumor model |
| - | in-vivo, | BC, | NA |
| 813- | GAR, | GEM, | Dietary Garcinol Arrests Pancreatic Cancer in p53 and K-ras Conditional Mutant Mouse Model |
| - | in-vivo, | PC, | NA |
| 812- | GAR, | Anti-proliferative and anti-invasive effects of garcinol from Garcinia indica on gallbladder carcinoma cells |
| - | in-vitro, | Gall, | GBC-SD | - | in-vitro, | Gall, | NOZ |
| 811- | GAR, | Garcinol exhibits anti-proliferative activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 810- | GAR, | GEM, | Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures |
| - | in-vitro, | PC, | NA |
| 809- | GAR, | High-Throughput Screen of Natural Product Libraries for Hsp90 Inhibitors |
| - | Review, | NA, | NA |
| 807- | GAR, | Garcinol inhibits cell proliferation and promotes apoptosis in pancreatic adenocarcinoma cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 |
| 829- | GAR, | The Role of T-Cadherin (CDH13) in Treatment Options with Garcinol in Melanoma |
| - | vitro+vivo, | Melanoma, | NA |
| 827- | GAR, | Garcinol Is an HDAC11 Inhibitor |
| - | in-vitro, | NA, | NA |
| 794- | GAR, | Garcinol Enhances TRAIL-Induced Apoptotic Cell Death through Up-Regulation of DR5 and Down-Regulation of c-FLIP Expression |
| - | in-vitro, | RCC, | NA | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | NA |
| 806- | GAR, | Garcinol exerts anti-cancer effect in human cervical cancer cells through upregulation of T-cadherin |
| - | vitro+vivo, | Pca, | HeLa | - | vitro+vivo, | Cerv, | SiHa |
| 795- | GAR, | Garcinol—A Natural Histone Acetyltransferase Inhibitor and New Anti-Cancer Epigenetic Drug |
| - | Review, | NA, | NA |
| 796- | GAR, | Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression |
| - | vitro+vivo, | Pca, | HeLa |
| 797- | GAR, | CUR, | Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | OS, | U2OS | - | in-vitro, | OS, | SaOS2 |
| 798- | GAR, | Garcinol, an acetyltransferase inhibitor, suppresses proliferation of breast cancer cell line MCF-7 promoted by 17β-estradiol |
| - | in-vitro, | BC, | MCF-7 |
| 793- | GAR, | Garcinol inhibits tumour cell proliferation, angiogenesis, cell cycle progression and induces apoptosis via NF-κB inhibition in oral cancer |
| - | in-vitro, | SCC, | SCC9 | - | in-vitro, | SCC, | SCC4 | - | in-vitro, | SCC, | SCC25 |
| 799- | GAR, | Apoptosis-inducing effect of garcinol is mediated by NF-kappaB signaling in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | NMSC, | MCF10 |
| 800- | GAR, | Garcinol Regulates EMT and Wnt Signaling Pathways In Vitro and In Vivo, Leading to Anticancer Activity against Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | NA, | NA |
| 801- | GAR, | Cisplatin, | Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers |
| - | in-vivo, | HNSCC, | NA |
| 802- | GAR, | Garcinol acts as an antineoplastic agent in human gastric cancer by inhibiting the PI3K/AKT signaling pathway |
| - | in-vitro, | GC, | HGC27 |
| 803- | GAR, | Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 804- | GAR, | Garcinol inhibits the proliferation of endometrial cancer cells by inducing cell cycle arrest |
| - | in-vitro, | EC, | HEC1B | - | in-vitro, | EC, | ISH |
| 805- | GAR, | Cisplatin, | PacT, | Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells |
| - | Review, | NA, | NA |
| 1190- | Gb, | Extract of Ginkgo biloba exacerbates liver metastasis in a mouse colon cancer Xenograft model |
| - | in-vivo, | CRC, | SW-620 |
| 1186- | Gb, | Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis |
| - | in-vitro, | PC, | NA | - | in-vitro, | Nor, | HUVECs | - | in-vivo, | PC, | NA |
| 1187- | Gb, | Ginkgolic Acid C 17:1, Derived from Ginkgo biloba Leaves, Suppresses Constitutive and Inducible STAT3 Activation through Induction of PTEN and SHP-1 Tyrosine Phosphatase |
| - | in-vitro, | Melanoma, | U251 | - | in-vitro, | Melanoma, | MM.1S |
| 1188- | Gb, | The potential of Ginkgo biloba in the treatment of human diseases and the relationship to Nrf2-mediated antioxidant protection |
| - | Review, | NA, | NA |
| 1189- | Gb, | New insight into the mechanisms of Ginkgo biloba leaves in the treatment of cancer |
| - | Review, | NA, | NA |
| - | vitro+vivo, | Kidney, | HK-2 |
| 4245- | Gb, | Standardized extract of Ginkgo biloba enhances memory persistence over time |
| - | in-vivo, | NA, | NA |
| 4244- | Gb, | Effects of Six-Week Ginkgo biloba Supplementation on Aerobic Performance, Blood Pro/Antioxidant Balance, and Serum Brain-Derived Neurotrophic Factor in Physically Active Men |
| - | Human, | Nor, | NA |
| 3721- | Gb, | Ginkgo biloba Extract in Alzheimer’s Disease: From Action Mechanisms to Medical Practice |
| - | Review, | AD, | NA |
| 3723- | Gb, | Can We Use Ginkgo biloba Extract to Treat Alzheimer’s Disease? Lessons from Preclinical and Clinical Studies |
| - | Review, | AD, | NA |
| 3722- | Gb, | Alzheimer's disease: Research summaries – Do Ginkgo products help? |
| - | Review, | AD, | NA |
| 1118- | Ge, | Grape Seed Proanthocyanidins Inhibit Migration and Invasion of Bladder Cancer Cells by Reversing EMT through Suppression of TGF- β Signaling Pathway |
| - | in-vitro, | Bladder, | T24 | - | in-vitro, | Bladder, | 5637 |
| 792- | GE, | The role of germanium in diseases: exploring its important biological effects |
| 791- | GE, | Germanium Sesquioxide Organic Germanium |
| 790- | GE, | A Toxicological Evaluation of Germanium Sesquioxide (Organic Germanium) |
| - | vitro+vivo, | NA, | NA |
| 789- | GE, | Complete remission of pulmonary spindle cell carcinoma after treatment with oral germanium sesquioxide |
| - | Case Report, | SCC, | NA |
| 1241- | Ge, | PACs, | Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietin signaling |
| - | in-vitro, | Nor, | NA |
| 1240- | Ge, | PACs, | Grape Seed Proanthocyanidins Inhibit Melanoma Cell Invasiveness by Reduction of PGE2 Synthesis and Reversal of Epithelial-to-Mesenchymal Transition |
| - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Melanoma, | Hs294T |
| 1292- | Ge, | EGCG, | Antiproliferative and Apoptotic Effects Triggered by Grape Seed Extract (GSE) versus Epigallocatechin and Procyanidins on Colon Cancer Cell Lines |
| - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | CRC, | HCT8 |
| 1435- | GEN, | SFN, | The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 1504- | GEN, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
| - | Review, | NA, | NA |
| 927- | GEN, | PacT, | Bioenhancers from mother nature and their applicability in modern medicine |
| - | Review, | Nor, | NA |
| 28- | GEN, | Genistein decreases the breast cancer stem-like cell population through Hedgehog pathway |
| - | in-vivo, | BC, | MCF-7 |
| 29- | GEN, | Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway |
| - | in-vivo, | Pca, | NA |
| 4664- | GEN, | CUR, | RES, | EGCG, | SFN | Targeting cancer stem cells by nutraceuticals for cancer therapy |
| - | Review, | Var, | NA |
| 2997- | GEN, | Genistein Inhibition of Topoisomerase IIα Expression Participated by Sp1 and Sp3 in HeLa Cell |
| - | in-vitro, | Cerv, | HeLa |
| 2998- | GEN, | Cellular and Molecular Mechanisms Modulated by Genistein in Cancer |
| - | Review, | Var, | NA |
| 30- | Ger, | A sesquiterpene lactone from Siegesbeckia glabrescens suppresses Hedgehog/Gli-mediated transcription in pancreatic cancer cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | AsPC-1 |
| 1005- | GI, | Ginger Constituent 6-Shogaol Inhibits Inflammation- and Angiogenesis-Related Cell Functions in Primary Human Endothelial Cells |
| - | vitro+vivo, | Nor, | HUVECs |
| 1116- | GI, | 6-Shogaol Inhibits the Cell Migration of Colon Cancer by Suppressing the EMT Process Through the IKKβ/NF-κB/Snail Pathway |
| - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | CRC, | HCT116 |
| 2464- | GI, | The Effect of Ginger (Zingiber officinale) on Platelet Aggregation: A Systematic Literature Review |
| - | Review, | Nor, | NA |
| 2465- | GI, | Effect of daily ginger consumption on platelet aggregation |
| - | Trial, | Nor, | NA |
| 4247- | GI, | 6-Shogaol from Dried Ginger Protects against Intestinal Ischemia/Reperfusion by Inhibiting Cell Apoptosis via the BDNF/TrkB/PI3K/AKT Pathway |
| - | vitro+vivo, | NA, | NA |
| 4246- | GI, | Ginger oil-loaded transdermal adhesive patch treats post-traumatic stress disorder |
| - | in-vivo, | NA, | NA |
| 4242- | Gins, | Ginseng Extract G115 Attenuates Ethanol-Induced Depression in Mice by Increasing Brain BDNF Levels |
| - | in-vivo, | NA, | NA |
| 4243- | Gins, | Effects of Ginseng on Neurological Disorders |
| - | Review, | Stroke, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3829- | Gins, | Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3998- | Gins, | Ginseng for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| - | Trial, | AD, | NA |
| 4003- | Gins, | Neuroprotective Potentials of Panax Ginseng Against Alzheimer's Disease: A Review of Preclinical and Clinical Evidences |
| - | Review, | adrenal, | NA |
| 3999- | Gins, | Panax ginseng enhances cognitive performance in Alzheimer disease |
| - | Trial, | NA, | NA |
| 4000- | Gins, | Heat-processed ginseng enhances the cognitive function in patients with moderately severe Alzheimer's disease |
| - | Human, | AD, | NA |
| 4001- | Gins, | An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease |
| - | Human, | AD, | NA |
| 4002- | Gins, | Improvement of cognitive deficit in Alzheimer's disease patients by long term treatment with korean red ginseng |
| - | Trial, | AD, | NA |
| 4004- | Gins, | Effects of fermented ginseng on memory impairment and β-amyloid reduction in Alzheimer’s disease experimental models |
| - | in-vivo, | AD, | NA |
| 4301- | Gins, | Red Ginseng Inhibits Tau Aggregation and Promotes Tau Dissociation In Vitro |
| - | in-vitro, | AD, | NA |
| 4302- | Gins, | Panax ginseng: A modulator of amyloid, tau pathology, and cognitive function in Alzheimer's disease |
| - | Review, | AD, | NA |
| 4511- | GLA, | Gamma-Linolenic Acid (GLA) Protects against Ionizing Radiation-Induced Damage: An In Vitro and In Vivo Study |
| - | vitro+vivo, | Nor, | RAW264.7 |
| 4513- | GLA, | Antineoplastic Effects of Gamma Linolenic Acid on Hepatocellular Carcinoma Cell Lines |
| - | in-vitro, | Liver, | HUH7 |
| 4510- | GLA, | Gamma-linolenic acid therapy of human glioma-a review of in vitro, in vivo, and clinical studies |
| - | Review, | NA, | NA |
| 4509- | GLA, | Gamma-linolenic Acid (GLA) sensitizes pancreatic cancer cells to gemcitabine |
| - | in-vitro, | PC, | PANC1 |
| 4508- | GLA, | aLinA, | α-Linolenic and γ-linolenic acids exercise differential antitumor effects on HT-29 human colorectal cancer cells |
| - | in-vitro, | Colon, | HT29 |
| 4507- | GLA, | Effect of γ-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene |
| - | in-vitro, | BC, | BT474 | - | in-vitro, | BC, | SkBr3 | - | in-vitro, | BC, | MDA-MB-453 | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | GC, | NCI-N87 |
| 4506- | GLA, | A basal level of γ-linolenic acid depletes Ca2+ stores and induces endoplasmic reticulum and oxidative stresses to cause death of breast cancer BT-474 cells |
| - | in-vitro, | BC, | BT474 |
| 4505- | GLA, | Gamma linolenic acid suppresses hypoxia-induced proliferation and invasion of non-small cell lung cancer cells by inhibition of HIF1α |
| - | in-vitro, | NSCLC, | Calu-1 |
| 31- | GlaB, | Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors |
| - | in-vitro, | BCC, | NA |
| 32- | GlaB, | Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors |
| - | in-vivo, | MB, | NA |
| 401- | GoldNP, | MF, | In vitro evaluation of electroporated gold nanoparticles and extremely-low frequency electromagnetic field anticancer activity against Hep-2 laryngeal cancer cells |
| - | in-vitro, | Laryn, | HEp2 |
| 4420- | GoldNP, | Rad, | Computational modeling and experimental synthesis of BSA-coated bimetallic theranostic MnO₂-Au@curcumin nanoplatform for synergistic radiochemotherapy of breast cancer |
| - | in-vitro, | BC, | 4T1 |
| 4597- | GoldNP, | Chit, | Influence of chitosan coating on the oral bioavailability of gold nanoparticles in rats |
| - | in-vivo, | NA, | NA |
| 1407- | GoldNP, | Z, | The antioxidant effects of silver, gold, and zinc oxide nanoparticles on male mice in in vivo condition |
| - | in-vivo, | NA, | NA |
| 1901- | GoldNP, | Rad, | The role of thioredoxin reductase in gold nanoparticle radiosensitization effects |
| - | in-vitro, | Lung, | A549 |
| 1904- | GoldNP, | SNP, | Unveiling the Potential of Innovative Gold(I) and Silver(I) Selenourea Complexes as Anticancer Agents Targeting TrxR and Cellular Redox Homeostasis |
| - | in-vitro, | Lung, | H157 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Colon, | HCT15 | - | in-vitro, | Melanoma, | A375 |
| 3526- | GoldNP, | Rad, | Advances in nanoparticle-based radiotherapy for cancer treatment |
| - | Review, | Var, | NA |
| 941- | Gos, | Rad, | The Lactate Dehydrogenase Inhibitor Gossypol Inhibits Radiation-Induced Pulmonary Fibrosis |
| - | in-vivo, | NA, | NA |
| 849- | Gra, | Annona muricata silver nanoparticles exhibit strong anticancer activities against cervical and prostate adenocarcinomas through regulation of CASP9 and the CXCL1/CXCR2 genes axis |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | PNT1A | - | in-vitro, | NA, | HeLa |
| 851- | Gra, | Antiproliferation Activity and Apoptotic Mechanism of Soursop (Annona muricata L.) Leaves Extract and Fractions on MCF7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | CV1 |
| 848- | Gra, | SNP, | Synthesis, Characterization and Evaluation of Antioxidant and Cytotoxic Potential of Annona muricata Root Extract-derived Biogenic Silver Nanoparticles |
| - | in-vitro, | CRC, | HCT116 |
| 847- | Gra, | Natural substances (acetogenins) from the family Annonaceae are powerful inhibitors of mitochondrial NADH dehydrogenase (Complex I). |
| 846- | Gra, | Cytotoxic effect of Annona muricata Linn leaves extract on Capan-1 cells |
| - | in-vitro, | NA, | Ca9-22 |
| 845- | Gra, | A Review on Annona muricata and Its Anticancer Activity |
| - | Review, | NA, | NA |
| 844- | Gra, | Annona muricata Leaf Extract Triggered Intrinsic Apoptotic Pathway to Attenuate Cancerous Features of Triple Negative Breast Cancer MDA-MB-231 Cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| - | in-vitro, | NMSC, | A431 | - | in-vitro, | NMSC, | UW-BCC1 | - | in-vitro, | Nor, | NHEKn |
| 842- | Gra, | Phytochemical screening, anti-oxidant activity and in vitro anticancer potential of ethanolic and water leaves extracts of Annona muricata (Graviola) |
| - | in-vitro, | NA, | NA | - | in-vitro, | Nor, | NA |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Nor, | CCD841 |
| - | in-vitro, | SCC, | SCC25 |
| 839- | Gra, | Functional proteomic analysis revels that the ethanol extract of Annona muricata L. induces liver cancer cell apoptosis through endoplasmic reticulum stress pathway |
| - | in-vitro, | Liver, | HepG2 |
| 838- | Gra, | Antiproliferative activity of aqueous leaf extract of Annona muricata L. on the prostate, BPH-1 cells, and some target genes |
| - | in-vitro, | Pca, | BPH1 |
| 837- | Gra, | Quantitative assessment of the relative antineoplastic potential of the n-butanolic leaf extract of Annona muricata Linn. in normal and immortalized human cell lines |
| - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | Nor, | WRL68 | - | in-vitro, | Nor, | HaCaT |
| 836- | Gra, | Graviola: A Novel Promising Natural-Derived Drug That Inhibits Tumorigenicity and Metastasis of Pancreatic Cancer Cells In Vitro and In Vivo Through Altering Cell Metabolism |
| - | vitro+vivo, | PC, | NA |
| 835- | Gra, | Annona muricata leaves induced apoptosis in A549 cells through mitochondrial-mediated pathway and involvement of NF-κB |
| - | in-vitro, | Lung, | A549 |
| 834- | Gra, | Anticancer Properties of Graviola (Annona muricata): A Comprehensive Mechanistic Review |
| - | Review, | NA, | NA |
| 833- | Gra, | Cytotoxic Effect of Annona muricata leaf extracts on tumor cell lines in vitro |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Lung, | A549 |
| 850- | Gra, | Selective cytotoxic and anti-metastatic activity in DU-145 prostate cancer cells induced by Annona muricata L. bark extract and phytochemical, annonacin |
| - | in-vitro, | PC, | PC3 | - | in-vitro, | Pca, | DU145 |
| 852- | Gra, | Silver Nanoparticles from Annona muricata Peel and Leaf Extracts as a Potential Potent, Biocompatible and Low Cost Antitumor Tool |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Melanoma, | A375 |
| 853- | Gra, | SNP, | Solid lipid nanoparticles of Annona muricata fruit extract: formulation, optimization and in vitro cytotoxicity studies |
| 854- | Gra, | SNP, | Green Synthesis of Silver Nanoparticles Using Annona muricata Extract as an Inducer of Apoptosis in Cancer Cells and Inhibitor for NLRP3 Inflammasome via Enhanced Autophagy |
| - | vitro+vivo, | AML, | THP1 | - | in-vitro, | AML, | AMJ13 | - | vitro+vivo, | lymphoma, | HBL |
| 855- | Gra, | Antiproliferative activity of ionic liquid-graviola fruit extract against human breast cancer (MCF-7) cell lines using flow cytometry techniques |
| - | in-vitro, | BC, | MCF-7 |
| 856- | Gra, | https://pubmed.ncbi.nlm.nih.gov/33048613/ |
| - | in-vitro, | BC, | MCF-7 |
| 857- | Gra, | The Value of Caspase-3 after the Application of Annona muricata Leaf Extract in COLO-205 Colorectal Cancer Cell Line |
| - | in-vitro, | CRC, | COLO205 |
| 858- | Gra, | Annona muricata leaves induce G₁ cell cycle arrest and apoptosis through mitochondria-mediated pathway in human HCT-116 and HT-29 colon cancer cells |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 |
| 2437- | Gra, | Graviola inhibits hypoxia-induced NADPH oxidase activity in prostate cancer cells reducing their proliferation and clonogenicity |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | PWR-1E |
| 2438- | Gra, | Emerging therapeutic potential of graviola and its constituents in cancers |
| - | Review, | Var, | NA |
| 1232- | Gra, | Graviola: A Systematic Review on Its Anticancer Properties |
| - | Review, | NA, | NA |
| 1233- | Gra, | THERAPEUTIC ELIGIBILITY OF GRAVIOLA VERSUS 5-FLUOROURACIL: APOPTOTIC EFFICACY ON HEAD AND NECK SQUAMOUS CELL CARCINOMA AND NORMAL EPITHELIUM CELLS |
| - | in-vitro, | HNSCC, | NA |
| 1234- | Gra, | Graviola attenuates DMBA-induced breast cancer possibly through augmenting apoptosis and antioxidant pathway and downregulating estrogen receptors |
| - | in-vivo, | BC, | NA |
| 108- | GSL, | A sesquiterpene lactone from Siegesbeckia glabrescens suppresses Hedgehog/Gli-mediated transcription in pancreatic cancer cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | C3H10T1/2 |
| 4306- | H2, | Molecular Hydrogen as an Emerging Candidate for Preventing Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4307- | H2, | Hydrogen Gas Attenuates Toxic Metabolites and Oxidative Stress-Mediated Signaling to Inhibit Neurodegeneration and Enhance Memory in Alzheimer’s Disease Models |
| - | in-vivo, | AD, | NA |
| 4308- | H2, | A biomimetic upconversion nanoreactors for near-infrared driven H2 release to inhibit tauopathy in Alzheimer's disease therapy |
| - | in-vivo, | AD, | NA |
| 4343- | H2, | Inhibitory effects of hydrogen on in vitro platelet activation and in vivo prevention of thrombosis formation |
| - | vitro+vivo, | NA, | NA |
| 4344- | H2, | Hydrogen May Inhibit Collagen-Induced Platelet Aggregation: An ex vivo and in vivo Study |
| - | in-vivo, | NA, | NA | - | ex-vivo, | NA, | NA |
| 4345- | H2, | The Benefit of Hydrogen Gas as an Adjunctive Therapy for Chronic Obstructive Pulmonary Disease |
| - | Human, | NA, | NA |
| 4346- | H2, | Medical Application of Hydrogen in Hematological Diseases |
| - | Review, | NA, | NA |
| 4347- | H2, | Hydrogen may inhibit collagen-induced platelet aggregation: an ex vivo and in vivo study |
| - | ex-vivo, | NA, | NA |
| 3787- | H2, | Hydrogen, a Novel Therapeutic Molecule, Regulates Oxidative Stress, Inflammation, and Apoptosis |
| - | Review, | AD, | NA |
| 3762- | H2, | Effects of Molecular Hydrogen Assessed by an Animal Model and a Randomized Clinical Study on Mild Cognitive Impairment |
| - | in-vivo, | AD, | NA |
| 3777- | H2, | Molecular Hydrogen: an Emerging Therapeutic Medical Gas for Brain Disorders |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
| 3776- | H2, | The role of hydrogen in Alzheimer's disease |
| - | Review, | AD, | NA |
| 3775- | H2, | Molecular hydrogen therapy for neurological diseases: a review of current evidence |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3774- | H2, | The role of hydrogen in Alzheimer’s disease |
| - | Review, | AD, | NA |
| 3773- | H2, | Role and mechanism of molecular hydrogen in the treatment of Parkinson’s diseases |
| - | Review, | Park, | NA |
| 3772- | H2, | Therapeutic potential of hydrogen-rich water in zebrafish model of Alzheimer’s disease: targeting oxidative stress, inflammation, and the gut-brain axis |
| - | in-vivo, | AD, | NA |
| 3770- | H2, | Role of Molecular Hydrogen in Ageing and Ageing-Related Diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3761- | H2, | Therapeutic Inhalation of Hydrogen Gas for Alzheimer's Disease Patients and Subsequent Long-Term Follow-Up as a Disease-Modifying Treatment: An Open Label Pilot Study |
| - | Human, | AD, | NA |
| 3763- | H2, | Long-Term Inhalation of Hydrogen Gas for Patients with Advanced Alzheimer's Disease: A Case Report Showing Improvement in Fecal Incontinence |
| - | Case Report, | AD, | NA |
| 3764- | H2, | Therapeutic Effects of Hydrogen Gas Inhalation on Trimethyltin-Induced Neurotoxicity and Cognitive Impairment in the C57BL/6 Mice Model |
| - | in-vivo, | AD, | NA |
| 3765- | H2, | Therapeutic Inhalation of Hydrogen Gas for Alzheimer’s Disease Patients and Subsequent Long-Term Follow-Up as a Disease-Modifying Treatment: An Open Label Pilot Study |
| - | Study, | AD, | NA |
| 3766- | H2, | The role of hydrogen in Alzheimer′s disease |
| - | Review, | AD, | NA |
| 3767- | H2, | The role of hydrogen therapy in Alzheimer's disease management: Insights into mechanisms, administration routes, and future challenges |
| - | Review, | AD, | NA |
| 3768- | H2, | Effects of Hydrogen Gas Inhalation on Community-Dwelling Adults of Various Ages: A Single-Arm, Open-Label, Prospective Clinical Trial |
| - | Trial, | AD, | NA |
| 4237- | H2, | Hydrogen-Rich Saline Protects Against Spinal Cord Injury in Rats |
| - | in-vitro, | NA, | NA |
| 4236- | H2, | Neuroprotective effects of hydrogen inhalation in an experimental rat intracerebral hemorrhage model |
| - | in-vivo, | Stroke, | NA |
| - | in-vivo, | Sepsis, | NA |
| 4234- | H2, | Hydrogen gas alleviates sepsis-induced neuroinflammation and cognitive impairment through regulation of DNMT1 and DNMT3a-mediated BDNF promoter IV methylation in mice |
| - | in-vivo, | Sepsis, | NA |
| 2503- | H2, | Brain Metastases Completely Disappear in Non-Small Cell Lung Cancer Using Hydrogen Gas Inhalation: A Case Report |
| - | Case Report, | Lung, | NA |
| 2504- | H2, | Hydrogen gas activates coenzyme Q10 to restore exhausted CD8+ T cells, especially PD-1+Tim3+terminal CD8+ T cells, leading to better nivolumab outcomes in patients with lung cancer |
| - | Trial, | Lung, | NA |
| 2505- | H2, | Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis |
| - | Trial, | CRC, | NA |
| 2506- | H2, | Molecular hydrogen suppresses activated Wnt/β-catenin signaling |
| - | in-vivo, | Arthritis, | NA |
| 2525- | H2, | Hydrogen-Rich Saline Attenuates Cardiac and Hepatic Injury in Doxorubicin Rat Model by Inhibiting Inflammation and Apoptosis |
| - | in-vivo, | NA, | NA |
| 2508- | H2, | Molecular hydrogen is a promising therapeutic agent for pulmonary disease |
| - | Review, | Var, | NA | - | Review, | Sepsis, | NA |
| 2524- | H2, | Protective effect of hydrogen-rich water on liver function of colorectal cancer patients treated with mFOLFOX6 chemotherapy |
| - | Trial, | NA, | NA |
| 2523- | H2, | Prospects of molecular hydrogen in cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2522- | H2, | A Systematic Review of Molecular Hydrogen Therapy in Cancer Management |
| - | Review, | Var, | NA |
| 2521- | H2, | Oxyhydrogen Gas: A Promising Therapeutic Approach for Lung, Breast and Colorectal Cancer |
| - | Review, | CRC, | NA | - | Review, | Lung, | NA | - | Review, | BC, | NA |
| 2520- | H2, | The Impact of Molecular Hydrogen on Mitochondrial ROS and Apoptosis in Colorectal Cancer Cells |
| - | in-vitro, | CRC, | NA |
| 2519- | H2, | Hydrogen: an advanced and safest gas option for cancer treatment |
| - | Review, | Var, | NA |
| 2518- | H2, | Hydrogen Therapy Reverses Cancer-Associated Fibroblasts Phenotypes and Remodels Stromal Microenvironment to Stimulate Systematic Anti-Tumor Immunity |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | Nor, | 3T3 |
| 2517- | H2, | Molecular Hydrogen Enhances Proliferation of Cancer Cells That Exhibit Potent Mitochondrial Unfolded Protein Response |
| - | in-vitro, | Var, | A549 | - | in-vitro, | NA, | HCT116 | - | in-vitro, | NA, | HeLa | - | in-vitro, | NA, | HepG2 | - | in-vitro, | NA, | HT1080 | - | in-vitro, | NA, | PC3 | - | in-vitro, | NA, | SH-SY5Y |
| 2515- | H2, | Recent Advances in Studies of Molecular Hydrogen against Sepsis |
| - | Review, | Sepsis, | NA |
| 2507- | H2, | Hydrogen protects against chronic intermittent hypoxia induced renal dysfunction by promoting autophagy and alleviating apoptosis |
| - | in-vivo, | NA, | NA |
| 2509- | H2, | Hydrogen inhibits endometrial cancer growth via a ROS/NLRP3/caspase-1/GSDMD-mediated pyroptotic pathway |
| - | in-vitro, | Endo, | AN3CA | - | in-vivo, | Endo, | NA |
| 2510- | H2, | Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals |
| - | in-vivo, | Stroke, | NA |
| 2511- | H2, | Molecular hydrogen suppresses glioblastoma growth via inducing the glioma stem-like cell differentiation |
| - | in-vivo, | GBM, | U87MG |
| 2512- | H2, | Hydrogen Attenuates Allergic Inflammation by Reversing Energy Metabolic Pathway Switch |
| - | in-vivo, | asthmatic, | NA |
| 2513- | H2, | Hydrogen therapy: from mechanism to cerebral diseases |
| - | Review, | Stroke, | NA |
| 2514- | H2, | Hydrogen: A Novel Option in Human Disease Treatment |
| - | Review, | NA, | NA |
| 2516- | H2, | Hydrogen Gas in Cancer Treatment |
| - | Review, | Var, | NA |
| 3152- | H2, | VitC, | Rad, | Hydrogen and Vitamin C Combination Therapy: A Novel Method of Radioprotection |
| - | in-vitro, | Nor, | HUVECs | - | in-vivo, | NA, | NA |
| 2526- | H2, | Influence of hydrogen-occluding-silica on migration and apoptosis in human esophageal cells in vitro |
| - | in-vitro, | ESCC, | KYSE-510 |
| 2527- | H2, | The healing effect of hydrogen-rich water on acute radiation-induced skin injury in rats |
| - | in-vivo, | Wounds, | NA |
| 2528- | H2, | Local generation of hydrogen for enhanced photothermal therapy |
| - | in-vitro, | Var, | NA |
| 2529- | H2, | Guidelines for the selection of hydrogen gas inhalers based on hydrogen explosion accidents |
| - | Analysis, | Nor, | NA |
| 2530- | H2, | Improvement of psoriasis-associated arthritis and skin lesions by treatment with molecular hydrogen: A report of three cases |
| - | Case Report, | PSA, | NA |
| 3769- | H2S, | Research progress of hydrogen sulfide in Alzheimer's disease from laboratory to hospital: a narrative review |
| - | Review, | AD, | NA |
| 1412- | HCA, | Identification of ATP Citrate Lyase as a Positive Regulator of Glycolytic Function in Glioblastomas |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | LN229 |
| 1413- | HCA, | Effects of acute (-)-hydroxycitrate supplementation on substrate metabolism at rest and during exercise in humans |
| - | Human, | Nor, | NA |
| 1414- | HCA, | Bioefficacy of a novel calcium-potassium salt of (-)-hydroxycitric acid |
| - | Human, | Nor, | NA |
| 1415- | HCA, | Hydroxycitrate delays early mortality in mice and promotes muscle regeneration while inducing a rich hepatic energetic status |
| - | in-vivo, | Nor, | NA |
| 1635- | HCA, | Hydroxycitric acid prevents hyperoxaluric-induced nephrolithiasis and oxidative stress via activation of the Nrf2/Keap1 signaling pathway |
| - | vitro+vivo, | Nor, | NA |
| 1634- | HCA, | Hydroxycitrate: a potential new therapy for calcium urolithiasis |
| - | Human, | Nor, | NA |
| 1633- | HCA, | Hydroxycitric Acid Alleviated Lung Ischemia-Reperfusion Injury by Inhibiting Oxidative Stress and Ferroptosis through the Hif-1α Pathway |
| - | in-vivo, | NA, | NA | - | in-vitro, | Nor, | HUVECs |
| 1637- | HCA, | OLST, | Orlistat and Hydroxycitrate Ameliorate Colon Cancer in Rats: The Impact of Inflammatory Mediators |
| - | in-vivo, | Colon, | NA |
| 1625- | HCA, | In S. cerevisiae hydroxycitric acid antagonizes chronological aging and apoptosis regardless of citrate lyase |
| - | Review, | Nor, | NA |
| 1589- | HCA, | ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism |
| - | Review, | NA, | NA |
| 1627- | HCA, | Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance |
| - | Review, | Var, | NA |
| 1628- | HCA, | ALA, | Addition of Hydroxy Citrate improves effect of ALA |
| - | Review, | Var, | NA |
| 1629- | HCA, | Tam, | Hydroxycitric acid reverses tamoxifen resistance through inhibition of ATP citrate lyase |
| - | in-vitro, | BC, | MCF-7 |
| 1630- | HCA, | Chemistry and biochemistry of (-)-hydroxycitric acid from Garcinia |
| - | Review, | NA, | NA |
| 1631- | HCA, | An overview of the safety and efficacy of a novel, natural(-)-hydroxycitric acid extract (HCA-SX) for weight management |
| - | Review, | Obesity, | NA |
| 286- | HCA, | ALA, | Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report |
| 294- | HCA, | In Vitro and In Vivo Toxicity of Garcinia or Hydroxycitric Acid: A Review |
| 293- | HCA, | Tam, | Hydroxycitric acid potentiates the cytotoxic effect of tamoxifen in MCF-7 breast cancer cells through inhibition of ATP citrate lyase |
| - | in-vitro, | BC, | MCF-7 |
| 292- | HCA, | Hydroxycitric Acid Inhibits Chronic Myelogenous Leukemia Growth through Activation of AMPK and mTOR Pathway |
| - | in-vitro, | AML, | K562 |
| 602- | HCAs, | Prooxidant activity of hydroxycinnamic acids on DNA damage in the presence of Cu(II) ions: mechanism and structure-activity relationship |
| - | Analysis, | NA, | NA |
| 1638- | HCAs, | Anticancer potential of hydroxycinnamic acids: mechanisms, bioavailability, and therapeutic applications |
| - | Review, | Nor, | NA |
| 1641- | HCAs, | Lung cancer induced by Benzo(A)Pyrene: ChemoProtective effect of sinapic acid in swiss albino mice |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | Lung, | NA |
| 1644- | HCAs, | PBG, | Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) sensitizes LNCaP prostate cancer cells to TRAIL-induced apoptosis |
| - | in-vitro, | Pca, | LNCaP |
| 1643- | HCAs, | Mechanisms involved in the anticancer effects of sinapic acid |
| - | Review, | Var, | NA |
| 1657- | HCAs, | Anticancer Activity of Sinapic Acid by Inducing Apoptosis in HT-29 Human Colon Cancer Cell Line 2023 |
| - | in-vitro, | CRC, | HT-29 |
| 1649- | HCAs, | Anticancer Properties of Hydroxycinnamic Acids -A Review |
| - | Review, | Var, | NA |
| 1645- | HCAs, | Chapter 8 - Hydroxycinnamic Acids: Natural Sources, Biosynthesis, Possible Biological Activities, and Roles in Islamic Medicine |
| - | Review, | Nor, | NA |
| 2400- | HCAs, | The Mixture of Ferulic Acid and P-Coumaric Acid Suppresses Colorectal Cancer through lncRNA 495810/PKM2 Mediated Aerobic Glycolysis |
| - | in-vitro, | CRC, | NA | - | in-vivo, | CRC, | NA |
| 2407- | HCAs, | 2'-hydroxycinnamaldehyde inhibits cancer cell proliferation and tumor growth by targeting the pyruvate kinase M2 |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 8- | HCO3, | Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana |
| - | in-vitro, | PC, | HaCaT | - | in-vitro, | Pca, | PANC1 |
| 1439- | HCQ, | Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine |
| - | in-vitro, | Melanoma, | NA | - | in-vitro, | CRC, | HCT116 |
| 1438- | HCQ, | Chemo, | Adding Chloroquine to Conventional Treatment for Glioblastoma Multiforme |
| - | Trial, | GBM, | NA |
| 1441- | HCQ, | Chemo, | Case report: stage 4 pancreatic cancer to remission using paricalcitol and hydroxychloroquine in addition to traditional chemotherapy |
| - | Case Report, | GBM, | NA |
| 1912- | HCQ, | TMZ, | Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy |
| - | in-vivo, | GBM, | U87MG |
| - | Analysis, | NA, | NA |
| 1153- | HNK, | Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vivo, | NA, | NA |
| 1154- | HNK, | MET, | Honokiol inhibits the growth of hormone-resistant breast cancer cells: its promising effect in combination with metformin |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | SkBr3 | - | in-vitro, | BC, | MDA-MB-231 |
| 1120- | HNK, | Honokiol suppresses renal cancer cells' metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling |
| - | vitro+vivo, | RCC, | NA |
| 1119- | HNK, | Honokiol inhibits epithelial—mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E‐cadherin axis |
| - | vitro+vivo, | BC, | NA |
| 1087- | HNK, | Honokiol Inhibits Non-Small Cell Lung Cancer Cell Migration by Targeting PGE2-Mediated Activation of β-Catenin Signaling |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | H226 |
| 960- | HNK, | Honokiol Inhibits HIF-1α-Mediated Glycolysis to Halt Breast Cancer Growth |
| - | vitro+vivo, | BC, | MCF-7 | - | vitro+vivo, | BC, | MDA-MB-231 |
| 1021- | HNK, | Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer |
| - | in-vivo, | Lung, | NA |
| 1004- | HNK, | RAPA, | Honokiol downregulates PD-L1 expression and enhances antitumor effects of mTOR inhibitors in renal cancer cells |
| - | in-vitro, | RCC, | NA |
| 2894- | HNK, | Pharmacological features, health benefits and clinical implications of honokiol |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2881- | HNK, | Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis |
| - | in-vitro, | PC, | PANC1 |
| 2882- | HNK, | Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling |
| - | in-vitro, | PC, | PANC1 |
| 2883- | HNK, | Honokiol targets mitochondria to halt cancer progression and metastasis |
| - | Review, | Var, | NA |
| 2884- | HNK, | Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 2885- | HNK, | Honokiol: a novel natural agent for cancer prevention and therapy |
| 2886- | HNK, | Liposomal honokiol inhibits non-small cell lung cancer progression and enhances PD-1 blockade via suppressing M2 macrophages polarization |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vivo, | NA, | NA |
| 2887- | HNK, | Honokiol Restores Microglial Phagocytosis by Reversing Metabolic Reprogramming |
| - | in-vitro, | AD, | BV2 |
| 2888- | HNK, | Honokiol mediated inhibition of PI3K/mTOR pathway: A potential strategy to overcome immunoresistance in glioma, breast and prostate carcinoma without impacting T cell function |
| - | in-vitro, | Var, | PC3 | - | in-vitro, | BC, | BT549 |
| 2889- | HNK, | doxoR, | Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice |
| - | in-vivo, | Nor, | NA |
| 2890- | HNK, | SIRT3 activation promotes enteric neurons survival and differentiation |
| 2892- | HNK, | Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | H385 | - | in-vitro, | Nor, | BEAS-2B |
| 2893- | HNK, | doxoR, | Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts |
| - | in-vivo, | Nor, | NA |
| 2902- | HNK, | Rad, | Honokiol Mitigates Ionizing Radiation-Induced Injury by Maintaining the Redox Balance of the TrxR/Trx System |
| - | in-vitro, | Nor, | BEAS-2B |
| 2895- | HNK, | Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity |
| - | in-vitro, | Lung, | PC9 |
| 2896- | HNK, | Honokiol inhibits hypoxia-inducible factor-1 pathway |
| - | in-vivo, | Colon, | CT26 |
| 2897- | HNK, | Honokiol Inhibits Proliferation, Invasion and Induces Apoptosis Through Targeting Lyn Kinase in Human Lung Adenocarcinoma Cells |
| - | in-vitro, | Lung, | PC9 | - | in-vitro, | Lung, | A549 |
| 2898- | HNK, | Honokiol Suppression of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Cell Biological Activity and Its Mechanism |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | NCI-N87 | - | in-vitro, | BC, | MGC803 | - | in-vitro, | GC, | SGC-7901 |
| 2899- | HNK, | SIRT3 activator honokiol ameliorates surgery/anesthesia-induced cognitive decline in mice through anti-oxidative stress and anti-inflammatory in hippocampus |
| - | in-vivo, | Nor, | NA |
| 2891- | HNK, | Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs |
| - | Review, | Var, | NA |
| 2900- | HNK, | The Role and Therapeutic Perspectives of Sirtuin 3 in Cancer Metabolism Reprogramming, Metastasis, and Chemoresistance |
| - | Review, | Var, | NA |
| 2901- | HNK, | doxoR, | Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts |
| - | in-vivo, | Nor, | NA |
| 2879- | HNK, | Honokiol Inhibits Lung Tumorigenesis through Inhibition of Mitochondrial Function |
| - | in-vitro, | Lung, | H226 | - | in-vivo, | NA, | NA |
| 2880- | HNK, | Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 2863- | HNK, | Honokiol induces paraptosis-like cell death through mitochondrial ROS-dependent endoplasmic reticulum stress in hepatocellular carcinoma Hep3B cells |
| - | in-vitro, | Liver, | Hep3B |
| 2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
| - | Review, | Var, | NA |
| 2865- | HNK, | Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma |
| - | in-vitro, | MB, | DAOY | - | vitro+vivo, | NA, | NA |
| 2866- | HNK, | Honokiol and its analogues as anticancer compounds: Current mechanistic insights and structure-activity relationship |
| - | Review, | Var, | NA |
| 2867- | HNK, | Honokiol ameliorates oxidative stress-induced DNA damage and apoptosis of c2c12 myoblasts by ROS generation and mitochondrial pathway |
| - | in-vitro, | Nor, | C2C12 |
| 2868- | HNK, | Honokiol: A review of its pharmacological potential and therapeutic insights |
| - | Review, | Var, | NA | - | Review, | Sepsis, | NA |
| 2869- | HNK, | Nature's neuroprotector: Honokiol and its promise for Alzheimer's and Parkinson's |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2870- | HNK, | Honokiol attenuates oxidative stress and vascular calcification via the upregulation of heme oxygenase-1 in chronic kidney disease |
| - | in-vitro, | CKD, | NA |
| 2872- | HNK, | Honokiol alleviated neurodegeneration by reducing oxidative stress and improving mitochondrial function in mutant SOD1 cellular and mouse models of amyotrophic lateral sclerosis |
| - | in-vivo, | ALS, | NA | - | NA, | Stroke, | NA | - | NA, | AD, | NA | - | NA, | Park, | NA |
| 2873- | HNK, | Honokiol Alleviates Oxidative Stress-Induced Neurotoxicity via Activation of Nrf2 |
| - | in-vitro, | Nor, | PC12 |
| 2874- | HNK, | Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6‐mediated matrix metalloproteinase 9 |
| - | in-vitro, | Lung, | H1299 |
| 2875- | HNK, | Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | in-vitro, | SCC, | H226 |
| 2876- | HNK, | Honokiol from Magnolia spp. induces G1 arrest via disruption of EGFR stability through repressing HDAC6 deacetylated Hsp90 function in lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | HCC827 |
| 2877- | HNK, | Targeting histone deacetylase-3 blocked epithelial-mesenchymal plasticity and metastatic dissemination in gastric cancer |
| - | in-vitro, | GC, | AGS |
| 2878- | HNK, | Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6-mediated matrix metalloproteinase 9 |
| - | in-vitro, | Lung, | H1299 |
| 2871- | HNK, | Antihyperalgesic Properties of Honokiol in Inflammatory Pain Models by Targeting of NF-κB and Nrf2 Signaling |
| - | in-vivo, | Nor, | NA |
| 4522- | HNK, | MAG, | Honokiol Is More Potent than Magnolol in Reducing Head and Neck Cancer Cell Growth |
| - | in-vitro, | HNSCC, | FaDu |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | LoVo | - | in-vivo, | CRC, | HCT116 |
| 4688- | HNK, | Honokiol Suppresses Renal Cancer Cells’ Metastasis via Dual-Blocking Epithelial-Mesenchymal Transition and Cancer Stem Cell Properties through Modulating miR-141/ZEB2 Signaling |
| - | vitro+vivo, | RCC, | A498 |
| 4659- | HNK, | Honokiol Eliminates Human Oral Cancer Stem-Like Cells Accompanied with Suppression of Wnt/β-Catenin Signaling and Apoptosis Induction |
| - | in-vitro, | Oral, | NA |
| 4241- | HNK, | Effects of Honokiol on Neurological Injury and Cognitive Function in Mice with Intracerebral Hemorrhage by Regulating BDNF-TrkB-CREB Signaling Pathway |
| - | in-vivo, | Stroke, | NA |
| - | in-vivo, | NA, | NA |
| 4239- | HNK, | Honokiol reverses depressive-like behavior and decrease in brain BDNF levels induced by chronic corticosterone injections in mice |
| - | in-vivo, | NA, | NA |
| 4238- | HNK, | Neuropharmacological potential of honokiol and its derivatives from Chinese herb Magnolia species: understandings from therapeutic viewpoint |
| - | Review, | AD, | NA | - | NA, | Park, | NA |
| 2079- | HNK, | Honokiol Microemulsion Causes Stage-Dependent Toxicity Via Dual Roles in Oxidation-Reduction and Apoptosis through FoxO Signaling Pathway |
| - | in-vitro, | Nor, | PC12 |
| 2080- | HNK, | Honokiol Induces Ferroptosis by Upregulating HMOX1 in Acute Myeloid Leukemia Cells |
| - | in-vitro, | AML, | THP1 | - | in-vitro, | AML, | U937 | - | in-vitro, | AML, | SK-HEP-1 |
| 2081- | HNK, | Honokiol induces ferroptosis in colon cancer cells by regulating GPX4 activity |
| - | in-vitro, | Colon, | RKO | - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Colon, | SW48 | - | in-vitro, | Colon, | HT-29 | - | in-vitro, | Colon, | LS174T | - | in-vitro, | Colon, | HCT8 | - | in-vitro, | Colon, | SW480 | - | in-vivo, | NA, | NA |
| 2082- | HNK, | Revealing the role of honokiol in human glioma cells by RNA-seq analysis |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 1286- | HNK, | The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells |
| - | in-vitro, | CLL, | NA |
| 2073- | HNK, | Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo |
| - | in-vitro, | OS, | U2OS | - | in-vivo, | NA, | NA |
| 2072- | HNK, | Honokiol Suppresses Cell Proliferation and Tumor Migration through ROS in Human Anaplastic Thyroid Cancer Cells |
| - | in-vitro, | Thyroid, | NA |
| 2071- | HNK, | Identification of senescence rejuvenation mechanism of Magnolia officinalis extract including honokiol as a core ingredient |
| - | Review, | Nor, | HaCaT |
| 886- | HPT, | Impact of hyper- and hypothermia on cellular and whole-body physiology |
| - | Analysis, | NA, | NA |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | SUM159 |
| 4633- | HT, | Unlocking the effective alliance of β-lapachone and hydroxytyrosol against triple-negative breast cancer cells |
| - | in-vitro, | BC, | NA |
| 4634- | HT, | Hydroxytyrosol in cancer research: recent and historical insights on discoveries and mechanisms of action |
| - | Review, | Var, | NA |
| 4635- | HT, | Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention in Women at High Risk of Cancer |
| - | Trial, | BC, | NA |
| - | in-vitro, | BC, | SUM159 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vitro, | BC, | BT549 |
| 4637- | HT, | Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells |
| - | in-vitro, | Nor, | RWPE-1 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PC3 |
| 4638- | HT, | Hydroxytyrosol induces apoptosis in human colon cancer cells through ROS generation |
| - | in-vitro, | CRC, | DLD1 | - | NA, | NA, | 1- |
| 4639- | HT, | Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 4640- | HT, | The anti-cancer potential of hydroxytyrosol |
| - | Review, | Var, | NA |
| 4641- | HT, | Hydroxytyrosol induced ferroptosis through Nrf2 signaling pathway in colorectal cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| 4642- | HT, | Hydroxytyrosol, a natural molecule from olive oil, suppresses the growth of human hepatocellular carcinoma cells via inactivating AKT and nuclear factor-kappa B pathways |
| - | in-vitro, | HCC, | HepG2 | - | NA, | NA, | Hep3B | - | NA, | NA, | SK-HEP-1 |
| 4644- | HT, | The Hydroxytyrosol Induces the Death for Apoptosis of Human Melanoma Cells |
| - | in-vitro, | Melanoma, | NA |
| 4645- | HT, | Hydroxytyrosol: Bioavailability, toxicity, and clinical applications |
| - | Review, | NA, | NA |
| 601- | HTyr, | Dihydroxyphenylethanol induces apoptosis by activating serine/threonine protein phosphatase PP2A and promotes the endoplasmic reticulum stress response in human colon carcinoma cells |
| - | in-vivo, | NA, | HT-29 |
| 4213- | Hup, | Huperzine A-Liposomes Efficiently Improve Neural Injury in the Hippocampus of Mice with Chronic Intermittent Hypoxia |
| - | in-vivo, | NA, | NA |
| 4209- | Hup, | Huperzine A, reduces brain iron overload and alleviates cognitive deficit in mice exposed to chronic intermittent hypoxia |
| - | in-vivo, | NA, | NA |
| 4210- | Hup, | A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies–Emphasis on Alzheimer’s Disease Pathogenesis |
| - | Review, | AD, | NA |
| 4211- | Hup, | Huperzine A ameliorates obesity-related cognitive performance impairments involving neuronal insulin signaling pathway in mice |
| - | in-vitro, | NA, | NA |
| 4212- | Hup, | Huperzine A Alleviates Oxidative Glutamate Toxicity in Hippocampal HT22 Cells via Activating BDNF/TrkB-Dependent PI3K/Akt/mTOR Signaling Pathway |
| - | in-vitro, | Nor, | HT22 |
| 3805- | Hup, | Isolation, diversity and acetylcholinesterase inhibitory activity of the culturable endophytic fungi harboured in Huperzia serrata from Jinggang Mountain, China |
| - | Analysis, | AD, | NA |
| 3804- | Hup, | Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials |
| - | Review, | AD, | NA |
| 3803- | Hup, | Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3802- | Hup, | New insights into huperzine A for the treatment of Alzheimer's disease |
| - | Review, | AD, | NA |
| 3801- | Hup, | An update on huperzine A as a treatment for Alzheimer's disease |
| - | Review, | AD, | NA |
| 3800- | Hup, | Role of huperzine a in the treatment of Alzheimer's disease |
| - | Review, | AD, | NA |
| 3799- | Hup, | The use of Huperzia species for the treatment of Alzheimer's disease |
| - | NA, | AD, | NA |
| 1278- | I3C, | Indole-3-carbinol inhibits prostate cancer cell migration via degradation of beta-catenin |
| - | in-vivo, | Pca, | DU145 |
| 1277- | I3C, | GEN, | Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein |
| - | in-vitro, | PC, | PANC1 |
| 33- | InA, | Inoscavin A, a pyrone compound isolated from a Sanghuangporus vaninii extract, inhibits colon cancer cell growth and induces cell apoptosis via the hedgehog signaling pathway |
| - | vitro+vivo, | Colon, | NA |
| 1293- | Ins, | Inositol Hexaphosphate Inhibits Growth and Induces G1 Arrest and Apoptotic Death of Androgen-Dependent Human Prostate Carcinoma LNCaP Cells |
| - | vitro+vivo, | Pca, | LNCaP |
| 2172- | iod, | A prospective study of iodine status, thyroid function, and prostate cancer risk: follow-up of the First National Health and Nutrition Examination Survey |
| - | Study, | Pca, | NA |
| 1088- | IP6, | Preventive Inositol Hexaphosphate Extracted from Rice Bran Inhibits Colorectal Cancer through Involvement of Wnt/β-Catenin and COX-2 Pathways |
| - | in-vivo, | CRC, | NA |
| 2180- | itraC, | Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent |
| - | Review, | Var, | NA |
| 2179- | itraC, | Repurposing itraconazole for the treatment of cancer |
| - | Review, | Var, | NA |
| 2178- | itraC, | Itraconazole inhibits tumor growth via CEBPB-mediated glycolysis in colorectal cancer |
| - | in-vivo, | CRC, | HCT116 |
| 2177- | itraC, | Itraconazole improves survival outcomes in patients with colon cancer by inducing autophagic cell death and inhibiting transketolase expression |
| - | Study, | Colon, | NA | - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | HCT116 |
| 1166- | IVM, | The importin α/β-specific inhibitor Ivermectin affects HIF-dependent hypoxia response pathways |
| - | in-vitro, | NA, | NA |
| 1167- | IVM, | The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer |
| - | vitro+vivo, | NA, | NA |
| 1168- | IVM, | SRF, | Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways |
| - | in-vitro, | HCC, | NA |
| 1175- | IVM, | PDT, | Drug induced mitochondria dysfunction to enhance photodynamic therapy of hypoxic tumors |
| - | in-vitro, | Var, | NA |
| 1070- | IVM, | Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation |
| - | vitro+vivo, | GBM, | NA |
| 974- | JG, | Juglone down-regulates the Akt-HIF-1α and VEGF signaling pathways and inhibits angiogenesis in MIA Paca-2 pancreatic cancer in vitro |
| - | in-vitro, | PC, | MIA PaCa-2 |
| 1121- | JG, | Juglone suppresses epithelial-mesenchymal transition in prostate cancer cells via the protein kinase B/glycogen synthase kinase-3β/Snail signaling pathway |
| - | in-vitro, | Pca, | LNCaP |
| 1918- | JG, | ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro |
| - | in-vitro, | Liver, | HepG2 | - | in-vivo, | NA, | NA |
| 1927- | JG, | Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway |
| - | in-vitro, | GC, | SGC-7901 |
| 1926- | JG, | Mechanism of juglone-induced apoptosis of MCF-7 cells by the mitochondrial pathway |
| - | in-vitro, | BC, | MCF-7 |
| 1925- | JG, | Redox regulation of mitochondrial functional activity by quinones |
| - | in-vitro, | NA, | NA |
| 1917- | JG, | Inhibition of human leukemia cells growth by juglone is mediated via autophagy induction, endogenous ROS production, and inhibition of cell migration and invasion |
| - | in-vitro, | AML, | HL-60 |
| 1919- | JG, | The Anti-Glioma Effect of Juglone Derivatives through ROS Generation |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 1920- | JG, | TQ, | Plum, | Natural quinones induce ROS-mediated apoptosis and inhibit cell migration in PANC-1 human pancreatic cancer cell line |
| - | in-vitro, | PC, | PANC1 |
| 1921- | JG, | Juglone induces ferroptotic effect on hepatocellular carcinoma and pan-cancer via the FOSL1-HMOX1 axis |
| - | in-vitro, | PC, | NA | - | vitro+vivo, | PC, | NA |
| 1922- | JG, | Juglone induces apoptosis of tumor stem-like cells through ROS-p38 pathway in glioblastoma |
| - | in-vitro, | GBM, | U87MG |
| 1923- | JG, | Mechanism of Juglone-Induced Cell Cycle Arrest and Apoptosis in Ishikawa Human Endometrial Cancer Cells |
| - | in-vitro, | Endo, | NA |
| 1924- | JG, | Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway |
| - | in-vitro, | Lung, | A549 |
| 4011- | K+, | Sodium and potassium intakes among US adults: NHANES 2003–2008 |
| - | Analysis, | NA, | NA |
| 4012- | K+, | Abnormal potassium-channel function in platelets in Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 4010- | K+, | Potassium-sparing diuretics might reduce risk of Alzheimer's disease |
| - | Review, | AD, | NA |
| 4007- | K+, | The increased potassium intake improves cognitive performance and attenuates histopathological markers in a model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 4014- | K+, | The effects of boiling and leaching on the content of potassium and other minerals in potatoes |
| - | Analysis, | NA, | NA |
| 4013- | K+, | Apamin Improves Prefrontal Nicotinic Impairment in Mouse Model of Alzheimer's Disease |
| - | in-vitro, | AD, | NA |
| 4009- | K+, | Na+ and K+ ion imbalances in Alzheimer’s disease |
| - | Human, | AD, | NA |
| 4008- | K+, | Potassium channels in the neuronal homeostasis and neurodegenerative pathways underlying Alzheimer's disease: An update |
| - | Review, | AD, | NA |
| 4005- | K+, | Potassium |
| - | Review, | Nor, | NA | - | Review, | Stroke, | NA |
| 4006- | K+, | Rubidium and potassium levels are altered in Alzheimer's disease brain and blood but not in cerebrospinal fluid |
| - | in-vitro, | AD, | NA |
| 2390- | KaempF, | Kaempferol Can Reverse the 5-Fu Resistance of Colorectal Cancer Cells by Inhibiting PKM2-Mediated Glycolysis |
| - | in-vitro, | CRC, | HCT8 |
| 1272- | LA, | Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults |
| - | Trial, | Nor, | NA |
| 1243- | LA, | Lactobacilli Modulate Hypoxia-Inducible Factor (HIF)-1 Regulatory Pathway in Triple Negative Breast Cancer Cell Line |
| - | in-vitro, | BC, | MDA-MB-231 |
| 865- | Lae, | Amygdalin: A Review on Its Characteristics, Antioxidant Potential, Gastrointestinal Microbiota Intervention, Anticancer Therapeutic and Mechanisms, Toxicity, and Encapsulation |
| 867- | Lae, | Effects of the Gut microbiota on Amygdalin and its use as an anti-cancer therapy: Substantial review on the key components involved in altering dose efficacy and toxicity |
| - | Review, | NA, | NA |
| 866- | Lae, | Amygdalin from Apricot Kernels Induces Apoptosis and Causes Cell Cycle Arrest in Cancer Cells: An Updated Review |
| - | Review, | NA, | NA |
| 864- | Lae, | Can Amygdalin Provide any Benefit in Integrative Anticancer Treatment? |
| - | Review, | NA, | NA |
| 863- | Lae, | Amygdalin inhibits the growth of renal cell carcinoma cells in vitro |
| - | in-vitro, | RCC, | NA |
| 862- | Lae, | Molecular mechanism of amygdalin action in vitro: review of the latest research |
| - | Review, | NA, | NA |
| 861- | Lae, | Chit, | SNP, | Synthesis of polygonal chitosan microcapsules for the delivery of amygdalin loaded silver nanoparticles in breast cancer therapy |
| 859- | Lae, | Vitamin B17 and its Proposed Application in Treating Cancer |
| - | Analysis, | NA, | NA |
| 870- | Lae, | Physician Beware: Severe Cyanide Toxicity from Amygdalin Tablets Ingestion |
| - | Case Report, | NA, | NA |
| 868- | Lae, | The Postulated Mechanism of Action of Amygdalin (Vitamin B17) on Cancer Cells |
| - | Review, | NA, | NA |
| 860- | Lae, | Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery |
| - | Review, | NA, | NA |
| 869- | Lae, | Recent updates and future perspectives about amygdalin as a potential anticancer agent: A review |
| 2351- | lamb, | Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 2453- | LE, | The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors |
| - | Review, | Var, | NA |
| 1040- | LE, | Licorice extract inhibits growth of non-small cell lung cancer by down-regulating CDK4-Cyclin D1 complex and increasing CD8+ T cell infiltration |
| - | in-vivo, | Lung, | H1975 |
| 1266- | LE, | Glycyrrhizin suppresses epithelial-mesenchymal transition by inhibiting high-mobility group box1 via the TGF-β1/Smad2/3 pathway in lung epithelial cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B |
| 1306- | LE, | Modulations of the Bcl-2/Bax family were involved in the chemopreventive effects of licorice root (Glycyrrhiza uralensis Fisch) in MCF-7 human breast cancer cell |
| - | in-vitro, | BC, | MCF-7 |
| - | in-vitro, | BC, | MCF-7 |
| 1787- | LE, | Licorice and cancer |
| - | Review, | Var, | NA |
| 1790- | LEC, | DHA, | Dietary Crude Lecithin Increases Systemic Availability of Dietary Docosahexaenoic Acid with Combined Intake in Rats |
| - | in-vivo, | Nor, | NA |
| 1796- | LEC, | A comprehensive review on pleiotropic effects and therapeutic potential of soy lecithin |
| - | Review, | NA, | NA |
| 1795- | LEC, | Chit, | Self-assembled lecithin-chitosan nanoparticles improve the oral bioavailability and alter the pharmacokinetics of raloxifene |
| - | in-vivo, | Nor, | NA |
| 1789- | LEC, | Lecithin Supplements and Breast Cancer Risk |
| - | Analysis, | NA, | NA |
| 1794- | LEC, | Effects of abomasal infusion of soybean or sunflower lecithin on nutrient digestibility and milk production in lactating dairy cows |
| - | in-vivo, | NA, | NA |
| 1793- | LEC, | Unmasking Sunflower Lecithin: Does Science Support the Claims? |
| - | Review, | NA, | NA |
| 1791- | LEC, | Vegetable lecithins: A review of their compositional diversity, impact on lipid metabolism and potential in cardiometabolic disease prevention |
| - | Review, | Nor, | NA |
| 3706- | LEC, | Lecithin for dementia and cognitive impairment |
| - | Review, | AD, | NA |
| 4233- | LEC, | Lecithinized brain-derived neurotrophic factor promotes the differentiation of embryonic stem cells in vitro and in vivo |
| - | in-vitro, | Nor, | NA |
| 1122- | LF, | MTX, | Lactoferrin Reverses Methotrexate Driven Epithelial Barrier Defect by Inhibiting TGF-β Mediated Epithelial to Mesenchymal Transition |
| - | in-vivo, | Colon, | Caco-2 |
| 1200- | LT, | Inhibition of Fatty Acid Synthase by Luteolin Post-Transcriptionally Downregulates c-Met Expression Independent of Proteosomal/Lysosomal Degradation |
| - | in-vitro, | Pca, | DU145 |
| 1100- | LT, | Luteolin, a flavonoid, as an anticancer agent: A review |
| - | Review, | NA, | NA |
| 1171- | LT, | The inhibition of β-catenin activity by luteolin isolated from Paulownia flowers leads to growth arrest and apoptosis in cholangiocarcinoma |
| - | in-vitro, | CCA, | NA |
| 1125- | LT, | Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity |
| - | in-vitro, | BC, | NA |
| 979- | LT, | Luteolin Regulation of Estrogen Signaling and Cell Cycle Pathway Genes in MCF-7 Human Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 |
| 982- | LT, | Inhibitory effect of luteolin on estrogen biosynthesis in human ovarian granulosa cells by suppression of aromatase (CYP19) |
| - | in-vitro, | Ovarian, | KGN |
| 1064- | LT, | Cisplatin, | Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells |
| - | vitro+vivo, | Lung, | LNM35 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 986- | LT, | doxoR, | Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | MCF-7 |
| 973- | LT, | Luteolin impairs hypoxia adaptation and progression in human breast and colon cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | BC, | MDA-MB-231 |
| 1025- | LT, | Api, | Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer |
| - | in-vivo, | Lung, | NA |
| 1060- | LT, | BTZ, | Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma |
| - | vitro+vivo, | Melanoma, | NA |
| 1084- | LT, | CHr, | Luteolin and chrysin differentially inhibit cyclooxygenase-2 expression and scavenge reactive oxygen species but similarly inhibit prostaglandin-E2 formation in RAW 264.7 cells |
| - | in-vitro, | Nor, | RAW264.7 |
| 1275- | LT, | Mechanism of luteolin induces ferroptosis in nasopharyngeal carcinoma cells |
| - | in-vitro, | Laryn, | NA |
| 1317- | LT, | Luteolin Suppresses Teratoma Cell Growth and Induces Cell Apoptosis via Inhibiting Bcl-2 |
| - | vitro+vivo, | Ovarian, | PA1 |
| - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | PC, | Bxpc-3 |
| 4687- | LT, | QC, | Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells |
| - | in-vitro, | Pca, | DU145 |
| 4293- | LT, | Regulatory Role of NF-κB on HDAC2 and Tau Hyperphosphorylation in Diabetic Encephalopathy and the Therapeutic Potential of Luteolin |
| - | in-vivo, | Diabetic, | NA |
| 4295- | LT, | Luteolin Reduces Alzheimer’s Disease Pathologies Induced by Traumatic Brain Injury |
| - | in-vivo, | AD, | NA |
| 4294- | LT, | Luteolin reduces zinc-induced tau phosphorylation at Ser262/356 in an ROS-dependent manner in SH-SY5Y cells |
| - | in-vitro, | NA, | SH-SY5Y |
| 4292- | LT, | Luteolin for neurodegenerative diseases: a review |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | MS, | NA | - | Review, | Stroke, | NA |
| 4338- | LT, | Luteolin: a natural product with multiple mechanisms for atherosclerosis |
| - | Review, | NA, | NA |
| 4339- | LT, | Luteolin inhibits GPVI-mediated platelet activation, oxidative stress, and thrombosis |
| - | in-vivo, | NA, | NA |
| 2346- | LT, | Luteolin suppressed PKM2 and promoted autophagy for inducing the apoptosis of hepatocellular carcinoma cells |
| - | in-vitro, | HCC, | HepG2 |
| 2915- | LT, | Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells |
| - | in-vitro, | Colon, | HT29 | - | in-vitro, | CRC, | SNU-407 | - | in-vitro, | Nor, | FHC |
| 2916- | LT, | Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2917- | LT, | Rad, | Luteolin acts as a radiosensitizer in non‑small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade |
| - | in-vitro, | Lung, | NA |
| 2918- | LT, | Luteolin inhibits melanoma growth in vitro and in vivo via regulating ECM and oncogenic pathways but not ROS |
| - | in-vitro, | Melanoma, | A375 | - | in-vivo, | Melanoma, | NA | - | in-vitro, | Melanoma, | SK-MEL-28 |
| 2919- | LT, | Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence |
| - | Review, | Var, | NA |
| 2920- | LT, | Formulation, characterization, in vitro and in vivo evaluations of self-nanoemulsifying drug delivery system of luteolin |
| - | in-vitro, | Nor, | NA | - | in-vivo, | Nor, | NA |
| 2921- | LT, | Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies |
| - | Review, | Nor, | NA |
| 2922- | LT, | Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC |
| - | in-vitro, | Liver, | HUH7 |
| 2923- | LT, | Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells |
| - | in-vitro, | NA, | NA |
| 2924- | LT, | Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1 |
| - | in-vitro, | GC, | NA | - | in-vivo, | NA, | NA |
| 2925- | LT, | Luteolin Induces Carcinoma Cell Apoptosis through Binding Hsp90 to Suppress Constitutive Activation of STAT3 |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | BC, | MCF-7 |
| 2926- | LT, | Luteolin ameliorates rat myocardial ischemia-reperfusion injury through peroxiredoxin II activation: LUT's cardioprotection through PRX II |
| - | in-vitro, | Nor, | H9c2 |
| 2927- | LT, | Luteolin Causes 5′CpG Demethylation of the Promoters of TSGs and Modulates the Aberrant Histone Modifications, Restoring the Expression of TSGs in Human Cancer Cells |
| - | in-vitro, | Cerv, | HeLa |
| 2928- | LT, | Luteolin-mediated increase in miR-26a inhibits prostate cancer cell growth and induces cell cycle arrest targeting EZH2 |
| 2929- | LT, | Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention |
| - | in-vitro, | Ovarian, | NA |
| 2930- | LT, | Luteolin confers renoprotection against ischemia–reperfusion injury via involving Nrf2 pathway and regulating miR320 |
| - | in-vitro, | Nor, | NA |
| 2913- | LT, | Luteolin induces apoptosis by impairing mitochondrial function and targeting the intrinsic apoptosis pathway in gastric cancer cells |
| - | in-vitro, | GC, | HGC27 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | GC, | MKN45 |
| 2914- | LT, | Therapeutic Potential of Luteolin on Cancer |
| - | Review, | Var, | NA |
| 2903- | LT, | Luteolin induces apoptosis by ROS/ER stress and mitochondrial dysfunction in gliomablastoma |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vivo, | NA, | NA |
| 2904- | LT, | Luteolin from Purple Perilla mitigates ROS insult particularly in primary neurons |
| - | in-vitro, | Park, | SK-N-SH | - | in-vitro, | AD, | NA |
| 2905- | LT, | Luteolin blocks the ROS/PI3K/AKT pathway to inhibit mesothelial-mesenchymal transition and reduce abdominal adhesions |
| - | in-vivo, | NA, | HMrSV5 |
| 2906- | LT, | Luteolin, a flavonoid with potentials for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 2907- | LT, | Protective effect of luteolin against oxidative stress‑mediated cell injury via enhancing antioxidant systems |
| - | in-vitro, | Nor, | NA |
| 2908- | LT, | Luteolin attenuates neutrophilic oxidative stress and inflammatory arthritis by inhibiting Raf1 activity |
| - | in-vitro, | Arthritis, | NA |
| 2909- | LT, | Revisiting luteolin: An updated review on its anticancer potential |
| - | Review, | Var, | NA |
| 2910- | LT, | FA, | Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 2911- | LT, | Luteolin targets MKK4 to attenuate particulate matter-induced MMP-1 and inflammation in human keratinocytes |
| - | in-vitro, | Nor, | HaCaT |
| 2912- | LT, | Luteolin: a flavonoid with a multifaceted anticancer potential |
| - | Review, | Var, | NA |
| 2595- | LT, | Regulation of Nrf2/ARE Pathway by Dietary Flavonoids: A Friend or Foe for Cancer Management? |
| - | Review, | Var, | NA |
| 2589- | LT, | Chemo, | Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway |
| - | in-vitro, | BC, | MDA-MB-231 |
| 2588- | LT, | Chemo, | Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway |
| - | in-vitro, | CRC, | HCT116 |
| 2587- | LT, | Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs |
| - | in-vitro, | Lung, | A549 |
| 4194- | Lut, | Zeax, | Effect of macular pigment carotenoids on cognitive functions: A systematic review |
| - | Review, | NA, | NA |
| 4195- | Lut, | Zeax, | Low Xanthophylls, Retinol, Lycopene, and Tocopherols in Grey and White Matter of Brains with Alzheimer’s Disease |
| - | Human, | AD, | NA |
| 4193- | Lut, | Zeax, | Effects of a Lutein and Zeaxanthin Intervention on Cognitive Function: A Randomized, Double-Masked, Placebo-Controlled Trial of Younger Healthy Adults |
| - | Trial, | NA, | NA |
| 4192- | Lut, | Zeax, | Lutein and Zeaxanthin Supplementation Improves Dynamic Visual and Cognitive Performance in Children: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study |
| - | Trial, | NA, | NA |
| 4232- | Lut, | Luteolin Treatment Ameliorates Brain Development and Behavioral Performance in a Mouse Model of CDKL5 Deficiency Disorder |
| - | in-vivo, | NA, | NA |
| 4231- | Lut, | Luteolin and its antidepressant properties: From mechanism of action to potential therapeutic application |
| - | Review, | AD, | NA |
| 3977- | Lut, | Zeax, | Dietary carotenoids related to risk of incident Alzheimer dementia (AD) and brain AD neuropathology: a community-based cohort of older adults |
| - | Trial, | AD, | NA |
| 3984- | Lut, | VitE, | Serum concentrations of vitamin E and carotenoids are altered in Alzheimer's disease: A case-control study |
| - | Study, | AD, | NA |
| 3983- | Lut, | Zeax, | The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial |
| - | Trial, | AD, | NA |
| 3982- | Lut, | Zeax, | Nutritional Intervention to Prevent Alzheimer's Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined |
| - | Trial, | AD, | NA |
| 3981- | Lut, | Zeax, | VitE, | Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial |
| - | Trial, | AD, | NA |
| 3980- | Lut, | Zeax, | Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease |
| - | Trial, | AD, | NA |
| 3978- | Lut, | Zeax, | Effects of Lutein/Zeaxanthin Supplementation on the Cognitive Function of Community Dwelling Older Adults: A Randomized, Double-Masked, Placebo-Controlled Trial |
| - | Trial, | AD, | NA |
| 3979- | Lut, | Increases in Plasma Lutein through Supplementation Are Correlated with Increases in Physical Activity and Reductions in Sedentary Time in Older Adults |
| - | Trial, | AD, | NA |
| 3277- | Lyco, | Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent |
| - | Review, | Var, | NA |
| 3260- | Lyco, | Lycopene in human health |
| - | Review, | NA, | NA |
| 3278- | Lyco, | Anti-inflammatory effect of lycopene in SW480 human colorectal cancer cells |
| - | in-vitro, | Colon, | SW480 |
| 3279- | Lyco, | The role of lycopene and its derivatives in the regulation of transcription systems: implications for cancer prevention |
| - | Review, | Var, | NA |
| 3280- | Lyco, | Lycopene as A Carotenoid Provides Radioprotectant and Antioxidant Effects by Quenching Radiation-Induced Free Radical Singlet Oxygen: An Overview |
| - | Review, | Var, | NA |
| 3281- | Lyco, | Chemo, | Lycopene Supplementation for Patients Under Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| - | Review, | Var, | NA |
| 3285- | Lyco, | Comparative evaluation of antiplatelet effect of lycopene with aspirin and the effect of their combination on platelet aggregation: An in vitro study |
| - | in-vitro, | Nor, | NA |
| 3286- | Lyco, | Inhibitory effects of lycopene on in vitro platelet activation and in vivo prevention of thrombus formation |
| - | in-vitro, | Nor, | NA |
| 3287- | Lyco, | Recent technological strategies for enhancing the stability of lycopene in processing and production |
| - | Review, | NA, | NA |
| 3276- | Lyco, | Lycopene modulates cellular proliferation, glycolysis and hepatic ultrastructure during hepatocellular carcinoma |
| - | in-vivo, | HCC, | NA |
| 3275- | Lyco, | Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer |
| - | Review, | Var, | NA |
| 3274- | Lyco, | Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | C4-2B |
| 3273- | Lyco, | Lycopene |
| - | Review, | Var, | NA |
| 3268- | Lyco, | Lycopene as a Natural Antioxidant Used to Prevent Human Health Disorders |
| - | Review, | AD, | NA |
| 3267- | Lyco, | Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways |
| - | in-vitro, | Nor, | HUVECs |
| 3266- | Lyco, | Effects of lycopene on number and function of human peripheral blood endothelial progenitor cells cultivated with high glucose |
| - | in-vitro, | Nor, | NA |
| 3265- | Lyco, | Lycopene inhibits pyroptosis of endothelial progenitor cells induced by ox-LDL through the AMPK/mTOR/NLRP3 pathway |
| - | in-vitro, | Nor, | NA |
| 3264- | Lyco, | Pharmacological potentials of lycopene against aging and aging‐related disorders: A review |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3263- | Lyco, | Lycopene protects against myocardial ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening |
| - | in-vitro, | Nor, | H9c2 | - | in-vitro, | Stroke, | NA |
| 3262- | Lyco, | Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1 |
| - | in-vitro, | adrenal, | SK-HEP-1 |
| 3261- | Lyco, | Lycopene and Vascular Health |
| - | Review, | Stroke, | NA |
| 4230- | Lyco, | Supplementation of lycopene attenuates oxidative stress induced neuroinflammation and cognitive impairment via Nrf2/NF-κB transcriptional pathway |
| - | in-vivo, | AD, | NA |
| 4229- | Lyco, | Implicating the role of lycopene in restoration of mitochondrial enzymes and BDNF levels in β-amyloid induced Alzheimer׳s disease |
| - | in-vivo, | AD, | NA |
| 4228- | Lyco, | A review for the pharmacological effect of lycopene in central nervous system disorders |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4227- | Lyco, | Lycopene Alleviates Depression-Like Behavior in Chronic Social Defeat Stress-Induced Mice by Promoting Synaptic Plasticity via the BDNF-TrkB Pathway |
| - | in-vivo, | NA, | NA |
| 3816- | Lyco, | Lut, | Zeax, | Serum lycopene, lutein and zeaxanthin, and the risk of Alzheimer's disease mortality in older adults |
| - | Review, | AD, | NA |
| 3828- | Lyco, | Lycopene alleviates oxidative stress via the PI3K/Akt/Nrf2pathway in a cell model of Alzheimer's disease |
| - | in-vitro, | AD, | M146L |
| 3533- | Lyco, | Chemo, | Lycopene and chemotherapy toxicity |
| - | Review, | Var, | NA |
| 3532- | Lyco, | Lycopene alleviates oxidative stress via the PI3K/Akt/Nrf2pathway in a cell model of Alzheimer’s disease |
| - | in-vitro, | AD, | NA |
| 3530- | Lyco, | Lycopene Scavenges Cellular ROS, Modulates Autophagy and Improves Survival through 7SK snRNA Interaction in Smooth Muscle Cells |
| - | in-vitro, | Stroke, | NA |
| 3529- | Lyco, | The antioxidant and anti-inflammatory properties of lycopene in mice lungs exposed to cigarette smoke |
| - | in-vivo, | Nor, | NA |
| 3528- | Lyco, | The Importance of Antioxidant Activity for the Health-Promoting Effect of Lycopene |
| - | Review, | Nor, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3531- | Lyco, | Lycopene attenuates the inflammation and apoptosis in aristolochic acid nephropathy by targeting the Nrf2 antioxidant system |
| - | in-vivo, | Nor, | NA |
| 4777- | Lyco, | Lycopene Inhibits Activation of Epidermal Growth Factor Receptor and Expression of Cyclooxygenase-2 in Gastric Cancer Cells |
| - | in-vitro, | GC, | AGS |
| 4778- | Lyco, | Lycopene exerts cytotoxic effects by mitochondrial reactive oxygen species–induced apoptosis in glioblastoma multiforme |
| - | in-vitro, | GBM, | GBM8401 |
| 4779- | Lyco, | Lycopene Inhibits Reactive Oxygen Species-Mediated NF-κB Signaling and Induces Apoptosis in Pancreatic Cancer Cells |
| - | in-vitro, | PC, | PANC1 |
| 4781- | Lyco, | 5-FU, | Chemo, | Cisplatin, | Antioxidant and anti-inflammatory activities of lycopene against 5-fluorouracil-induced cytotoxicity in Caco2 cells |
| - | in-vitro, | Colon, | Caco-2 |
| 4782- | Lyco, | New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene |
| - | Review, | Var, | NA |
| 4803- | Lyco, | Enhanced cytotoxic and apoptosis inducing activity of lycopene oxidation products in different cancer cell lines |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Melanoma, | A431 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | A549 |
| - | Review, | Var, | NA |
| 4801- | Lyco, | Lycopene in the Prevention of Cardiovascular Diseases |
| - | Review, | CardioV, | NA |
| 4800- | Lyco, | Recent insights on pharmacological potential of lycopene and its nanoformulations: an emerging paradigm towards improvement of human health |
| - | Review, | Var, | NA |
| 4799- | Lyco, | Anticancer Properties of Lycopene |
| - | Review, | Var, | NA |
| 4798- | Lyco, | Enhancing Anticancer Treatment Efficacy With Lycopene: A Comprehensive Review of Clinical and Preclinical Evidence |
| - | Review, | Var, | NA |
| 4797- | Lyco, | A mechanistic updated overview on lycopene as potential anticancer agent |
| - | Review, | Var, | NA |
| 4796- | Lyco, | The Anti-proliferation Effects of Lycopene on Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 4795- | Lyco, | Updates on the Anticancer Profile of Lycopene and its Probable Mechanism against Breast and Gynecological Cancer |
| - | Review, | BC, | NA |
| 4794- | Lyco, | Anticancer Effect of Lycopene in Gastric Carcinogenesis |
| - | Review, | GC, | NA |
| 4793- | Lyco, | Lycopene treatment inhibits activation of Jak1/Stat3 and Wnt/β-catenin signaling and attenuates hyperproliferation in gastric epithelial cells |
| - | in-vitro, | GC, | AGS |
| 4792- | Lyco, | A Comprehensive Review on the Molecular Mechanism of Lycopene in Cancer Therapy |
| - | Review, | Var, | NA |
| 4791- | Lyco, | Investigating into anti-cancer potential of lycopene: Molecular targets |
| - | Review, | Var, | NA |
| 4790- | Lyco, | Role of Lycopene in the Control of ROS-Mediated Cell Growth: Implications in Cancer Prevention |
| - | Review, | Var, | NA |
| 4789- | Lyco, | Inhibitory Effect of Lycopene on Amyloid-β-Induced Apoptosis in Neuronal Cells |
| - | in-vitro, | AD, | SH-SY5Y |
| 4788- | Lyco, | Lycopene as a potential anticancer agent: Current evidence on synergism, drug delivery systems and epidemiology (Review) |
| - | Review, | Var, | NA |
| 4786- | Lyco, | Anti-proliferative and apoptosis-inducing activity of lycopene against three subtypes of human breast cancer cell lines |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | SkBr3 |
| 4785- | Lyco, | The Protective Anticancer Effect of Natural Lycopene Supercritical CO2 Watermelon Extracts in Adenocarcinoma Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 |
| 4784- | Lyco, | Protective effects of lycopene in cancer, cardiovascular, and neurodegenerative diseases: An update on epidemiological and mechanistic perspectives |
| - | Review, | Diabetic, | NA | - | Review, | CardioV, | NA |
| 4783- | Lyco, | Lycopene suppresses gastric cancer cell growth without affecting normal gastric epithelial cells |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | Nor, | GES-1 |
| 4780- | Lyco, | Potential inhibitory effect of lycopene on prostate cancer |
| - | Review, | Pca, | NA |
| 1013- | Lyco, | Lycopene induces apoptosis by inhibiting nuclear translocation of β-catenin in gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 1041- | Lyco, | immuno, | Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells |
| - | in-vivo, | Lung, | NA |
| 1126- | Lyco, | Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway |
| - | vitro+vivo, | Oral, | NA |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Liver, | HepG2 |
| 1720- | Lyco, | Antioxidant and Pro-oxidant Activities of Carotenoids |
| - | Review, | Nor, | NA |
| 1719- | Lyco, | Lycopene for the prevention and treatment of prostate disease. |
| - | Review, | Var, | NA |
| 1718- | Lyco, | The role of carotenoids in the prevention of human pathologies |
| - | Review, | Var, | NA |
| 1717- | Lyco, | Potential Role of Carotenoids as Antioxidants in Human Health and Disease |
| - | Review, | Var, | NA |
| 1716- | Lyco, | Anti-inflammatory Activity of β-Carotene, Lycopene and Tri-n-butylborane, a Scavenger of Reactive Oxygen Species |
| - | in-vitro, | AML, | RAW264.7 |
| 1715- | Lyco, | Pro-oxidant Actions of Carotenoids in Triggering Apoptosis of Cancer Cells: A Review of Emerging Evidence |
| - | Review, | Var, | NA |
| 1714- | Lyco, | Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load |
| - | in-vitro, | Ovarian, | OV-MZ-6 | - | in-vivo, | NA, | NA |
| 1713- | Lyco, | Lycopene: A Potent Antioxidant with Multiple Health Benefits |
| - | Review, | Nor, | NA |
| 1712- | Lyco, | Lycopene Protects against Smoking-Induced Lung Cancer by Inducing Base Excision Repair |
| - | in-vitro, | Lung, | A549 |
| 1711- | Lyco, | Nutritional Importance of Carotenoids and Their Effect on Liver Health: A Review |
| - | Review, | Var, | NA |
| 1710- | Lyco, | Lycopene: A Natural Arsenal in the War against Oxidative Stress and Cardiovascular Diseases |
| - | Review, | CardioV, | NA |
| 1709- | Lyco, | Lycopene prevents carcinogen-induced cutaneous tumor by enhancing activation of the Nrf2 pathway through p62-triggered autophagic Keap1 degradation |
| - | in-vitro, | Nor, | JB6 |
| 1708- | Lyco, | The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies |
| - | Review, | Var, | NA |
| 2547- | M-Blu, | SDT, | The effect of dual-frequency ultrasound waves on B16F10 melanoma cells: Sonodynamic therapy using nanoliposomes containing methylene blue |
| - | in-vitro, | Melanoma, | B16-BL6 |
| 2542- | M-Blu, | In Vitro Methylene Blue and Carboplatin Combination Triggers Ovarian Cancer Cells Death |
| - | in-vitro, | Ovarian, | OV1369 | - | in-vitro, | Ovarian, | OV1946 | - | in-vitro, | Nor, | ARPE-19 |
| 2543- | M-Blu, | The use of methylene blue to control the tumor oxygenation level |
| - | in-vivo, | Lung, | NA |
| 2544- | M-Blu, | Methylene blue and its importance in medicine |
| - | Review, | NA, | NA |
| 2545- | M-Blu, | Reversing the Warburg Effect as a Treatment for Glioblastoma |
| - | in-vitro, | GBM, | U87MG | - | NA, | AD, | NA | - | in-vitro, | GBM, | A172 | - | in-vitro, | GBM, | T98G |
| 2541- | M-Blu, | Spectroscopic Study of Methylene Blue Interaction with Coenzymes and its Effect on Tumor Metabolism |
| - | in-vivo, | Var, | NA |
| 2546- | M-Blu, | SDT, | The sonodynamic antitumor effect of methylene blue on sarcoma180 cells in vitro |
| - | in-vitro, | sarcoma, | S180 |
| 2540- | M-Blu, | Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2535- | M-Blu, | SDT, | Apoptosis of ovarian cancer cells induced by methylene blue-mediated sonodynamic action |
| - | in-vitro, | Ovarian, | HO-8910 |
| 2534- | M-Blu, | doxoR, | PDT, | Methylene Blue-Mediated Photodynamic Therapy in Combination With Doxorubicin: A Novel Approach in the Treatment of HT-29 Colon Cancer Cells |
| - | in-vitro, | CRC, | HT-29 |
| 2533- | M-Blu, | PDT, | Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 2532- | M-Blu, | PDT, | Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies |
| - | Review, | Var, | NA |
| 2531- | M-Blu, | Anticancer activity of methylene blue via inhibition of heat shock protein 70 |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | NA, | NA |
| 1089- | MAG, | Magnolol potently suppressed lipopolysaccharide-induced iNOS and COX-2 expression via downregulating MAPK and NF-κB signaling pathways |
| - | in-vitro, | AML, | RAW264.7 |
| 1198- | MAG, | Mitochondria-targeted magnolol inhibits OXPHOS, proliferation, and tumor growth via modulation of energetics and autophagy in melanoma cells |
| - | in-vivo, | Melanoma, | NA |
| 1197- | MAG, | Magnolol as STAT3 inhibitor for treating multiple sclerosis by restricting Th17 cells |
| - | in-vivo, | MS, | NA |
| 1196- | MAG, | 2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression |
| - | in-vitro, | HCC, | NA |
| 972- | MAG, | Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells |
| - | vitro+vivo, | Bladder, | T24 |
| 4514- | MAG, | Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential |
| - | Review, | Var, | NA |
| 4526- | MAG, | HNK, | Targeting apoptosis pathways in cancer with magnolol and honokiol, bioactive constituents of the bark of Magnolia officinalis |
| - | Review, | Var, | NA |
| 4535- | MAG, | 5-FU, | Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways |
| - | in-vitro, | Cerv, | NA |
| 4534- | MAG, | Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | COLO205 |
| 4533- | MAG, | Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways |
| - | in-vitro, | GC, | SGC-7901 |
| 4532- | MAG, | Cisplatin, | Magnolol Attenuates Cisplatin-Induced Muscle Wasting by M2c Macrophage Activation |
| - | in-vivo, | Var, | NA |
| 4531- | MAG, | Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway |
| - | in-vitro, | CRC, | HCT116 |
| 4530- | MAG, | Magnolol inhibits cancer stemness and IL-6/Stat3 signaling in oral carcinomas |
| - | in-vitro, | Oral, | NA |
| 4529- | MAG, | Effectiveness of Magnolol, a Lignan from Magnolia Bark, in Diabetes, Its Complications and Comorbidities—A Review |
| - | Review, | Diabetic, | NA |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
| 4527- | MAG, | Magnolol inhibits growth and induces apoptosis in esophagus cancer KYSE-150 cell lines via the MAP kinase pathway |
| - | in-vitro, | ESCC, | TE1 | - | in-vitro, | ESCC, | Eca109 | - | vitro+vivo, | SCC, | KYSE150 |
| 4536- | MAG, | Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis |
| - | in-vitro, | Liver, | HepG2 | - | in-vivo, | CRC, | COLO205 |
| 4525- | MAG, | HNK, | Magnolol and Honokiol: Two Natural Compounds with Similar Chemical Structure but Different Physicochemical and Stability Properties |
| - | Study, | Nor, | NA |
| 4524- | MAG, | Magnolol facilitates mitochondrial-peroxisome dysfunction and induces oxeiptosis in lung cancer cells following transfer via tunneling nanotubes |
| - | vitro+vivo, | Lung, | NA |
| 4521- | MAG, | HNK, | Safety and Toxicology of Magnolol and Honokiol |
| - | Review, | Nor, | NA |
| 4520- | MAG, | Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling |
| - | vitro+vivo, | PC, | PANC1 |
| 4519- | MAG, | Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer |
| - | Review, | Var, | NA |
| 4518- | MAG, | Cisplatin, | Evaluating the Magnolol Anticancer Potential in MKN-45 Gastric Cancer Cells |
| - | in-vitro, | GC, | MKN45 |
| 4517- | MAG, | Mitochondrion-targeted magnolol derivatives exert synergistic anticancer activity by modulating energy metabolism and tumor microenvironment |
| - | vitro+vivo, | Var, | NA |
| 4516- | MAG, | Magnolol Induces Apoptosis and Suppresses Immune Evasion in Non-small Cell Lung Cancer Xenograft Models |
| - | in-vivo, | NSCLC, | NA |
| 4515- | MAG, | Magnolol as a Potential Anticancer Agent: A Proposed Mechanistic Insight |
| - | Review, | Var, | NA |
| 4537- | MAG, | Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action |
| - | in-vivo, | Melanoma, | NA | - | in-vitro, | Melanoma, | A431 |
| 1314- | MAG, | Magnolol induces apoptosis via activation of both mitochondrial and death receptor pathways in A375-S2 cells |
| - | in-vitro, | Melanoma, | A375 |
| 2450- | Matr, | The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors |
| - | Review, | Var, | NA |
| 2643- | MCT, | Medium Chain Triglycerides enhances exercise endurance through the increased mitochondrial biogenesis and metabolism |
| - | Review, | Nor, | NA |
| 2644- | MCT, | The Effects of Medium-Chain Triglyceride Oil Supplementation on Endurance Performance and Substrate Utilization in Healthy Populations: A Systematic Review |
| - | Review, | Nor, | NA |
| 3902- | MCT, | Effects of Caprylic Triglyceride on Cognitive Performance and Cerebral Glucose Metabolism in Mild Alzheimer’s Disease: A Single-Case Observation |
| - | Case Report, | AD, | NA |
| 3905- | MCT, | Medium Chain Triglycerides induce mild ketosis and may improve cognition in Alzheimer's disease. A systematic review and meta-analysis of human studies |
| - | Review, | AD, | NA |
| 3904- | MCT, | Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s disease |
| - | Human, | AD, | NA |
| 3903- | MCT, | Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer’s disease |
| - | Case Report, | AD, | NA |
| 3901- | MCT, | Potential of Capric Acid in Neurological Disorders: An Overview |
| - | Review, | AD, | NA |
| - | in-vitro, | AD, | NA |
| 3899- | MCT, | COCONUT OIL: NON-ALTERNATIVE DRUG TREATMENT AGAINST ALZHEIMER´S DISEASE |
| - | Human, | AD, | NA |
| 3898- | MCT, | Potential of coconut oil and medium chain triglycerides in the prevention and treatment of Alzheimer's disease |
| - | Review, | AD, | NA |
| 3897- | MCT, | The medium-chain fatty acid decanoic acid reduces oxidative stress levels in neuroblastoma cells |
| - | in-vitro, | AD, | NA |
| 3896- | MCT, | Improvement of Main Cognitive Functions in Patients with Alzheimer's Disease after Treatment with Coconut Oil Enriched Mediterranean Diet: A Pilot Study |
| - | Trial, | AD, | NA |
| 3895- | MCT, | How does coconut oil affect cognitive performance in alzheimer patients? |
| - | Human, | AD, | NA |
| 2500- | meben, | Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme |
| - | in-vitro, | GBM, | U87MG | - | in-vivo, | GBM, | NA |
| 1898- | MeJa, | Methyl jasmonate and its potential in cancer therapy |
| - | Review, | Var, | NA |
| 1899- | MeJa, | Methyl jasmonate induces production of reactive oxygen species and alterations in mitochondrial dynamics that precede photosynthetic dysfunction and subsequent cell death |
| - | in-vitro, | NA, | NA |
| 1784- | MEL, | Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials |
| - | Review, | NA, | NA |
| 1783- | MEL, | The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials |
| - | Review, | Var, | NA |
| 1785- | MEL, | Antitumoral melatonin-loaded nanostructured lipid carriers |
| - | in-vitro, | Var, | NA |
| 1786- | MEL, | What is known about melatonin, chemotherapy and altered gene expression in breast cancer (Review) |
| - | Review, | NA, | NA |
| 1782- | MEL, | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities |
| - | Review, | Var, | NA |
| 1781- | MEL, | Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial |
| - | Trial, | Lung, | NA |
| 1780- | MEL, | Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer with Ageing |
| - | Review, | Var, | NA |
| 1779- | MEL, | Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review |
| - | Review, | BC, | NA |
| 1778- | MEL, | Melatonin: a well-documented antioxidant with conditional pro-oxidant actions |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 1777- | MEL, | Melatonin as an antioxidant: under promises but over delivers |
| - | Review, | NA, | NA |
| 1776- | MEL, | Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis |
| - | Review, | NA, | NA |
| 1775- | MEL, | Chemo, | Rad, | A Systematic Review of the Chemo/Radioprotective Effects of Melatonin against Ototoxic Adverse Effects Induced by Chemotherapy and Radiotherapy |
| - | Review, | Var, | NA |
| 971- | MEL, | Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP |
| 995- | MEL, | Melatonin Treatment Triggers Metabolic and Intracellular pH Imbalance in Glioblastoma |
| - | vitro+vivo, | GBM, | NA |
| 1063- | MEL, | HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | PC9 |
| 1042- | MEL, | Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | LLC1 |
| 4705- | MEL, | Melatonin: beyond circadian regulation - exploring its diverse physiological roles and therapeutic potential |
| - | Review, | Nor, | NA |
| 2457- | MET, | Metformin Impairs Glucose Consumption and Survival in Calu-1 Cells by Direct Inhibition of Hexokinase-II |
| - | in-vitro, | Lung, | Calu-1 |
| 2456- | MET, | Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 2491- | MET, | Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase |
| - | in-vivo, | Nor, | NA |
| 2492- | MET, | The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective |
| - | Review, | Nor, | NA |
| 2493- | MET, | Metformin Inhibits Gluconeogenesis by a Redox-Dependent Mechanism In Vivo |
| - | in-vivo, | Nor, | NA |
| 2371- | MET, | The role of pyruvate kinase M2 in anticancer therapeutic treatments |
| - | Review, | Var, | NA |
| 2386- | MET, | Mechanisms of metformin inhibiting cancer invasion and migration |
| - | Review, | Var, | NA |
| 2385- | MET, | Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model |
| - | in-vitro, | AD, | H4 | - | in-vitro, | NA, | HEK293 | - | in-vivo, | NA, | NA | - | in-vitro, | NA, | SH-SY5Y |
| 2384- | MET, | Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication |
| - | in-vitro, | Thyroid, | BCPAP | - | in-vivo, | NA, | NA | - | in-vitro, | Thyroid, | TPC-1 |
| 2387- | MET, | GEM, | Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis |
| - | in-vitro, | CCA, | HCC9810 |
| 2383- | MET, | Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2 |
| - | in-vitro, | RCC, | A498 |
| 2379- | MET, | Down‐regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer |
| - | in-vitro, | Bladder, | T24 | - | in-vitro, | BC, | UMUC3 |
| 2378- | MET, | Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway |
| - | in-vitro, | SCC, | CAL27 | - | in-vivo, | NA, | NA |
| 2377- | MET, | Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | SiHa |
| 2376- | MET, | Metformin Inhibits Epithelial-to-Mesenchymal Transition of Keloid Fibroblasts via the HIF-1α/PKM2 Signaling Pathway |
| - | in-vitro, | Nor, | NA |
| 2375- | MET, | Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling |
| - | in-vitro, | GC, | SGC-7901 |
| 2436- | MET, | Metformin alleviates nickel-induced autophagy and apoptosis via inhibition of hexokinase-2, activating lipocalin-2, in human bronchial epithelial cells |
| - | in-vitro, | Nor, | BEAS-2B |
| 2374- | MET, | Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | SkBr3 | - | in-vitro, | BC, | MDA-MB-231 |
| 994- | MET, | Tumor metabolism destruction via metformin-based glycolysis inhibition and glucose oxidase-mediated glucose deprivation for enhanced cancer therapy |
| - | in-vitro, | Var, | NA |
| 1066- | MET, | Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma |
| - | in-vitro, | SCC, | NA |
| 970- | MET, | Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer |
| 1043- | MET, | immuno, | Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy |
| - | in-vitro, | NA, | NA |
| 1204- | MET, | Metformin induces ferroptosis through the Nrf2/HO-1 signaling in lung cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 2486- | metroC, | capec, | Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases |
| - | Case Report, | HCC, | NA |
| 2487- | metroC, | Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma |
| - | Review, | HCC, | NA |
| 2488- | metroC, | Metronomic S-1 Chemotherapy and Vandetanib: An Efficacious and Nontoxic Treatment for Hepatocellular Carcinoma |
| - | in-vitro, | HCC, | HUH7 | - | in-vivo, | HCC, | NA |
| 2489- | metroC, | capec, | Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma |
| - | Case Report, | HCC, | NA |
| 2490- | metroC, | Durable complete response of hepatocellular carcinoma after metronomic capecitabine |
| - | Case Report, | HCC, | NA |
| 2247- | MF, | Effects of Pulsed Electromagnetic Field Treatment on Skeletal Muscle Tissue Recovery in a Rat Model of Collagenase-Induced Tendinopathy: Results from a Proteome Analysis |
| - | in-vivo, | Nor, | NA |
| 2257- | MF, | HPT, | HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer |
| - | in-vitro, | Ovarian, | NA |
| 2246- | MF, | The Use of Pulsed Electromagnetic Field to Modulate Inflammation and Improve Tissue Regeneration: A Review |
| - | in-vitro, | Nor, | NA |
| 2245- | MF, | Quantum based effects of therapeutic nuclear magnetic resonance persistently reduce glycolysis |
| - | in-vitro, | Nor, | NIH-3T3 |
| 2244- | MF, | Little strokes fell big oaks: The use of weak magnetic fields and reactive oxygen species to fight cancer |
| - | Review, | Var, | NA |
| 2243- | MF, | Pulsed electromagnetic fields increase osteogenetic commitment of MSCs via the mTOR pathway in TNF-α mediated inflammatory conditions: an in-vitro study |
| - | in-vitro, | Nor, | NA |
| 2242- | MF, | Electromagnetic stimulation increases mitochondrial function in osteogenic cells and promotes bone fracture repair |
| - | in-vitro, | Nor, | NA |
| 2241- | MF, | Pulsed electromagnetic therapy in cancer treatment: Progress and outlook |
| - | Review, | Var, | NA |
| 2240- | MF, | Pulsed electromagnetic field induces Ca2+-dependent osteoblastogenesis in C3H10T1/2 mesenchymal cells through the Wnt-Ca2+/Wnt-β-catenin signaling pathway |
| - | in-vitro, | Nor, | C3H10T1/2 |
| 2239- | MF, | Time-varying magnetic fields increase cytosolic free Ca2+ in HL-60 cells |
| - | in-vitro, | AML, | HL-60 |
| 2238- | MF, | Electromagnetic fields act via activation of voltage-gated calcium channels to produce beneficial or adverse effects |
| - | Review, | Var, | NA |
| 2237- | MF, | The Effect of Pulsed Electromagnetic Field Stimulation of Live Cells on Intracellular Ca2+ Dynamics Changes Notably Involving Ion Channels |
| - | in-vitro, | AML, | KG-1 | - | in-vitro, | Nor, | HUVECs |
| 2236- | MF, | Changes in Ca2+ release in human red blood cells under pulsed magnetic field |
| - | in-vitro, | Nor, | NA |
| 2235- | MF, | Increase of intracellular Ca2+ concentration in Listeria monocytogenes under pulsed magnetic field |
| - | in-vitro, | Inf, | NA |
| 2260- | MF, | Alternative magnetic field exposure suppresses tumor growth via metabolic reprogramming |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | LN229 | - | in-vivo, | NA, | NA |
| 2261- | MF, | Tumor-specific inhibition with magnetic field |
| - | in-vitro, | Nor, | GP-293 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Lung, | A549 |
| 2248- | MF, | Magnetic fields modulate metabolism and gut microbiome in correlation with Pgc-1α expression: Follow-up to an in vitro magnetic mitohormetic study |
| - | in-vivo, | Nor, | NA |
| 2249- | MF, | Pulsed electromagnetic fields modulate energy metabolism during wound healing process: an in vitro model study |
| - | in-vitro, | Nor, | L929 |
| 2250- | MF, | MNPs, | Confronting stem cells with surface-modified magnetic nanoparticles and low-frequency pulsed electromagnetic field |
| - | Review, | NA, | NA |
| 2251- | MF, | Rad, | BEMER Electromagnetic Field Therapy Reduces Cancer Cell Radioresistance by Enhanced ROS Formation and Induced DNA Damage |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | HNSCC, | UTSCC15 | - | in-vitro, | CRC, | DLD1 | - | in-vitro, | PC, | MIA PaCa-2 |
| 2252- | MF, | HPT, | Cellular Response to ELF-MF and Heat: Evidence for a Common Involvement of Heat Shock Proteins? |
| - | Review, | NA, | NA |
| 2253- | MF, | Low-frequency pulsed electromagnetic field promotes functional recovery, reduces inflammation and oxidative stress, and enhances HSP70 expression following spinal cord injury |
| - | in-vivo, | Nor, | NA |
| 2256- | MF, | HPT, | Effects of exposure to repetitive pulsed magnetic stimulation on cell proliferation and expression of heat shock protein 70 in normal and malignant cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HBL-100 |
| 2255- | MF, | Pulsed Electromagnetic Fields Induce Skeletal Muscle Cell Repair by Sustaining the Expression of Proteins Involved in the Response to Cellular Damage and Oxidative Stress |
| - | in-vitro, | Nor, | SkMC |
| 2254- | MF, | Effect of 60 Hz electromagnetic fields on the activity of hsp70 promoter: an in vivo study |
| - | in-vivo, | Nor, | NA |
| 4348- | MF, | Pulsed electromagnetic field attenuates bone fragility in estrogen-deficient osteoporosis in rats |
| - | in-vivo, | ostP, | NA |
| 4349- | MF, | Long-term effect of full-body pulsed electromagnetic field and exercise protocol in the treatment of men with osteopenia or osteoporosis: A randomized placebo-controlled trial |
| - | Trial, | ostP, | NA |
| 4351- | MF, | Inhibition of proliferation of human lymphoma cells U937 by a 50 Hz electromagnetic field |
| - | in-vitro, | lymphoma, | NA |
| 4352- | MF, | Differences in lethality between cancer cells and human lymphocytes caused by LF-electromagnetic fields |
| - | in-vitro, | lymphoma, | K562 | - | NA, | NA, | U937 | - | NA, | NA, | HL-60 |
| 4353- | MF, | Chemo, | Pulsed Electromagnetic Field Enhances Doxorubicin-induced Reduction in the Viability of MCF-7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 |
| 4354- | MF, | doxoR, | Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach |
| - | in-vivo, | BC, | MDA-MB-231 | - | in-vivo, | BC, | MCF-7 |
| 4355- | MF, | Ambient and supplemental magnetic fields promote myogenesis via a TRPC1-mitochondrial axis: evidence of a magnetic mitohormetic mechanism |
| - | in-vitro, | Nor, | C2C12 |
| 4356- | MF, | Pulsed electromagnetic fields synergize with graphene to enhance dental pulp stem cell-derived neurogenesis by selectively targeting TRPC1 channels |
| - | in-vitro, | Nor, | NA |
| 4571- | MF, | Magnetic Fields and Reactive Oxygen Species |
| - | Review, | NA, | NA |
| 4568- | MF, | Extremely low-frequency pulses of faint magnetic field induce mitophagy to rejuvenate mitochondria |
| - | Study, | NA, | NA |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | MCF-7 |
| 3942- | MF, | Chronic-Exposure Low-Frequency Magnetic Fields (Magnetotherapy and Magnetic Stimulation) Influence Serum Serotonin Concentrations in Patients with Low Back Pain-Clinical Observation Study |
| - | Human, | AD, | NA |
| 3476- | MF, | Pulsed Electromagnetic Fields Stimulate HIF-1α-Independent VEGF Release in 1321N1 Human Astrocytes Protecting Neuron-like SH-SY5Y Cells from Oxygen-Glucose Deprivation |
| - | in-vitro, | Stroke, | 1321N1 | - | in-vitro, | Park, | NA |
| 3477- | MF, | Electromagnetic fields regulate calcium-mediated cell fate of stem cells: osteogenesis, chondrogenesis and apoptosis |
| - | Review, | NA, | NA |
| 3478- | MF, | One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study |
| - | Trial, | BC, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | C2C12 |
| 3479- | MF, | Evaluation of Pulsed Electromagnetic Field Effects: A Systematic Review and Meta-Analysis on Highlights of Two Decades of Research In Vitro Studies |
| - | Review, | NA, | NA |
| 3480- | MF, | Cellular and Molecular Effects of Magnetic Fields |
| - | Review, | NA, | NA |
| 3482- | MF, | Pulsed Electromagnetic Fields Increase Angiogenesis and Improve Cardiac Function After Myocardial Ischemia in Mice |
| - | in-vitro, | NA, | NA |
| 3483- | MF, | Pulsed Electromagnetic Fields Protect Against Brain Ischemia by Modulating the Astrocytic Cholinergic Anti-inflammatory Pathway |
| - | NA, | Stroke, | NA |
| 3484- | MF, | Extremely low frequency pulsed electromagnetic fields cause antioxidative defense mechanisms in human osteoblasts via induction of •O2 − and H2O2 |
| - | in-vitro, | Nor, | NA |
| 3485- | MF, | Cytoprotective effects of low-frequency pulsed electromagnetic field against oxidative stress in glioblastoma cells |
| - | in-vitro, | GBM, | U87MG |
| 3486- | MF, | Pulsed electromagnetic field potentiates etoposide-induced MCF-7 cell death |
| - | in-vitro, | NA, | NA |
| 3487- | MF, | Rad, | High-specificity protection against radiation-induced bone loss by a pulsed electromagnetic field |
| - | Review, | Var, | NA |
| 3498- | MF, | Effect of Static Magnetic Field on Oxidant/Antioxidant Parameters in Cancerous and Noncancerous Human Gastric Tissues |
| - | in-vitro, | GC, | NA |
| 3500- | MF, | Moderate Static Magnet Fields Suppress Ovarian Cancer Metastasis via ROS-Mediated Oxidative Stress |
| - | in-vitro, | Ovarian, | SKOV3 |
| 3501- | MF, | Unveiling the Power of Magnetic-Driven Regenerative Medicine: Bone Regeneration and Functional Reconstruction |
| - | Review, | NA, | NA |
| 3481- | MF, | No effects of pulsed electromagnetic fields on expression of cell adhesion molecules (integrin, CD44) and matrix metalloproteinase-2/9 in osteosarcoma cell lines |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | OS, | SaOS2 |
| 3536- | MF, | Targeting Mesenchymal Stromal Cells/Pericytes (MSCs) With Pulsed Electromagnetic Field (PEMF) Has the Potential to Treat Rheumatoid Arthritis |
| - | Review, | Arthritis, | NA | - | Review, | Stroke, | NA |
| 3474- | MF, | Pulsed electromagnetic fields potentiate the paracrine function of mesenchymal stem cells for cartilage regeneration |
| - | in-vitro, | Nor, | NA |
| 3457- | MF, | Cellular stress response to extremely low‐frequency electromagnetic fields (ELF‐EMF): An explanation for controversial effects of ELF‐EMF on apoptosis |
| - | Review, | Var, | NA |
| 3458- | MF, | Magnetic Control of Protein Expression via Magneto-mechanical Actuation of ND-PEGylated Iron Oxide Nanocubes for Cell Therapy |
| - | in-vitro, | GBM, | NA |
| 3459- | MF, | EFFECT OF PULSED ELECTROMAGNETIC FIELDS ON ENDOPLASMIC RETICULUM STRESS |
| - | in-vitro, | Cerv, | HeLa |
| 3462- | MF, | The Effect of a Static Magnetic Field on microRNA in Relation to the Regulation of the Nrf2 Signaling Pathway in a Fibroblast Cell Line That Had Been Treated with Fluoride Ions |
| - | in-vitro, | Nor, | NA |
| 3463- | MF, | Pulsed Electromagnetic Fields Alleviates Hepatic Oxidative Stress and Lipids Accumulation in db/db mice |
| - | in-vivo, | NA, | NA |
| 3464- | MF, | Progressive Study on the Non-thermal Effects of Magnetic Field Therapy in Oncology |
| - | Review, | Var, | NA |
| 3465- | MF, | Magnetic fields and angiogenesis |
| - | Review, | Var, | NA |
| 3466- | MF, | The effect of magnetic fields on tumor occurrence and progression: Recent advances |
| - | Review, | Var, | NA |
| 3468- | MF, | An integrative review of pulsed electromagnetic field therapy (PEMF) and wound healing |
| - | Review, | NA, | NA |
| 3473- | MF, | Therapeutic use of pulsed electromagnetic field therapy reduces prostate volume and lower urinary tract symptoms in benign prostatic hyperplasia |
| - | Human, | BPH, | NA |
| 3472- | MF, | Pulsed electromagnetic field alleviates synovitis and inhibits the NLRP3/Caspase-1/GSDMD signaling pathway in osteoarthritis rats |
| - | in-vivo, | ostP, | NA |
| 3471- | MF, | The prevention effect of pulsed electromagnetic fields treatment on senile osteoporosis in vivo via improving the inflammatory bone microenvironment |
| - | in-vivo, | Nor, | NA |
| 3470- | MF, | Pulsed electromagnetic fields inhibit IL-37 to alleviate CD8+ T cell dysfunction and suppress cervical cancer progression |
| - | in-vitro, | Cerv, | HeLa |
| 3475- | MF, | A Pulsed Electromagnetic Field Protects against Glutamate-Induced Excitotoxicity by Modulating the Endocannabinoid System in HT22 Cells |
| - | in-vitro, | Nor, | HT22 | - | Review, | AD, | NA |
| 3469- | MF, | Pulsed Electromagnetic Fields (PEMF)—Physiological Response and Its Potential in Trauma Treatment |
| - | Review, | NA, | NA |
| 3467- | MF, | Pulsed Magnetic Field Induces Angiogenesis and Improves Cardiac Function of Surgically Induced Infarcted Myocardium in Sprague-Dawley Rats |
| - | in-vivo, | Nor, | NA |
| 3566- | MF, | Positive and Negative Effects of Administering a Magnetic Field to Patients with Rheumatoid Arthritis (RA) |
| - | Study, | Arthritis, | NA |
| 3568- | MF, | The Efficacy of Pulsed Electromagnetic Fields on Pain, Stiffness, and Physical Function in Osteoarthritis: A Systematic Review and Meta-Analysis |
| - | Review, | Arthritis, | NA |
| 3569- | MF, | Current Evidence Using Pulsed Electromagnetic Fields in Osteoarthritis: A Systematic Review |
| - | Review, | Arthritis, | NA |
| 4102- | MF, | Modulation of antioxidant enzyme gene expression by extremely low frequency electromagnetic field in post-stroke patients |
| - | Human, | Stroke, | NA |
| 4106- | MF, | Cognitive Decline: Current Intervention Strategies and Integrative Therapeutic Approaches for Alzheimer's Disease |
| - | Review, | AD, | NA |
| 4105- | MF, | Extremely low frequency electromagnetic fields stimulation modulates autoimmunity and immune responses: a possible immuno-modulatory therapeutic effect in neurodegenerative diseases |
| - | Review, | AD, | NA |
| 4104- | MF, | Effects of exposure to extremely low-frequency electromagnetic fields on spatial and passive avoidance learning and memory, anxiety-like behavior and oxidative stress in male rats |
| - | in-vivo, | NA, | NA |
| 4103- | MF, | Comparing the Effects of Long-term Exposure to Extremely Low-frequency Electromagnetic Fields With Different Values on Learning, Memory, Anxiety, and β-amyloid Deposition in Adult Rats |
| - | in-vivo, | NA, | NA |
| 4109- | MF, | Overexpression of miR-26b-5p regulates the cell cycle by targeting CCND2 in GC-2 cells under exposure to extremely low frequency electromagnetic fields |
| - | in-vitro, | NA, | NA |
| 4092- | MF, | Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology |
| - | Review, | Var, | NA |
| 4093- | MF, | Low-intensity electromagnetic fields induce human cryptochrome to modulate intracellular reactive oxygen species |
| - | in-vivo, | NA, | NA |
| - | Study, | Stroke, | NA |
| 4095- | MF, | Frequency-tuned electromagnetic field therapy improves post-stroke motor function: A pilot randomized controlled trial |
| - | Trial, | Stroke, | NA |
| 4096- | MF, | Extremely Low‐Frequency and Low‐Intensity Electromagnetic Field Technology (ELF‐EMF) Sculpts Microtubules |
| - | in-vitro, | AD, | NA |
| 4097- | MF, | Theta Frequency Electromagnetic Stimulation Enhances Functional Recovery After Stroke |
| - | Trial, | Stroke, | NA |
| 4098- | MF, | Extremely low frequency electromagnetic field (ELF-EMF) reduces oxidative stress and improves functional and psychological status in ischemic stroke patients |
| - | Trial, | Stroke, | NA |
| 4099- | MF, | Extremely low frequency electromagnetic field reduces oxidative stress during the rehabilitation of post-acute stroke patients |
| - | Trial, | Stroke, | NA |
| 4100- | MF, | Neurobiological effects and mechanisms of magnetic fields: a review from 2000 to 2023 |
| - | Review, | Var, | NA |
| 4101- | MF, | Benign Effect of Extremely Low-Frequency Electromagnetic Field on Brain Plasticity Assessed by Nitric Oxide Metabolism during Poststroke Rehabilitation |
| - | Human, | Stroke, | NA |
| 4120- | MF, | Low-Frequency Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex Enhances Recognition Memory in Alzheimer's Disease |
| - | Human, | AD, | NA |
| 4110- | MF, | Pulsed Electromagnetic Fields: A Novel Attractive Therapeutic Opportunity for Neuroprotection After Acute Cerebral Ischemia |
| - | Review, | Stroke, | NA |
| 4111- | MF, | Coupling of pulsed electromagnetic fields (PEMF) therapy to molecular grounds of the cell |
| - | Review, | Arthritis, | NA |
| 4112- | MF, | Novel protective effects of pulsed electromagnetic field ischemia/reperfusion injury rats |
| - | in-vivo, | Stroke, | NA |
| 4119- | MF, | Therapeutic potential and mechanisms of repetitive transcranial magnetic stimulation in Alzheimer’s disease: a literature review |
| - | Review, | AD, | NA |
| 4118- | MF, | Effects of transcranial magnetic stimulation on neurobiological changes in Alzheimer's disease |
| - | Review, | AD, | NA |
| 4116- | MF, | Low‑frequency pulsed electromagnetic field promotes functional recovery, reduces inflammation and oxidative stress, and enhances HSP70 expression following spinal cord injury |
| - | in-vivo, | NA, | NA |
| 4117- | MF, | Pulsed electromagnetic fields improve the healing process of Achilles tendinopathy: a pilot study in a rat model |
| - | in-vivo, | NA, | NA |
| 4015- | MF, | Evaluation of the PTEN and circRNA-CDR1as Gene Expression Changes in Gastric Cancer and Normal Cell Lines Following the Exposure to Weak and Moderate 50 Hz Electromagnetic Fields |
| - | in-vitro, | GC, | AGS | - | in-vitro, | Nor, | HU02 |
| 3728- | MF, | Long-term exposure to ELF-MF ameliorates cognitive deficits and attenuates tau hyperphosphorylation in 3xTg AD mice |
| - | in-vivo, | AD, | NA |
| 3727- | MF, | RKIP-Mediated NF-κB Signaling is involved in ELF-MF-mediated improvement in AD rat |
| - | in-vivo, | AD, | NA |
| 3726- | MF, | Spatial memory recovery in Alzheimer's rat model by electromagnetic field exposure |
| - | in-vivo, | AD, | NA |
| 3725- | MF, | Short-term effects of extremely low frequency electromagnetic fields exposure on Alzheimer's disease in rats |
| - | in-vivo, | AD, | NA |
| 3746- | MF, | Low-Frequency Pulsed Electromagnetic Field Is Able to Modulate miRNAs in an Experimental Cell Model of Alzheimer's Disease |
| - | in-vitro, | AD, | NA |
| 3744- | MF, | Cognitive improvement via a modulated rhythmic pulsed magnetic field in D-galactose-induced accelerated aging mice |
| - | in-vivo, | AD, | NA |
| 3724- | MF, | RF, | Electromagnetic Field in Alzheimer's Disease: A Literature Review of Recent Preclinical and Clinical Studies |
| - | Review, | AD, | NA |
| 3739- | MF, | Early intervention using long-term rhythmic pulsed magnetic stimulation alleviates cognitive decline in a 5xFAD mouse model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3740- | MF, | Gamma rhythm low field magnetic stimulation alleviates neuropathologic changes and rescues memory and cognitive impairments in a mouse model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3741- | MF, | Promising application of Pulsed Electromagnetic Fields (PEMFs) in musculoskeletal disorders |
| - | Review, | NA, | NA |
| 3742- | MF, | The role of magnetic fields in neurodegenerative diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3734- | MF, | Extremely low frequency electromagnetic fields promote cognitive function and hippocampal neurogenesis of rats with cerebral ischemia |
| - | in-vivo, | AD, | NA |
| 3735- | MF, | Examining the effects of extremely low-frequency magnetic fields on cognitive functions and functional brain markers in aged mice |
| - | in-vivo, | AD, | NA |
| 3737- | MF, | The Effect of Time-Dependence of 10 Hz Electromagnetic Field on Spatial Learning and Memory in Rats |
| - | in-vivo, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 4147- | MF, | PEMFs Restore Mitochondrial and CREB/BDNF Signaling in Oxidatively Stressed PC12 Cells Targeting Neurodegeneration |
| - | in-vitro, | AD, | PC12 |
| 4148- | MF, | Increase in Blood Levels of Growth Factors Involved in the Neuroplasticity Process by Using an Extremely Low Frequency Electromagnetic Field in Post-stroke Patients |
| - | Human, | Stroke, | NA |
| 4150- | MF, | Enhanced effect of combining bone marrow mesenchymal stem cells (BMMSCs) and pulsed electromagnetic fields (PEMF) to promote recovery after spinal cord injury in mice |
| - | in-vitro, | NA, | NA |
| 4149- | MF, | Pulsed Electro-Magnetic Field (PEMF) Effect on Bone Healing in Animal Models: A Review of Its Efficacy Related to Different Type of Damage |
| - | Review, | NA, | NA |
| 1762- | MF, | Fe, | Triggering the apoptosis of targeted human renal cancer cells by the vibration of anisotropic magnetic particles attached to the cell membrane |
| - | in-vitro, | RCC, | NA |
| 493- | MF, | Extremely low-frequency electromagnetic field induces acetylation of heat shock proteins and enhances protein folding |
| - | in-vitro, | NA, | HEK293 | - | in-vitro, | Liver, | AML12 |
| 504- | MF, | Effect of Magnetic Fields on Tumor Growth and Viability |
| - | in-vivo, | NA, | NA |
| 494- | MF, | Effects of Various Densities of 50 Hz Electromagnetic Field on Serum IL-9, IL-10, and TNF-α Levels |
| - | in-vivo, | NA, | NA |
| 495- | MF, | How a High-Gradient Magnetic Field Could Affect Cell Life |
| - | in-vitro, | NA, | HeLa |
| 496- | MF, | Low-Frequency Magnetic Fields (LF-MFs) Inhibit Proliferation by Triggering Apoptosis and Altering Cell Cycle Distribution in Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | ZR-75-1 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 |
| 497- | MF, | In Vitro and in Vivo Study of the Effect of Osteogenic Pulsed Electromagnetic Fields on Breast and Lung Cancer Cells |
| - | vitro+vivo, | NA, | MCF-7 | - | vitro+vivo, | NA, | A549 |
| 498- | MF, | Stimulation of osteogenic differentiation in human osteoprogenitor cells by pulsed electromagnetic fields: an in vitro study |
| - | in-vitro, | NA, | NA |
| 499- | MF, | The Effect of Pulsed Electromagnetic Fields on Angiogenesis |
| - | Review, | NA, | NA |
| 500- | MF, | Anti-Oxidative and Immune Regulatory Responses of THP-1 and PBMC to Pulsed EMF Are Field-Strength Dependent |
| - | in-vitro, | AML, | THP1 |
| 501- | MF, | Low Intensity and Frequency Pulsed Electromagnetic Fields Selectively Impair Breast Cancer Cell Viability |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 502- | MF, | Electromagnetic field investigation on different cancer cell lines |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Colon, | SW480 | - | in-vitro, | CRC, | HCT116 |
| 503- | MF, | Effects of acute and chronic low frequency electromagnetic field exposure on PC12 cells during neuronal differentiation |
| - | in-vitro, | NA, | PC12 |
| 526- | MF, | Inhibition of Cancer Cell Growth by Exposure to a Specific Time-Varying Electromagnetic Field Involves T-Type Calcium Channels |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Pca, | HeLa | - | vitro+vivo, | Melanoma, | B16-BL6 | - | in-vitro, | Nor, | HEK293 |
| 492- | MF, | Weak electromagnetic fields (50 Hz) elicit a stress response in human cells |
| - | in-vitro, | AML, | HL-60 |
| 491- | MF, | Pre-exposure of neuroblastoma cell line to pulsed electromagnetic field prevents H2 O2 -induced ROS production by increasing MnSOD activity |
| - | in-vitro, | neuroblastoma, | SH-SY5Y |
| 490- | MF, | Extremely Low Frequency Magnetic Field (ELF-MF) Exposure Sensitizes SH-SY5Y Cells to the Pro-Parkinson's Disease Toxin MPP(.) |
| - | in-vitro, | Park, | SH-SY5Y |
| 489- | MF, | Time-varying magnetic fields of 60 Hz at 7 mT induce DNA double-strand breaks and activate DNA damage checkpoints without apoptosis |
| - | in-vitro, | NA, | HeLa | - | in-vitro, | NA, | IMR90 |
| 488- | MF, | Repetitive exposure to a 60-Hz time-varying magnetic field induces DNA double-strand breaks and apoptosis in human cells |
| - | in-vitro, | NA, | HeLa | - | in-vitro, | NA, | IMR90 |
| 487- | MF, | Extremely Low-Frequency Electromagnetic Fields Cause G1 Phase Arrest through the Activation of the ATM-Chk2-p21 Pathway |
| - | in-vitro, | NMSC, | HaCaT |
| 486- | MF, | mTOR Activation by PI3K/Akt and ERK Signaling in Short ELF-EMF Exposed Human Keratinocytes |
| - | in-vitro, | Nor, | HaCaT |
| 582- | MF, | immuno, | VitC, | Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy |
| - | in-vitro, | Pca, | TRAMP-C1 | - | in-vivo, | NA, | NA |
| 585- | MF, | VitC, | Impact of pulsed magnetic field treatment on enzymatic inactivation and quality of cloudy apple juice |
| 587- | MF, | VitC, | Effect of stationary magnetic field strengths of 150 and 200 mT on reactive oxygen species production in soybean |
| 590- | MF, | VitC, | Sub-millitesla magnetic field effects on the recombination reaction of flavin and ascorbic acid radicals |
| - | in-vitro, | NA, | NA |
| 592- | MF, | VitC, | Alternative radical pairs for cryptochrome-based magnetoreception |
| 594- | MF, | VitC, | Static Magnetic Field Effect on the Fremy's Salt-Ascorbic Acid Chemical Reaction Studied by Continuous-Wave Electron Paramagnetic Resonance |
| - | Analysis, | NA, | NA |
| 535- | MF, | Electromagnetic Fields Trigger Cell Death in Glioblastoma Cells through Increasing miR-126-5p and Intracellular Ca2+ Levels |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | GBM, | A172 | - | in-vitro, | Pca, | HeLa |
| - | in-vitro, | AML, | THP1 | - | in-vitro, | NA, | PC12 | - | in-vivo, | Cerv, | HeLa |
| 527- | MF, | Effects of Fifty-Hertz Electromagnetic Fields on Granulocytic Differentiation of ATRA-Treated Acute Promyelocytic Leukemia NB4 Cells |
| - | in-vitro, | AML, | APL NB4 |
| 528- | MF, | Caff, | Pulsed electromagnetic fields affect the intracellular calcium concentrations in human astrocytoma cells |
| - | in-vitro, | GBM, | U373MG |
| 524- | MF, | Inhibition of Angiogenesis Mediated by Extremely Low-Frequency Magnetic Fields (ELF-MFs) |
| - | vitro+vivo, | PC, | MS-1 | - | vitro+vivo, | PC, | HUVECs |
| 539- | MF, | Pulsed Magnetic Field Improves the Transport of Iron Oxide Nanoparticles through Cell Barriers |
| - | in-vitro, | NA, | NA |
| 538- | MF, | The extremely low frequency electromagnetic stimulation selective for cancer cells elicits growth arrest through a metabolic shift |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Melanoma, | MSTO-211H |
| 537- | MF, | immuno, | Integrating electromagnetic cancer stress with immunotherapy: a therapeutic paradigm |
| - | Review, | Var, | NA |
| 536- | MF, | Comparison of pulsed and continuous electromagnetic field generated by WPT system on human dermal and neural cells |
| - | in-vitro, | Nor, | SH-SY5Y | - | in-vitro, | GBM, | T98G | - | in-vitro, | Nor, | HDFa |
| 522- | MF, | Low Magnetic Field Exposure Alters Prostate Cancer Cell Properties |
| - | in-vitro, | Pca, | PC3 |
| 534- | MF, | Effect of extremely low frequency electromagnetic field parameters on the proliferation of human breast cancer |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | Nor, | MCF10 |
| 505- | MF, | Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach |
| - | Case Report, | NA, | NA |
| 533- | MF, | Effects of extremely low-frequency magnetic fields on human MDA-MB-231 breast cancer cells: proteomic characterization |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 532- | MF, | A 50 Hz magnetic field influences the viability of breast cancer cells 96 h after exposure |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 531- | MF, | 6-mT 0-120-Hz magnetic fields differentially affect cellular ATP levels |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | RPE-1 | - | in-vitro, | Nor, | GP-293 |
| 530- | MF, | Low frequency sinusoidal electromagnetic fields promote the osteogenic differentiation of rat bone marrow mesenchymal stem cells by modulating miR-34b-5p/STAC2 |
| - | in-vivo, | Nor, | NA |
| 529- | MF, | Low-frequency magnetic field therapy for glioblastoma: Current advances, mechanisms, challenges and future perspectives |
| - | Review, | GBM, | NA |
| 514- | MF, | Therapeutic electromagnetic field effects on angiogenesis and tumor growth |
| - | in-vivo, | NA, | NA |
| 506- | MF, | doxoR, | Pulsed Electromagnetic Field Stimulation Promotes Anti-cell Proliferative Activity in Doxorubicin-treated Mouse Osteosarcoma Cells |
| - | in-vitro, | OS, | LM8 |
| 507- | MF, | Effects of extremely low frequency electromagnetic fields on the tumor cell inhibition and the possible mechanism |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | GP-293 |
| 508- | MF, | doxoR, | Synergistic cytotoxic effects of an extremely low-frequency electromagnetic field with doxorubicin on MCF-7 cell line |
| - | in-vitro, | BC, | MCF-7 |
| - | Review, | NA, | NA |
| 510- | MF, | Effect of a 9 mT pulsed magnetic field on C3H/Bi female mice with mammary carcinoma. A comparison between the 12 Hz and the 460 Hz frequencies |
| - | in-vivo, | NA, | NA |
| 511- | MF, | Optimization of a therapeutic electromagnetic field (EMF) to retard breast cancer tumor growth and vascularity |
| - | in-vivo, | NA, | NA |
| 512- | MF, | Pulsed Electromagnetic Fields (PEMFs) Trigger Cell Death and Senescence in Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | FF95 |
| 513- | MF, | Exposure to a specific time-varying electromagnetic field inhibits cell proliferation via cAMP and ERK signaling in cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MCF-7 | - | in-vivo, | Pca, | HeLa |
| 515- | MF, | Pulsed Low-Frequency Magnetic Fields Induce Tumor Membrane Disruption and Altered Cell Viability |
| - | in-vitro, | Lung, | A549 |
| 525- | MF, | Pulsed electromagnetic fields regulate metabolic reprogramming and mitochondrial fission in endothelial cells for angiogenesis |
| - | in-vitro, | Nor, | HUVECs |
| 517- | MF, | Rad, | Therapeutic Electromagnetic Field (TEMF) and gamma irradiation on human breast cancer xenograft growth, angiogenesis and metastasis |
| - | in-vivo, | NA, | MDA-MB-231 |
| 518- | MF, | Moderate and strong static magnetic fields directly affect EGFR kinase domain orientation to inhibit cancer cell proliferation |
| - | in-vitro, | NA, | HCT116 |
| 519- | MF, | Effects of 50-Hz magnetic field exposure on superoxide radical anion formation and HSP70 induction in human K562 cells |
| - | in-vitro, | AML, | K562 |
| 520- | MF, | Exposure to a 50-Hz magnetic field induced mitochondrial permeability transition through the ROS/GSK-3β signaling pathway |
| - | in-vitro, | Nor, | NA |
| 521- | MF, | Magnetic field effects in biology from the perspective of the radical pair mechanism |
| - | Analysis, | NA, | NA |
| 197- | MF, | A mechanism for action of oscillating electric fields on cells |
| 196- | MF, | Mechanism for action of electromagnetic fields on cells |
| 194- | MF, | Electromagnetic Field as a Treatment for Cerebral Ischemic Stroke |
| - | Review, | Stroke, | NA |
| 192- | MF, | The use of magnetic fields in treatment of patients with rheumatoid arthritis. Review of the literature |
| - | Review, | Arthritis, | NA |
| 188- | MFrot, | MF, | Spinning magnetic field patterns that cause oncolysis by oxidative stress in glioma cells |
| - | in-vitro, | GBM, | GBM115 | - | in-vitro, | GBM, | DIPG |
| 219- | MFrot, | MF, | The expression and intranuclear distribution of nucleolin in HL-60 and K-562 cells after repeated, short-term exposition to rotating magnetic fields |
| - | in-vitro, | AML, | HL-60 | - | in-vitro, | AML, | K562 |
| 189- | MFrot, | MF, | Cancer treatment by magneto-mechanical effect of particles, a review |
| - | vitro+vivo, | Var, | NA |
| 187- | MFrot, | MF, | Method for noninvasive whole-body stimulation with spinning oscillating magnetic fields and its safety in mice |
| - | in-vivo, | GBM, | NA |
| - | Human, | Lung, | NA |
| 191- | MFrot, | MF, | Early exposure of rotating magnetic fields promotes central nervous regeneration in planarian Girardia sinensis |
| - | in-vivo, | Nor, | NA |
| 193- | MFrot, | MF, | Rotating Magnetic Field Mitigates Ankylosing Spondylitis Targeting Osteocytes and Chondrocytes via Ameliorating Immune Dysfunctions |
| - | in-vivo, | Arthritis, | NA |
| 195- | MFrot, | MF, | Application of Rotating Magnetic Fields Increase the Activity of Antimicrobials Against Wound Biofilm Pathogens |
| - | Human, | Wounds, | NA |
| 198- | MFrot, | MF, | Biological effects of rotating magnetic field: A review from 1969 to 2021 |
| - | Review, | Var, | NA |
| 199- | MFrot, | MF, | Modulation of Cellular Response to Different Parameters of the Rotating Magnetic Field (RMF)—An In Vitro Wound Healing Study |
| - | in-vivo, | Wounds, | L929 | - | NA, | NA, | HaCaT |
| 200- | MFrot, | MF, | Moderate intensity low frequency rotating magnetic field inhibits breast cancer growth in mice |
| - | in-vivo, | BC, | MDA-MB-231 | - | in-vivo, | BC, | MCF-7 |
| 201- | MFrot, | MF, | Gradient Rotating Magnetic Fields Impairing F-Actin-Related Gene CCDC150 to Inhibit Triple-Negative Breast Cancer Metastasis by Inactivating TGF-β1/SMAD3 Signaling Pathway |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | MDA-MB-468 |
| 202- | MFrot, | MF, | Systematic simulation of tumor cell invasion and migration in response to time-varying rotating magnetic field |
| - | Analysis, | Var, | MDA-MB-231 |
| 203- | MFrot, | MF, | Rotating Magnetic Field Induced Oscillation of Magnetic Particles for in vivo Mechanical Destruction of Malignant Glioma |
| - | vitro+vivo, | GBM, | U87MG |
| 204- | MFrot, | MF, | Rotating magnetic field improved cognitive and memory impairments in a sporadic ad model of mice by regulating microglial polarization |
| - | in-vivo, | AD, | NA |
| 205- | MFrot, | MF, | Intermittent F-actin Perturbations by Magnetic Fields Inhibit Breast Cancer Metastasis |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 185- | MFrot, | MF, | Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device |
| - | Human, | GBM, | NA |
| 218- | MFrot, | MF, | Extremely low frequency magnetic fields inhibit adipogenesis of human mesenchymal stem cells |
| - | in-vitro, | Nor, | NA |
| 220- | MFrot, | MF, | Effect of low frequency magnetic fields on melanoma: tumor inhibition and immune modulation |
| - | in-vitro, | Melanoma, | B16-F10 |
| 209- | MFrot, | MF, | The effect of a rotating magnetic field on the antioxidant system in healthy volunteers - preliminary study |
| - | Human, | NA, | NA |
| 221- | MFrot, | MF, | Low Frequency Magnetic Fields Enhance Antitumor Immune Response against Mouse H22 Hepatocellular Carcinoma |
| - | in-vivo, | Liver, | NA |
| 222- | MFrot, | MF, | LF-MF inhibits iron metabolism and suppresses lung cancer through activation of P53-miR-34a-E2F1/E2F3 pathway |
| - | in-vitro, | Lung, | A549 |
| 223- | MFrot, | MF, | The effect of rotating magnetic fields on the growth of Deal's guinea pig sarcoma transplanted subcutaneously in guinea pigs |
| - | in-vivo, | NA, | NA |
| 224- | MFrot, | MF, | A pilot study of extremely low-frequency magnetic fields in advanced non-small cell lung cancer: Effects on survival and palliation of general symptoms |
| - | Human, | NSCLC, | NA |
| 225- | MFrot, | MF, | Extremely low frequency magnetic fields regulate differentiation of regulatory T cells: Potential role for ROS-mediated inhibition on AKT |
| - | vitro+vivo, | Lung, | NA |
| 226- | MFrot, | MF, | Involvement of midkine expression in the inhibitory effects of low-frequency magnetic fields on cancer cells |
| - | in-vitro, | NA, | A549 | - | in-vitro, | NA, | LoVo |
| 227- | MFrot, | MF, | Low Frequency Magnetic Fields Induce Autophagy-associated Cell Death in Lung Cancer through miR-486-mediated Inhibition of Akt/mTOR Signaling Pathway |
| - | in-vivo, | Lung, | A549 | - | in-vitro, | Lung, | A549 |
| 228- | MFrot, | MF, | Rotating magnetic field ameliorates experimental autoimmune encephalomyelitis by promoting T cell peripheral accumulation and regulating the balance of Treg and Th1/Th17 |
| - | NA, | MS, | NA |
| 229- | MFrot, | MF, | Molecular mechanism of effect of rotating constant magnetic field on organisms |
| - | in-vivo, | Nor, | NA |
| 230- | MFrot, | MF, | Study on the Effect of Rotating Magnetic Field on Cellular Response of Mammalian Cells |
| - | in-vitro, | Nor, | L929 |
| 217- | MFrot, | MF, | Effect of low-frequency rotary magnetic fields on advanced gastric cancer |
| - | in-vivo, | GC, | HL-60 | - | in-vivo, | GC, | SK-HEP-1 |
| 216- | MFrot, | MF, | Elongated Nanoparticle Aggregates in Cancer Cells for Mechanical Destruction with Low Frequency Rotating Magnetic Field |
| - | in-vitro, | GBM, | U87MG |
| 215- | MFrot, | MF, | Magneto-mechanical destruction of cancer-associated fibroblasts using ultra-small iron oxide nanoparticles and low frequency rotating magnetic fields |
| - | in-vitro, | PC, | CAF |
| 214- | MFrot, | MF, | Modification of bacterial cellulose through exposure to the rotating magnetic field |
| - | in-vitro, | Nor, | NA |
| 213- | MFrot, | MF, | Rotating Magnetic Field-Assisted Reactor Enhances Mechanisms of Phage Adsorption on Bacterial Cell Surface |
| - | in-vitro, | NA, | NA |
| 212- | MFrot, | MF, | Rotating magnetic field inhibits Aβ protein aggregation and alleviates cognitive impairment in Alzheimer’s disease mice |
| - | in-vivo, | AD, | SH-SY5Y |
| 184- | MFrot, | MF, | Rotating Magnetic Fields Inhibit Mitochondrial Respiration, Promote Oxidative Stress and Produce Loss of Mitochondrial Integrity in Cancer Cells |
| - | in-vitro, | GBM, | GBM |
| 186- | MFrot, | MF, | Selective induction of rapid cytotoxic effect in glioblastoma cells by oscillating magnetic fields |
| - | in-vitro, | GBM, | GBM | - | in-vitro, | Lung, | NA |
| 595- | MFrot, | VitC, | MF, | The Effect of Alternating Magnetic Field Exposure and Vitamin C on Cancer Cells |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | NA, | HT1080 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | OS, | U2OS | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | CCD-18Co |
| 516- | MFrot, | immuno, | MF, | Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth |
| - | vitro+vivo, | GBM, | U87MG |
| 3567- | MFrot, | MF, | The Effect of Extremely Low-Frequency Magnetic Field on Stroke Patients: A Systematic Review |
| - | Review, | Stroke, | NA |
| 3491- | MFrot, | MF, | Magnetically controlled cyclic microscale deformation of in vitro cancer invasion models |
| - | in-vitro, | BC, | MDA-MB-231 |
| 3492- | MFrot, | Chemo, | MF, | Synergistic Effect of Chemotherapy and Magnetomechanical Actuation of Fe-Cr-Nb-B Magnetic Particles on Cancer Cells |
| 3493- | MFrot, | MF, | Mechanical nanosurgery of chemoresistant glioblastoma using magnetically controlled carbon nanotubes |
| - | in-vivo, | GBM, | NA |
| 3494- | MFrot, | MF, | Magnetically switchable mechano-chemotherapy for enhancing the death of tumour cells by overcoming drug-resistance |
| - | in-vitro, | Var, | NA |
| 3495- | MFrot, | MF, | Synthesis of urchin-like nickel nanoparticles with enhanced rotating magnetic field-induced cell necrosis and tumor inhibition |
| - | in-vivo, | BC, | NA |
| 3496- | MFrot, | GoldNP, | MF, | Enhancement of chemotherapy effects by non-lethal magneto-mechanical actuation of gold-coated magnetic nanoparticles |
| - | in-vitro, | Cerv, | HeLa |
| 3497- | MFrot, | MF, | The Effect of a Rotating Magnetic Field on the Regenerative Potential of Platelets |
| - | Human, | Nor, | NA |
| 3488- | MFrot, | MF, | Rotating magnetic field improves cognitive and memory impairments in APP/PS1 mice by activating autophagy and inhibiting the PI3K/AKT/mTOR signaling pathway |
| - | in-vivo, | AD, | NA |
| 3499- | MFrot, | MF, | Rotating magnetic field delays human umbilical vein endothelial cell aging and prolongs the lifespan of Caenorhabditis elegans |
| - | in-vitro, | Nor, | HUVECs |
| 3535- | MFrot, | MF, | Pulsed Electromagnetic Field Stimulation in Osteogenesis and Chondrogenesis: Signaling Pathways and Therapeutic Implications |
| - | Review, | Nor, | NA |
| 3489- | MFrot, | MF, | Rotating magnetic field inhibits Aβ protein aggregation and alleviates cognitive impairment in Alzheimer's disease mice. |
| - | in-vivo, | AD, | NA |
| 3745- | MFrot, | MF, | The neurobiological foundation of effective repetitive transcranial magnetic brain stimulation in Alzheimer's disease |
| - | Review, | AD, | NA |
| 2262- | MFrot, | MF, | Effects of 0.4 T Rotating Magnetic Field Exposure on Density, Strength, Calcium and Metabolism of Rat Thigh Bones |
| - | in-vivo, | ostP, | NA |
| 2258- | MFrot, | MF, | EXTH-68. ONCOMAGNETIC TREATMENT SELECTIVELY KILLS GLIOMA CANCER CELLS BY INDUCING OXIDATIVE STRESS AND DNA DAMAGE |
| - | in-vitro, | GBM, | GBM | - | in-vitro, | Nor, | SVGp12 |
| 2259- | MFrot, | MF, | Method and apparatus for oncomagnetic treatment |
| - | in-vitro, | GBM, | NA |
| 2311- | MFrot, | MF, | Magnetic fields as a potential therapy for diabetic wounds based on animal experiments and clinical trials |
| - | in-vivo, | Nor, | HaCaT |
| 4569- | MFrot, | Case Report: A new noninvasive device-based treatment of a mesencephalic H3 K27M glioma |
| - | Case Report, | GBM, | NA |
| 4567- | MFrot, | Oncogenic pathways and the electron transport chain: a dangeROS liaison |
| - | Review, | Var, | NA |
| 4566- | MFrot, | On the mitochondrial aspect of reactive oxygen species action in external magnetic fields |
| - | Study, | Var, | NA |
| 1737- | MFrot, | Fe, | MF, | Feature Matching of Microsecond-Pulsed Magnetic Fields Combined with Fe3O4 Particles for Killing A375 Melanoma Cells |
| - | in-vitro, | MB, | A375 |
| 777- | Mg, | Biodegradable Mg Implants Suppress the Growth of Ovarian Tumor |
| - | vitro+vivo, | Ovarian, | SKOV3 |
| 769- | Mg, | Magnesium and cancer: more questions than answers |
| - | Review, | NA, | NA |
| 770- | Mg, | Magnesium and cancer: a dangerous liason |
| - | Analysis, | NA, | NA |
| 771- | Mg, | Magnesium Ion: A New Switch in Tumor Treatment |
| 772- | Mg, | https://pmc.ncbi.nlm.nih.gov/articles/PMC4759402/ |
| - | Analysis, | NA, | NA |
| 773- | Mg, | Methyl Jasmonate-induced Increase in Intracellular Magnesium Promotes Apoptosis in Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 |
| 774- | Mg, | Calc, | Chemo, | Dietary Intake of Magnesium or Calcium and Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Patients |
| - | Analysis, | NA, | NA |
| 775- | Mg, | The Supplement of Magnesium Element to Inhibit Colorectal Tumor Cells |
| - | vitro+vivo, | CRC, | DLD1 |
| 787- | Mg, | Magnesium and Human Health: Perspectives and Research Directions |
| 778- | Mg, | Magnesium and the inflammatory response: potential physiopathological implications |
| 779- | Mg, | Mg alloys with antitumor and anticorrosion properties for orthopedic oncology: A review from mechanisms to application strategies |
| 780- | Mg, | Degradable magnesium implants inhibit gallbladder cancer |
| - | vitro+vivo, | Gall, | NA |
| 781- | Mg, | Hypomagnesemia in the Cancer Patient |
| - | Analysis, | NA, | NA |
| 782- | Mg, | Oral magnesium supplements for cancer treatment‐induced hypomagnesemia: Results from a pilot randomized trial |
| - | Trial, | Var, | NA |
| 783- | Mg, | Magnesium intake and incidence of pancreatic cancer: the VITamins and Lifestyle study |
| 784- | Mg, | Direct and indirect associations between dietary magnesium intake and breast cancer risk |
| - | Analysis, | NA, | NA |
| 785- | Mg, | Magnesium: The overlooked electrolyte in blood cancers? |
| - | Analysis, | NA, | NA |
| 786- | Mg, | VitC, | A narrative review on the role of magnesium in immune regulation, inflammation, infectious diseases, and cancer |
| 788- | Mg, | Timeline (Bioavailability) of Magnesium Compounds in Hours: Which Magnesium Compound Works Best? |
| 4169- | Mg, | Effects of Elevation of Brain Magnesium on Fear Conditioning, Fear Extinction, and Synaptic Plasticity in the Infralimbic Prefrontal Cortex and Lateral Amygdala |
| - | in-vivo, | NA, | NA |
| 4168- | Mg, | Antidepressant-like activity of magnesium in the olfactory bulbectomy model is associated with the AMPA/BDNF pathway |
| - | in-vivo, | NA, | NA |
| 1890- | MGO, | The Dual-Role of Methylglyoxal in Tumor Progression – Novel Therapeutic Approaches |
| - | Review, | Var, | NA |
| 1892- | MGO, | Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior: recent advances and mechanistic insights |
| - | Review, | NA, | NA |
| 1891- | MGO, | Methylglyoxal induces mitochondria-dependent apoptosis in sarcoma |
| - | in-vitro, | SCC, | NA |
| 656- | MNPs, | MF, | Effects of combined delivery of extremely low frequency electromagnetic field and magnetic Fe3O4 nanoparticles on hepatic cell lines |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | HL7702 |
| 929- | Moringa, | Bioenhancers from mother nature and their applicability in modern medicine |
| - | Review, | Nor, | NA |
| 4226- | Moringa, | The Oil Formulation Derived from Moringa Oleifera Seeds Ameliorates Behavioral Abnormalities in Water-immersion Restraint Stress Mouse Model |
| - | in-vivo, | NA, | NA |
| 3837- | Moringa, | Moringa oleifera: A Tree of Life as a Promising Medicinal Plant for Neurodegenerative Diseases |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
| 3834- | Moringa, | Moringa Oleifera Alleviates Homocysteine-Induced Alzheimer's Disease-Like Pathology and Cognitive Impairments |
| - | in-vivo, | AD, | NA |
| 3835- | Moringa, | Moringa Oleifera Alleviates Aβ Burden and Improves Synaptic Plasticity and Cognitive Impairments in APP/PS1 Mice |
| - | in-vivo, | AD, | NA |
| 3836- | Moringa, | Effects of Moringa oleifera on working memory: an experimental study with memory-impaired Wistar rats tested in radial arm maze |
| - | in-vivo, | AD, | NA |
| 3839- | Moringa, | Nutritional Value of Moringa oleifera Lam. Leaf Powder Extracts and Their Neuroprotective Effects via Antioxidative and Mitochondrial Regulation |
| 3838- | Moringa, | Characterization, Large-Scale HSCCC Separation and Neuroprotective Effects of Polyphenols from Moringa oleifera Leaves |
| - | in-vitro, | AD, | PC12 | - | Review, | Stroke, | NA |
| 3840- | Moringa, | Moringa oleifera Mitigates Memory Impairment and Neurodegeneration in Animal Model of Age-Related Dementia |
| - | in-vivo, | AD, | NA |
| 3841- | Moringa, | Cerebroprotective effect of Moringa oleifera against focal ischemic stroke induced by middle cerebral artery occlusion |
| - | in-vivo, | Stroke, | NA |
| 3842- | Moringa, | Bioactive Components in Moringa Oleifera Leaves Protect against Chronic Disease |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 3844- | Moringa, | Review of the Safety and Efficacy of Moringa oleifera |
| - | Review, | NA, | NA |
| 3845- | Moringa, | Protective effects of Moringa oleifera Lam. leaves against arsenic-induced toxicity in mice |
| - | in-vitro, | NA, | NA |
| 3850- | MSM, | The Influence of Methylsulfonylmethane on Inflammation-Associated Cytokine Release before and following Strenuous Exercise |
| - | Human, | NA, | NA |
| 3852- | MSM, | DMSO modulates CNS function in a preclinical Alzheimer's disease model |
| - | in-vivo, | AD, | NA |
| 3851- | MSM, | Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial |
| - | Trial, | Arthritis, | NA |
| 3849- | MSM, | Beauty from within: Oral administration of a sulfur-containing supplement methylsulfonylmethane improves signs of skin ageing |
| - | Human, | Nor, | NA |
| 3848- | MSM, | Modulatory effect of methylsulfonylmethane against BPA/γ-radiation induced neurodegenerative alterations in rats: Influence of TREM-2/DAP-12/Syk pathway |
| - | in-vitro, | AD, | NA |
| 3847- | MSM, | Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement |
| - | Review, | Arthritis, | NA |
| 3846- | MSM, | Accumulation of methylsulfonylmethane in the human brain: identification by multinuclear magnetic resonance spectroscopy |
| - | Human, | NA, | NA |
| 1203- | MSM, | Methylsulfonylmethane Suppresses Breast Cancer Growth by Down-Regulating STAT3 and STAT5b Pathways |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 1170- | MushCha, | Chaga mushroom extract suppresses oral cancer cell growth via inhibition of energy metabolism |
| - | in-vitro, | Oral, | HSC4 |
| 1182- | MushCha, | Ergosterol peroxide from Chaga mushroom (Inonotus obliquus) exhibits anti-cancer activity by down-regulation of the β-catenin pathway in colorectal cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | DLD1 |
| 3813- | mushLions, | Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice |
| - | in-vitro, | AD, | NA |
| 3815- | mushLions, | Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines |
| - | Review, | Stroke, | NA | - | Review, | Park, | NA | - | Review, | AD, | NA |
| 3814- | mushLions, | Lion's Mane (Hericium erinaceus) Exerts Anxiolytic Effects in the rTg4510 Tau Mouse Model |
| - | in-vitro, | AD, | NA |
| - | in-vitro, | AD, | NA |
| 3811- | mushLions, | Hericium erinaceus (Bull.) Pers. Ethanolic Extract with Antioxidant Properties on Scopolamine-Induced Memory Deficits in a Zebrafish Model of Cognitive Impairment |
| - | in-vitro, | NA, | NA |
| 3810- | mushLions, | Key Mechanisms and Potential Implications of Hericium erinaceus in NLRP3 Inflammasome Activation by Reactive Oxygen Species during Alzheimer’s Disease |
| - | Review, | NA, | NA |
| 3809- | mushLions, | The Monkey Head Mushroom and Memory Enhancement in Alzheimer's Disease |
| - | Review, | NA, | NA |
| 3808- | mushLions, | Neuroprotective Metabolites of Hericium erinaceus Promote Neuro-Healthy Aging |
| - | in-vitro, | NA, | NA |
| 3807- | mushLions, | Searching for a Longevity Food, We Bump into Hericium erinaceus Primordium Rich in Ergothioneine: The “Longevity Vitamin” Improves Locomotor Performances during Aging |
| 3806- | mushLions, | Dietary Supplementation of Lion's Mane Medicinal Mushroom, Hericium erinaceus (Agaricomycetes), and Spatial Memory in Wild-Type Mice |
| - | in-vitro, | NA, | NA |
| 2484- | mushLions, | Neurotrophic and Neuroprotective Effects of Hericium erinaceus |
| - | Review, | Stroke, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 1573- | MushReishi, | Ganoderma lucidum (Reishi mushroom) for cancer treatment |
| - | Review, | NA, | NA |
| 930- | MushShi, | Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation |
| - | in-vitro, | Ovarian, | NA |
| 2- | MushShi, | The Effects of Active Hexose Correlated Compound (AHCC) on Levels of CD4+ and CD8+ in Patients with Epithelial Ovarian Cancer or Peritoneal Cancer Receiving Platinum Based Chemotherapy |
| 3- | MushShi, | AHCC Activation and Selection of Human Lymphocytes via Genotypic and Phenotypic Changes to an Adherent Cell Type: A Possible Novel Mechanism of T Cell Activation |
| 1128- | Myr, | Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition in ovarian cancer |
| - | vitro+vivo, | Ovarian, | NA |
| 1141- | Myr, | Myricetin: targeting signaling networks in cancer and its implication in chemotherapy |
| - | Review, | NA, | NA |
| 1044- | Myr, | Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells |
| - | in-vitro, | Lung, | NA |
| 1273- | Myr, | Myricetin Induces Ferroptosis and Inhibits Gastric Cancer Progression by Targeting NOX4 |
| - | vitro+vivo, | GC, | NA |
| 1998- | Myr, | CUR, | Thioredoxin-dependent system. Application of inhibitors |
| - | Review, | Var, | NA |
| 1997- | Myr, | QC, | Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity |
| - | in-vitro, | Lung, | A549 |
| 116- | Myrrh, | The Role of Myrrh Metabolites in Cancer, Inflammation, and Wound Healing: Prospects for a Multi-Targeted Drug Therapy |
| - | in-vitro, | AML, | HL-60 | - | in-vitro, | AML, | K562 | - | in-vitro, | BC, | KAIMRC1 |
| 4167- | NAC, | N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action |
| - | Review, | NA, | NA |
| 4160- | NAD, | The biochemical pathways of central nervous system neural degeneration in niacin deficiency |
| - | Review, | NA, | NA |
| 4036- | NAD, | VitB3, | NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency |
| - | in-vivo, | AD, | NA |
| 4035- | NAD, | VitB3, | NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STING |
| - | in-vitro, | AD, | NA |
| 2939- | NAD, | Rad, | NMN ameliorated radiation induced damage in NRF2-deficient cell and mice via regulating SIRT6 and SIRT7 |
| - | in-vitro, | Nor, | NA |
| 2938- | NAD, | NAD+ supplementation limits triple-negative breast cancer metastasis via SIRT1-P66Shc signaling |
| - | in-vivo, | BC, | NA |
| 2937- | NAD, | High-Dosage NMN Promotes Ferroptosis to Suppress Lung Adenocarcinoma Growth through the NAM-Mediated SIRT1-AMPK-ACC Pathway |
| - | in-vitro, | Lung, | A549 |
| 2936- | NAD, | The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update |
| 2935- | NAD, | Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner |
| - | in-vitro, | Nor, | NA |
| - | Trial, | Nor, | NA |
| 2932- | NAD, | Neuroprotective effects and mechanisms of action of nicotinamide mononucleotide (NMN) in a photoreceptor degenerative model of retinal detachment |
| - | in-vitro, | Nor, | NA |
| 2931- | NAD, | NAD+ Repletion Rescues Female Fertility during Reproductive Aging |
| - | in-vivo, | Nor, | NA |
| 2933- | NAD, | Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns |
| - | Review, | Nor, | NA | - | NA, | AD, | NA | - | NA, | Diabetic, | NA | - | NA, | Stroke, | NA | - | NA, | LiverDam, | NA | - | NA, | Park, | NA |
| 3759- | NarG, | RT, | CGA, | RosA, | Polyphenols as acetylcholinesterase inhibitors: Structural specificity and impact on human disease |
| - | Review, | AD, | NA |
| 4224- | NarG, | The Effect of Naringin on Cognitive-Behavioral Functions, CREB/BDNF Signaling, Cholinergic Activity, and Neuronal Density in the Hippocampus of an MSG-Induced Obesity Rat Model |
| - | in-vivo, | Obesity, | NA | - | NA, | AD, | NA |
| 4225- | NarG, | Naringin treatment improves functional recovery by increasing BDNF and VEGF expression, inhibiting neuronal apoptosis after spinal cord injury |
| - | in-vivo, | NA, | NA |
| 4223- | NarG, | Effect of 2-Week Naringin Supplementation on Neurogenesis and BDNF Levels in Ischemia–Reperfusion Model of Rats |
| - | in-vivo, | Stroke, | NA |
| 981- | NarG, | QC, | Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer |
| - | in-vivo, | NA, | NA |
| 1015- | NarG, | Naringin induces endoplasmic reticulum stress-mediated apoptosis, inhibits β-catenin pathway and arrests cell cycle in cervical cancer cells |
| - | in-vitro, | Cerv, | SiHa | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | C33A |
| 1129- | NarG, | Naringenin Attenuated Prostate Cancer Invasion via Reversal of Epithelial-to-Mesenchymal Transition and Inhibited uPA Activity |
| - | in-vitro, | Pca, | PC3 |
| 928- | NarG, | PacT, | Bioenhancers from mother nature and their applicability in modern medicine |
| - | Review, | Nor, | NA |
| 1311- | NarG, | Rad, | Naringenin sensitizes lung cancer NCI-H23 cells to radiation by downregulation of akt expression and metastasis while promoting apoptosis |
| - | in-vitro, | Lung, | H23 |
| 1800- | NarG, | Naringenin |
| - | Human, | Nor, | NA |
| 1808- | NarG, | Intake of flavonoids and lung cancer |
| - | Analysis, | NA, | NA |
| 1807- | NarG, | A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies |
| - | Review, | NA, | NA |
| 1806- | NarG, | Naringin: Nanotechnological Strategies for Potential Pharmaceutical Applications |
| - | Review, | NA, | NA |
| 1805- | NarG, | Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota |
| - | in-vitro, | Ovarian, | A2780S | - | in-vivo, | NA, | NA |
| 1804- | NarG, | Beneficial effects of citrus flavanones naringin and naringenin and their food sources on lipid metabolism: An update on bioavailability, pharmacokinetics, and mechanisms |
| - | Review, | NA, | NA |
| 1803- | NarG, | Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: Efficacy and molecular mechanisms of action, a comprehensive narrative review |
| - | Review, | Var, | NA |
| 1802- | NarG, | ATV, | Bioenhancing effects of naringin on atorvastatin |
| - | in-vivo, | Nor, | NA |
| 1801- | NarG, | A Narrative Review on Naringin and Naringenin as a Possible Bioenhancer in Various Drug-Delivery Formulations |
| - | Review, | Var, | NA |
| 1799- | NarG, | Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics |
| - | Review, | NA, | NA |
| 1798- | NarG, | Naringenin: A potential flavonoid phytochemical for cancer therapy |
| - | Review, | NA, | NA |
| 1797- | NarG, | Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway |
| - | in-vitro, | BC, | MDA-MB-231 |
| 1271- | NCL, | Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics |
| - | vitro+vivo, | Ovarian, | SKOV3 |
| 1270- | NCL, | Rad, | Niclosamide enhances the antitumor effects of radiation by inhibiting the hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway in human lung cancer cells |
| - | in-vivo, | Lung, | NA |
| 1269- | NCL, | Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway |
| - | in-vitro, | Pca, | DU145 |
| 1268- | NCL, | carbop, | Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer |
| - | in-vitro, | Ovarian, | NA |
| 1267- | NCL, | Niclosamide suppresses migration of hepatocellular carcinoma cells and downregulates matrix metalloproteinase-9 expression |
| - | in-vitro, | HCC, | NA |
| 946- | Nimb, | Nimbolide retards T cell lymphoma progression by altering apoptosis, glucose metabolism, pH regulation, and ROS homeostasis |
| - | in-vivo, | NA, | NA |
| 1911- | Nos, | Noscapine inhibits tumor growth in TMZ-resistant gliomas |
| - | in-vitro, | GBM, | NA | - | in-vivo, | GBM, | NA |
| 150- | NRF, | CUR, | docx, | Subverting ER-Stress towards Apoptosis by Nelfinavir and Curcumin Coexposure Augments Docetaxel Efficacy in Castration Resistant Prostate Cancer Cells |
| - | in-vitro, | Pca, | C4-2B |
| 991- | OA, | Blockade of glycolysis-dependent contraction by oroxylin a via inhibition of lactate dehydrogenase-a in hepatic stellate cells |
| - | in-vivo, | NA, | NA | - | in-vivo, | Nor, | NA |
| 968- | OA, | Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilization |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MBT-2 |
| 1130- | OA, | Oroxylin A Suppresses the Cell Proliferation, Migration, and EMT via NF-κB Signaling Pathway in Human Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 1229- | OA, | Review of the Clinical Effect of Orlistat |
| - | Review, | NA, | NA |
| 4643- | OLE, | HT, | Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine |
| - | Review, | Var, | NA |
| 4626- | OLE, | A Comprehensive Review on the Anti-Cancer Effects of Oleuropein |
| - | Review, | Var, | NA |
| 4627- | OLE, | Oleuropein regulates ubiquitination-mediated Mcl-1 turnover and exhibits antitumor activity |
| - | in-vitro, | Oral, | NA |
| 4628- | OLE, | Effects of oleuropein on tumor cell growth and bone remodelling: Potential clinical implications for the prevention and treatment of malignant bone diseases |
| 4629- | OLE, | Oleuropein exhibits anticancer effects by inducing apoptosis and inhibiting cell motility in MCF7 and MDA-MB231 breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | NA, | NA, | MCF-7 |
| 4630- | OLE, | Targeting resistant breast cancer stem cells in a three-dimensional culture model with oleuropein encapsulated in methacrylated alginate microparticles |
| - | in-vitro, | BC, | NA |
| 4631- | OLE, | Evidence to Support the Anti-Cancer Effect of Olive Leaf Extract and Future Directions |
| - | Review, | Var, | NA |
| 4649- | OLEC, | Anticancer molecular mechanisms of oleocanthal |
| 4648- | OLEC, | The Effect of Dietary Intervention With High-Oleocanthal and Oleacein Olive Oil in Patients With Early-Stage Chronic Lymphocytic Leukemia: A Pilot Randomized Trial |
| - | Trial, | CLL, | NA |
| 4647- | OLEC, | Oleocanthal, an Antioxidant Phenolic Compound in Extra Virgin Olive Oil (EVOO): A Comprehensive Systematic Review of Its Potential in Inflammation and Cancer |
| - | Review, | Var, | NA |
| 4646- | OLEC, | Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology |
| - | Review, | Var, | NA |
| 1225- | OLST, | Orlistat Induces Ferroptosis in Pancreatic Neuroendocrine Tumors by Inactivating the MAPK Pathway |
| - | vitro+vivo, | PC, | NA |
| 1045- | OLST, | Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line |
| - | in-vitro, | AML, | Jurkat |
| 969- | OLST, | Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy |
| - | Review, | NA, | NA |
| 1228- | OLST, | Orlistat Mitigates Oxidative Stress-Linked Myocardial Damage via NF-κβ- and Caspase-Dependent Activities in Obese Rats |
| - | in-vivo, | Obesity, | NA |
| 1227- | OLST, | Anti-Obesity Drug Orlistat Alleviates Western-Diet-Driven Colitis-Associated Colon Cancer via Inhibition of STAT3 and NF-κB-Mediated Signaling |
| - | in-vivo, | CRC, | NA |
| 1226- | OLST, | Knockdown of PGM1 enhances anticancer effects of orlistat in gastric cancer under glucose deprivation |
| - | vitro+vivo, | GC, | NA |
| 1812- | Oxy, | Hyperbaric oxygen suppressed tumor progression through the improvement of tumor hypoxia and induction of tumor apoptosis in A549-cell-transferred lung cancer |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | Lung, | NA | - | in-vitro, | NA, | BEAS-2B |
| 1811- | Oxy, | Hyperbaric oxygen therapy and cancer—a review |
| - | Review, | NA, | NA |
| 1814- | Oxy, | Hyperbaric oxygen therapy for malignancy: a review |
| - | Review, | Var, | NA |
| 1813- | Oxy, | Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment |
| - | Review, | Var, | NA |
| 2451- | PA, | The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors |
| - | Review, | Var, | NA |
| 2452- | PA, | Targeting Pyruvate Kinase M2 and Hexokinase II, Pachymic Acid Impairs Glucose Metabolism and Induces Mitochondrial Apoptosis |
| - | in-vitro, | BC, | SkBr3 |
| 2396- | PACs, | PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma |
| - | in-vitro, | HCC, | HCCLM3 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | L02 |
| 1239- | PACs, | Cranberry proanthocyanidins inhibit MMP production and activity |
| - | in-vitro, | Nor, | NA |
| 959- | PACs, | Grape seed extract inhibits VEGF expression via reducing HIF-1α protein expression |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | BC, | MDA-MB-231 |
| 1988- | Part, | Parthenolide Induces ROS-Mediated Apoptosis in Lymphoid Malignancies |
| - | in-vitro, | lymphoma, | NCI-H929 |
| 1996- | Part, | Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells |
| - | in-vitro, | CRC, | COLO205 |
| 1995- | Part, | The protective effect of parthenolide in an in vitro model of Parkinson's disease through its regulation of nuclear factor-kappa B and oxidative stress |
| - | in-vitro, | Park, | SH-SY5Y |
| 1994- | Part, | Parthenolide Inhibits Tumor Cell Growth and Metastasis in Melanoma A2058 Cells |
| - | in-vitro, | Melanoma, | A2058 | - | in-vitro, | Nor, | L929 |
| 1993- | Part, | Parthenolide induces apoptosis and autophagy through the suppression of PI3K/Akt signaling pathway in cervical cancer |
| - | in-vitro, | Cerv, | HeLa |
| 1992- | Part, | Parthenolide induces ROS-dependent cell death in human gastric cancer cell |
| - | in-vitro, | BC, | MGC803 |
| 1991- | Part, | A novel SLC25A1 inhibitor, parthenolide, suppresses the growth and stemness of liver cancer stem cells with metabolic vulnerability |
| - | in-vitro, | Liver, | HUH7 |
| 1990- | Part, | Parthenolide alleviates cognitive dysfunction and neurotoxicity via regulation of AMPK/GSK3β(Ser9)/Nrf2 signaling pathway |
| - | in-vitro, | AD, | PC12 |
| 1989- | Part, | Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties |
| - | Review, | Var, | NA |
| 1987- | Part, | Rad, | A NADPH oxidase dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | PrEC |
| 1986- | Part, | Modulation of Cell Surface Protein Free Thiols: A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide |
| - | in-vitro, | NA, | NA |
| 1985- | Part, | KEAP1 Is a Redox Sensitive Target That Arbitrates the Opposing Radiosensitive Effects of Parthenolide in Normal and Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Nor, | PrEC | - | in-vivo, | NA, | NA |
| 1984- | Part, | Targeting Thioredoxin Reductase by Parthenolide Contributes to Inducing Apoptosis of HeLa Cells |
| - | in-vitro, | Cerv, | HeLa |
| 1983- | Part, | Targeting thioredoxin reductase by micheliolide contributes to radiosensitizing and inducing apoptosis of HeLa cells |
| - | in-vitro, | Cerv, | HeLa |
| 2031- | PB, | Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model |
| - | in-vivo, | AD, | NA |
| 2036- | PB, | Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate |
| - | in-vitro, | Pca, | NA | - | in-vivo, | NA, | NA |
| 2037- | PB, | Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria |
| - | in-vitro, | GBM, | NA | - | in-vivo, | GBM, | NA |
| 2035- | PB, | Sodium Phenylbutyrate Controls Neuroinflammatory and Antioxidant Activities and Protects Dopaminergic Neurons in Mouse Models of Parkinson’s Disease |
| - | in-vitro, | Nor, | glial | - | in-vivo, | NA, | NA |
| 2034- | PB, | Protective effects of 4-phenylbutyrate derivatives on the neuronal cell death and endoplasmic reticulum stress |
| - | in-vitro, | Nor, | SH-SY5Y |
| 2033- | PB, | Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model |
| - | in-vivo, | AD, | NA |
| 2032- | PB, | Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice |
| - | in-vivo, | AD, | NA |
| 2062- | PB, | Sodium 4-phenylbutyrate induces apoptosis of human lung carcinoma cells through activating JNK pathway |
| - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | H1792 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | SK-LU-1 | - | in-vitro, | Nor, | HBE4-E6/E7 |
| 2049- | PB, | Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors |
| - | Review, | Var, | NA |
| 2061- | PB, | Chemo, | Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | COLO357 | - | in-vitro, | PC, | Bxpc-3 |
| 2059- | PB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| 2058- | PB, | Induction of Human-Lung-Cancer-A549-Cell Apoptosis by 4-Hydroperoxy-2-decenoic Acid Ethyl Ester through Intracellular ROS Accumulation and the Induction of Proapoptotic CHOP Expression |
| - | in-vitro, | Lung, | A549 |
| 2057- | PB, | Trichomonas vaginalis induces apoptosis via ROS and ER stress response through ER–mitochondria crosstalk in SiHa cells |
| - | in-vitro, | Cerv, | SiHa |
| 2056- | PB, | Endoplasmic Reticulum Stress Induces ROS Production and Activates NLRP3 Inflammasome Via the PERK-CHOP Signaling Pathway in Dry Eye Disease |
| - | in-vitro, | Nor, | HCE-2 |
| 2055- | PB, | The Effects of Butyric Acid on the Differentiation, Proliferation, Apoptosis, and Autophagy of IPEC-J2 Cells |
| - | in-vitro, | Nor, | IPEC-J2 |
| 2054- | PB, | Sodium butyrate induces ferroptosis in endometrial cancer cells via the RBM3/SLC7A11 axis |
| - | in-vitro, | EC, | ISH | - | in-vitro, | EC, | HEC1B |
| 2053- | PB, | 4-Phenyl butyric acid prevents glucocorticoid-induced osteoblast apoptosis by attenuating endoplasmic reticulum stress |
| - | in-vitro, | ostP, | 3T3 |
| 2052- | PB, | Lipid-regulating properties of butyric acid and 4-phenylbutyric acid: Molecular mechanisms and therapeutic applications |
| - | Review, | NA, | NA |
| 2051- | PB, | Beneficial Effects of Sodium Phenylbutyrate Administration during Infection with Salmonella enterica Serovar Typhimurium |
| - | in-vivo, | Inf, | NA |
| 2038- | PB, | A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies |
| - | Trial, | Var, | NA |
| 2048- | PB, | Sodium Phenylbutyrate Inhibits Tumor Growth and the Epithelial-Mesenchymal Transition of Oral Squamous Cell Carcinoma In Vitro and In Vivo |
| - | in-vitro, | OS, | CAL27 | - | in-vitro, | Oral, | HSC3 | - | in-vitro, | OS, | SCC4 | - | in-vivo, | NA, | NA |
| 2046- | PB, | Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | Nor, | MCF10 |
| 2045- | PB, | Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell line |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | LN-18 |
| 2044- | PB, | DCA, | Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetate |
| - | in-vivo, | NA, | NA |
| 2043- | PB, | Cisplatin, | Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin |
| - | in-vitro, | HNSCC, | UM-SCC-1 |
| 2042- | PB, | Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury |
| - | in-vitro, | Nor, | NA |
| 2041- | PB, | The Effect of Glucose Concentration and Sodium Phenylbutyrate Treatment on Mitochondrial Bioenergetics and ER Stress in 3T3-L1 Adipocytes |
| - | in-vitro, | Nor, | 3T3 |
| 2063- | PB, | Rad, | Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation |
| - | in-vitro, | GBM, | U87MG | - | NA, | NA, | U251 |
| 2039- | PB, | TXNIP mediates the differential responses of A549 cells to sodium butyrate and sodium 4‐phenylbutyrate treatment |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 |
| 2029- | PB, | Phenylbutyric Acid: simple structure - multiple effects |
| - | Review, | Var, | NA |
| 2030- | PB, | 4-Phenylbutyric acid protects against neuronal cell death by primarily acting as a chemical chaperone rather than histone deacetylase inhibitor |
| - | Review, | Nor, | NA |
| 2074- | PB, | Chemo, | The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | Calu-6 | - | in-vitro, | Lung, | H1650 |
| - | Trial, | CRC, | NA |
| 2076- | PB, | Sodium Butyrate Induces Endoplasmic Reticulum Stress and Autophagy in Colorectal Cells: Implications for Apoptosis |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 |
| 2070- | PB, | Phenylbutyrate-induced apoptosis is associated with inactivation of NF-kappaB IN HT-29 colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 2069- | PB, | Toxic and metabolic effect of sodium butyrate on SAS tongue cancer cells: role of cell cycle deregulation and redox changes |
| - | in-vitro, | Tong, | NA |
| 2068- | PB, | Phenylbutyrate-induced glutamine depletion in humans: effect on leucine metabolism |
| - | in-vivo, | Nor, | NA |
| 2067- | PB, | Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer |
| - | in-vitro, | PC, | NA |
| 2066- | PB, | Rad, | Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas |
| - | in-vitro, | GBM, | U251 |
| 2065- | PB, | TMZ, | Inhibition of Mitochondria- and Endoplasmic Reticulum Stress-Mediated Autophagy Augments Temozolomide-Induced Apoptosis in Glioma Cells |
| - | in-vitro, | GBM, | NA |
| 2064- | PB, | Rad, | Phenylbutyrate Attenuates the Expression of Bcl-XL, DNA-PK, Caveolin-1, and VEGF in Prostate Cancer Cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 2025- | PB, | Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate |
| - | Case Report, | GBM, | NA |
| 2026- | PB, | Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study |
| - | Trial, | GBM, | NA |
| 2027- | PB, | Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors |
| - | Trial, | Var, | NA |
| 2028- | PB, | Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms |
| - | Review, | Var, | NA |
| 2078- | PB, | Butyrate-induced apoptosis in HCT116 colorectal cancer cells includes induction of a cell stress response |
| - | in-vitro, | CRC, | HCT116 |
| 2077- | PB, | Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells |
| - | in-vitro, | Liver, | HUH7 |
| 2421- | PB, | Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c‐myc/hexokinase 2 pathway |
| - | in-vitro, | HCC, | HCCLM3 | - | in-vivo, | NA, | NA | - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | Nor, | L02 |
| 2429- | PB, | Impact of butyrate on PKM2 and HSP90β expression in human colon tissues of different transformation stages: a comparison of gene and protein data |
| - | in-vitro, | Colon, | NA |
| 4156- | PB, | The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain |
| - | in-vivo, | AD, | NA |
| 998- | PB, | Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect |
| - | in-vivo, | NA, | NA |
| - | in-vitro, | HCC, | HepG2 |
| 2381- | PBG, | Chinese Poplar Propolis Inhibits MDA-MB-231 Cell Proliferation in an Inflammatory Microenvironment by Targeting Enzymes of the Glycolytic Pathway |
| - | in-vitro, | BC, | MDA-MB-231 |
| 2380- | PBG, | Potential Strategies for Overcoming Drug Resistance Pathways Using Propolis and Its Polyphenolic/Flavonoid Compounds in Combination with Chemotherapy and Radiotherapy |
| - | Review, | Var, | NA |
| 2430- | PBG, | The cytotoxic effects of propolis on breast cancer cells involve PI3K/Akt and ERK1/2 pathways, mitochondrial membrane potential, and reactive oxygen species generation |
| - | in-vitro, | BC, | MDA-MB-231 |
| 3248- | PBG, | Propolis as a promising functional ingredient: A comprehensive review on extraction, bioactive properties, bioavailability, and industrial applications |
| - | Review, | NA, | NA |
| 3247- | PBG, | Bioavailability and In Vivo Antioxidant Activity of a Standardized Polyphenol Mixture Extracted from Brown Propolis |
| - | Review, | NA, | NA |
| 1664- | PBG, | Anticancer Activity of Propolis and Its Compounds |
| - | Review, | Var, | NA |
| 1670- | PBG, | Lung response to propolis treatment during experimentally induced lung adenocarcinoma |
| - | in-vivo, | Lung, | NA |
| 1665- | PBG, | Evidence on the Health Benefits of Supplemental Propolis |
| - | Review, | Nor, | NA |
| 1666- | PBG, | Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer |
| - | Review, | Var, | NA |
| 1667- | PBG, | Ethanolic extract of Brazilian green propolis sensitizes prostate cancer cells to TRAIL-induced apoptosis |
| - | in-vitro, | Pca, | LNCaP |
| 1668- | PBG, | Propolis: A Detailed Insight of Its Anticancer Molecular Mechanisms |
| - | Review, | Var, | NA |
| 1669- | PBG, | Chemo, | Antioxidant and anti-inflammatory effects of oral propolis in patients with breast cancer treated with chemotherapy: a Randomized controlled trial |
| - | Trial, | BC, | NA |
| 1672- | PBG, | The Potential Use of Propolis as an Adjunctive Therapy in Breast Cancers |
| - | Review, | BC, | NA |
| 1663- | PBG, | Propolis and Their Active Constituents for Chronic Diseases |
| - | Review, | Var, | NA |
| 1662- | PBG, | The immunomodulatory and anticancer properties of propolis |
| - | Review, | Var, | NA |
| 1661- | PBG, | Propolis: a natural compound with potential as an adjuvant in cancer therapy - a review of signaling pathways |
| - | Review, | Var, | NA |
| 1660- | PBG, | Emerging Adjuvant Therapy for Cancer: Propolis and its Constituents |
| - | Review, | Var, | NA |
| 1659- | PBG, | Improvement of insulin resistance, blood pressure and interstitial pH in early developmental stage of insulin resistance in OLETF rats by intake of propolis extracts |
| - | in-vivo, | Nor, | NA |
| 1658- | PBG, | Body Fluid pH Balance in Metabolic Health and Possible Benefits of Dietary Alkaline Foods |
| - | Review, | Var, | NA |
| 1648- | PBG, | Contribution of Green Propolis to the Antioxidant, Physical, and Sensory Properties of Fruity Jelly Candies Made with Sugars or Fructans |
| - | Review, | Nor, | NA |
| 1647- | PBG, | CA, | Antioxidant Properties and Phenolic Composition of Greek Propolis Extracts |
| - | Analysis, | Nor, | NA |
| 1671- | PBG, | Importance of pH Homeostasis in Metabolic Health and Diseases: Crucial Role of Membrane Proton Transport |
| - | Review, | Nor, | NA |
| 1682- | PBG, | Honey, Propolis, and Royal Jelly: A Comprehensive Review of Their Biological Actions and Health Benefits |
| - | Review, | Var, | NA |
| 1681- | PBG, | Propolis: Its Role and Efficacy in Human Health and Diseases |
| - | Review, | Nor, | NA |
| 1683- | PBG, | Rad, | Protective effect of propolis in protecting against radiation-induced oxidative stress in the liver as a distant organ |
| - | in-vivo, | Nor, | NA |
| 1684- | PBG, | Antitumor Activity of Chinese Propolis in Human Breast Cancer MCF-7 and MDA-MB-231 Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | HUVECs |
| 1685- | PBG, | Antitumor Activity of Chinese Propolis in Human Breast Cancer MCF-7 and MDA-MB-231 Cells |
| - | in-vitro, | BC, | MCF-7 |
| 1686- | PBG, | Different propolis samples, phenolic content, and breast cancer cell lines: Variable cytotoxicity ranging from ineffective to potent |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | SkBr3 | - | in-vitro, | BC, | MDA-MB-231 |
| 1680- | PBG, | Protection against Ultraviolet A-Induced Skin Apoptosis and Carcinogenesis through the Oxidative Stress Reduction Effects of N-(4-bromophenethyl) Caffeamide, a Propolis Derivative |
| - | in-vitro, | Nor, | HS68 |
| 1679- | PBG, | Constituents of Propolis: Chrysin, Caffeic Acid, p-Coumaric Acid, and Ferulic Acid Induce PRODH/POX-Dependent Apoptosis in Human Tongue Squamous Cell Carcinoma Cell (CAL-27) |
| - | in-vitro, | SCC, | CAL27 |
| 1678- | PBG, | 5-FU, | sericin, | In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of PI3K/AKT/mTOR pathway |
| - | in-vitro, | CRC, | Caco-2 | - | in-vivo, | NA, | NA |
| 1673- | PBG, | An Insight into Anticancer Effect of Propolis and Its Constituents: A Review of Molecular Mechanisms |
| - | Review, | Var, | NA |
| 1674- | PBG, | SDT, | HPT, | Study on the effect of a triple cancer treatment of propolis, thermal cycling-hyperthermia, and low-intensity ultrasound on PANC-1 cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | Nor, | H6c7 |
| 1675- | PBG, | Portuguese Propolis Antitumoral Activity in Melanoma Involves ROS Production and Induction of Apoptosis |
| - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Melanoma, | WM983B |
| 1676- | PBG, | Use of Stingless Bee Propolis and Geopropolis against Cancer—A Literature Review of Preclinical Studies |
| - | Review, | Var, | NA |
| 1677- | PBG, | Propolis Inhibits UVA-Induced Apoptosis of Human Keratinocyte HaCaT Cells by Scavenging ROS |
| - | in-vitro, | Nor, | HaCaT |
| 1231- | PBG, | Caffeic acid phenethyl ester inhibits MDA-MB-231 cell proliferation in inflammatory microenvironment by suppressing glycolysis and lipid metabolism |
| - | in-vitro, | BC, | MDA-MB-231 |
| 4218- | PBG, | The Neuroprotective Effects of Brazilian Green Propolis on Neurodegenerative Damage in Human Neuronal SH-SY5Y Cells |
| - | in-vitro, | Nor, | SH-SY5Y | - | in-vitro, | AD, | NA |
| 4219- | PBG, | Propolis Increases Brain Derived Neurotrophic Factor Expression in the Prefrontal Cortex of Rat Stress Model |
| - | in-vivo, | AD, | NA |
| 3250- | PBG, | Allergic Inflammation: Effect of Propolis and Its Flavonoids |
| - | Review, | NA, | NA |
| 3249- | PBG, | Can Propolis Be a Useful Adjuvant in Brain and Neurological Disorders and Injuries? A Systematic Scoping Review of the Latest Experimental Evidence |
| - | Review, | Var, | NA |
| 3251- | PBG, | The Antioxidant and Anti-Inflammatory Effects of Flavonoids from Propolis via Nrf2 and NF-κB Pathways |
| - | Review, | AD, | NA | - | Review, | Diabetic, | NA | - | Review, | Var, | NA | - | in-vitro, | Nor, | H9c2 |
| 3252- | PBG, | Propolis Extract and Its Bioactive Compounds—From Traditional to Modern Extraction Technologies |
| - | Review, | NA, | NA |
| 3253- | PBG, | Brazilian red propolis extract enhances expression of antioxidant enzyme genes in vitro and in vivo |
| - | in-vitro, | Nor, | HEK293 | - | in-vivo, | Nor, | NA |
| 3254- | PBG, | Brazilian green propolis water extract up-regulates the early expression level of HO-1 and accelerates Nrf2 after UVA irradiation |
| - | in-vitro, | Nor, | NA |
| 3255- | PBG, | Propolis reversed cigarette smoke-induced emphysema through macrophage alternative activation independent of Nrf2 |
| - | in-vivo, | Nor, | NA |
| 3256- | PBG, | Mechanisms of Apoptosis and Cell Cycle Arrest Induced by Propolis in Cancer Therapy |
| - | Review, | Var, | NA |
| 3257- | PBG, | The Potential Use of Propolis as a Primary or an Adjunctive Therapy in Respiratory Tract-Related Diseases and Disorders: A Systematic Scoping Review |
| - | Review, | Var, | NA |
| 3259- | PBG, | Propolis and its therapeutic effects on renal diseases: A review |
| - | Review, | Nor, | NA |
| 34- | PFB, | Naturally occurring small-molecule inhibitors of hedgehog/GLI-mediated transcription |
| - | in-vitro, | PC, | PANC1 |
| 1774- | PG, | Geno- and cytotoxicity of propyl gallate food additive |
| - | in-vitro, | Lung, | A549 |
| 1763- | PG, | Generation of Hydrogen Peroxide in Cancer Cells: Advancing Therapeutic Approaches for Cancer Treatment |
| - | Review, | NA, | NA |
| 1764- | PG, | Cu, | DNA strand break induction and enhanced cytotoxicity of propyl gallate in the presence of copper(II) |
| - | in-vitro, | Nor, | GM05757 |
| 1766- | PG, | Propyl gallate induces human pulmonary fibroblast cell death through the regulation of Bax and caspase-3 |
| - | in-vitro, | Nor, | NA |
| 1767- | PG, | Propyl gallate induces cell death in human pulmonary fibroblast through increasing reactive oxygen species levels and depleting glutathione |
| - | in-vitro, | Nor, | NA |
| 1768- | PG, | Propyl gallate reduces the growth of lung cancer cells through caspase‑dependent apoptosis and G1 phase arrest of the cell cycle |
| - | in-vitro, | Lung, | Calu-6 | - | in-vitro, | Lung, | A549 |
| 1769- | PG, | The Anti-Apoptotic Effects of Caspase Inhibitors in Propyl Gallate-Treated Lung Cancer Cells Are Related to Changes in Reactive Oxygen Species and Glutathione Levels |
| - | in-vitro, | Lung, | Calu-6 | - | in-vitro, | Lung, | A549 |
| 1770- | PG, | Propyl gallate sensitizes human lung cancer cells to cisplatin-induced apoptosis by targeting heme oxygenase-1 for TRC8-mediated degradation |
| - | in-vitro, | Lung, | NA |
| 1771- | PG, | Pharmacokinetic and toxicological overview of propyl gallate food additive |
| - | Human, | Nor, | NA |
| 1772- | PG, | Propyl gallate decreases the proliferation of Calu-6 and A549 lung cancer cells via affecting reactive oxygen species and glutathione levels |
| - | in-vitro, | Lung, | Calu-6 | - | in-vitro, | Lung, | A549 |
| 1765- | PG, | Enhanced cell death effects of MAP kinase inhibitors in propyl gallate-treated lung cancer cells are related to increased ROS levels and GSH depletion |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | Calu-6 |
| 1258- | PI, | Piperlongumine Alleviates Mouse Colitis and Colitis-Associated Colorectal Cancer |
| - | in-vivo, | CRC, | NA |
| 1254- | PI, | VitC, | Piperlongumine combined with vitamin C as a new adjuvant therapy against gastric cancer regulates the ROS–STAT3 pathway |
| - | in-vivo, | GC, | NA |
| 1255- | PI, | ALA, | Antileukemic effects of piperlongumine and alpha lipoic acid combination on Jurkat, MEC1 and NB4 cells in vitro |
| - | in-vitro, | CLL, | NA |
| 1256- | PI, | Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models |
| - | in-vitro, | adrenal, | PHEO | - | in-vivo, | NA, | NA |
| 1257- | PI, | Piperlongumine attenuates bile duct ligation-induced liver fibrosis in mice via inhibition of TGF-β1/Smad and EMT pathways |
| - | ex-vivo, | LiverDam, | NA |
| 3595- | PI, | Black pepper and health claims: a comprehensive treatise |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3600- | PI, | Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer's disease: optimization, biological efficacy, and potential toxicity |
| - | in-vivo, | AD, | NA |
| 3599- | PI, | Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3598- | PI, | Piperine attenuates cognitive impairment in an experimental mouse model of sporadic Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3597- | PI, | Chronic diseases, inflammation, and spices: how are they linked? |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Var, | NA |
| 3596- | PI, | Antioxidant efficacy of black pepper (Piper nigrum L.) and piperine in rats with high fat diet induced oxidative stress |
| - | in-vivo, | Nor, | NA |
| 3587- | PI, | Piperine: A review of its biological effects |
| - | Review, | Park, | NA | - | Review, | AD, | NA |
| 3589- | PI, | Anti-inflammatory and antiarthritic effects of piperine in human interleukin 1β-stimulated fibroblast-like synoviocytes and in rat arthritis models |
| - | in-vivo, | Arthritis, | NA |
| 4220- | PI, | Piperine ameliorated memory impairment and myelin damage in lysolecethin induced hippocampal demyelination |
| - | in-vivo, | AD, | NA | - | in-vivo, | MS, | NA |
| 4221- | PI, | Piperine-like alkamides from Piper nigrum induce BDNF promoter and promote neurite outgrowth in Neuro-2a cells |
| - | in-vitro, | NA, | NA |
| 4222- | PI, | Potential of piperine for neuroprotection in sepsis-associated encephalopathy |
| - | in-vivo, | Sepsis, | NA |
| 1016- | PI, | Piperine suppresses the Wnt/β-catenin pathway and has anti-cancer effects on colorectal cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | DLD1 |
| 1059- | PI, | Piperine Inhibits TGF-β Signaling Pathways and Disrupts EMT-Related Events in Human Lung Adenocarcinoma Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Liver, | HepG2 |
| 925- | PI, | Bioenhancers from mother nature and their applicability in modern medicine |
| - | Review, | Nor, | NA |
| 1164- | PI, | Inhibition of T cell activation by the phytochemical piperine |
| - | in-vitro, | Nor, | NA |
| 1131- | PI, | Piperlongumine‑loaded nanoparticles inhibit the growth, migration and invasion and epithelial‑to‑mesenchymal transition of triple‑negative breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 |
| 1163- | PI, | The Effect of Piperine on MMP-9, VEGF, and E-cadherin Expression in Breast Cancer MCF-7 Cell Line |
| - | in-vitro, | BC, | MC38 |
| 1165- | PI, | Piperine inhibits IL-1β-induced IL-6 expression by suppressing p38 MAPK and STAT3 activation in gastric cancer cells |
| - | in-vitro, | GC, | TMK-1 |
| - | in-vitro, | NA, | NA |
| 992- | PL, | Piperlongumine based nanomedicine impairs glycolytic metabolism in triple negative breast cancer stem cells through modulation of GAPDH & FBP1 |
| - | in-vivo, | BC, | NA |
| 1950- | PL, | Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 |
| 1938- | PL, | Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation |
| - | Study, | PSA, | NA | - | in-vivo, | NA, | NA |
| 1939- | PL, | Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | HUH7 | - | in-vivo, | NA, | NA |
| 1940- | PL, | Piperlongumine Inhibits Migration of Glioblastoma Cells via Activation of ROS-Dependent p38 and JNK Signaling Pathways |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | U87MG |
| 1941- | PL, | Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer |
| - | in-vitro, | HNSCC, | NA |
| 1942- | PL, | Piperlongumine inhibits antioxidant enzymes, increases ROS levels, induces DNA damage and G2/M cell cycle arrest in breast cell lines |
| - | in-vitro, | BC, | MCF-7 |
| 1943- | PL, | Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells |
| - | in-vitro, | GBM, | NA | - | in-vivo, | NA, | NA |
| 1944- | PL, | Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress |
| - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 |
| 1945- | PL, | SANG, | The Synergistic Effect of Piperlongumine and Sanguinarine on the Non-Small Lung Cancer |
| - | in-vitro, | Lung, | A549 |
| 1946- | PL, | PI, | Piperlonguminine and Piperine Analogues as TrxR Inhibitors that Promote ROS and Autophagy and Regulate p38 and Akt/mTOR Signaling |
| - | in-vitro, | Liver, | NA |
| 1947- | PL, | Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | NA |
| 1948- | PL, | born, | Natural borneol serves as an adjuvant agent to promote the cellular uptake of piperlongumine for improving its antiglioma efficacy |
| - | in-vitro, | GBM, | NA |
| 1949- | PL, | Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Cerv, | HeLa |
| 1951- | PL, | Piperlongumine Analogs Promote A549 Cell Apoptosis through Enhancing ROS Generation |
| - | in-vitro, | Lung, | A549 |
| 1952- | PL, | 5-FU, | Piperlongumine induces ROS accumulation to reverse resistance of 5-FU in human colorectal cancer via targeting TrxR |
| - | in-vivo, | CRC, | HCT8 |
| 1953- | PL, | Designing piperlongumine-directed anticancer agents by an electrophilicity-based prooxidant strategy: A mechanistic investigation |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | WI38 |
| 2961- | PL, | Piperlongumine inhibits esophageal squamous cell carcinoma in vitro and in vivo by triggering NRF2/ROS/TXNIP/NLRP3-dependent pyroptosis |
| - | in-vitro, | ESCC, | KYSE-30 |
| 2960- | PL, | Synthesis of Piperlongumine Analogues and Discovery of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators as Potential Neuroprotective Agents |
| - | Analysis, | Nor, | NA |
| 2959- | PL, | Piperlongumine mitigates LPS-induced inflammation and lung injury via targeting MD2/TLR4 |
| - | in-vivo, | Nor, | NA |
| 2958- | PL, | Natural product piperlongumine inhibits proliferation of oral squamous carcinoma cells by inducing ferroptosis and inhibiting intracellular antioxidant capacity |
| - | in-vitro, | Oral, | HSC3 |
| 2957- | PL, | Piperlongumine Induces Cell Cycle Arrest via Reactive Oxygen Species Accumulation and IKKβ Suppression in Human Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 |
| 2956- | PL, | Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis |
| - | in-vitro, | PC, | NA |
| 2955- | PL, | Heme Oxygenase-1 Determines the Differential Response of Breast Cancer and Normal Cells to Piperlongumine |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 2954- | PL, | The metabolites from traditional Chinese medicine targeting ferroptosis for cancer therapy |
| - | Review, | Var, | NA |
| 2953- | PL, | Piperlongumine Acts as an Immunosuppressant by Exerting Prooxidative Effects in Human T Cells Resulting in Diminished TH17 but Enhanced Treg Differentiation |
| - | in-vitro, | Nor, | NA |
| 2952- | PL, | Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization |
| - | in-vitro, | Bladder, | T24 | - | in-vivo, | Bladder, | NA |
| 2951- | PL, | Aur, | Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells |
| - | in-vitro, | GBM, | U87MG |
| 2950- | PL, | Overview of piperlongumine analogues and their therapeutic potential |
| - | Review, | Var, | NA |
| 2949- | PL, | Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | U87MG |
| 2948- | PL, | The promising potential of piperlongumine as an emerging therapeutics for cancer |
| - | Review, | Var, | NA |
| 2947- | PL, | Piperlongumine: the amazing amide alkaloid from Piper in the treatment of breast cancer |
| - | Review, | Var, | NA |
| 2946- | PL, | Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent |
| - | Review, | Var, | NA |
| 2945- | PL, | Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells |
| - | in-vitro, | CRC, | HCT116 |
| 2944- | PL, | Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS/Akt Pathway in Human Thyroid Cancer Cells |
| - | in-vitro, | Thyroid, | IHH4 | - | in-vitro, | Thyroid, | 8505C | - | in-vivo, | NA, | NA |
| 2943- | PL, | Piperlongumine Inhibits Thioredoxin Reductase 1 by Targeting Selenocysteine Residues and Sensitizes Cancer Cells to Erastin |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Lung, | A549 | - | in-vitro, | BC, | MCF-7 |
| 2942- | PL, | Piperlongumine increases sensitivity of colorectal cancer cells to radiation: Involvement of ROS production via dual inhibition of glutathione and thioredoxin systems |
| - | in-vitro, | CRC, | CT26 | - | in-vitro, | CRC, | DLD1 | - | in-vivo, | CRC, | CT26 |
| 2941- | PL, | Selective killing of cancer cells by a small molecule targeting the stress response to ROS |
| - | in-vivo, | BC, | MDA-MB-231 | - | in-vitro, | OS, | U2OS | - | in-vitro, | BC, | MDA-MB-453 |
| 2940- | PL, | Piperlongumine Induces Reactive Oxygen Species (ROS)-dependent Downregulation of Specificity Protein Transcription Factors |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Kidney, | 786-O | - | in-vitro, | BC, | SkBr3 |
| 2649- | PL, | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| - | Review, | Var, | NA |
| 2972- | PL, | Piperlongumine Is an NLRP3 Inhibitor With Anti-inflammatory Activity |
| - | in-vitro, | AML, | THP1 |
| 2963- | PL, | Piperlongumine activates Sirtuin1 and improves cognitive function in a murine model of Alzheimer’s disease |
| - | in-vitro, | AD, | HEK293 |
| 2964- | PL, | Preformulation Studies on Piperlongumine |
| - | Analysis, | Nor, | NA |
| 2995- | PL, | Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover |
| - | in-vitro, | Lung, | H1975 | - | in-vitro, | Lung, | PC9 | - | in-vivo, | NA, | NA |
| 2996- | PL, | Application of longinamide in inhibiting the activation of NLRP3 inflammasome |
| - | NA, | AD, | NA | - | NA, | Park, | NA |
| 2999- | PL, | Piperlongumine alleviates corneal allograft rejection via suppressing angiogenesis and inflammation |
| - | in-vivo, | Nor, | HUVECs |
| 3000- | PL, | Biological and physical approaches on the role of piplartine (piperlongumine) in cancer |
| - | in-vitro, | Nor, | HUVECs | - | in-vitro, | Laryn, | HEp2 |
| 2965- | PL, | docx, | Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple negative breast cancer |
| - | Analysis, | Var, | NA |
| 2962- | PL, | Synthesis of Piperlongumine Analogues and Discovery of Nuclear Factor Erythroid 2‑Related Factor 2 (Nrf2) Activators as Potential Neuroprotective Agents |
| - | in-vitro, | Nor, | PC12 |
| 2966- | PL, | A strategy to improve the solubility and bioavailability of the insoluble drug piperlongumine through albumin nanoparticles |
| - | in-vitro, | LiverDam, | NA |
| 2967- | PL, | Piperlongumine and its derivatives against cancer: A recent update and future prospective |
| - | Review, | Var, | NA |
| 2968- | PL, | Chit, | Preparation of piperlongumine-loaded chitosan nanoparticles for safe and efficient cancer therapy |
| - | in-vitro, | GC, | AGS |
| 2969- | PL, | Piperlongumine induces autophagy by targeting p38 signaling |
| - | in-vitro, | OS, | U2OS | - | in-vitro, | Cerv, | HeLa |
| 2970- | PL, | Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways |
| - | in-vitro, | AML, | NA |
| 2971- | PL, | Piperlongumine attenuates IL-1β-induced inflammatory response in chondrocytes |
| - | NA, | OS, | NA |
| 2973- | PL, | The Natural Alkaloid Piperlongumine Inhibits Metastatic Activity and Epithelial-to-Mesenchymal Transition of Triple-Negative Mammary Carcinoma Cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | 4T1 |
| 2651- | Plum, | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| - | Review, | Var, | NA |
| 2004- | Plum, | Plumbagin Inhibits Proliferative and Inflammatory Responses of T Cells Independent of ROS Generation But by Modulating Intracellular Thiols |
| - | in-vivo, | Var, | NA |
| 2006- | Plum, | Plumbagin induces apoptosis in human osteosarcoma through ROS generation, endoplasmic reticulum stress and mitochondrial apoptosis pathway |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | Nor, | hFOB1.19 |
| 2005- | Plum, | Plumbagin induces apoptosis in lymphoma cells via oxidative stress mediated glutathionylation and inhibition of mitogen-activated protein kinase phosphatases (MKP1/2) |
| - | in-vivo, | Nor, | EL4 | - | in-vitro, | AML, | Jurkat |
| 1046- | ProBio, | immuno, | Combination Therapy of Bifidobacterium longum RAPO With Anti-PD-1 Treatment Enhances Anti-tumor Immune Response in Association With Gut Microbiota Modulation |
| - | in-vivo, | NA, | NA |
| 4170- | ProBio, | PB, | Prebiotic feeding elevates central brain derived neurotrophic factor, N-methyl-d-aspartate receptor subunits and d-serine |
| - | in-vivo, | NA, | NA |
| 3917- | PS, | Phosphatidylserine, inflammation, and central nervous system diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 3906- | PS, | Effects of phosphatidylserine in Alzheimer's disease |
| - | Study, | AD, | NA |
| 3907- | PS, | Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease. A neuropsychological, EEG, and PET investigation |
| - | Study, | AD, | NA |
| 3908- | PS, | The effect of phosphatidylserine-containing omega-3 fatty acids on memory abilities in subjects with subjective memory complaints: a pilot study |
| - | Human, | AD, | NA |
| 3909- | PS, | Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer's type (SDAT) |
| - | Study, | AD, | NA |
| 3910- | PS, | Neuroprotective Effect of Bean Phosphatidylserine on TMT-Induced Memory Deficits in a Rat Model |
| - | in-vivo, | AD, | NA |
| - | Human, | AD, | NA |
| 3912- | PS, | Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration |
| - | Study, | AD, | NA |
| 3913- | PS, | An open trial of plant-source derived phosphatydilserine for treatment of age-related cognitive decline |
| - | Human, | AD, | NA |
| 3914- | PS, | Soybean-Derived Phosphatidylserine Improves Memory Function of the Elderly Japanese Subjects with Memory Complaints |
| - | Trial, | AD, | NA |
| - | Trial, | AD, | NA |
| 3916- | PS, | The effect of soybean-derived phosphatidylserine on cognitive performance in elderly with subjective memory complaints: a pilot study |
| - | Human, | AD, | NA |
| 3928- | PTS, | The effects of pterostilbene on neutrophil activity in experimental model of arthritis |
| - | in-vivo, | Arthritis, | NA |
| 3931- | PTS, | Pterostilbene Protects against Osteoarthritis through NLRP3 Inflammasome Inactivation and Improves Gut Microbiota as Evidenced by In Vivo and In Vitro Studies |
| - | in-vivo, | Arthritis, | NA |
| 3930- | PTS, | A Review of Pterostilbene Antioxidant Activity and Disease Modification |
| - | Review, | Var, | NA | - | Review, | adrenal, | NA | - | Review, | Stroke, | NA |
| 3929- | PTS, | New Insights into Dietary Pterostilbene: Sources, Metabolism, and Health Promotion Effects |
| - | Review, | Var, | NA | - | Review, | Arthritis, | NA |
| 3927- | PTS, | Effects of Pterostilbene on Cardiovascular Health and Disease |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3926- | PTS, | Pterostilbene exert an anti-arthritic effect by attenuating inflammation, oxidative stress, and alteration of gut microbiota |
| - | in-vivo, | Arthritis, | NA |
| 3925- | PTS, | Analysis of Safety from a Human Clinical Trial with Pterostilbene |
| - | Trial, | NA, | NA |
| 3924- | PTS, | Effect of resveratrol and pterostilbene on aging and longevity |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3923- | PTS, | Pterostilbene Supplement Benefits: Longevity Miracle or Hoax |
| - | Review, | AD, | NA |
| 3922- | PTS, | Pterostilbene attenuates amyloid-β induced neurotoxicity with regulating PDE4A-CREB-BDNF pathway |
| - | in-vivo, | AD, | NA |
| 3920- | PTS, | Resveratrol, pterostilbene, and dementia |
| - | Review, | AD, | NA |
| 3919- | PTS, | Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3918- | PTS, | Pterostilbene inhibits amyloid-β-induced neuroinflammation in a microglia cell line by inactivating the NLRP3/caspase-1 inflammasome pathway |
| - | in-vitro, | AD, | BV2 |
| 1236- | PTS, | Pterostilbene inhibits the metastasis of TNBC via suppression of β-catenin-mediated epithelial to mesenchymal transition and stemness |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 1237- | PTS, | Pterostilbene induces cell apoptosis and inhibits lipogenesis in SKOV3 ovarian cancer cells by activation of AMPK-induced inhibition of Akt/mTOR signaling cascade |
| - | in-vitro, | Ovarian, | SKOV3 |
| 1238- | PTS, | Pterostilbene suppresses gastric cancer proliferation and metastasis by inhibiting oncogenic JAK2/STAT3 signaling: In vitro and in vivo therapeutic intervention |
| - | in-vitro, | GC, | NA | - | in-vivo, | NA, | NA |
| 4690- | PTS, | immuno, | Pterostilbene: Mechanisms of its action as oncostatic agent in cell models and in vivo studies |
| - | Review, | Var, | NA |
| 4689- | PTS, | Pterostilbene Suppresses both Cancer Cells and Cancer Stem-Like Cells in Cervical Cancer with Superior Bioavailability to Resveratrol |
| 4692- | PTS, | Pterostilbene Suppresses both Cancer Cells and Cancer Stem-Like Cells in Cervical Cancer with Superior Bioavailability to Resveratrol |
| - | in-vitro, | Cerv, | HeLa |
| 4691- | PTS, | Pterostilbene as a Potent Chemopreventive Agent in Cancer |
| 4704- | PTS, | Cisplatin, | Pterostilbene Sensitizes Cisplatin-Resistant Human Bladder Cancer Cells with Oncogenic HRAS |
| - | in-vitro, | Bladder, | NA |
| 4703- | PTS, | RES, | Pterostilbene and resveratrol: Exploring their protective mechanisms against skin photoaging - A scoping review |
| - | NA, | Nor, | NA |
| 4702- | PTS, | Pterostilbene Inhibits Pancreatic Cancer In Vitro |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 |
| 4701- | PTS, | RES, | Targeting cancer stem cells and signaling pathways by resveratrol and pterostilbene |
| - | Review, | Var, | NA |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 4699- | PTS, | Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vivo, | BC, | MDA-MB-231 |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 4697- | PTS, | Pterostilbene and cancer: current review |
| - | Review, | Var, | NA |
| 4696- | PTS, | BlueBerry Isolate, Pterostilbene, Functions as a Potential Anticancer Stem Cell Agent in Suppressing Irradiation-Mediated Enrichment of Hepatoma Stem Cells |
| - | in-vitro, | HCC, | NA |
| 4695- | PTS, | Pterostilbene in Cancer Therapy: Enhancing Treatment Efficacy and Overcoming Resistance |
| - | Review, | Var, | NA |
| 4694- | PTS, | Pterostilbene as a Multifaceted Anticancer Agent: Molecular Mechanisms, Therapeutic Potential and Future Directions |
| 4693- | PTS, | Pterostilbene in the treatment of inflammatory and oncological diseases |
| 2408- | PTS, | Pterostilbene suppresses the growth of esophageal squamous cell carcinoma by inhibiting glycolysis and PKM2/STAT3/c-MYC signaling pathway |
| - | in-vitro, | ESCC, | NA |
| 2409- | PTS, | Pterostilbene Induces Pyroptosis in Breast Cancer Cells through Pyruvate Kinase 2/Caspase-8/Gasdermin C Signaling Pathway |
| - | in-vitro, | BC, | EMT6 | - | in-vitro, | BC, | 4T1 | - | in-vitro, | Nor, | HC11 |
| 2431- | QC, | The Protective Effect of Quercetin against the Cytotoxicity Induced by Fumonisin B1 in Sertoli Cells |
| - | in-vitro, | Nor, | TM4 |
| 2300- | QC, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2343- | QC, | Pharmacological Activity of Quercetin: An Updated Review |
| - | Review, | Nor, | NA |
| 2342- | QC, | Quercetin Inhibits the Proliferation of Glycolysis-Addicted HCC Cells by Reducing Hexokinase 2 and Akt-mTOR Pathway |
| - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vivo, | NA, | NA |
| 2303- | QC, | doxoR, | Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 2344- | QC, | Quercetin: A natural solution with the potential to combat liver fibrosis |
| - | Review, | Nor, | NA |
| 2341- | QC, | Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 2340- | QC, | Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2) |
| - | in-vitro, | OS, | NA |
| 2339- | QC, | Quercetin protects against LPS-induced lung injury in mice via SIRT1-mediated suppression of PKM2 nuclear accumulation |
| - | in-vivo, | Nor, | NA |
| 2338- | QC, | Quercetin: A Flavonoid with Potential for Treating Acute Lung Injury |
| - | Review, | Nor, | NA |
| 4787- | QC, | Quercetin: A Phytochemical with Pro-Apoptotic Effects in Colon Cancer Cells |
| - | Review, | CRC, | NA |
| 4686- | QC, | Quercetin suppresses endometrial cancer stem cells via ERα-mediated inhibition of STAT3 signaling |
| - | in-vitro, | EC, | EMN8 | - | in-vitro, | EC, | EMN21 |
| 4665- | QC, | Ash, | Api, | Targeting cancer stem cells by nutraceuticals for cancer therapy |
| - | Review, | Var, | NA |
| 4827- | QC, | CUR, | Synthetic Pathways and the Therapeutic Potential of Quercetin and Curcumin |
| - | Review, | Var, | NA |
| 4297- | QC, | Quercetin attenuates tau hyperphosphorylation and improves cognitive disorder via suppression of ER stress in a manner dependent on AMPK pathway |
| - | in-vitro, | AD, | SH-SY5Y |
| 4296- | QC, | A Flavonoid on the Brain: Quercetin as a Potential Therapeutic Agent in Central Nervous System Disorders |
| - | Review, | AD, | NA |
| 4162- | QC, | Quercetin attenuates cell apoptosis in focal cerebral ischemia rat brain via activation of BDNF-TrkB-PI3K/Akt signaling pathway |
| - | in-vivo, | Stroke, | NA |
| 3352- | QC, | A review of quercetin: Antioxidant and anticancer properties |
| - | Review, | Var, | NA |
| 3361- | QC, | Quercetin ameliorates testosterone secretion disorder by inhibiting endoplasmic reticulum stress through the miR-1306-5p/HSD17B7 axis in diabetic rats |
| - | in-vivo, | Nor, | NA | - | in-vitro, | NA, | NA |
| 3353- | QC, | Quercetin triggers cell apoptosis-associated ROS-mediated cell death and induces S and G2/M-phase cell cycle arrest in KON oral cancer cells |
| - | in-vitro, | Oral, | KON | - | in-vitro, | Nor, | MRC-5 |
| 3354- | QC, | Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine |
| - | Review, | Var, | NA |
| 3355- | QC, | Quercetin exhibits cytotoxicity in cancer cells by inducing two-ended DNA double-strand breaks |
| - | in-vitro, | Cerv, | HeLa |
| 3356- | QC, | Targeting DNA methyltransferases for cancer therapy |
| - | Review, | Var, | NA |
| 3357- | QC, | The polyphenol quercetin induces cell death in leukemia by targeting epigenetic regulators of pro-apoptotic genes |
| - | in-vitro, | AML, | HL-60 | - | NA, | NA, | U937 |
| 3358- | QC, | Effects of quercetin on the DNA methylation pattern in tumor therapy: an updated review |
| - | Review, | NA, | NA |
| 3359- | QC, | Quercetin modifies 5′CpG promoter methylation and reactivates various tumor suppressor genes by modulating epigenetic marks in human cervical cancer cells |
| - | in-vitro, | Cerv, | HeLa |
| 3360- | QC, | Role of Flavonoids as Epigenetic Modulators in Cancer Prevention and Therapy |
| - | Review, | Var, | NA |
| 3340- | QC, | Quercetin regulates inflammation, oxidative stress, apoptosis, and mitochondrial structure and function in H9C2 cells by promoting PVT1 expression |
| - | in-vitro, | Nor, | H9c2 |
| 3351- | QC, | Quercetin Exerts Differential Neuroprotective Effects Against H2O2 and Aβ Aggregates in Hippocampal Neurons: the Role of Mitochondria |
| - | Review, | AD, | NA |
| 3350- | QC, | Quercetin and the mitochondria: A mechanistic view |
| - | Review, | NA, | NA |
| 3349- | QC, | Quercetin Exerted Protective Effects in a Rat Model of Sepsis via Inhibition of Reactive Oxygen Species (ROS) and Downregulation of High Mobility Group Box 1 (HMGB1) Protein Expression |
| - | in-vivo, | Sepsis, | NA |
| 3348- | QC, | Quercetin and iron metabolism: What we know and what we need to know |
| - | Review, | NA, | NA |
| 3347- | QC, | Recent Advances in Potential Health Benefits of Quercetin |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3346- | QC, | Regulation of the Intracellular ROS Level Is Critical for the Antiproliferative Effect of Quercetin in the Hepatocellular Carcinoma Cell Line HepG2 |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | HUH7 |
| 3344- | QC, | Quercetin induced ROS production triggers mitochondrial cell death of human embryonic stem cells |
| - | in-vitro, | Nor, | hESC |
| 3343- | QC, | Quercetin, a Flavonoid with Great Pharmacological Capacity |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Arthritis, | NA |
| 3342- | QC, | Quercetin modulates OTA-induced oxidative stress and redox signalling in HepG2 cells — up regulation of Nrf2 expression and down regulation of NF-κB and COX-2 |
| - | in-vitro, | Nor, | HepG2 |
| 3341- | QC, | Antioxidant Activities of Quercetin and Its Complexes for Medicinal Application |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA |
| 3372- | QC, | FIS, | KaempF, | Anticancer Potential of Selected Flavonols: Fisetin, Kaempferol, and Quercetin on Head and Neck Cancers |
| - | Review, | HNSCC, | NA |
| 3381- | QC, | Quercetin induces cell death in cervical cancer by reducing O-GlcNAcylation of adenosine monophosphate-activated protein kinase |
| - | in-vitro, | Cerv, | HeLa |
| 3380- | QC, | Quercetin as a JAK–STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases |
| - | Review, | Var, | NA | - | Review, | Park, | NA | - | Review, | AD, | NA |
| 3379- | QC, | The Effect of Quercetin Nanosuspension on Prostate Cancer Cell Line LNCaP via Hedgehog Signaling Pathway |
| - | in-vitro, | Pca, | LNCaP |
| 3378- | QC, | CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia |
| - | in-vitro, | AML, | NA |
| 3377- | QC, | Quercetin inhibits a large panel of kinases implicated in cancer cell biology |
| 3376- | QC, | Inhibiting CDK6 Activity by Quercetin Is an Attractive Strategy for Cancer Therapy |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 |
| 3375- | QC, | Quercetin Mediated TET1 Expression Through MicroRNA-17 Induced Cell Apoptosis in Melanoma Cells |
| - | in-vitro, | Melanoma, | B16-BL6 |
| 3374- | QC, | Therapeutic effects of quercetin in oral cancer therapy: a systematic review of preclinical evidence focused on oxidative damage, apoptosis and anti-metastasis |
| - | Review, | Oral, | NA | - | Review, | AD, | NA |
| 3373- | QC, | The Effect of Quercetin in the Yishen Tongluo Jiedu Recipe on the Development of Prostate Cancer through the Akt1-related CXCL12/ CXCR4 Pathway |
| - | in-vitro, | Pca, | DU145 |
| 3362- | QC, | The effect of quercetin on cervical cancer cells as determined by inducing tumor endoplasmic reticulum stress and apoptosis and its mechanism of action |
| - | in-vitro, | Cerv, | HeLa |
| 3371- | QC, | Quercetin induces MGMT+ glioblastoma cells apoptosis via dual inhibition of Wnt3a/β-Catenin and Akt/NF-κB signaling pathways |
| - | in-vitro, | GBM, | T98G |
| 3370- | QC, | Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3) |
| - | in-vitro, | Pca, | PC3 |
| 3369- | QC, | Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects |
| - | Review, | Pca, | NA |
| 3368- | QC, | The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update |
| - | Review, | Var, | NA |
| 3367- | QC, | Targeting Nrf2 signaling pathway by quercetin in the prevention and treatment of neurological disorders: An overview and update on new developments |
| - | Review, | Stroke, | NA | - | Review, | AD, | NA |
| 3366- | QC, | Quercetin Attenuates Endoplasmic Reticulum Stress and Apoptosis in TNBS-Induced Colitis by Inhibiting the Glucose Regulatory Protein 78 Activation |
| - | in-vivo, | IBD, | NA |
| 3365- | QC, | Quercetin attenuates sepsis-induced acute lung injury via suppressing oxidative stress-mediated ER stress through activation of SIRT1/AMPK pathways |
| - | in-vivo, | Sepsis, | NA |
| 3364- | QC, | Quercetin Protects Human Thyroid Cells against Cadmium Toxicity |
| - | in-vitro, | Nor, | NA |
| 3363- | QC, | The Protective Effect of Quercetin on Endothelial Cells Injured by Hypoxia and Reoxygenation |
| - | in-vitro, | Nor, | HBMECs |
| 3338- | QC, | Quercetin: Its Antioxidant Mechanism, Antibacterial Properties and Potential Application in Prevention and Control of Toxipathy |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA |
| 3337- | QC, | Endoplasmic Reticulum Stress-Relieving Effect of Quercetin in Thapsigargin-Treated Hepatocytes |
| - | in-vitro, | NA, | HepG2 |
| 3336- | QC, | Neuroprotective Effects of Quercetin in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3335- | QC, | Recent advances on the improvement of quercetin bioavailability |
| - | Review, | NA, | NA |
| 3334- | QC, | Pharmacokinetics of Quercetin Absorption from Apples and Onions in Healthy Humans |
| - | Trial, | Nor, | NA |
| 3339- | QC, | Quercetin suppresses ROS production and migration by specifically targeting Rac1 activation in gliomas |
| - | in-vitro, | GBM, | C6 | - | in-vitro, | GBM, | IMR32 |
| 3609- | QC, | Factors modulating bioavailability of quercetin-related flavonoids and the consequences of their vascular function |
| - | Review, | Var, | NA |
| 3610- | QC, | Bioavailability of quercetin: problems and promises |
| 3601- | QC, | Overviews of Biological Importance of Quercetin: A Bioactive Flavonoid |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3602- | QC, | The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice |
| - | in-vivo, | AD, | NA |
| 3603- | QC, | Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus |
| - | Review, | AD, | NA | - | Review, | Diabetic, | NA |
| 3604- | QC, | Quercetin enrich diet during the early-middle not middle-late stage of alzheimer’s disease ameliorates cognitive dysfunction |
| - | in-vivo, | AD, | NA |
| 3605- | QC, | Protective effect of quercetin in primary neurons against Aβ(1–42): relevance to Alzheimer's disease |
| - | Review, | AD, | NA |
| 3607- | QC, | Mechanisms of Neuroprotection by Quercetin: Counteracting Oxidative Stress and More |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3608- | QC, | Chronic diseases, inflammation, and spices: how are they linked? |
| - | Review, | Var, | NA |
| 3606- | QC, | The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women with Rheumatoid Arthritis: A Double-Blind, Randomized Controlled Trial |
| - | Trial, | Arthritis, | NA |
| 3611- | QC, | Quercetin and vitamin C supplementation: effects on lipid profile and muscle damage in male athletes |
| - | Trial, | Nor, | NA |
| 3796- | QC, | BBR, | Biomarker discovery and phytochemical interventions in Alzheimer's disease: A path to therapeutic advances |
| - | Review, | AD, | NA |
| 3534- | QC, | Lyco, | Synergistic protection of quercetin and lycopene against oxidative stress via SIRT1-Nox4-ROS axis in HUVEC cells |
| - | in-vitro, | Nor, | HUVECs |
| 1493- | QC, | New quercetin-coated titanate nanotubes and their radiosensitization effect on human bladder cancer |
| - | NA, | Bladder, | NA |
| 980- | QC, | Dietary Quercetin Exacerbates the Development of Estrogen-Induced Breast Tumors in Female ACI Rats |
| - | in-vivo, | BC, | NA |
| 1201- | QC, | Quercetin: a silent retarder of fatty acid oxidation in breast cancer metastasis through steering of mitochondrial CPT1 |
| - | in-vivo, | BC, | NA |
| 74- | QC, | EGCG, | Prospective randomized trial evaluating blood and prostate tissue concentrations of green tea polyphenols and quercetin in men with prostate cancer |
| - | Human, | Pca, | NA |
| 66- | QC, | Emerging impact of quercetin in the treatment of prostate cancer |
| - | in-vitro, | Pca, | NA |
| 67- | QC, | RES, | Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | LAPC-4 |
| 68- | QC, | BaP, | Differential protein expression of peroxiredoxin I and II by benzo(a)pyrene and quercetin treatment in 22Rv1 and PrEC prostate cell lines |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PrEC |
| 69- | QC, | Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5 |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP |
| 70- | QC, | Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | LAPC-4 |
| 71- | QC, | Role of Bax in quercetin-induced apoptosis in human prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PrEC | - | in-vitro, | Pca, | YPEN-1 | - | in-vitro, | Pca, | HCT116 |
| 72- | QC, | Selenium- or quercetin-induced retardation of DNA synthesis in primary prostate cells occurs in the presence of a concomitant reduction in androgen-receptor activity |
| - | in-vitro, | Pca, | PECs | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | NIH-3T3 |
| 73- | QC, | The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90 |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 64- | QC, | Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts |
| - | in-vitro, | Colon, | HT-29 | - | in-vitro, | Colon, | SW-620 | - | in-vitro, | Colon, | Caco-2 |
| 75- | QC, | Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells |
| - | in-vitro, | Pca, | HEK293 | - | in-vitro, | NA, | 22Rv1 | - | in-vitro, | NA, | C4-2B |
| 76- | QC, | Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy |
| - | in-vitro, | Pca, | PC3 |
| - | in-vitro, | Pca, | CD44+ | - | in-vitro, | NA, | CD133+ | - | in-vitro, | NA, | PC3 | - | in-vitro, | NA, | LNCaP |
| 78- | QC, | Effects of quercetin on insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and induction of apoptosis in human prostate cancer cells |
| - | in-vitro, | Pca, | PC3 |
| 79- | QC, | Chemopreventive Effect of Quercetin in MNU and Testosterone Induced Prostate Cancer of Sprague-Dawley Rats |
| - | in-vivo, | Pca, | NA |
| 80- | QC, | Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway |
| - | in-vitro, | Pca, | PC3 |
| 81- | QC, | EGCG, | Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea |
| - | in-vivo, | Pca, | NA |
| 57- | QC, | Quercetin inhibits angiogenesis through thrombospondin-1 upregulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo |
| - | vitro+vivo, | PC, | NA |
| 49- | QC, | Plasma rich in quercetin metabolites induces G2/M arrest by upregulating PPAR-γ expression in human A549 lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 50- | QC, | Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer |
| - | vitro+vivo, | Ovarian, | A2780S |
| 51- | QC, | Effect of Quercetin on Cell Cycle and Cyclin Expression in Ovarian Carcinoma and Osteosarcoma Cell Lines |
| - | in-vitro, | Ovarian, | SKOV3 |
| 52- | QC, | Effect of Quercetin on Cell Cycle and Cyclin Expression in Ovarian Carcinoma and Osteosarcoma Cell Lines |
| - | in-vitro, | BC, | MCF-7 |
| 53- | QC, | Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer |
| - | in-vitro, | BC, | NA |
| 54- | QC, | Quercetin‑3‑methyl ether suppresses human breast cancer stem cell formation by inhibiting the Notch1 and PI3K/Akt signaling pathways |
| - | in-vitro, | BC, | MCF-7 |
| 55- | QC, | Quercetin inhibits the growth of human gastric cancer stem cells by inducing mitochondrial-dependent apoptosis through the inhibition of PI3K/Akt signaling |
| - | in-vitro, | GC, | GCSCs |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | PATU-8988 |
| 65- | QC, | Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB |
| - | in-vitro, | BC, | NA |
| 58- | QC, | doxoR, | Quercetin induces cell cycle arrest and apoptosis in CD133+ cancer stem cells of human colorectal HT29 cancer cell line and enhances anticancer effects of doxorubicin |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | NA, | CD133+ |
| - | in-vitro, | BC, | MDA-MB-231 |
| - | in-vitro, | Pca, | pCSCs |
| 61- | QC, | Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | ARPE-19 |
| 62- | QC, | GoldNP, | Gold nanoparticles-conjugated quercetin induces apoptosis via inhibition of EGFR/PI3K/Akt-mediated pathway in breast cancer cell lines (MCF-7 and MDA-MB-231) |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 63- | QC, | Quercetin facilitates cell death and chemosensitivity through RAGE/PI3K/AKT/mTOR axis in human pancreatic cancer cells |
| - | in-vitro, | Pca, | NA |
| 83- | QC, | Quercetin induces p53-independent apoptosis in human prostate cancer cells by modulating Bcl-2-related proteins: a possible mediation by IGFBP-3 |
| - | in-vitro, | Pca, | PC3 |
| 41- | QC, | Quercetin induces mitochondrial-derived apoptosis via reactive oxygen species-mediated ERK activation in HL-60 leukemia cells and xenograft |
| - | vitro+vivo, | AML, | HL-60 |
| 100- | QC, | Inhibition of Prostate Cancer Cell Colony Formation by the Flavonoid Quercetin Correlates with Modulation of Specific Regulatory Genes |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 48- | QC, | Quercetin Potentiates Apoptosis by Inhibiting Nuclear Factor-kappaB Signaling in H460 Lung Cancer Cells |
| - | in-vitro, | NSCLC, | H460 |
| 47- | QC, | Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells |
| - | in-vitro, | NSCLC, | H460 | - | in-vitro, | NSCLC, | A549 |
| 46- | QC, | Quercetin, but Not Its Glycosidated Conjugate Rutin, Inhibits Azoxymethane-Induced Colorectal Carcinogenesis in F344 Rats |
| - | in-vitro, | Colon, | F344 |
| 45- | QC, | Quercetin Inhibit Human SW480 Colon Cancer Growth in Association with Inhibition of Cyclin D1 and Survivin Expression through Wnt/β-Catenin Signaling Pathway |
| - | in-vitro, | Colon, | CX-1 | - | in-vitro, | Colon, | SW480 | - | in-vitro, | Colon, | HT-29 | - | in-vitro, | Colon, | HCT116 |
| 44- | QC, | Preclinical Colorectal Cancer Chemopreventive Efficacy and p53-Modulating Activity of 3′,4′,5′-Trimethoxyflavonol, a Quercetin Analog |
| - | in-vivo, | CRC, | HCT116 |
| 43- | QC, | Investigation of the anti-cancer effect of quercetin on HepG2 cells in vivo |
| - | in-vivo, | Liver, | HepG3 |
| 42- | QC, | Quercetin induces apoptosis by activating caspase-3 and regulating Bcl-2 and cyclooxygenase-2 pathways in human HL-60 cells |
| - | in-vitro, | AML, | HL-60 |
| 99- | QC, | Quercetin Inhibits Epithelial-to-Mesenchymal Transition (EMT) Process and Promotes Apoptosis in Prostate Cancer via Downregulating lncRNA MALAT1 |
| - | in-vitro, | Pca, | PC3 |
| 40- | QC, | Quercetin arrests G2/M phase and induces caspase-dependent cell death in U937 cells |
| - | in-vitro, | lymphoma, | U937 |
| 39- | QC, | A Comprehensive Analysis and Anti-Cancer Activities of Quercetin in ROS-Mediated Cancer and Cancer Stem Cells |
| - | Analysis, | NA, | NA |
| 38- | QC, | Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 37- | QC, | Low Concentrations of Flavonoids Are Protective in Rat H4IIE Cells Whereas High Concentrations Cause DNA Damage and Apoptosis |
| - | in-vivo, | Hepat, | H4IIE |
| 36- | QC, | Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression-independent manner in HPV-positive human cervical cancer-derived cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | SiHa |
| 35- | QC, | Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 98- | QC, | Quercetin postconditioning attenuates myocardial ischemia/reperfusion injury in rats through the PI3K/Akt pathway |
| - | in-vivo, | Stroke, | NA |
| 84- | QC, | Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression |
| - | in-vitro, | Pca, | PC3 |
| 85- | QC, | Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3) |
| - | in-vitro, | Pca, | PC3 |
| 86- | QC, | Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3) |
| - | in-vitro, | Pca, | PC3 |
| 87- | QC, | Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 88- | QC, | PacT, | Quercetin Enhanced Paclitaxel Therapeutic Effects Towards PC-3 Prostate Cancer Through ER Stress Induction and ROS Production |
| - | vitro+vivo, | Pca, | PC3 |
| 89- | QC, | doxoR, | Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met |
| - | in-vitro, | Pca, | PC3 |
| 90- | QC, | HP, | Combination of quercetin and hyperoside inhibits prostate cancer cell growth and metastasis via regulation of microRNA‑21 |
| - | in-vitro, | Pca, | PC3 |
| 91- | QC, | The roles of endoplasmic reticulum stress and mitochondrial apoptotic signaling pathway in quercetin-mediated cell death of human prostate cancer PC-3 cells |
| - | in-vitro, | Pca, | PC3 |
| 92- | QC, | Quercetin Inhibits Angiogenesis Mediated Human Prostate Tumor Growth by Targeting VEGFR- 2 Regulated AKT/mTOR/P70S6K Signaling Pathways |
| - | vitro+vivo, | Pca, | HUVECs | - | vitro+vivo, | Pca, | PC3 |
| 93- | QC, | Chemical Proteomics Identifies Heterogeneous Nuclear Ribonucleoprotein (hnRNP) A1 as the Molecular Target of Quercetin in Its Anti-cancer Effects in PC-3 Cells |
| - | in-vitro, | Pca, | PC3 |
| 94- | QC, | HPT, | Effects of quercetin on the heat-induced cytotoxicity of prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | JCA-1 |
| 95- | QC, | Quercetin, a natural dietary flavonoid, acts as a chemopreventive agent |
| - | in-vitro, | Pca, | PC3 |
| 96- | QC, | docx, | Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways |
| - | vitro+vivo, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 97- | QC, | HPT, | Effects of the flavonoid drug Quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo |
| - | in-vitro, | Pca, | PC3 |
| 82- | QC, | AG, | Arctigenin in combination with quercetin synergistically enhances the anti-proliferative effect in prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 912- | QC, | 2DG, | Selected polyphenols potentiate the apoptotic efficacy of glycolytic inhibitors in human acute myeloid leukemia cell lines. Regulation by protein kinase activities |
| 913- | QC, | Effects of low dose quercetin: Cancer cell-specific inhibition of cell cycle progression |
| - | in-vitro, | BC, | SkBr3 | - | in-vitro, | BC, | MDA-MB-435 |
| 914- | QC, | Quercetin and Cancer Chemoprevention |
| - | Review, | NA, | NA |
| 915- | QC, | Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management |
| - | Review, | NA, | NA |
| 916- | QC, | Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells |
| - | Review, | Ovarian, | NA |
| 917- | QC, | BML, | Pap, | Quercetin: A Versatile Flavonoid |
| - | Review, | Nor, | NA |
| 918- | QC, | CUR, | VitC, | Anti- and pro-oxidant effects of oxidized quercetin, curcumin or curcumin-related compounds with thiols or ascorbate as measured by the induction period method |
| - | Analysis, | NA, | NA |
| 919- | QC, | Quercetin Regulates Sestrin 2-AMPK-mTOR Signaling Pathway and Induces Apoptosis via Increased Intracellular ROS in HCT116 Colon Cancer Cells |
| - | in-vitro, | CRC, | HCT116 |
| 920- | QC, | Interfering with ROS Metabolism in Cancer Cells: The Potential Role of Quercetin |
| - | Review, | NA, | NA |
| 921- | QC, | Essential requirement of reduced glutathione (GSH) for the anti-oxidant effect of the flavonoid quercetin |
| - | in-vitro, | lymphoma, | U937 |
| 922- | QC, | Quercetin and ovarian cancer: An evaluation based on a systematic review |
| - | Review, | NA, | NA |
| 923- | QC, | Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health |
| - | Review, | Var, | NA |
| 926- | QC, | PacT, | doxoR, | Tam, | Bioenhancers from mother nature and their applicability in modern medicine |
| - | Review, | Nor, | NA |
| 910- | QC, | The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism |
| 894- | QC, | The antioxidant, rather than prooxidant, activities of quercetin on normal cells: quercetin protects mouse thymocytes from glucose oxidase-mediated apoptosis |
| - | in-vitro, | Nor, | NA |
| 873- | QC, | RES, | CUR, | PI, | Combination Effects of Quercetin, Resveratrol and Curcumin on In Vitro Intestinal Absorption |
| - | in-vitro, | Nor, | NA |
| 889- | QC, | The multifaceted role of quercetin derived from its mitochondrial mechanism |
| - | vitro+vivo, | Var, | NA |
| 890- | QC, | PROOXIDANT ACTIVITIES OF ANTIOXIDANTS AND THEIR IMPACT ON HEALTH |
| - | Review, | Var, | NA |
| 891- | QC, | Chapter 9 - Quercetin: Prooxidant Effect and Apoptosis in Cancer |
| - | in-vitro, | Var, | NA |
| 892- | QC, | Antioxidant vs. pro-oxidant activities of quercetin in aqueous phase: A Density Functional Theory study |
| - | Analysis, | Var, | NA |
| 893- | QC, | Quercetin: Prooxidant Effect and Apoptosis in Cancer |
| - | Analysis, | Var, | NA |
| 911- | QC, | SFN, | Pilot study evaluating broccoli sprouts in advanced pancreatic cancer (POUDER trial) - study protocol for a randomized controlled trial |
| 895- | QC, | Theoretical Study of the Antioxidant Activity of Quercetin Oxidation Products |
| - | Analysis, | Var, | NA |
| 896- | QC, | Antioxidant and pro-oxidant actions of the plant phenolics quercetin, gossypol and myricetin: Effects on lipid peroxidation, hydroxyl radical generation and bleomycin-dependent damage to DNA |
| - | in-vivo, | Var, | NA |
| 897- | QC, | Anti- and prooxidant effects of chronic quercetin administration in rats |
| - | in-vivo, | Nor, | NA |
| 898- | QC, | Anti- and pro-oxidant activity of rutin and quercetin derivatives |
| - | Analysis, | Var, | NA |
| 899- | QC, | Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites |
| - | in-vivo, | Var, | NA |
| 900- | QC, | Quercetin Affects Erythropoiesis and Heart Mitochondrial Function in Mice |
| - | in-vivo, | Nor, | NA |
| 909- | QC, | Exploring the therapeutic potential of quercetin in cancer treatment: Targeting long non-coding RNAs |
| - | Review, | NA, | NA |
| 908- | QC, | Molecular Targets Underlying the Anticancer Effects of Quercetin: An Update |
| - | Review, | NA, | NA |
| 907- | QC, | A Comprehensive Study on the Anti-cancer Effects of Quercetin and Its Epigenetic Modifications in Arresting Progression of Colon Cancer Cell Proliferation |
| - | Review, | NA, | NA |
| 906- | QC, | The interplay between reactive oxygen species and antioxidants in cancer progression and therapy: a narrative review |
| - | Review, | NA, | NA |
| 905- | QC, | Anti- and pro-oxidant effects of quercetin in copper-induced low density lipoprotein oxidation. Quercetin as an effective antioxidant against pro-oxidant effects of urate |
| - | Analysis, | NA, | NA |
| 904- | QC, | Antioxidant and prooxidant effects of quercetin on glyceraldehyde-3-phosphate dehydrogenase |
| - | Analysis, | NA, | NA |
| 903- | QC, | Potential toxicity of quercetin: The repression of mitochondrial copy number via decreased POLG expression and excessive TFAM expression in irradiated murine bone marrow |
| - | in-vivo, | NA, | NA |
| 902- | QC, | Prooxidant activities of quercetin, p-courmaric acid and their derivatives analysed by quantitative structure–activity relationship |
| - | Analysis, | NA, | NA |
| 901- | QC, | Antioxidant/prooxidant effects of α-tocopherol, quercetin and isorhamnetin on linoleic acid peroxidation induced by Cu(II) and H2O2 |
| - | Analysis, | Var, | NA |
| 156- | Ralox, | Tam, | GEN, | CUR, | Modulators of estrogen receptor inhibit proliferation and migration of prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 101- | RES, | Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis |
| - | in-vitro, | GC, | SGC-7901 |
| 102- | RES, | Effect of resveratrol on proliferation and apoptosis of human pancreatic cancer MIA PaCa-2 cells may involve inhibition of the Hedgehog signaling pathway |
| - | in-vitro, | PC, | MIA PaCa-2 |
| 103- | RES, | CUR, | QC, | The effect of resveratrol, curcumin and quercetin combination on immuno-suppression of tumor microenvironment for breast tumor-bearing mice |
| - | vitro+vivo, | BC, | 4T1 |
| 104- | RES, | QC, | Resveratrol and Quercetin in Combination Have Anticancer Activity in Colon Cancer Cells and Repress Oncogenic microRNA-27a |
| - | in-vitro, | Colon, | HT-29 |
| 105- | RES, | QC, | The Effect of Resveratrol and Quercetin on Epithelial-Mesenchymal Transition in Pancreatic Cancer Stem Cell |
| - | in-vitro, | Pca, | CD133+ |
| 967- | RES, | Resveratrol binds and inhibits transcription factor HIF-1α in pancreatic cancer |
| - | Analysis, | PC, | NA |
| 1047- | RES, | Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 993- | RES, | Resveratrol reverses the Warburg effect by targeting the pyruvate dehydrogenase complex in colon cancer cells |
| - | in-vitro, | CRC, | Caco-2 | - | in-vivo, | Nor, | HCEC 1CT |
| 871- | RES, | CUR, | QC, | The effect of resveratrol, curcumin and quercetin combination on immuno-suppression of tumor microenvironment for breast tumor-bearing mice |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | BC, | 4T1 |
| 924- | RES, | Resveratrol sequentially induces replication and oxidative stresses to drive p53-CXCR2 mediated cellular senescence in cancer cells |
| - | in-vitro, | OS, | U2OS | - | in-vitro, | Lung, | A549 |
| 877- | RES, | Resveratrol Inhibits Invasion and Metastasis of Colorectal Cancer Cells via MALAT1 Mediated Wnt/β-Catenin Signal Pathway |
| - | in-vitro, | CRC, | LoVo | - | in-vitro, | CRC, | HCT116 |
| 878- | RES, | Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression |
| - | vitro+vivo, | CRC, | LoVo |
| 879- | RES, | Evidence that TNF-β induces proliferation in colorectal cancer cells and resveratrol can down-modulate it |
| - | in-vitro, | CRC, | HCT116 |
| 880- | RES, | Forkhead Proteins Are Critical for Bone Morphogenetic Protein-2 Regulation and Anti-tumor Activity of Resveratrol |
| - | in-vitro, | BC, | MDA-MB-231 |
| 881- | RES, | Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | Pca, | DU145 |
| 882- | RES, | Resveratrol: A Double-Edged Sword in Health Benefits |
| - | Review, | NA, | NA |
| 883- | RES, | Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy |
| 884- | RES, | PTS, | Resveratrol and Pterostilbene Exhibit Anticancer Properties Involving the Downregulation of HPV Oncoprotein E6 in Cervical Cancer Cells |
| - | in-vitro, | Cerv, | HeLa |
| 885- | RES, | Resveratrol induces intracellular Ca2 + rise via T-type Ca2 + channels in a mesothelioma cell line |
| - | in-vitro, | RCC, | REN | - | in-vitro, | Nor, | MeT5A |
| 4153- | RES, | Effect of oral resveratrol on the BDNF gene expression in the hippocampus of the rat brain |
| - | in-vivo, | AD, | NA |
| 4154- | RES, | Resveratrol improves postnatal hippocampal neurogenesis and brain derived neurotrophic factor in prenatally stressed rats |
| - | in-vivo, | AD, | NA |
| 3858- | RES, | Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment |
| - | Review, | AD, | NA |
| 3863- | RES, | MEL, | VitA,RetA, | Target Enzymes Considered for the Treatment of Alzheimer's Disease and Parkinson's Disease |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3798- | RES, | Resveratrol reverses hippocampal synaptic markers injury and SIRT1 inhibition against developmental Pb exposure |
| - | in-vivo, | NA, | NA |
| 3614- | RES, | Resveratrol--a boon for treating Alzheimer's disease? |
| - | Review, | AD, | NA |
| 3613- | RES, | Resveratrol for Alzheimer's disease |
| - | Review, | AD, | NA |
| 3612- | RES, | Resveratrol in Alzheimer's disease: a review of pathophysiology and therapeutic potential |
| - | Review, | AD, | NA |
| 2328- | RES, | Resveratrol Inhibits Cancer Cell Metabolism by Down Regulating Pyruvate Kinase M2 via Inhibition of Mammalian Target of Rapamycin |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 |
| 2329- | RES, | Resveratrol induces apoptosis in human melanoma cell through negatively regulating Erk/PKM2/Bcl-2 axis |
| - | in-vitro, | Melanoma, | A375 |
| 2330- | RES, | Resveratrol Induces Cancer Cell Apoptosis through MiR-326/PKM2-Mediated ER Stress and Mitochondrial Fission |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | BC, | MCF-7 |
| 2331- | RES, | Resveratrol improves follicular development of PCOS rats via regulating glycolysis pathway and targeting SIRT1 |
| - | in-vivo, | Nor, | NA |
| 2332- | RES, | Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism |
| - | Review, | Var, | NA |
| 2333- | RES, | Resveratrol regulates insulin resistance to improve the glycolytic pathway by activating SIRT2 in PCOS granulosa cells |
| - | in-vitro, | Nor, | NA |
| 2334- | RES, | Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy |
| - | Review, | Var, | NA |
| 2471- | RES, | Resveratrol Regulates Glucose and Lipid Metabolism in Diabetic Rats by Inhibition of PDK1/AKT Phosphorylation and HIF-1α Expression |
| - | in-vivo, | Diabetic, | NA |
| 2443- | RES, | Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review |
| - | Review, | Var, | NA |
| 2442- | RES, | High absorption but very low bioavailability of oral resveratrol in humans |
| - | in-vitro, | Nor, | NA |
| 2441- | RES, | Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions |
| - | Review, | Var, | NA |
| 2440- | RES, | Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway |
| - | in-vitro, | Lung, | H460 | - | in-vivo, | Lung, | NA | - | in-vitro, | Lung, | H1650 | - | in-vitro, | Lung, | HCC827 |
| 2439- | RES, | By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice |
| - | in-vitro, | HCC, | HCCLM3 | - | in-vitro, | Nor, | L02 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | HUH7 |
| 2467- | RES, | Resveratrol inhibits Ca2+ signals and aggregation of platelets |
| - | in-vitro, | Nor, | NA |
| 2472- | RES, | Resveratrol Restores Sirtuin 1 (SIRT1) Activity and Pyruvate Dehydrogenase Kinase 1 (PDK1) Expression after Hemorrhagic Injury in a Rat Model |
| - | in-vivo, | Nor, | NA |
| 2650- | RES, | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| - | Review, | Var, | NA |
| 2568- | RES, | Resveratrol: A Miracle Drug for Vascular Pathologies |
| - | Review, | Var, | NA |
| 2564- | RES, | Effect of resveratrol on platelet aggregation by fibrinogen protection |
| - | in-vitro, | NA, | NA |
| 2565- | RES, | https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2007.06788.x |
| - | in-vitro, | NA, | NA | - | in-vivo, | NA, | NA |
| 2566- | RES, | A comprehensive review on the neuroprotective potential of resveratrol in ischemic stroke |
| - | Review, | Stroke, | NA |
| 2567- | RES, | Neuroprotective Effects of Resveratrol in Ischemic Brain Injury |
| - | Review, | Stroke, | NA |
| 3069- | RES, | Resveratrol Inhibits NLRP3 Inflammasome-Induced Pyroptosis and miR-155 Expression in Microglia Through Sirt1/AMPK Pathway |
| - | in-vitro, | Nor, | N9 |
| 3080- | RES, | Resveratrol: A miraculous natural compound for diseases treatment |
| - | Review, | Var, | NA |
| 3068- | RES, | Resveratrol decreases the expression of genes involved in inflammation through transcriptional regulation |
| - | in-vitro, | lymphoma, | U937 |
| 3070- | RES, | Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma |
| - | in-vitro, | RCC, | ACHN | - | in-vitro, | RCC, | 786-O | - | in-vivo, | NA, | NA |
| 3071- | RES, | Resveratrol and Its Anticancer Effects |
| - | Review, | Var, | NA |
| 3072- | RES, | Resveratrol ameliorates glioblastoma inflammatory response by reducing NLRP3 inflammasome activation through inhibition of the JAK2/STAT3 pathway |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | U87MG |
| 3073- | RES, | Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy |
| - | in-vitro, | Nor, | NA |
| 3074- | RES, | Possible therapeutic targets for NLRP3 inflammasome-induced breast cancer |
| - | Review, | BC, | NA |
| 3075- | RES, | Rad, | The Protection Effect of Resveratrol Against Radiation-Induced Inflammatory Bowel Disease via NLRP-3 Inflammasome Repression in Mice |
| - | in-vivo, | Nor, | NA |
| 3076- | RES, | Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells |
| - | Review, | Var, | NA |
| 3077- | RES, | Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways |
| - | in-vitro, | Chon, | HTB94 |
| 3078- | RES, | The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment |
| - | Review, | Pca, | NA |
| 3079- | RES, | Therapeutic role of resveratrol against hepatocellular carcinoma: A review on its molecular mechanisms of action |
| - | Review, | Var, | NA |
| 3052- | RES, | Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | Bxpc-3 |
| 3067- | RES, | Proteomic Profiling Reveals That Resveratrol Inhibits HSP27 Expression and Sensitizes Breast Cancer Cells to Doxorubicin Therapy |
| - | in-vitro, | BC, | MCF-7 |
| 3066- | RES, | Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells |
| 3065- | RES, | Resveratrol-induced cytotoxicity in human Burkitt's lymphoma cells is coupled to the unfolded protein response |
| - | in-vitro, | lymphoma, | NA |
| 3064- | RES, | Resveratrol Suppresses Cancer Cell Glucose Uptake by Targeting Reactive Oxygen Species–Mediated Hypoxia-Inducible Factor-1α Activation |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | BC, | T47D | - | in-vitro, | Lung, | LLC1 |
| 3063- | RES, | Resveratrol: A Review of Pre-clinical Studies for Human Cancer Prevention |
| - | Review, | Var, | NA |
| 3062- | RES, | Resveratrol enhances post-injury muscle regeneration by regulating antioxidant and mitochondrial biogenesis |
| - | in-vivo, | Nor, | NA |
| 3061- | RES, | The Anticancer Effects of Resveratrol: Modulation of Transcription Factors |
| - | Review, | Var, | NA |
| 3060- | RES, | Resveratrol targeting NRF2 disrupts the binding between KEAP1 and NRF2-DLG motif to ameliorate oxidative stress damage in mice pulmonary infection |
| - | in-vitro, | Nor, | RAW264.7 | - | in-vivo, | NA, | NA |
| 3059- | RES, | Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury |
| - | in-vivo, | Nor, | HK-2 |
| 3058- | RES, | Resveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathways |
| - | in-vivo, | NA, | NA |
| 3057- | RES, | The therapeutic effect of resveratrol: Focusing on the Nrf2 signaling pathway |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3056- | RES, | Less is more for cancer chemoprevention: evidence of a non-linear dose response for the protective effects of resveratrol in humans and mice |
| - | in-vivo, | Nor, | NA |
| 3055- | RES, | Resveratrol and Tumor Microenvironment: Mechanistic Basis and Therapeutic Targets |
| - | Review, | Var, | NA |
| 3054- | RES, | Resveratrol induced reactive oxygen species and endoplasmic reticulum stress-mediated apoptosis, and cell cycle arrest in the A375SM malignant melanoma cell line |
| - | in-vitro, | Melanoma, | A375 |
| 3053- | RES, | Resveratrol represses estrogen-induced mammary carcinogenesis through NRF2-UGT1A8-estrogen metabolic axis activation |
| - | in-vitro, | NA, | NA |
| 3082- | RES, | Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vivo, | NA, | NA |
| 2981- | RES, | Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways |
| - | in-vitro, | Colon, | HT-29 | - | in-vitro, | Colon, | SW48 |
| 2982- | RES, | The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1 |
| - | in-vitro, | Melanoma, | MSTO-211H |
| 2983- | RES, | Resveratrol Improves Diabetic Retinopathy via Regulating MicroRNA-29b/Specificity Protein 1/Apoptosis Pathway by Enhancing Autophagy |
| - | in-vitro, | Nor, | NA |
| 2984- | RES, | Involvement of miR-539-5p in the inhibition of de novo lipogenesis induced by resveratrol in white adipose tissue |
| - | in-vivo, | Nor, | NA |
| 2985- | RES, | Resveratrol Inhibits Diabetic-Induced Müller Cells Apoptosis through MicroRNA-29b/Specificity Protein 1 Pathway |
| - | in-vivo, | Nor, | NA | - | vitro+vivo, | Diabetic, | NA |
| 2986- | RES, | Effect of the natural compound trans‑resveratrol on human MCM4 gene transcription |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | AML, | HL-60 |
| 2987- | RES, | Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1 |
| - | in-vivo, | Nor, | NA |
| 2988- | RES, | The Antimetastatic Effects of Resveratrol on Hepatocellular Carcinoma through the Downregulation of a Metastasis-Associated Protease by SP-1 Modulation |
| - | in-vitro, | HCC, | HUH7 |
| 2989- | RES, | Resveratrol Represses Pokemon Expression in Human Glioma Cells |
| - | in-vitro, | GBM, | NA |
| 2990- | RES, | Resveratrol reduces cerebral edema through inhibition of de novo SUR1 expression induced after focal ischemia |
| - | in-vivo, | Stroke, | NA |
| 2991- | RES, | Chemo, | Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells |
| - | in-vitro, | Melanoma, | MSTO-211H | - | in-vitro, | Nor, | MeT5A |
| 3100- | RES, | Neuroprotective effects of resveratrol in Alzheimer disease pathology |
| - | Review, | AD, | NA |
| 3099- | RES, | Resveratrol and cognitive decline: a clinician perspective |
| - | Review, | Nor, | NA | - | NA, | AD, | NA |
| 3098- | RES, | Regulation of Cell Signaling Pathways and miRNAs by Resveratrol in Different Cancers |
| - | Review, | Var, | NA |
| 3097- | RES, | Resveratrol Induces Notch2-mediated Apoptosis and Suppression of Neuroendocrine Markers in Medullary Thyroid Cancer |
| - | in-vitro, | Thyroid, | TT |
| 3096- | RES, | Identification of potential target genes of non-small cell lung cancer in response to resveratrol treatment by bioinformatics analysis |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 3095- | RES, | Resveratrol suppresses migration, invasion and stemness of human breast cancer cells by interfering with tumor-stromal cross-talk |
| - | in-vitro, | BC, | NA |
| 3094- | RES, | Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 3093- | RES, | Pro-Oxidant Effect of Resveratrol on Human Breast Cancer MCF-7 Cells is Associated with CK2 Inhibition |
| - | in-vitro, | BC, | MCF-7 |
| 3092- | RES, | Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action |
| - | Review, | BC, | MDA-MB-231 | - | Review, | BC, | MCF-7 |
| 3091- | RES, | Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | ALVA-41 |
| 3090- | RES, | The Effects of Resveratrol Targeting MicroRNA-4325P/PDGF-B to Regulate Tumor Angiogenesis in Osteosarcoma Microenvironment |
| - | in-vitro, | OS, | MG63 |
| 3089- | RES, | The Role of Resveratrol in Cancer Therapy |
| - | Review, | Var, | NA |
| 3088- | RES, | Notch signaling mediated repressive effects of resveratrol in inducing caspasedependent apoptosis in MCF-7 breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 3087- | RES, | Resveratrol cytotoxicity is energy-dependent |
| - | Review, | Var, | NA |
| 3086- | RES, | Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 3085- | RES, | Resveratrol interrupts Wnt/β-catenin signalling in cervical cancer by activating ten-eleven translocation 5-methylcytosine dioxygenase 1 |
| - | in-vitro, | Cerv, | NA |
| 3084- | RES, | Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D |
| 3083- | RES, | Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 3081- | RES, | Resveratrol and p53: How are they involved in CRC plasticity and apoptosis? |
| - | Review, | CRC, | NA |
| 2687- | RES, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | NA, | NA | - | Review, | AD, | NA |
| 4284- | RES, | Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex |
| - | in-vitro, | AD, | HEK293 | - | NA, | Stroke, | NA | - | in-vivo, | AD, | NA |
| 4286- | RES, | Neuroprotective Properties of Resveratrol and Its Derivatives—Influence on Potential Mechanisms Leading to the Development of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4287- | RES, | Resveratrol targeting tau proteins, amyloid-beta aggregations, and their adverse effects: An updated review |
| - | Review, | AD, | NA |
| 4288- | RES, | Trans-resveratrol Inhibits Tau Phosphorylation in the Brains of Control and Cadmium Chloride-Treated Rats by Activating PP2A and PI3K/Akt Induced-Inhibition of GSK3β |
| - | in-vivo, | AD, | NA |
| 4289- | RES, | Resveratrol Attenuates Formaldehyde Induced Hyperphosphorylation of Tau Protein and Cytotoxicity in N2a Cells |
| - | in-vitro, | AD, | NA |
| 4285- | RES, | Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy |
| - | in-vivo, | AD, | NA |
| 4706- | RES, | Resveratrol as a circadian clock modulator: mechanisms of action and therapeutic applications |
| - | Review, | Nor, | NA |
| 4668- | RES, | Resveratrol Impedes the Stemness, Epithelial-Mesenchymal Transition, and Metabolic Reprogramming of Cancer Stem Cells in Nasopharyngeal Carcinoma through p53 Activation |
| - | in-vitro, | NPC, | NA |
| 4657- | RES, | Resveratrol, cancer and cancer stem cells: A review on past to future |
| - | Review, | Var, | NA |
| 4670- | RES, | CUR, | EGCG, | TQ, | Targeting aging pathways with natural compounds: a review of curcumin, epigallocatechin gallate, thymoquinone, and resveratrol |
| - | Review, | Nor, | NA |
| 4662- | RES, | A Promising Resveratrol Analogue Suppresses CSCs in Non-Small-Cell Lung Cancer via Inhibition of the ErbB2 Signaling Pathway |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H460 |
| 4663- | RES, | Exploring resveratrol’s inhibitory potential on lung cancer stem cells: a scoping review of mechanistic pathways across cancer models |
| - | Review, | Var, | NA |
| 4669- | RES, | Inhibition of RAD51 by siRNA and Resveratrol Sensitizes Cancer Stem Cells Derived from HeLa Cell Cultures to Apoptosis |
| - | in-vitro, | Cerv, | NA |
| 4666- | RES, | Structural modification of resveratrol analogue exhibits anticancer activity against lung cancer stem cells via suppression of Akt signaling pathway |
| - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | H292 | - | in-vitro, | Lung, | A549 |
| 4667- | RES, | CUR, | SFN, | Physiological modulation of cancer stem cells by natural compounds: Insights from preclinical models |
| - | Review, | Var, | NA |
| 1506- | RES, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
| - | Review, | NA, | NA |
| 1391- | RES, | BBR, | Effects of Resveratrol, Berberine and Their Combinations on Reactive Oxygen Species, Survival and Apoptosis in Human Squamous Carcinoma (SCC-25) Cells |
| - | in-vitro, | Tong, | SCC25 |
| 1492- | RES, | Resveratrol: Biological and pharmaceutical properties as anticancer molecule |
| - | Review, | Var, | NA |
| 1491- | RES, | Resveratrol Augments Doxorubicin and Cisplatin Chemotherapy: A Novel Therapeutic Strategy |
| 1490- | RES, | Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues |
| - | Review, | Var, | NA |
| 1489- | RES, | Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer |
| - | Review, | Var, | NA |
| 1511- | RES, | Chemo, | Combination therapy in combating cancer |
| - | Review, | NA, | NA |
| 1282- | RES, | Resveratrol Inhibits CD4+ T Cell Activation by Enhancing the Expression and Activity of Sirt1 |
| - | vitro+vivo, | NA, | NA |
| 3490- | RF, | Multidimensional insights into the repeated electromagnetic field stimulation and biosystems interaction in aging and age-related diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3461- | RF, | Electromagnetic Field Stimulation Therapy for Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3730- | RF, | Transcranial electromagnetic treatment against Alzheimer's disease: why it has the potential to trump Alzheimer's disease drug development |
| - | Review, | AD, | NA |
| 3743- | RF, | Repeated electromagnetic field stimulation lowers amyloid-β peptide levels in primary human mixed brain tissue cultures |
| - | in-vitro, | AD, | NA |
| 3729- | RF, | Review of the Evidence that Transcranial Electromagnetic Treatment will be a Safe and Effective Therapeutic Against Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 3731- | RF, | Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice |
| - | in-vivo, | AD, | NA |
| 3732- | RF, | Electromagnetic treatment to old Alzheimer's mice reverses β-amyloid deposition, modifies cerebral blood flow, and provides selected cognitive benefit |
| - | in-vivo, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 3736- | RF, | Long-term electromagnetic pulse exposure induces Abeta deposition and cognitive dysfunction through oxidative stress and overexpression of APP and BACE1 |
| - | in-vivo, | AD, | NA |
| 3738- | RF, | Electromagnetic Field Stimulation Therapy for Alzheimer's Disease |
| - | Review, | AD, | NA |
| 4570- | RF, | Role of Mitochondria in the Oxidative Stress Induced by Electromagnetic Fields: Focus on Reproductive Systems |
| - | Review, | Nor, | NA |
| 4357- | RF, | Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies |
| - | Review, | Var, | NA |
| 1749- | RosA, | Rosmarinic Acid and Related Dietary Supplements: Potential Applications in the Prevention and Treatment of Cancer |
| - | Review, | Var, | NA |
| 1742- | RosA, | Rosmarinic acid, a natural polyphenol, has a potential pro-oxidant risk via NADH-mediated oxidative DNA damage |
| - | Analysis, | Var, | NA |
| 1743- | RosA, | New insights into the competition between antioxidant activities and pro-oxidant risks of rosmarinic acid |
| - | Analysis, | Var, | NA |
| 1744- | RosA, | Therapeutic Applications of Rosmarinic Acid in Cancer-Chemotherapy-Associated Resistance and Toxicity |
| - | Review, | Var, | NA |
| 1745- | RosA, | Rosmarinic acid and its derivatives: Current insights on anticancer potential and other biomedical applications |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 1746- | RosA, | Rosmarinic acid sensitizes cell death through suppression of TNF-α-induced NF-κB activation and ROS generation in human leukemia U937 cells |
| - | in-vitro, | AML, | U937 |
| 1747- | RosA, | Molecular Pathways of Rosmarinic Acid Anticancer Activity in Triple-Negative Breast Cancer Cells: A Literature Review |
| - | Review, | BC, | MDA-MB-231 | - | Review, | BC, | MDA-MB-468 |
| 1748- | RosA, | The Role of Rosmarinic Acid in Cancer Prevention and Therapy: Mechanisms of Antioxidant and Anticancer Activity |
| - | Review, | Var, | NA |
| 106- | RosA, | Rutin, a Quercetin Glycoside, Restores Chemosensitivity in Human Breast Cancer Cells |
| - | in-vivo, | BC, | MCF-7 |
| 1048- | RosA, | Ger, | Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis |
| - | in-vivo, | Colon, | MC38 |
| 3033- | RosA, | Rosemary (Rosmarinus officinalis) Extract Modulates CHOP/GADD153 to Promote Androgen Receptor Degradation and Decreases Xenograft Tumor Growth |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | LNCaP | - | vitro+vivo, | NA, | NA |
| 3020- | RosA, | Protective Effect of Rosmarinic Acid on Endotoxin-Induced Neuronal Damage Through Modulating GRP78/PERK/MANF Pathway |
| - | in-vivo, | Nor, | NA | - | in-vitro, | NA, | SH-SY5Y |
| 3029- | RosA, | Rosmarinic Acid, a Component of Rosemary Tea, Induced the Cell Cycle Arrest and Apoptosis through Modulation of HDAC2 Expression in Prostate Cancer Cell Lines |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 3028- | RosA, | Network pharmacology mechanism of Rosmarinus officinalis L.(Rosemary) to improve cell viability and reduces apoptosis in treating Alzheimer’s disease |
| - | in-vitro, | AD, | HT22 | - | in-vivo, | NA, | NA |
| 3027- | RosA, | Rosmarinic acid inhibits proliferation and invasion of hepatocellular carcinoma cells SMMC 7721 via PI3K/AKT/mTOR signal pathway |
| - | in-vitro, | HCC, | SMMC-7721 cell |
| 3026- | RosA, | Modulatory Effect of Rosmarinic Acid on H2O2-Induced Adaptive Glycolytic Response in Dermal Fibroblasts |
| - | in-vitro, | Nor, | NA |
| - | in-vivo, | IBD, | NA |
| 3024- | RosA, | rmMANF prevents sepsis-associated lung injury via inhibiting endoplasmic reticulum stress-induced ferroptosis in mice |
| - | in-vivo, | Sepsis, | NA |
| 3023- | RosA, | Rosmarinic acid alleviates septic acute respiratory distress syndrome in mice by suppressing the bronchial epithelial RAS-mediated ferroptosis |
| - | in-vivo, | Sepsis, | NA |
| 3022- | RosA, | Rosmarinic acid against cognitive impairment via RACK1/HIF-1α regulated microglial polarization in sepsis-surviving mice |
| - | in-vitro, | Sepsis, | NA |
| 3021- | RosA, | Rosmarinic acid ameliorates septic-associated mortality and lung injury in mice via GRP78/IRE1α/JNK pathway |
| - | in-vivo, | Sepsis, | NA |
| 3030- | RosA, | Anticancer Activity of Rosmarinus officinalis L.: Mechanisms of Action and Therapeutic Potentials |
| - | Review, | Var, | NA |
| - | in-vivo, | Nor, | NA |
| 3018- | RosA, | Rosemary (Rosmarinus officinalis L.) polyphenols and inflammatory bowel diseases: Major phytochemicals, functional properties, and health effects |
| - | Review, | IBD, | NA |
| - | in-vitro, | Lung, | A549 |
| 3016- | RosA, | Rosmarinic Acid Inhibits Cell Growth and Migration in Head and Neck Squamous Cell Carcinoma Cell Lines by Attenuating Epidermal Growth Factor Receptor Signaling |
| - | in-vitro, | HNSCC, | UM-SCC-6 | - | in-vitro, | HNSCC, | UM-SCC-10B |
| 3015- | RosA, | Rad, | Rosmarinic Acid Prevents Radiation-Induced Pulmonary Fibrosis Through Attenuation of ROS/MYPT1/TGFβ1 Signaling Via miR-19b-3p |
| - | in-vivo, | Nor, | IMR90 |
| 3014- | RosA, | Rosmarinic Acid Supplementation Acts as an Effective Antioxidant for Restoring the Antioxidation/Oxidation Balance in Wistar Rats with Cadmium-Induced Toxicity |
| - | in-vivo, | Nor, | NA |
| 3013- | RosA, | Rosmarinic acid inhibits angiogenesis and its mechanism of action in vitro |
| - | in-vitro, | NA, | NA |
| 3012- | RosA, | Rad, | Rosmarinic Acid Prevents Radiation-Induced Pulmonary Fibrosis Through Attenuation of ROSMYPT1TGFβ1 Signaling Via miR-19b-3p |
| - | in-vitro, | Nor, | IMR90 |
| 3010- | RosA, | Exploring the mechanism of rosmarinic acid in the treatment of lung adenocarcinoma based on bioinformatics methods and experimental validation |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | NA, | NA |
| 3001- | RosA, | Therapeutic Potential of Rosmarinic Acid: A Comprehensive Review |
| - | Review, | Var, | NA |
| 3002- | RosA, | Anticancer Effects of Rosemary (Rosmarinus officinalis L.) Extract and Rosemary Extract Polyphenols |
| - | Review, | Var, | NA |
| 3003- | RosA, | Comprehensive Insights into Biological Roles of Rosmarinic Acid: Implications in Diabetes, Cancer and Neurodegenerative Diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3004- | RosA, | Rosmarinic acid counteracts activation of hepatic stellate cells via inhibiting the ROS-dependent MMP-2 activity: Involvement of Nrf2 antioxidant system |
| - | in-vitro, | Nor, | HSC-T6 |
| 3005- | RosA, | Nanoformulated rosemary extract impact on oral cancer: in vitro study |
| - | in-vitro, | Laryn, | HEp2 |
| 3006- | RosA, | Rosmarinic acid attenuates glioblastoma cells and spheroids’ growth and EMT/stem-like state by PTEN/PI3K/AKT downregulation and ERK-induced apoptosis |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | LN229 |
| 3007- | RosA, | Hepatoprotective effects of rosmarinic acid: Insight into its mechanisms of action |
| - | Review, | NA, | NA |
| 3008- | RosA, | Rosmarinic acid decreases viability, inhibits migration and modulates expression of apoptosis-related CASP8/CASP3/NLRP3 genes in human metastatic melanoma cells |
| - | in-vitro, | Melanoma, | SK-MEL-28 |
| 3009- | RosA, | Rosmarinic acid sensitizes cell death through suppression of TNF-alpha-induced NF-kappaB activation and ROS generation in human leukemia U937 cells |
| - | in-vitro, | AML, | U937 |
| 3011- | RosA, | Rosmarinic Acid Exhibits Anticancer Effects via MARK4 Inhibition |
| - | in-vitro, | GBM, | SH-SY5Y | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | Nor, | MCF10 |
| 3039- | RosA, | Rosmarinic acid liposomes suppress ferroptosis in ischemic brain via inhibition of TfR1 in BMECs |
| - | in-vivo, | Nor, | NA | - | in-vivo, | Stroke, | NA |
| 3038- | RosA, | Prooxidant action of rosmarinic acid: transition metal-dependent generation of reactive oxygen species |
| - | in-vitro, | Nor, | NA |
| 3037- | RosA, | Unraveling rosmarinic acid anticancer mechanisms in oral cancer malignant transformation |
| - | in-vitro, | Oral, | SCC9 | - | in-vitro, | Oral, | HSC3 |
| 3036- | RosA, | Anti-Warburg effect of rosmarinic acid via miR-155 in colorectal carcinoma cells |
| - | in-vitro, | CRC, | HCT8 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | LS174T |
| 3035- | RosA, | Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling |
| - | in-vitro, | PC, | NA | - | in-vivo, | NA, | NA |
| 3034- | RosA, | RES, | Ba, | The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 3031- | RosA, | Effects of rosmarinic acid against aflatoxin B1 and ochratoxin-A-induced cell damage in a human hepatoma cell line (Hep G2) |
| - | in-vitro, | Liver, | HepG2 |
| 3757- | RosA, | Sage, | Croc, | NarG, | Caff | Food-derived Acetylcholinesterase Inhibitors as Potential Agents against Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3755- | RosA, | CUR, | Development of Acetylcholinesterase (AChE) Inhibitor |
| - | Study, | AD, | NA |
| 3792- | RosA, | Molecular docking and dynamics simulations revealed the potential inhibitory activity of honey-iQfood ingredients against GSK-3β and CDK5 protein targets for brain health |
| - | Analysis, | AD, | NA |
| 3618- | RosA, | Antioxidant and Antimicrobial Properties of Rosemary (Rosmarinus officinalis, L.): A Review |
| - | Review, | AD, | NA |
| 3615- | RosA, | Potential Therapeutic Use of the Rosemary Diterpene Carnosic Acid for Alzheimer's Disease, Parkinson's Disease, and Long-COVID through NRF2 Activation to Counteract the NLRP3 Inflammasome |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3616- | RosA, | Therapeutic effects of rosemary (Rosmarinus officinalis L.) and its active constituents on nervous system disorders |
| - | Review, | AD, | NA |
| 3617- | RosA, | Aroma, | Effect of aromatherapy on patients with Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3619- | RosA, | Rosmarinic acid suppresses Alzheimer’s disease development by reducing amyloid β aggregation by increasing monoamine secretion |
| - | Review, | AD, | NA |
| 3620- | RosA, | Rosmarinus officinalis and Methylphenidate Exposure Improves Cognition and Depression and Regulates Anxiety-Like Behavior in AlCl3-Induced Mouse Model of Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 3632- | RosA, | CA, | QC, | Evolving Role of Natural Products from Traditional Medicinal Herbs in the Treatment of Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3621- | RosA, | Short-Term Study on the Effects of Rosemary on Cognitive Function in an Elderly Population |
| - | Trial, | AD, | NA |
| 3622- | RosA, | Rosmarinic acid prevents lipid peroxidation and increase in acetylcholinesterase activity in brain of streptozotocin-induced diabetic rats |
| - | in-vivo, | Diabetic, | NA |
| 3623- | RosA, | Rosmarinic acid inhibits some metabolic enzymes including glutathione S-transferase, lactoperoxidase, acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase isoenzymes |
| - | in-vitro, | AD, | NA |
| 3932- | RT, | Rutin as a Natural Therapy for Alzheimer's Disease: Insights into its Mechanisms of Action |
| - | Review, | AD, | NA |
| 3933- | RT, | The Pharmacological Potential of Rutin |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA | - | Review, | Arthritis, | NA |
| 3934- | RT, | Rutin: A Potential Therapeutic Agent for Alzheimer Disease |
| - | Review, | AD, | NA |
| 3935- | RT, | Sodium rutin ameliorates Alzheimer's disease-like pathology by enhancing microglial amyloid-β clearance |
| - | in-vivo, | AD, | NA |
| 3936- | RT, | Rutin improves spatial memory in Alzheimer's disease transgenic mice by reducing Aβ oligomer level and attenuating oxidative stress and neuroinflammation |
| - | in-vivo, | AD, | NA |
| 3937- | RT, | Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer’s disease |
| - | in-vivo, | AD, | NA |
| 966- | RT, | Antioxidant Mechanism of Rutin on Hypoxia-Induced Pulmonary Arterial Cell Proliferation |
| - | vitro+vivo, | Nor, | NA |
| 1132- | RT, | Rutin Promotes Proliferation and Orchestrates Epithelial–Mesenchymal Transition and Angiogenesis in MCF-7 and MDA-MB-231 Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 4575- | RT, | SNP, | Rutin-Loaded Silver Nanoparticles With Antithrombotic Function |
| - | in-vivo, | NA, | NA |
| 1251- | RT, | OLST, | Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | PC, | PANC1 | - | in-vivo, | NA, | NA |
| 4217- | Sage, | RosA, | Aroma, | Neuroprotective Potential of Aromatic Herbs: Rosemary, Sage, and Lavender |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3643- | Sage, | Effects of cholinesterase inhibiting sage (Salvia officinalis) on mood, anxiety and performance on a psychological stressor battery |
| - | Human, | Nor, | NA |
| 3645- | Sage, | RosA, | Acetylcholinesterase inhibitory, antioxidant and phytochemical properties of selected medicinal plants of the Lamiaceae family |
| - | Study, | AD, | NA |
| 3644- | Sage, | Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers |
| - | Human, | AD, | NA |
| 3642- | Sage, | Chronic Supplementation with a Mix of Salvia officinalis and Salvia lavandulaefolia Improves Morris Water Maze Learning in Normal Adult C57Bl/6J Mice |
| - | in-vivo, | AD, | NA |
| 3641- | Sage, | Systematic Review of Clinical Trials Assessing Pharmacological Properties of Salvia Species on Memory, Cognitive Impairment and Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3640- | Sage, | Evaluation of Traditional Herb Extract Salvia officinalis in Treatment of Alzheimers Disease |
| - | in-vivo, | AD, | NA |
| 3639- | Sage, | Pharmacological properties of Salvia officinalis and its components |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 3638- | Sage, | Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial |
| - | Trial, | AD, | NA |
| 2040- | SAHA, | The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | CRC, | T24 | - | in-vitro, | BC, | MCF-7 |
| 323- | Sal, | SNP, | Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Ovarian, | A2780S |
| 3939- | SAMe, | VitB12, | ALC, | Efficacy of a Vitamin/Nutriceutical Formulation for Moderate-stage to Later-stage Alzheimer's disease: A Placebo-controlled Pilot Study |
| - | Trial, | NA, | NA |
| 3938- | SAMe, | S-adenosyl-L-methionine in the treatment of Alzheimer's disease |
| - | Human, | AD, | NA |
| 4115- | SAMe, | Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. |
| - | Review, | AD, | NA |
| 4114- | SAMe, | S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research |
| - | Review, | AD, | NA |
| 1210- | SANG, | Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1α pathways in breast cancer |
| - | in-vitro, | BC, | NA |
| 1209- | SANG, | Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration |
| - | in-vitro, | Lung, | A549 |
| 1208- | SANG, | Sanguinarine induces apoptosis in osteosarcoma by attenuating the binding of STAT3 to the single-stranded DNA-binding protein 1 (SSBP1) promoter region |
| - | in-vitro, | OS, | NA |
| 1134- | SANG, | Sanguinarine inhibits epithelial–mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | HUH7 |
| 1090- | SANG, | Sanguinarine inhibits invasiveness and the MMP-9 and COX-2 expression in TPA-induced breast cancer cells by inducing HO-1 expression. |
| - | in-vitro, | BC, | MCF-7 |
| 1307- | SANG, | Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway |
| - | in-vitro, | CRC, | HT-29 |
| 1388- | Sco, | Scoulerine promotes cell viability reduction and apoptosis by activating ROS-dependent endoplasmic reticulum stress in colorectal cancer cells |
| - | in-vitro, | CRC, | NA |
| 1403- | SDT, | BBR, | From 2D to 3D In Vitro World: Sonodynamically-Induced Prooxidant Proapoptotic Effects of C60-Berberine Nanocomplex on Cancer Cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | LLC1 |
| 2548- | SDT, | Sonoporation, a Novel Frontier for Cancer Treatment: A Review of the Literature |
| - | Review, | Var, | NA |
| 2537- | SDT, | Design and Challenges of Sonodynamic Therapy System for Cancer Theranostics: From Equipment to Sensitizers |
| - | Review, | Var, | NA |
| 2536- | SDT, | Sonodynamic Therapy: Rapid Progress and New Opportunities for Non-Invasive Tumor Cell Killing with Sound |
| - | Review, | Var, | NA |
| 2549- | SDT, | Landscape of Cellular Bioeffects Triggered by Ultrasound-Induced Sonoporation |
| - | Review, | Var, | NA |
| 2550- | SDT, | Intracellular Delivery and Calcium Transients Generated in Sonoporation Facilitated by Microbubbles |
| - | in-vitro, | Nor, | NA |
| 2551- | SDT, | Sonoporation: Past, Present, and Future |
| - | Review, | Var, | NA |
| 4608- | Se, | Selenium Nanoparticles for Biomedical Applications: From Development and Characterization to Therapeutics |
| - | Review, | Var, | NA | - | NA, | AD, | NA |
| 4615- | Se, | Rad, | Selenium as an adjuvant for modification of radiation response |
| - | Review, | Nor, | NA |
| 4614- | Se, | Rad, | Updates on clinical studies of selenium supplementation in radiotherapy |
| - | Review, | Nor, | NA |
| 4613- | Se, | Rad, | Effect of Selenium and Selenoproteins on Radiation Resistance |
| - | Review, | Nor, | NA |
| 4612- | Se, | Rad, | Histopathological Evaluation of Radioprotective Effects: Selenium Nanoparticles Protect Lung Tissue from Radiation Damage |
| - | in-vivo, | Nor, | NA |
| 4611- | Se, | Rad, | Radioprotective Effect of Selenium Nanoparticles: A Mini Review |
| - | Review, | Var, | NA |
| 4610- | Se, | Rad, | Protection during radiotherapy: selenium |
| - | Review, | Var, | NA |
| 4601- | Se, | SNP, | Antioxidant and hepatoprotective role of selenium against silver nanoparticles |
| - | in-vivo, | Nor, | NA |
| 4602- | Se, | SNP, | GoldNP, | Advances in nephroprotection: the therapeutic role of selenium, silver, and gold nanoparticles in renal health |
| - | NA, | Nor, | NA |
| 4603- | Se, | Therapeutic applications of selenium nanoparticles |
| - | Review, | Var, | NA |
| 4604- | Se, | SNP, | Chit, | The ameliorative effect of selenium-loaded chitosan nanoparticles against silver nanoparticles-induced ovarian toxicity in female albino rats |
| - | in-vivo, | Nor, | NA |
| 4605- | Se, | Selenium nanoparticles: An insight on its Pro-oxidant andantioxidant properties |
| - | Review, | NA, | NA |
| 4606- | Se, | VitC, | Antibacterial and anti-biofilm efficacy of selenium nanoparticles against Pseudomonas aeruginosa: Characterization and in vitro analysis |
| - | in-vitro, | NA, | NA |
| 4607- | Se, | SNP, | A Review on synthesis and their antibacterial activity of Silver and Selenium nanoparticles against biofilm forming Staphylococcus aureus |
| - | Review, | NA, | NA |
| 4609- | Se, | Physiological Benefits of Novel Selenium Delivery via Nanoparticles |
| - | Review, | Var, | NA | - | Review, | IBD, | NA | - | Review, | Diabetic, | NA |
| 4725- | Se, | Targeting the Nrf2-Prx1 Pathway with Selenium to Enhance the Efficacy and Selectivity of Cancer Therapy |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | CRC, | HT29 |
| 4727- | Se, | Selenium inhibits ferroptosis in ulcerative colitis through the induction of Nrf2/Gpx4 |
| - | in-vivo, | Col, | NA |
| 4724- | Se, | Chapter Four - Selenium in the Redox Regulation of the Nrf2 and the Wnt Pathway |
| - | Review, | Var, | NA |
| 4723- | Se, | Selenium Induces Ferroptosis in Colorectal Cancer Cells via Direct Interaction with Nrf2 and Gpx4 |
| - | in-vitro, | CRC, | HCT116 |
| 4722- | Se, | The Yin and Yang of Nrf2-Regulated Selenoproteins in Carcinogenesis |
| - | Review, | Var, | NA |
| 4721- | Se, | A review on selenium nanoparticles and their biomedical applications |
| - | Review, | AD, | NA | - | Review, | Diabetic, | NA | - | Review, | Arthritis, | NA |
| 4720- | Se, | Selenium Nanoparticle in the Management of Oxidative Stress During Cancer Chemotherapy |
| - | Review, | Var, | NA |
| - | in-vivo, | Var, | NA |
| 4718- | Se, | High-Dose Selenium Induces Ferroptotic Cell Death in Ovarian Cancer |
| - | in-vitro, | Ovarian, | NA |
| 4717- | Se, | A systematic review of Selenium as a complementary treatment in cancer patients |
| - | Review, | Var, | NA |
| 4716- | Se, | Selenium Substitution During Radiotherapy of Solid Tumours – Laboratory Data from Two Observation Studies in Gynaecological and Head and Neck Cancer Patients |
| - | in-vivo, | HNSCC, | NA |
| 4715- | Se, | The Interaction of Selenium with Chemotherapy and Radiation on Normal and Malignant Human Mononuclear Blood Cells |
| 4714- | Se, | Selenium in cancer management: exploring the therapeutic potential |
| - | Review, | Var, | NA |
| 4713- | Se, | VitC, | VitK3, | Selenium supplementation protects cancer cells from the oxidative stress and cytotoxicity induced by the combination of ascorbate and menadione sodium bisulfite |
| - | in-vitro, | GBM, | NA |
| 4712- | Se, | Selenium and selenoproteins: key regulators of ferroptosis and therapeutic targets in cancer |
| - | Review, | Var, | NA |
| 4711- | Se, | Association of selenium status and blood glutathione concentrations in blacks and whites |
| - | Human, | Nor, | NA |
| 4741- | Se, | Selenium in Oncological Intervention |
| - | Review, | Var, | NA |
| 4756- | Se, | Selenium‐Containing Nanoparticles Combine the NK Cells Mediated Immunotherapy with Radiotherapy and Chemotherapy |
| 4755- | Se, | Chemo, | Selenium Prevention of Alopecia, Bladder and Kidney Toxicity Induced by Chemotherapeutic Agents |
| - | in-vitro, | Var, | NA |
| 4754- | Se, | Chemo, | The effect of selenium yeast in the prevention of adverse reactions related to platinum-based combination therapy in patients with malignant tumors |
| - | Trial, | Var, | NA |
| 4753- | Se, | Chemo, | Selenium and Lung Cancer: A Systematic Review and Meta Analysis |
| - | Review, | Lung, | NA |
| 4752- | Se, | CUR, | Chemo, | Curcumin-Modified Selenium Nanoparticles Improve S180 Tumour Therapy in Mice by Regulating the Gut Microbiota and Chemotherapy |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | sarcoma, | S180 |
| 4751- | Se, | Chemo, | Selenium Protects Against Toxicity Induced by Anticancer Drugs and Augments Antitumor Activity: A Highly Selective, New, and Novel Approach for the Treatment of Solid Tumors |
| - | in-vivo, | Var, | NA |
| 4750- | Se, | Rad, | Selenium in Radiation Oncology—15 Years of Experiences in Germany |
| - | Review, | Var, | NA |
| 4749- | Se, | Chemo, | antiOx, | Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy |
| - | Trial, | Ovarian, | NA |
| - | Trial, | GC, | NA |
| 4747- | Se, | Chemo, | antiOx, | Phase I trial of selenium plus chemotherapy in gynecologic cancers |
| - | Trial, | Ovarian, | NA |
| 4745- | Se, | Chemo, | Translational Selenium Nanoparticles Promotes Clinical Non-small-cell Lung Cancer Chemotherapy via Activating Selenoprotein-driven Immune Manipulation |
| - | Study, | NSCLC, | NA |
| 4744- | Se, | Chemo, | antiOx, | Ingestion of selenium and other antioxidants during prostate cancer radiotherapy: A good thing? |
| - | Review, | Pca, | NA |
| 4743- | Se, | Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients |
| - | Review, | Var, | NA |
| 4742- | Se, | Antitumor Effects of Selenium |
| - | Review, | Var, | NA | - | Review, | Arthritis, | NA | - | Review, | Sepsis, | NA |
| 4726- | Se, | Oxy, | Oxygen therapy accelerates apoptosis induced by selenium compounds via regulating Nrf2/MAPK signaling pathway in hepatocellular carcinoma |
| - | in-vivo, | HCC, | NA |
| 4740- | Se, | Optimising Selenium for Modulation of Cancer Treatments |
| - | Review, | Var, | NA |
| 4739- | Se, | Chemo, | Rad, | Therapeutic Benefits of Selenium in Hematological Malignancies |
| - | Review, | Var, | NA |
| 4738- | Se, | doxoR, | Selenium Attenuates Doxorubicin-Induced Cardiotoxicity Through Nrf2-NLRP3 Pathway |
| - | NA, | Nor, | NA |
| 4737- | Se, | Rad, | Nrf2-modulation by seleno-hormetic agents and its potential for radiation protection |
| - | in-vivo, | Var, | NA |
| 4736- | Se, | SFN, | Synergy between sulforaphane and selenium in protection against oxidative damage in colonic CCD841 cells |
| - | in-vitro, | Nor, | CCD841 |
| 4735- | Se, | Selenium triggers Nrf2-AMPK crosstalk to alleviate cadmium-induced autophagy in rabbit cerebrum |
| - | in-vivo, | Nor, | NA |
| 4734- | Se, | CPT-11, | Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles |
| - | in-vitro, | CRC, | HCT8 | - | in-vivo, | NA, | NA |
| 4733- | Se, | Selenium supplementation of lung epithelial cells enhances nuclear factor E2-related factor 2 (Nrf2) activation following thioredoxin reductase inhibition |
| - | NA, | Nor, | NA |
| 4732- | Se, | Selenium inhibits ferroptosis and ameliorates autistic-like behaviors of BTBR mice by regulating the Nrf2/GPx4 pathway |
| - | in-vivo, | Autism, | NA |
| 4731- | Se, | Dietary selenium mitigates cadmium-induced apoptosis and inflammation in chicken testicles by inhibiting oxidative stress through the activation of the Nrf2/HO-1 signaling pathway |
| - | in-vivo, | Nor, | NA |
| 4730- | Se, | Association between plasma selenium level and NRF2 target genes expression in humans |
| - | Human, | Nor, | NA |
| 4729- | Se, | Selenium regulates Nrf2 signaling to prevent hepatotoxicity induced by hexavalent chromium in broilers |
| 4728- | Se, | Selective Impact of Selenium Compounds on Two Cytokine Storm Players |
| - | NA, | Covid, | NA |
| 4757- | Se, | Chemo, | The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients |
| - | Trial, | NA, | NA |
| 4494- | Se, | Advances in the study of selenium and human intestinal bacteria |
| - | Review, | IBD, | NA | - | Review, | Var, | NA |
| 4469- | Se, | Selenium Nanoparticles in Cancer Therapy: Unveiling Cytotoxic Mechanisms and Therapeutic Potential |
| - | Review, | Var, | NA |
| 4495- | Se, | Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort |
| - | Study, | CRC, | NA |
| 4496- | Se, | Selenium status and survival from colorectal cancer in the European prospective investigation of cancer and nutrition |
| - | Analysis, | CRC, | NA |
| 4497- | Se, | Selenium and inflammatory bowel disease |
| - | Review, | Var, | NA | - | Review, | IBD, | NA |
| 4498- | Se, | Selenium in Human Health and Gut Microflora: Bioavailability of Selenocompounds and Relationship With Diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | IBD, | NA |
| 4499- | Se, | Selenium and Selenoproteins in Gut Inflammation—A Review |
| - | Review, | IBD, | NA |
| 4500- | Se, | Dietary selenium affects host selenoproteome expression by influencing the gut microbiota |
| - | in-vivo, | Nor, | NA |
| 4501- | Se, | Mechanisms of the Cytotoxic Effect of Selenium Nanoparticles in Different Human Cancer Cell Lines |
| - | in-vitro, | GBM, | A172 | - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | L929 |
| 4502- | Se, | Modulatory effects of selenium nanoparticles on gut microbiota and metabolites of juvenile Nile tilapia (Oreochromis niloticus) by microbiome-metabolomic analysis |
| - | in-vivo, | Nor, | NA |
| 4503- | Se, | Prophylactic supplementation with biogenic selenium nanoparticles mitigated intestinal barrier oxidative damage through suppressing epithelial-immune crosstalk with gut-on-a-chip |
| - | in-vitro, | Nor, | NA |
| 4504- | Se, | Chit, | FA, | doxoR, | pH-responsive selenium nanoparticles stabilized by folate-chitosan delivering doxorubicin for overcoming drug-resistant cancer cells |
| - | in-vitro, | Var, | NA |
| 4453- | Se, | Selenium Nanoparticles: Green Synthesis and Biomedical Application |
| - | Review, | NA, | NA |
| 4452- | Se, | Chit, | Antioxidant capacities of the selenium nanoparticles stabilized by chitosan |
| - | in-vitro, | Nor, | 3T3 |
| 4451- | Se, | Effects of chitosan-stabilized selenium nanoparticles on cell proliferation, apoptosis and cell cycle pattern in HepG2 cells: comparison with other selenospecies |
| - | in-vitro, | Liver, | HepG2 |
| 4450- | Se, | Functionalized selenium nanoparticles with nephroprotective activity, the important roles of ROS-mediated signaling pathways |
| - | in-vitro, | Kidney, | NA |
| 4449- | Se, | PEG-nanolized ultrasmall selenium nanoparticles overcome drug resistance in hepatocellular carcinoma HepG2 cells through induction of mitochondria dysfunction |
| - | in-vitro, | Liver, | HepG2 |
| 4448- | Se, | Selenium Nanoparticles: A Comprehensive Examination of Synthesis Techniques and Their Diverse Applications in Medical Research and Toxicology Studies |
| - | Review, | Nor, | NA |
| 4446- | Se, | Antioxidant and Hepatoprotective Effects of Moringa oleifera-mediated Selenium Nanoparticles in Diabetic Rats. |
| - | in-vivo, | Diabetic, | NA |
| 4445- | Se, | DFE, | A comparative study on the hepatoprotective effect of selenium-nanoparticles and dates flesh extract on carbon tetrachloride induced liver damage in albino rats |
| - | in-vivo, | LiverDam, | NA |
| 4444- | Se, | Antioxidant and Hepatoprotective Efficiency of Selenium Nanoparticles Against Acetaminophen-Induced Hepatic Damage |
| - | in-vivo, | LiverDam, | NA |
| 4443- | Se, | Bioogenic selenium and its hepatoprotective activity |
| - | in-vivo, | LiverDam, | NA |
| 4441- | Se, | The Role of Selenium Nanoparticles in the Treatment of Liver Pathologies of Various Natures |
| - | Review, | Nor, | NA |
| 4440- | Se, | SNP, | Selenium, silver, and gold nanoparticles: Emerging strategies for hepatic oxidative stress and inflammation reduction |
| - | Review, | NA, | NA |
| 4492- | Se, | Selenium in cancer prevention: a review of the evidence and mechanism of action |
| - | Review, | Var, | NA |
| 4470- | Se, | Chit, | Synthesis and cytotoxic activities of selenium nanoparticles incorporated nano-chitosan |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 |
| 4471- | Se, | Green synthesis of selenium nanoparticles with extract of hawthorn fruit induced HepG2 cells apoptosis |
| - | in-vitro, | Liver, | HepG2 |
| 4472- | Se, | Therapeutic potential of selenium nanoparticles |
| - | Review, | Var, | NA |
| 4473- | Se, | Anti-cancerous effect and biological evaluation of green synthesized Selenium nanoparticles on MCF-7 breast cancer and HUVEC cell lines |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HUVECs |
| 4474- | Se, | In vitro growth of gut microbiota with selenium nanoparticles |
| 4467- | Se, | VitC, | Chit, | Nano-chitosan-coated, green-synthesized selenium nanoparticles as a novel antifungal agent against Sclerotinia sclerotiorum in vitro study |
| - | Study, | NA, | NA |
| 4466- | Se, | Synthesis and Characterization of Selenium Nanoparticles and its Effects on in vitro Rumen Feed Degradation, Ruminal Parameters, and Total Gas Production |
| - | Study, | NA, | NA |
| 4465- | Se, | VitC, | Selenium nanoparticles: Synthesis, in-vitro cytotoxicity, antioxidant activity and interaction studies with ct-DNA and HSA, HHb and Cyt c serum proteins |
| - | Study, | NA, | NA |
| 4464- | Se, | Antioxidant Properties of Selenium Nanoparticles Synthesized Using Tea and Herb Water Extracts |
| - | Study, | NA, | NA |
| 4463- | Se, | VitC, | Selenium nanoparticles: Synthesis, characterization and study of their cytotoxicity, antioxidant and antibacterial activity |
| - | Study, | Nor, | NA |
| 4480- | Se, | Chit, | Biogenic synthesized selenium nanoparticles combined chitosan nanoparticles controlled lung cancer growth via ROS generation and mitochondrial damage pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HK-2 |
| 4461- | Se, | VitC, | Synthesis, Characterization, and Cytotoxic Evaluation of Selenium Nanoparticles |
| 4457- | Se, | Selenium nanoparticles: a review on synthesis and biomedical applications |
| - | Review, | Var, | NA | - | NA, | Diabetic, | NA |
| 4491- | Se, | Chit, | VitC, | Synthesis of a Bioactive Composition of Chitosan–Selenium Nanoparticles |
| - | Study, | NA, | NA |
| 4458- | Se, | Selenium Nanoparticles for Antioxidant Activity and Selenium Enrichment in Plants |
| 4459- | Se, | VitC, | Nano and mesosized selenium and its synthesis using the ascorbic acid route |
| 4488- | Se, | Chit, | PEG, | Anticancer effect of selenium/chitosan/polyethylene glycol/allyl isothiocyanate nanocomposites against diethylnitrosamine-induced liver cancer in rats |
| - | in-vivo, | Liver, | HepG2 | - | in-vivo, | Nor, | HL7702 |
| 4460- | Se, | VitC, | Ascorbic acid-mediated selenium nanoparticles as potential antihyperuricemic, antioxidant, anticoagulant, and thrombolytic agents |
| 4486- | Se, | Chit, | Selenium-Modified Chitosan Induces HepG2 Cell Apoptosis and Differential Protein Analysis |
| - | in-vitro, | Liver, | HepG2 |
| 4462- | Se, | VitC, | Selenium nanoparticles: influence of reducing agents on particle stability and antibacterial activity at biogenic concentrations |
| - | Study, | Nor, | NA |
| 4485- | Se, | Selenium stimulates the antitumour immunity: Insights to future research |
| - | Review, | NA, | NA |
| 4484- | Se, | Chit, | PEG, | Anti-cancer potential of selenium-chitosan-polyethylene glycol-carvacrol nanocomposites in multiple myeloma U266 cells |
| - | in-vitro, | Melanoma, | U266 |
| 4483- | Se, | Chit, | Anti-cancer potential of chitosan-starch selenium Nanocomposite: Targeting osteoblastoma and insights of molecular docking |
| - | in-vitro, | OS, | NA |
| 4085- | Se, | Role of micronutrients in Alzheimer's disease: Review of available evidence |
| - | Review, | AD, | NA |
| 4214- | Se, | Selenium ameliorates cognitive impairment through activating BDNF/TrkB pathway |
| - | in-vivo, | NA, | NA |
| 4216- | Se, | Selenium ameliorates mercuric chloride-induced brain damage through activating BDNF/TrKB/PI3K/AKT and inhibiting NF-κB signaling pathways |
| - | in-vitro, | NA, | NA |
| 2140- | Se, | Selenium Exposure and Cancer Risk: an Updated Meta-analysis and Meta-regression |
| - | Review, | Var, | NA |
| 2141- | Se, | Selenium and cancer risk: Wide-angled Mendelian randomization analysis |
| - | Review, | NA, | NA |
| 2142- | Se, | A U-shaped association between selenium intake and cancer risk |
| - | Review, | NA, | NA |
| 1698- | Se, | Association between Dietary Zinc and Selenium Intake, Oxidative Stress-Related Gene Polymorphism, and Colorectal Cancer Risk in Chinese Population - A Case-Control Study |
| - | Human, | CRC, | NA |
| 1697- | Se, | Calc, | Calcium intake may explain the reduction of colorectal cancer odds by dietary selenium - a case-control study in Poland |
| - | Human, | CRC, | NA |
| 1687- | Se, | Selenium for preventing cancer |
| - | Analysis, | Var, | NA |
| 1688- | Se, | Potential Role of Selenium in the Treatment of Cancer and Viral Infections |
| - | Review, | Var, | NA |
| 1689- | Se, | Selenium and breast cancer - An update of clinical and epidemiological data |
| - | Analysis, | BC, | NA |
| 1690- | Se, | Selenium and cancer: a story that should not be forgotten-insights from genomics |
| - | Review, | Var, | NA |
| 1691- | Se, | The influence of selenium and selenoprotein gene variants on colorectal cancer risk |
| - | Analysis, | CRC, | NA |
| 1692- | Se, | Association of Selenoprotein and Selenium Pathway Genotypes with Risk of Colorectal Cancer and Interaction with Selenium Status |
| - | Analysis, | CRC, | NA |
| 1693- | Se, | Prediagnostic selenium status, selenoprotein gene variants and association with breast cancer risk in a European cohort study |
| - | Analysis, | BC, | NA |
| 1694- | Se, | Expression of Selenoprotein Genes and Association with Selenium Status in Colorectal Adenoma and Colorectal Cancer |
| - | Analysis, | CRC, | NA |
| 1695- | Se, | Serum Selenium Concentration as a Potential Diagnostic Marker for Early-Stage Colorectal Cancer: A Comparative Study |
| - | Trial, | CRC, | NA |
| 1696- | Se, | Selenium dietary intake and survival among CRC patients |
| - | Human, | CRC, | NA |
| 1707- | Se, | A Diet Lacking Selenium, but Not Zinc, Copper or Manganese, Induces Anticancer Activity in Mice with Metastatic Cancers |
| - | in-vivo, | Ovarian, | NA | - | in-vivo, | BC, | NA |
| 1706- | Se, | Selenium in Prostate Cancer: Prevention, Progression, and Treatment |
| - | Review, | Pca, | NA |
| 1705- | Se, | Serum Selenium Level and 10-Year Survival after Melanoma |
| - | Study, | Melanoma, | NA |
| 1704- | Se, | Prospective study of toenail selenium levels and cancer among women |
| - | Study, | Var, | NA |
| 1703- | Se, | An Assessment of Serum Selenium Concentration in Women with Endometrial Cancer |
| - | Study, | EC, | NA |
| 1702- | Se, | Supplemental Selenium May Decrease Ovarian Cancer Risk in African-American Women |
| - | Human, | Ovarian, | NA |
| 1701- | Se, | An Assessment of Serum Selenium Concentration in Women with Ovarian Cancer |
| - | Human, | Ovarian, | NA |
| 1700- | Se, | Metabolism of Selenium, Selenocysteine, and Selenoproteins in Ferroptosis in Solid Tumor Cancers |
| - | Review, | Var, | NA |
| 1699- | Se, | Vegetarianism and colorectal cancer risk in a low-selenium environment: effect modification by selenium status? A possible factor contributing to the null results in British vegetarians |
| - | Analysis, | CRC, | NA |
| 984- | Sel, | Effects of selenite on estrogen receptor-alpha expression and activity in MCF-7 breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 1018- | Sel, | Selenite-induced autophagy antagonizes apoptosis in colorectal cancer cells in vitro and in vivo |
| - | vitro+vivo, | CRC, | HCT116 | - | vitro+vivo, | CRC, | SW480 |
| - | vitro+vivo, | Lung, | NA |
| 1002- | Sel, | Osi, | Adag, | Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference |
| - | in-vitro, | Lung, | H1975 | - | in-vitro, | Lung, | H385 |
| 1062- | Sel, | Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | U87MG |
| 1017- | Sel, | Selenite induces apoptosis in colorectal cancer cells via AKT-mediated inhibition of β-catenin survival axis |
| - | vitro+vivo, | CRC, | NA |
| 1135- | Selenate, | Selenate induces epithelial-mesenchymal transition in a colorectal carcinoma cell line by AKT activation |
| - | in-vitro, | CRC, | DLD1 |
| 4190- | Sesame, | Sesame Seeds: A Nutrient-Rich Superfood |
| - | Review, | NA, | NA |
| 4189- | Sesame, | Sesame oil mitigates memory impairment, oxidative stress, and neurodegeneration in a rat model of Alzheimer's disease. A pivotal role of NF-κB/p38MAPK/BDNF/PPAR-γ pathways |
| - | in-vivo, | AD, | NA |
| 4202- | SFN, | Regulation of BDNF transcription by Nrf2 and MeCP2 ameliorates MPTP-induced neurotoxicity |
| - | Review, | Park, | NA |
| 4201- | SFN, | Activation of BDNF by transcription factor Nrf2 contributes to antidepressant-like actions in rodents |
| - | in-vivo, | NA, | NA |
| 4200- | SFN, | Sulforaphane activates anti-inflammatory microglia, modulating stress resilience associated with BDNF transcription |
| - | in-vitro, | NA, | NA |
| 4199- | SFN, | Sulforaphane and Brain Health: From Pathways of Action to Effects on Specific Disorders |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4198- | SFN, | Sulforaphane epigenetically enhances neuronal BDNF expression and TrkB signaling pathways |
| - | vitro+vivo, | AD, | NA |
| 3664- | SFN, | Sulforaphane Upregulates the Heat Shock Protein Co-Chaperone CHIP and Clears Amyloid-β and Tau in a Mouse Model of Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 3663- | SFN, | Efficacy of Sulforaphane in Neurodegenerative Diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3662- | SFN, | Sulforaphane Inhibits the Generation of Amyloid-β Oligomer and Promotes Spatial Learning and Memory in Alzheimer's Disease (PS1V97L) Transgenic Mice |
| - | in-vivo, | AD, | NA |
| 3661- | SFN, | Beneficial Effects of Sulforaphane Treatment in Alzheimer's Disease May Be Mediated through Reduced HDAC1/3 and Increased P75NTR Expression |
| - | in-vitro, | AD, | NA |
| 3656- | SFN, | Chronic diseases, inflammation, and spices: how are they linked? |
| - | Review, | AD, | NA |
| 3657- | SFN, | Sulforaphane exerts its anti-inflammatory effect against amyloid-β peptide via STAT-1 dephosphorylation and activation of Nrf2/HO-1 cascade in human THP-1 macrophages |
| - | NA, | AD, | THP1 |
| 3658- | SFN, | Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3659- | SFN, | Epigenetic modification of Nrf2 by sulforaphane increases the antioxidative and anti-inflammatory capacity in a cellular model of Alzheimer's disease |
| - | in-vitro, | AD, | NA |
| 3660- | SFN, | Sulforaphane - role in aging and neurodegeneration |
| - | Review, | AD, | NA |
| 1733- | SFN, | Sonic Hedgehog Signaling Inhibition Provides Opportunities for Targeted Therapy by Sulforaphane in Regulating Pancreatic Cancer Stem Cell Self-Renewal |
| - | in-vitro, | PC, | PanCSC | - | in-vitro, | Nor, | HPNE | - | in-vitro, | Nor, | HNPSC |
| 1722- | SFN, | Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems |
| - | Review, | Var, | NA |
| 1725- | SFN, | Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway |
| - | Review, | Var, | NA |
| 1732- | SFN, | Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | SUM159 | - | in-vivo, | NA, | NA |
| 1734- | SFN, | Sulforaphane Inhibits Nonmuscle Invasive Bladder Cancer Cells Proliferation through Suppression of HIF-1α-Mediated Glycolysis in Hypoxia |
| - | in-vitro, | Bladder, | RT112 |
| 1735- | SFN, | Activation of multiple molecular mechanisms for apoptosis in human malignant glioblastoma T98G and U87MG cells treated with sulforaphane |
| - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | U87MG |
| 1736- | SFN, | Antitumor and antimetastatic effects of dietary sulforaphane in a triple-negative breast cancer models |
| - | in-vitro, | BC, | NA | - | in-vivo, | BC, | NA |
| 1731- | SFN, | Targeting cancer stem cells with sulforaphane, a dietary component from broccoli and broccoli sprouts |
| - | Review, | Var, | NA |
| 1730- | SFN, | Sulforaphane: An emergent anti-cancer stem cell agent |
| - | Review, | Var, | NA |
| 1729- | SFN, | Discovery and development of sulforaphane as a cancer chemopreventive phytochemical |
| - | Review, | Nor, | NA |
| 1728- | SFN, | Broccoli sprouts: An exceptionally rich source of inducers of enzymes that protect against chemical carcinogens |
| - | Review, | Nor, | NA |
| 1727- | SFN, | Glucoraphanin, sulforaphane and myrosinase activity in germinating broccoli sprouts as affected by growth temperature and plant organs |
| - | Analysis, | Nor, | NA |
| 1726- | SFN, | Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential |
| - | Review, | Var, | NA |
| 1724- | SFN, | Sulforaphane: A review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials |
| - | Review, | Var, | NA |
| 1723- | SFN, | Sulforaphane as a potential remedy against cancer: Comprehensive mechanistic review |
| - | Review, | Var, | NA |
| 1494- | SFN, | doxoR, | Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model |
| - | in-vivo, | BC, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 1455- | SFN, | Sulforaphane Activates a lysosome-dependent transcriptional program to mitigate oxidative stress |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | 1321N1 |
| - | in-vitro, | Bladder, | T24 |
| 1483- | SFN, | Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment |
| - | in-vitro, | OS, | 143B | - | in-vitro, | Nor, | HEK293 | - | in-vivo, | OS, | NA |
| 1484- | SFN, | Sulforaphane’s Multifaceted Potential: From Neuroprotection to Anticancer Action |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 1430- | SFN, | Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy |
| - | Trial, | BC, | NA |
| 1429- | SFN, | Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast |
| - | in-vivo, | Nor, | NA | - | Human, | Nor, | NA |
| 1428- | SFN, | Broccoli or Sulforaphane: Is It the Source or Dose That Matters? |
| - | Review, | NA, | NA |
| 1454- | SFN, | Absorption and chemopreventive targets of sulforaphane in humans following consumption of broccoli sprouts or a myrosinase-treated broccoli sprout extract |
| - | Human, | Nor, | NA |
| 1453- | SFN, | Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7 |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 1452- | SFN, | Sulforaphane Suppresses the Nicotine-Induced Expression of the Matrix Metalloproteinase-9 via Inhibiting ROS-Mediated AP-1 and NF-κB Signaling in Human Gastric Cancer Cells |
| - | in-vitro, | GC, | AGS |
| 1432- | SFN, | Evaluation of biodistribution of sulforaphane after administration of oral broccoli sprout extract in melanoma patients with multiple atypical nevi |
| - | Human, | Melanoma, | NA |
| 1434- | SFN, | GEM, | Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity |
| - | in-vitro, | CCA, | HuCCT1 | - | in-vitro, | CCA, | HuH28 | - | in-vivo, | NA, | NA |
| 1481- | SFN, | docx, | Combination of Low-Dose Sulforaphane and Docetaxel on Mitochondrial Function and Metabolic Reprogramming in Prostate Cancer Cell Lines |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 1495- | SFN, | doxoR, | Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation |
| - | in-vivo, | Nor, | NA |
| 1496- | SFN, | VitD3, | Association between histone deacetylase activity and vitamin D-dependent gene expressions in relation to sulforaphane in human colorectal cancer cells |
| - | in-vitro, | CRC, | Caco-2 |
| 1497- | SFN, | Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells |
| - | in-vitro, | Nor, | PrEC | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 1498- | SFN, | Prolonged sulforaphane treatment activates survival signaling in nontumorigenic NCM460 colon cells but apoptotic signaling in tumorigenic HCT116 colon cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | NCM460 |
| 1499- | SFN, | Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway |
| - | in-vitro, | BC, | NA |
| 1500- | SFN, | A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase |
| - | in-vitro, | Nor, | HEK293 | - | in-vitro, | CRC, | HCT116 |
| 1501- | SFN, | The Inhibitory Effect of Sulforaphane on Bladder Cancer Cell Depends on GSH Depletion-Induced by Nrf2 Translocation |
| - | in-vitro, | CRC, | T24 |
| 1502- | SFN, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
| - | Review, | NA, | NA |
| 1436- | SFN, | PacT, | docx, | Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells |
| - | in-vivo, | BC, | SUM159 |
| 1437- | SFN, | Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition |
| - | Review, | NA, | NA |
| 1468- | SFN, | Cellular responses to dietary cancer chemopreventive agent D,L-sulforaphane in human prostate cancer cells are initiated by mitochondrial reactive oxygen species |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 1456- | SFN, | Sulforaphane regulates cell proliferation and induces apoptotic cell death mediated by ROS-cell cycle arrest in pancreatic cancer cells |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 |
| 1457- | SFN, | Sulforaphane Inhibits IL-1β-Induced IL-6 by Suppressing ROS Production, AP-1, and STAT3 in Colorectal Cancer HT-29 Cells |
| - | in-vitro, | CRC, | HT-29 |
| 1458- | SFN, | Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma |
| - | Review, | Bladder, | NA |
| 1459- | SFN, | Aur, | Auranofin Enhances Sulforaphane-Mediated Apoptosis in Hepatocellular Carcinoma Hep3B Cells through Inactivation of the PI3K/Akt Signaling Pathway |
| - | in-vitro, | Liver, | Hep3B | - | in-vitro, | Liver, | HepG2 |
| 1460- | SFN, | High levels of EGFR prevent sulforaphane-induced reactive oxygen species-mediated apoptosis in non-small-cell lung cancer cells |
| - | in-vitro, | Lung, | NA |
| 1461- | SFN, | Targets and mechanisms of sulforaphane derivatives obtained from cruciferous plants with special focus on breast cancer - contradictory effects and future perspectives |
| - | Review, | BC, | NA |
| 1462- | SFN, | Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells |
| - | in-vitro, | Bladder, | T24 |
| 1463- | SFN, | Sulforaphane induces reactive oxygen species-mediated mitotic arrest and subsequent apoptosis in human bladder cancer 5637 cells |
| - | in-vitro, | Bladder, | 5637 |
| 1464- | SFN, | d,l-Sulforaphane Induces ROS-Dependent Apoptosis in Human Gliomablastoma Cells by Inactivating STAT3 Signaling Pathway |
| - | in-vitro, | GBM, | NA |
| 1465- | SFN, | TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells |
| - | NA, | Bladder, | NA |
| 1466- | SFN, | Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway |
| - | vitro+vivo, | Thyroid, | FTC-133 |
| 1467- | SFN, | Sulforaphane generates reactive oxygen species leading to mitochondrial perturbation for apoptosis in human leukemia U937 cells |
| - | in-vitro, | AML, | U937 |
| 1480- | SFN, | Sulforaphane Induces Cell Death Through G2/M Phase Arrest and Triggers Apoptosis in HCT 116 Human Colon Cancer Cells |
| - | in-vitro, | CRC, | HCT116 |
| 1469- | SFN, | Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | Pca, | NA |
| 1470- | SFN, | Rad, | Sulforaphane induces ROS mediated induction of NKG2D ligands in human cancer cell lines and enhances susceptibility to NK cell mediated lysis |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Lung, | A549 | - | in-vitro, | lymphoma, | U937 |
| 1471- | SFN, | ROS-mediated activation of AMPK plays a critical role in sulforaphane-induced apoptosis and mitotic arrest in AGS human gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 1472- | SFN, | Sulforaphane Inhibits Autophagy and Induces Exosome-Mediated Paracrine Senescence via Regulating mTOR/TFE3 |
| - | in-vitro, | ESCC, | NA |
| 1431- | SFN, | Induction of the phase 2 response in mouse and human skin by sulforaphane-containing broccoli sprout extracts |
| - | in-vivo, | Nor, | NA |
| 1474- | SFN, | Sulforaphane induces p53‑deficient SW480 cell apoptosis via the ROS‑MAPK signaling pathway |
| - | in-vitro, | Colon, | SW480 |
| 1475- | SFN, | Form, | Combination of Formononetin and Sulforaphane Natural Drug Repress the Proliferation of Cervical Cancer Cells via Impeding PI3K/AKT/mTOR Pathway |
| - | in-vitro, | Cerv, | HeLa |
| 1476- | SFN, | PDT, | Enhancement of cytotoxic effect on human head and neck cancer cells by combination of photodynamic therapy and sulforaphane |
| - | in-vitro, | HNSCC, | NA |
| 1477- | SFN, | Sulforaphane Induces Oxidative Stress and Death by p53-Independent Mechanism: Implication of Impaired Glutathione Recycling |
| - | in-vitro, | OS, | MG63 |
| 1478- | SFN, | acet, | Anti-inflammatory and anti-oxidant effects of combination between sulforaphane and acetaminophen in LPS-stimulated RAW 264.7 macrophage cells |
| - | in-vitro, | Nor, | NA |
| - | in-vitro, | CRC, | HCT116 |
| 1315- | SFN, | Sulforaphane Induces Apoptosis of Acute Human Leukemia Cells Through Modulation of Bax, Bcl-2 and Caspase-3 |
| - | in-vitro, | AML, | K562 |
| - | in-vitro, | Pca, | NA |
| 2166- | SFN, | Sulforaphane targets cancer stemness and tumor initiating properties in oral squamous cell carcinomas via miR-200c induction |
| - | in-vitro, | Oral, | NA | - | in-vivo, | NA, | NA |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 |
| 2168- | SFN, | Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model |
| - | in-vivo, | AD, | NA |
| 1508- | SFN, | Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment |
| - | Review, | Var, | NA |
| - | in-vitro, | BrCC, | H720 | - | in-vivo, | BrCC, | NA | - | in-vitro, | BrCC, | H727 |
| 1509- | SFN, | Combination therapy in combating cancer |
| - | Review, | NA, | NA |
| 1507- | SFN, | Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects |
| - | in-vivo, | Colon, | NA | - | Human, | Nor, | NA |
| 2552- | SFN, | Chemo, | Chemopreventive activity of sulforaphane |
| - | Review, | Var, | NA |
| 2553- | SFN, | Mechanistic review of sulforaphane as a chemoprotective agent in bladder cancer |
| - | Review, | Bladder, | NA |
| 2554- | SFN, | Sulforaphane (SFN): An Isothiocyanate in a Cancer Chemoprevention Paradigm |
| - | Review, | Var, | NA |
| 2555- | SFN, | Chemopreventive functions of sulforaphane: A potent inducer of antioxidant enzymes and apoptosis |
| - | Review, | Var, | NA |
| 2556- | SFN, | The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review |
| - | Review, | Var, | NA |
| 3180- | SFN, | Exploring the therapeutic effects of sulforaphane: an in-depth review on endoplasmic reticulum stress modulation across different disease contexts |
| - | Review, | Var, | NA |
| 3200- | SFN, | Sulforaphane suppresses the activity of sterol regulatory element-binding proteins (SREBPs) by promoting SREBP precursor degradation |
| - | in-vitro, | Liver, | HUH7 |
| 3199- | SFN, | Sulforaphane improves chemotherapy efficacy by targeting cancer stem cell-like properties via the miR-124/IL-6R/STAT3 axis |
| - | in-vitro, | GC, | NA |
| 3198- | SFN, | Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells |
| - | in-vitro, | Pca, | NA |
| 3197- | SFN, | Sulforaphane Inhibits Self-renewal of Lung Cancer Stem Cells Through the Modulation of Polyhomeotic Homolog 3 and Sonic Hedgehog Signaling Pathways |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 3196- | SFN, | Sulforaphane eradicates pancreatic cancer stem cells by NF-κB |
| - | Review, | PC, | NA |
| 3195- | SFN, | AKT1/HK2 Axis-mediated Glucose Metabolism: A Novel Therapeutic Target of Sulforaphane in Bladder Cancer |
| - | in-vitro, | Bladder, | UMUC3 |
| 3194- | SFN, | Sulforaphane impedes mitochondrial reprogramming and histone acetylation in polarizing M1 (LPS) macrophages |
| - | in-vitro, | Nor, | NA |
| 3193- | SFN, | Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress |
| - | Review, | Var, | NA |
| 3192- | SFN, | Transcriptome analysis reveals a dynamic and differential transcriptional response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in chemoprevention |
| - | in-vitro, | Pca, | PC3 |
| 3191- | SFN, | Sulforaphane exhibits potent renoprotective effects in preclinical models of kidney diseases: A systematic review and meta-analysis |
| - | Review, | NA, | NA |
| 3189- | SFN, | Sulforaphane Inhibits TNF-α-Induced Adhesion Molecule Expression Through the Rho A/ROCK/NF-κB Signaling Pathway |
| - | in-vitro, | Nor, | ECV304 |
| 3188- | SFN, | Sulforaphane inhibited tumor necrosis factor-α induced migration and invasion in estrogen receptor negative human breast cancer cells |
| - | in-vitro, | BC, | NA |
| 3187- | SFN, | Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein |
| - | in-vitro, | Nor, | IB3-1 |
| 3186- | SFN, | A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet |
| - | in-vivo, | Nor, | NA |
| 3185- | SFN, | Sulforaphane decreases oxidative stress and inhibits NLRP3 inflammasome activation in a mouse model of ulcerative colitis |
| - | in-vivo, | Nor, | RAW264.7 |
| 3184- | SFN, | The Integrative Role of Sulforaphane in Preventing Inflammation, Oxidative Stress and Fatigue: A Review of a Potential Protective Phytochemical |
| - | Review, | Nor, | NA |
| 3183- | SFN, | Sulforaphane potentiates the efficacy of chemoradiotherapy in glioblastoma by selectively targeting thioredoxin reductase 1 |
| - | in-vitro, | GBM, | NA |
| 3182- | SFN, | Sulforaphane Modulates AQP8-Linked Redox Signalling in Leukemia Cells |
| - | in-vitro, | AML, | NA |
| 3181- | SFN, | Effect of sulforaphane on protein expression of Bip/GRP78 and caspase-12 in human hapetocelluar carcinoma HepG-2 cells |
| - | in-vitro, | HCC, | HepG2 |
| 3190- | SFN, | Sulforaphane inhibits TGF-β-induced fibrogenesis and inflammation in human Tenon’s fibroblasts |
| - | in-vitro, | Nor, | NA |
| 2447- | SFN, | Sulforaphane Bioavailability from Glucoraphanin-Rich Broccoli: Control by Active Endogenous Myrosinase |
| - | Review, | Nor, | NA |
| 2403- | SFN, | Reversal of the Warburg phenomenon in chemoprevention of prostate cancer by sulforaphane |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PC3 | - | in-vivo, | NA, | NA |
| 2404- | SFN, | Prostate cancer chemoprevention by sulforaphane in a preclinical mouse model is associated with inhibition of fatty acid metabolism |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 | - | in-vivo, | NA, | NA |
| 2449- | SFN, | Optimization of a blanching step to maximize sulforaphane synthesis in broccoli florets |
| - | Study, | Nor, | NA |
| 2448- | SFN, | Sulforaphane and bladder cancer: a potential novel antitumor compound |
| - | Review, | Bladder, | NA |
| 2405- | SFN, | Sulforaphane Targets the TBX15/KIF2C Pathway to Repress Glycolysis and Cell Proliferation in Gastric Carcinoma Cells |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | BGC-823 |
| 2446- | SFN, | CAP, | The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor |
| - | in-vitro, | Pca, | LNCaP |
| 2445- | SFN, | Sulforaphane-Induced Cell Cycle Arrest and Senescence are accompanied by DNA Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | SkBr3 |
| 2444- | SFN, | Sulforaphane Delays Fibroblast Senescence by Curbing Cellular Glucose Uptake, Increased Glycolysis, and Oxidative Damage |
| - | in-vitro, | Nor, | MRC-5 |
| 2406- | SFN, | Sulforaphane and Its Protective Role in Prostate Cancer: A Mechanistic Approach |
| - | Review, | Pca, | NA |
| 1136- | SFN, | Sulforaphane inhibits epithelial-mesenchymal transition by activating extracellular signal-regulated kinase 5 in lung cancer cells |
| - | in-vitro, | Lung, | NA | - | in-vivo, | NA, | NA |
| 963- | SFN, | Sulforaphane inhibits hypoxia-induced HIF-1α and VEGF expression and migration of human colon cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | GC, | AGS |
| 1061- | SFN, | Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumors |
| - | vitro+vivo, | NA, | NA |
| 1014- | SFN, | Sulforaphane Modulates Cell Migration and Expression of β-Catenin and Epithelial Mesenchymal Transition Markers in Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 110- | SFN, | Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway |
| - | in-vivo, | PC, | NA |
| 111- | SFN, | Sulforaphene Interferes with Human Breast Cancer Cell Migration and Invasion through Inhibition of Hedgehog Signaling |
| - | in-vitro, | BC, | SUM159 |
| 3943- | Shank, | Protective Mechanisms of Nootropic Herb Shankhpushpi (Convolvulus pluricaulis) against Dementia: Network Pharmacology and Computational Approach |
| - | Review, | AD, | NA |
| 3944- | Shank, | Role of Shankhpushpi (Convolvulus pluricaulis) in neurological disorders: An umbrella review covering evidence from ethnopharmacology to clinical studies |
| - | Review, | AD, | NA |
| 3945- | Shank, | Novel insights on acetylcholinesterase inhibition by Convolvuluspluricaulis, scopolamine and their combination in zebrafish |
| - | in-vivo, | AD, | NA |
| 3946- | Shank, | Phytochemical Profile, Pharmacological Attributes and Medicinal Properties of Convolvulus prostratus – A Cognitive Enhancer Herb for the Management of Neurodegenerative Etiologies |
| - | Review, | AD, | NA |
| 3947- | Shank, | Convolvulus pluricaulis (Shankhapushpi) ameliorates human microtubule-associated protein tau (hMAPτ) induced neurotoxicity in Alzheimer's disease Drosophila model |
| - | in-vivo, | AD, | NA |
| 3948- | Shank, | Neuroprotective role of Convolvulus pluricaulis on aluminium induced neurotoxicity in rat brain |
| - | in-vivo, | AD, | NA |
| 3648- | SIL, | Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years |
| - | Review, | NA, | NA |
| 3654- | SIL, | Effect of silymarin on biochemical parameters of oxidative stress in aged and young rat brain |
| - | in-vivo, | AD, | NA |
| 3653- | SIL, | Silibinin ameliorates Aβ25-35-induced memory deficits in rats by modulating autophagy and attenuating neuroinflammation as well as oxidative stress |
| - | in-vivo, | AD, | NA |
| 3652- | SIL, | Silibinin ameliorates anxiety/depression-like behaviors in amyloid β-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in hippocampus |
| - | in-vivo, | NA, | NA |
| 3651- | SIL, | Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease |
| - | Trial, | NA, | NA |
| 3655- | SIL, | Protective effect of silymarin on oxidative stress in rat brain |
| - | in-vivo, | AD, | NA |
| 3646- | SIL, | "Silymarin", a promising pharmacological agent for treatment of diseases |
| - | Review, | NA, | NA |
| 3647- | SIL, | Silymarin Modulates Microbiota in the Gut to Improve the Health of Sow from Late Gestation to Lactation |
| - | in-vivo, | NA, | NA |
| 3649- | SIL, | Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis |
| 3650- | SIL, | Silibinin: a novel inhibitor of Aβ aggregation |
| - | in-vitro, | AD, | SH-SY5Y |
| 4207- | SIL, | Silymarin sex-dependently improves cognitive functions and alters TNF-α, BDNF, and glutamate in the hippocampus of mice with mild traumatic brain injury |
| 4203- | SIL, | Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer’s Disease and Other Neurological Disorders |
| - | Review, | NA, | NA |
| 4204- | SIL, | Silymarin administration after cerebral ischemia improves survival of obese mice by increasing cortical BDNF and IGF1 levels |
| - | NA, | Stroke, | NA |
| 4205- | SIL, | The Therapeutic Effect of Silymarin and Silibinin on Depression and Anxiety Disorders and Possible Mechanism in the Brain: A Systematic Review |
| - | Review, | AD, | NA |
| 4206- | SIL, | Silymarin ameliorates experimentally induced depressive like behavior in rats: Involvement of hippocampal BDNF signaling, inflammatory cytokines and oxidative stress response |
| - | in-vivo, | NA, | NA |
| 3301- | SIL, | Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid |
| - | Review, | Var, | NA |
| 3282- | SIL, | Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions |
| - | Review, | NA, | NA |
| 3302- | SIL, | Protective effects of silymarin in glioblastoma cancer cells through redox system regulation |
| - | in-vitro, | GBM, | U87MG |
| 3303- | SIL, | Exploring the anti-cancer and antimetastatic effect of Silymarin against lung cancer |
| - | Review, | Var, | NA |
| 3304- | SIL, | Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells |
| - | in-vitro, | GC, | AGS | - | in-vivo, | NA, | NA |
| 3305- | SIL, | Silymarin inhibits proliferation of human breast cancer cells via regulation of the MAPK signaling pathway and induction of apoptosis |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vivo, | NA, | NA |
| 3306- | SIL, | Rad, | Radioprotective and radiosensitizing properties of silymarin/silibinin in response to ionizing radiation |
| - | Review, | Var, | NA |
| 3307- | SIL, | Flavolignans from Silymarin as Nrf2 Bioactivators and Their Therapeutic Applications |
| - | Review, | Var, | NA |
| 3308- | SIL, | Structural basis of Nrf2 activation by flavonolignans from silymarin |
| - | Analysis, | NA, | NA |
| 3309- | SIL, | Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives |
| - | Review, | NA, | NA |
| 3310- | SIL, | Silymarin attenuates paraquat-induced lung injury via Nrf2-mediated pathway in vivo and in vitro |
| - | in-vitro, | Lung, | A549 |
| 3311- | SIL, | Silymarin protects against acrylamide-induced neurotoxicity via Nrf2 signalling in PC12 cells |
| - | in-vitro, | Nor, | PC12 |
| 3300- | SIL, | Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy |
| - | Review, | Var, | NA |
| 3288- | SIL, | Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations |
| - | Review, | Var, | NA |
| 3315- | SIL, | Silymarin alleviates docetaxel-induced central and peripheral neurotoxicity by reducing oxidative stress, inflammation and apoptosis in rats |
| - | in-vivo, | Nor, | NA |
| 3299- | SIL, | Silymarin Effect on Mitophagy Pathway in the Human Colon Cancer HT-29 Cells |
| - | in-vitro, | Colon, | HT29 |
| 3298- | SIL, | Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 3297- | SIL, | Rad, | Studies on radiation sensitization efficacy by silymarin in colon carcinoma cells |
| - | in-vitro, | CRC, | HCT15 | - | in-vitro, | CRC, | RKO |
| 3296- | SIL, | Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway |
| - | in-vitro, | Oral, | Ca9-22 | - | in-vivo, | Oral, | YD10B |
| 3295- | SIL, | Hepatoprotective effect of silymarin |
| - | Review, | NA, | NA |
| 3294- | SIL, | Silymarin: a review on paving the way towards promising pharmacological agent |
| - | Review, | Nor, | NA | - | Review, | Arthritis, | NA |
| 3293- | SIL, | Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer |
| - | Review, | Var, | NA |
| 3292- | SIL, | Fe, | Anti-tumor activity of silymarin nanoliposomes in combination with iron: In vitro and in vivo study |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | BC, | 4T1 |
| 3291- | SIL, | Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases |
| - | Review, | Nor, | NA |
| 3324- | SIL, | Silymarin prevents NLRP3 inflammasome activation and protects against intracerebral hemorrhage |
| 3290- | SIL, | A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents |
| - | Analysis, | Var, | NA |
| 3289- | SIL, | Silymarin: a promising modulator of apoptosis and survival signaling in cancer |
| - | Review, | Var, | NA |
| 3333- | SIL, | Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice |
| - | in-vivo, | NA, | NA |
| 3332- | SIL, | Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2 |
| - | in-vitro, | Lung, | A549 |
| 3331- | SIL, | The clinical anti-inflammatory effects and underlying mechanisms of silymarin |
| - | Review, | NA, | NA |
| 3330- | SIL, | Mechanistic Insights into the Pharmacological Significance of Silymarin |
| - | Review, | Var, | NA |
| 3329- | SIL, | Silymarin regulates the HIF-1 and iNOS expression in the brain and Gills of the hypoxic-reoxygenated rainbow trout (Oncorhynchus mykis) |
| - | in-vivo, | Nor, | NA |
| 3328- | SIL, | Modulatory effect of silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia: emphasis on PTEN, HIF-1α, and NF-κB |
| - | in-vivo, | BPH, | NA |
| 3327- | SIL, | Effects of silymarin on HIF‑1α and MDR1 expression in HepG‑2 cells under hypoxia |
| - | in-vitro, | Liver, | HepG2 |
| 3326- | SIL, | Silymarin suppresses proliferation of human hepatocellular carcinoma cells under hypoxia through downregulation of the HIF-1α/VEGF pathway |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | Hep3B |
| 3325- | SIL, | Modulatory effect of silymarin on pulmonary vascular dysfunction through HIF-1α-iNOS following rat lung ischemia-reperfusion injury |
| - | in-vivo, | Nor, | NA |
| 3312- | SIL, | Silymarin Alleviates Oxidative Stress and Inflammation Induced by UV and Air Pollution in Human Epidermis and Activates β-Endorphin Release through Cannabinoid Receptor Type 2 |
| - | Human, | Nor, | NA |
| 3323- | SIL, | Anticancer therapeutic potential of silibinin: current trends, scope and relevance |
| - | Review, | Var, | NA |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 3321- | SIL, | Silymarin (Milk thistle) |
| - | Review, | AD, | NA |
| 3320- | SIL, | Neuroprotective Potential of Silymarin against CNS Disorders: Insight into the Pathways and Molecular Mechanisms of Action |
| - | Review, | AD, | NA |
| 3319- | SIL, | Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 3318- | SIL, | Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3317- | SIL, | Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer's Disease and Other Neurological Disorders |
| - | Review, | NA, | NA |
| 3316- | SIL, | Chemo, | Silymarin Nanoparticles Counteract Cognitive Impairment Induced by Doxorubicin and Cyclophosphamide in Rats; Insights into Mitochondrial Dysfunction and Nrf2/HO-1 Axis |
| 3314- | SIL, | Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative review |
| - | Review, | NA, | NA |
| 3313- | SIL, | Silymarin attenuates post-weaning bisphenol A-induced renal injury by suppressing ferroptosis and amyloidosis through Kim-1/Nrf2/HO-1 signaling modulation in male Wistar rats |
| - | in-vivo, | NA, | NA |
| 109- | SIL, | Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma |
| - | vitro+vivo, | RCC, | 769-P | - | in-vitro, | RCC, | 786-O | - | in-vitro, | RCC, | ACHN | - | in-vitro, | RCC, | OS-RC-2 |
| 1127- | SIL, | Silibinin suppresses epithelial–mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1 |
| - | in-vitro, | Lung, | A549 |
| 1140- | SIL, | Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth |
| - | in-vitro, | PC, | AsPC-1 | - | in-vivo, | PC, | NA | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 |
| 1001- | SIL, | Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism |
| - | in-vitro, | NA, | NA |
| 964- | SIL, | Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics |
| - | vitro+vivo, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 |
| 978- | SIL, | A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment |
| - | Review, | NA, | NA |
| 1316- | SIL, | Chemo, | Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity |
| - | Analysis, | Var, | NA |
| 1276- | SIL, | Silibinin inhibits TPA-induced cell migration and MMP-9 expression in thyroid and breast cancer cells |
| - | in-vitro, | BC, | NA | - | in-vitro, | Thyroid, | NA |
| 2410- | SIL, | Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vivo, | NA, | NA |
| 2306- | SIL, | CUR, | RES, | EA, | Identification of Natural Compounds as Inhibitors of Pyruvate Kinase M2 for Cancer Treatment |
| - | in-vitro, | BC, | MDA-MB-231 |
| 4128- | Silicon, | Silicon as Versatile Player in Plant and Human Biology: Overlooked and Poorly Understood |
| - | Review, | NA, | NA |
| 4122- | Silicon, | Silicon-rich mineral water as a non-invasive test of the 'aluminum hypothesis' in Alzheimer's disease |
| - | Trial, | AD, | NA |
| 4123- | Silicon, | The potential influence of silica present in drinking water on Alzheimer's disease and associated disorders |
| - | Review, | AD, | NA |
| 4125- | Silicon, | Oral silicon supplementation: an effective therapy for preventing oral aluminum absorption and retention in mammals |
| - | Review, | AD, | NA |
| 4126- | Silicon, | H2, | Oral Administration of Si-Based Agent Attenuates Oxidative Stress and Ischemia-Reperfusion Injury in a Rat Model: A Novel Hydrogen Administration Method |
| - | in-vivo, | NA, | NA |
| 4127- | Silicon, | Interference of Parenteral Nutrition Components in Silicon-Mediated Protection Against Aluminum Bioaccumulation |
| - | in-vivo, | AD, | NA |
| 4131- | Silicon, | Silicon reduces aluminum accumulation in rats: relevance to the aluminum hypothesis of Alzheimer disease |
| - | Study, | Nor, | NA |
| 4133- | Silicon, | Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study |
| - | Study, | AD, | NA |
| 4134- | Silicon, | Garden Cress (Lepidium sativum) Seeds Ameliorated Aluminum-Induced Alzheimer Disease in Rats Through Antioxidant, Anti-Inflammatory, and Antiapoptotic Effects |
| - | in-vivo, | AD, | NA |
| 4136- | Silicon, | Aluminum Should Now Be Considered a Primary Etiological Factor in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4129- | Silicon, | Silica and aluminum in drinking water and cognitive impairment in the elderly |
| - | Study, | AD, | NA |
| 2217- | SK, | Shikonin Inhibits Endoplasmic Reticulum Stress-Induced Apoptosis to Attenuate Renal Ischemia/Reperfusion Injury by Activating the Sirt1/Nrf2/HO-1 Pathway |
| - | in-vivo, | Nor, | NA | - | in-vitro, | Nor, | HK-2 |
| 2364- | SK, | Pyruvate Kinase M2 Mediates Glycolysis Contributes to Psoriasis by Promoting Keratinocyte Proliferation |
| - | in-vivo, | PSA, | NA |
| 2363- | SK, | Inhibition of PKM2 by shikonin impedes TGF-β1 expression by repressing histone lactylation to alleviate renal fibrosis |
| - | in-vivo, | CKD, | NA |
| 2362- | SK, | RIP1 and RIP3 contribute to shikonin-induced glycolysis suppression in glioma cells via increase of intracellular hydrogen peroxide |
| - | in-vitro, | GBM, | U87MG | - | in-vivo, | GBM, | NA | - | in-vitro, | GBM, | U251 |
| 2361- | SK, | Natural shikonin and acetyl-shikonin improve intestinal microbial and protein composition to alleviate colitis-associated colorectal cancer |
| - | in-vivo, | CRC, | NA |
| 2360- | SK, | Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway |
| - | in-vitro, | NPC, | HONE1 | - | in-vitro, | NPC, | SUNE-1 |
| 2359- | SK, | Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery |
| - | in-vivo, | Liver, | NA |
| 2358- | SK, | SIRT1 improves lactate homeostasis in the brain to alleviate parkinsonism via deacetylation and inhibition of PKM2 |
| - | in-vivo, | Park, | NA |
| 2357- | SK, | GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism |
| - | Study, | HCC, | NA | - | in-vivo, | NA, | NA |
| 2356- | SK, | ESM1 enhances fatty acid synthesis and vascular mimicry in ovarian cancer by utilizing the PKM2-dependent warburg effect within the hypoxic tumor microenvironment |
| - | in-vitro, | Ovarian, | CaOV3 | - | in-vitro, | Ovarian, | OV90 | - | in-vivo, | NA, | NA |
| 2355- | SK, | Pharmacological properties and derivatives of shikonin-A review in recent years |
| - | Review, | Var, | NA |
| 2354- | SK, | PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation |
| - | in-vivo, | Sepsis, | NA |
| 2225- | SK, | Shikonin protects skin cells against oxidative stress and cellular dysfunction induced by fine particulate matter |
| - | in-vitro, | Nor, | HaCaT |
| 2232- | SK, | Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis |
| - | in-vitro, | ESCC, | EC9706 |
| 2233- | SK, | Clinical trial on the effects of shikonin mixture on later stage lung cancer |
| - | Trial, | Lung, | NA |
| 2234- | SK, | Shikonin Suppresses Cell Tumorigenesis in Gastric Cancer Associated with the Inhibition of c-Myc and Yap-1 |
| - | in-vitro, | GC, | NA |
| 2231- | SK, | Shikonin Exerts Cytotoxic Effects in Human Colon Cancers by Inducing Apoptotic Cell Death via the Endoplasmic Reticulum and Mitochondria-Mediated Pathways |
| - | in-vitro, | CRC, | SNU-407 |
| 2230- | SK, | Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vivo, | NA, | NA |
| 2229- | SK, | Shikonin induces apoptosis and prosurvival autophagy in human melanoma A375 cells via ROS-mediated ER stress and p38 pathways |
| - | in-vitro, | Melanoma, | A375 |
| 2228- | SK, | Shikonin induced Apoptosis Mediated by Endoplasmic Reticulum Stress in Colorectal Cancer Cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT15 | - | in-vivo, | NA, | NA |
| 2227- | SK, | Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species |
| - | in-vitro, | GC, | BGC-823 | - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | Nor, | GES-1 |
| 2226- | SK, | Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: A potential new treatment for hepatocellular carcinoma |
| - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | Bel-7402 |
| 2224- | SK, | Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells |
| - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 |
| 2223- | SK, | Non-metabolic enzyme function of PKM2 in hepatocellular carcinoma: A review |
| - | in-vitro, | Var, | NA |
| 2222- | SK, | The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis |
| - | in-vitro, | OS, | U2OS | - | in-vitro, | OS, | 143B | - | in-vivo, | NA, | NA |
| 2221- | SK, | Shikonin Induces Apoptosis, Necrosis, and Premature Senescence of Human A549 Lung Cancer Cells through Upregulation of p53 Expression |
| - | in-vitro, | Lung, | A549 |
| 2220- | SK, | Shikonin Alleviates Gentamicin-Induced Renal Injury in Rats by Targeting Renal Endocytosis, SIRT1/Nrf2/HO-1, TLR-4/NF-κB/MAPK, and PI3K/Akt Cascades |
| - | in-vivo, | Nor, | NA |
| 2219- | SK, | Shikonin induces apoptosis of HaCaT cells via the mitochondrial, Erk and Akt pathways |
| - | in-vitro, | Nor, | HaCaT |
| 2218- | SK, | Shikonin Alleviates Endothelial Cell Injury Induced by ox-LDL via AMPK/Nrf2/HO-1 Signaling Pathway |
| - | in-vitro, | Nor, | HUVECs |
| 2216- | SK, | Shikonin upregulates the expression of drug-metabolizing enzymes and drug transporters in primary rat hepatocytes |
| - | in-vivo, | Nor, | NA |
| 2417- | SK, | Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H446 |
| 2370- | SK, | The role of pyruvate kinase M2 in anticancer therapeutic treatments |
| - | Review, | Var, | NA |
| 2415- | SK, | Shikonin induces programmed death of fibroblast synovial cells in rheumatoid arthritis by inhibiting energy pathways |
| - | in-vivo, | Arthritis, | NA |
| 2416- | SK, | Shikonin induces cell death by inhibiting glycolysis in human testicular cancer I-10 and seminoma TCAM-2 cells |
| - | in-vitro, | Testi, | TCAM-2 |
| 2418- | SK, | Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2 |
| - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 |
| 2419- | SK, | Regulation of glycolysis and the Warburg effect in wound healing |
| - | in-vivo, | Nor, | NA |
| 2420- | SK, | Pyruvate kinase M2 regulates mitochondrial homeostasis in cisplatin-induced acute kidney injury |
| - | in-vivo, | AKI, | NA |
| 2470- | SK, | PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism |
| - | in-vitro, | Lung, | H1299 |
| 2469- | SK, | Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2 |
| - | in-vitro, | Lung, | H1975 |
| 3050- | SK, | Systemic administration of Shikonin ameliorates cognitive impairment and neuron damage in NPSLE mice |
| - | in-vivo, | Nor, | NA |
| 3040- | SK, | Pharmacological Properties of Shikonin – A Review of Literature since 2002 |
| - | Review, | Var, | NA | - | Review, | IBD, | NA | - | Review, | Stroke, | NA |
| 3041- | SK, | Promising Nanomedicines of Shikonin for Cancer Therapy |
| - | Review, | Var, | NA |
| 3042- | SK, | The protective effects of Shikonin on lipopolysaccharide/D -galactosamine-induced acute liver injury via inhibiting MAPK and NF-kB and activating Nrf2/HO-1 signaling pathways |
| - | in-vivo, | Nor, | NA |
| 3043- | SK, | Shikonin Induces Apoptosis by Inhibiting Phosphorylation of IGF-1 Receptor in Myeloma Cells. |
| - | in-vitro, | Melanoma, | RPMI-8226 |
| 3044- | SK, | Shikonin Inhibits Non-Small-Cell Lung Cancer H1299 Cell Growth through Survivin Signaling Pathway |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 3045- | SK, | Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2 (PKM2) |
| - | in-vitro, | PC, | MIA PaCa-2 |
| 3046- | SK, | Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway |
| - | in-vitro, | Lung, | A549 |
| 3047- | SK, | Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL-6/STAT3 signaling pathway |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | 4T1 | - | in-vitro, | Nor, | MCF12A | - | in-vivo, | NA, | NA |
| 3049- | SK, | Shikonin Attenuates Chronic Cerebral Hypoperfusion-Induced Cognitive Impairment by Inhibiting Apoptosis via PTEN/Akt/CREB/BDNF Signaling |
| - | in-vivo, | Nor, | NA | - | NA, | Stroke, | NA |
| 3051- | SK, | Resveratrol mediates its anti-cancer effects by Nrf2 signaling pathway activation |
| - | Review, | Var, | NA |
| 1050- | SK, | Shikonin improves the effectiveness of PD-1 blockade in colorectal cancer by enhancing immunogenicity via Hsp70 upregulation |
| - | in-vitro, | Colon, | CT26 |
| 977- | SK, | A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells |
| - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HMEC |
| 1073- | SK, | Chemo, | Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 |
| 965- | SK, | Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW-620 |
| 1049- | SK, | Shikonin inhibits immune checkpoint PD-L1 expression on macrophage in sepsis by modulating PKM2 |
| - | in-vivo, | NA, | NA |
| 1280- | SK, | Shikonin Induces Apoptotic Cell Death via Regulation of p53 and Nrf2 in AGS Human Stomach Carcinoma Cells |
| - | in-vitro, | GC, | AGS |
| 1281- | SK, | Enhancement of NK cells proliferation and function by Shikonin |
| - | in-vivo, | Colon, | Caco-2 |
| 1284- | SK, | Shikonin induces ferroptosis in multiple myeloma via GOT1-mediated ferritinophagy |
| - | in-vitro, | Melanoma, | RPMI-8226 | - | in-vitro, | Melanoma, | U266 |
| 1312- | SK, | Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells |
| - | in-vitro, | OS, | 143B |
| 1346- | SK, | An Oxidative Stress Mechanism of Shikonin in Human Glioma Cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | Hs683 |
| 1345- | SK, | The Critical Role of Redox Homeostasis in Shikonin-Induced HL-60 Cell Differentiation via Unique Modulation of the Nrf2/ARE Pathway |
| - | in-vitro, | AML, | HL-60 |
| 1344- | SK, | Novel multiple apoptotic mechanism of shikonin in human glioma cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | Hs683 | - | in-vitro, | GBM, | M059K |
| 1343- | SK, | Simple ROS-responsive micelles loaded Shikonin for efficient ovarian cancer targeting therapy by disrupting intracellular redox homeostasis |
| - | in-vitro, | Ovarian, | A2780S | - | in-vivo, | NA, | A2780S |
| 1342- | SK, | RIP1 and RIP3 contribute to shikonin-induced DNA double-strand breaks in glioma cells via increase of intracellular reactive oxygen species |
| - | in-vitro, | GBM, | NA | - | in-vivo, | NA, | NA |
| 2011- | SK, | Shikonin Attenuates Acetaminophen-Induced Hepatotoxicity by Upregulation of Nrf2 through Akt/GSK3β Signaling |
| - | in-vitro, | Nor, | HL7702 | - | in-vivo, | Nor, | NA |
| 2010- | SK, | Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway |
| - | in-vitro, | Lung, | H1975 | - | in-vitro, | Lung, | H1650 | - | in-vitro, | Nor, | CCD19 |
| 2009- | SK, | Necroptosis inhibits autophagy by regulating the formation of RIP3/p62/Keap1 complex in shikonin-induced ROS dependent cell death of human bladder cancer |
| - | in-vitro, | Bladder, | NA |
| 2008- | SK, | Cisplatin, | Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo |
| - | in-vitro, | CRC, | HCT116 | - | in-vivo, | NA, | NA |
| 2007- | SK, | Shikonin Directly Targets Mitochondria and Causes Mitochondrial Dysfunction in Cancer Cells |
| - | in-vitro, | lymphoma, | U937 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | SkBr3 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | OS, | U2OS | - | NA, | Nor, | RPE-1 |
| 2191- | SK, | Shikonin Suppresses Skin Carcinogenesis via Inhibiting Cell Proliferation |
| - | in-vitro, | Melanoma, | NA |
| 2192- | SK, | Shikonin Inhibits Tumor Growth of ESCC by suppressing PKM2 mediated Aerobic Glycolysis and STAT3 Phosphorylation |
| - | in-vitro, | ESCC, | KYSE-510 | - | in-vitro, | ESCC, | Eca109 | - | in-vivo, | NA, | NA |
| 2190- | SK, | Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1α signaling pathway |
| - | in-vitro, | HCC, | HCCLM3 |
| 2189- | SK, | PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells |
| - | in-vitro, | Melanoma, | NA |
| 2188- | SK, | Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment |
| - | Review, | Var, | NA |
| 2187- | SK, | VitK3, | Shikonin, vitamin K3 and vitamin K5 inhibit multiple glycolytic enzymes in MCF-7 cells |
| - | in-vitro, | BC, | MCF-7 |
| 2186- | SK, | Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | HCCLM3 |
| 2185- | SK, | Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis |
| - | in-vitro, | Lung, | LLC1 | - | in-vitro, | Melanoma, | B16-BL6 | - | in-vivo, | NA, | NA |
| 2184- | SK, | Cisplatin, | PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis |
| - | in-vitro, | CRC, | T24 |
| 2183- | SK, | Shikonin Inhibites Migration and Invasion of Thyroid Cancer Cells by Downregulating DNMT1 |
| - | in-vitro, | Thyroid, | TPC-1 |
| 2182- | SK, | Cisplatin, | Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | PC9 | - | in-vivo, | NA, | NA |
| 2181- | SK, | Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2 |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Cerv, | HeLa |
| 2201- | SK, | Shikonin promotes ferroptosis in HaCaT cells through Nrf2 and alleviates imiquimod-induced psoriasis in mice |
| - | in-vitro, | PSA, | HaCaT | - | in-vivo, | NA, | NA |
| 2214- | SK, | Shikonin Attenuates Cochlear Spiral Ganglion Neuron Degeneration by Activating Nrf2-ARE Signaling Pathway |
| - | in-vitro, | Nor, | NA |
| 2213- | SK, | Shikonin attenuates cerebral ischemia/reperfusion injury via inhibiting NOD2/RIP2/NF-κB-mediated microglia polarization and neuroinflammation |
| - | in-vivo, | Stroke, | NA |
| 2212- | SK, | Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways |
| - | in-vitro, | AML, | NA |
| 2211- | SK, | Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways |
| - | in-vivo, | ostP, | NA |
| 2210- | SK, | Shikonin inhibits the cell viability, adhesion, invasion and migration of the human gastric cancer cell line MGC-803 via the Toll-like receptor 2/nuclear factor-kappa B pathway |
| - | in-vitro, | BC, | MGC803 |
| 2209- | SK, | Shikonin inhibits tumor invasion via down-regulation of NF-κB-mediated MMP-9 expression in human ACC-M cells |
| - | in-vitro, | adrenal, | ACC-M |
| 2203- | SK, | Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation |
| - | in-vitro, | Lung, | NA |
| 2202- | SK, | Enhancing Tumor Therapy of Fe(III)-Shikonin Supramolecular Nanomedicine via Triple Ferroptosis Amplification |
| - | in-vitro, | Var, | NA |
| 2215- | SK, | doxoR, | Shikonin alleviates doxorubicin-induced cardiotoxicity via Mst1/Nrf2 pathway in mice |
| - | in-vivo, | Nor, | NA |
| 2200- | SK, | Shikonin inhibits the growth of anaplastic thyroid carcinoma cells by promoting ferroptosis and inhibiting glycolysis |
| - | in-vitro, | Thyroid, | CAL-62 | - | in-vitro, | Thyroid, | 8505C |
| 2199- | SK, | Induction of Ferroptosis by Shikonin in Gastric Cancer via the DLEU1/mTOR/GPX4 Axis |
| - | in-vitro, | GC, | NA |
| 2198- | SK, | Shikonin suppresses proliferation of osteosarcoma cells by inducing ferroptosis through promoting Nrf2 ubiquitination and inhibiting the xCT/GPX4 regulatory axis |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | OS, | 143B |
| 2197- | SK, | Shikonin derivatives for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 2196- | SK, | Research progress in mechanism of anticancer action of shikonin targeting reactive oxygen species |
| - | Review, | Var, | NA |
| 2195- | SK, | Shikonin induces ferroptosis in osteosarcomas through the mitochondrial ROS-regulated HIF-1α/HO-1 axis |
| - | in-vitro, | OS, | NA |
| 2194- | SK, | Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo |
| - | in-vitro, | ESCC, | Eca109 | - | in-vitro, | ESCC, | EC9706 | - | in-vivo, | NA, | NA |
| 2193- | SK, | Shikonin Suppresses Lymphangiogenesis via NF-κB/HIF-1α Axis Inhibition |
| - | in-vitro, | Nor, | HMVEC-dLy |
| 1291- | SM, | Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios |
| - | in-vitro, | BC, | MDA-MB-231 |
| 1068- | SM, | Danshen Improves Survival of Patients With Breast Cancer and Dihydroisotanshinone I Induces Ferroptosis and Apoptosis of Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | BC, | NA | - | Human, | BC, | NA |
| 1191- | SM, | Salvia miltiorrhiza extract inhibits TPA‑induced MMP‑9 expression and invasion through the MAPK/AP‑1 signaling pathw |
| - | in-vitro, | BC, | MCF-7 |
| 1133- | SM, | Salvianolic Acid A, a Component of Salvia miltiorrhiza, Attenuates Endothelial-Mesenchymal Transition of HPAECs Induced by Hypoxia |
| - | in-vitro, | Nor, | HPAECs |
| 1195- | SM, | Salvia miltiorrhiza polysaccharide activates T Lymphocytes of cancer patients through activation of TLRs mediated -MAPK and -NF-κB signaling pathways |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | HCT116 |
| 1194- | SM, | Salvia miltiorrhiza protects against diabetic nephropathy through metabolome regulation and wnt/β-catenin and TGF-β signaling inhibition |
| - | in-vivo, | Diabetic, | NA |
| 1192- | SM, | Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1 |
| - | in-vitro, | GC, | AGS | - | in-vitro, | Liver, | HepG3 |
| 1193- | SM, | Cryptotanshinone from the Salvia miltiorrhiza Bunge Attenuates Ethanol-Induced Liver Injury by Activation of AMPK/SIRT1 and Nrf2 Signaling Pathways |
| - | in-vivo, | Alcohol, | NA | - | in-vitro, | Liver, | HepG2 |
| 887- | SNP, | Antibacterial potential of silver nanoparticles against isolated urinary tract infectious bacterial pathogens |
| - | in-vitro, | UTI, | NA |
| 888- | SNP, | Antibacterial Effects of Silver Nanoparticles on the Bacterial Strains Isolated from Catheterized Urinary Tract Infection Cases |
| - | in-vivo, | UTI, | NA |
| 335- | SNP, | PDT, | Biogenic Silver Nanoparticles for Targeted Cancer Therapy and Enhancing Photodynamic Therapy |
| - | Review, | NA, | NA |
| 333- | SNP, | HPT, | Enhancement effect of cytotoxicity response of silver nanoparticles combined with thermotherapy on C6 rat glioma cells |
| - | in-vivo, | GBM, | NA |
| 336- | SNP, | PDT, | Photodynamic ability of silver nanoparticles in inducing cytotoxic effects in breast and lung cancer cell lines |
| - | in-vitro, | BC, | MCF-7 |
| 337- | SNP, | immuno, | Silver nanoparticle induced immunogenic cell death can improve immunotherapy |
| - | Review, | NA, | NA |
| 338- | SNP, | Biogenic silver nanoparticles: In vitro and in vivo antitumor activity in bladder cancer |
| - | vitro+vivo, | Bladder, | 5637 |
| 339- | SNP, | Cancer cell specific cytotoxic potential of the silver nanoparticles synthesized using the endophytic fungus, Penicillium citrinum CGJ-C2 |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Melanoma, | A431 | - | in-vitro, | HCC, | HepG2 |
| 340- | SNP, | Screening bioactivities of Caesalpinia pulcherrima L. swartz and cytotoxicity of extract synthesized silver nanoparticles on HCT116 cell line |
| - | in-vitro, | CRC, | HCT116 |
| 341- | SNP, | Bioprospecting a native silver-resistant Bacillus safensis strain for green synthesis and subsequent antibacterial and anticancer activities of silver nanoparticles |
| - | in-vitro, | Liver, | HepG2 |
| 342- | SNP, | Silver nanoparticles; a new hope in cancer therapy? |
| - | Review, | NA, | NA |
| 343- | SNP, | Silver nanoparticles of different sizes induce a mixed type of programmed cell death in human pancreatic ductal adenocarcinoma |
| - | in-vitro, | PC, | PANC1 |
| 344- | SNP, | Cytotoxicity and ROS production of manufactured silver nanoparticles of different sizes in hepatoma and leukemia cells |
| - | in-vitro, | Liver, | HepG2 |
| 345- | SNP, | Antitumor activity of silver nanoparticles in Dalton’s lymphoma ascites tumor model |
| - | vitro+vivo, | lymphoma, | NA |
| 346- | SNP, | RSQ, | Investigating Silver Nanoparticles and Resiquimod as a Local Melanoma Treatment |
| - | in-vivo, | Melanoma, | SK-MEL-28 | - | in-vivo, | Melanoma, | WM35 |
| 347- | SNP, | The Role of Silver Nanoparticles in the Diagnosis and Treatment of Cancer: Are There Any Perspectives for the Future? |
| - | Review, | NA, | NA |
| 348- | SNP, | Induction of p53 mediated mitochondrial apoptosis and cell cycle arrest in human breast cancer cells by plant mediated synthesis of silver nanoparticles from Bergenia ligulata (Whole plant) |
| - | in-vitro, | BC, | MCF-7 |
| 349- | SNP, | Insight into the molecular mechanism, cytotoxic, and anticancer activities of phyto-reduced silver nanoparticles in MCF-7 breast cancer cell lines |
| - | in-vitro, | BC, | MCF-7 |
| 350- | SNP, | Cytotoxic and Apoptotic Effects of Green Synthesized Silver Nanoparticles via Reactive Oxygen Species-Mediated Mitochondrial Pathway in Human Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 |
| 351- | SNP, | Study of antitumor activity in breast cell lines using silver nanoparticles produced by yeast |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D |
| 352- | SNP, | Synthesis of silver nanoparticles (Ag NPs) for anticancer activities (MCF 7 breast and A549 lung cell lines) of the crude extract of Syzygium aromaticum |
| - | in-vitro, | BC, | MCF-7 |
| 353- | SNP, | The mechanism of cell death induced by silver nanoparticles is distinct from silver cations |
| - | in-vitro, | BC, | SUM159 |
| - | in-vitro, | neuroblastoma, | SH-SY5Y |
| 355- | SNP, | Cytotoxicity and Genotoxicity of Biogenic Silver Nanoparticles in A549 and BEAS-2B Cell Lines |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | NA, | BEAS-2B |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Bladder, | HTB-22 |
| 322- | SNP, | Cisplatin, | Heterogeneous Responses of Ovarian Cancer Cells to Silver Nanoparticles as a Single Agent and in Combination with Cisplatin |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | OVCAR-3 |
| 305- | SNP, | Activity and pharmacology of homemade silver nanoparticles in refractory metastatic head and neck squamous cell cancer |
| - | Case Report, | HNSCC, | NA |
| 306- | SNP, | Cancer Therapy by Silver Nanoparticles: Fiction or Reality? |
| - | Analysis, | NA, | NA |
| 309- | SNP, | Interference of silver, gold, and iron oxide nanoparticles on epidermal growth factor signal transduction in epithelial cells |
| - | in-vitro, | NA, | A431 |
| 312- | SNP, | wortm, | Inhibition of autophagy enhances the anticancer activity of silver nanoparticles |
| - | vitro+vivo, | NA, | HeLa |
| 316- | SNP, | Endoplasmic reticulum stress: major player in size-dependent inhibition of P-glycoprotein by silver nanoparticles in multidrug-resistant breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 317- | SNP, | Autophagic effects and mechanisms of silver nanoparticles in renal cells under low dose exposure |
| - | in-vitro, | Kidney, | HEK293 |
| 318- | SNP, | Silver nanoparticles regulate autophagy through lysosome injury and cell hypoxia in prostate cancer cells |
| - | in-vitro, | Pca, | PC3 |
| 319- | SNP, | Endoplasmic reticulum stress signaling is involved in silver nanoparticles-induced apoptosis |
| 320- | SNP, | Silver nanoparticles induce endoplasmatic reticulum stress response in zebrafish |
| - | vitro+vivo, | NA, | HUH7 |
| 321- | SNP, | I-131 doping of silver nanoparticles platform for tumor theranosis guided drug delivery |
| - | in-vivo, | NA, | NA |
| 334- | SNP, | Silver-Based Nanoparticles Induce Apoptosis in Human Colon Cancer Cells Mediated Through P53 |
| - | in-vitro, | Colon, | HCT116 |
| 324- | SNP, | CPT, | Silver Nanoparticles Potentiates Cytotoxicity and Apoptotic Potential of Camptothecin in Human Cervical Cancer Cells |
| - | in-vitro, | Cerv, | HeLa |
| 325- | SNP, | Silver nanoparticles modulate ABC transporter activity and enhance chemotherapy in multidrug resistant cancer |
| 326- | SNP, | TSA, | Modulating chromatin structure and DNA accessibility by deacetylase inhibition enhances the anti-cancer activity of silver nanoparticles |
| - | in-vitro, | Cerv, | HeLa |
| 327- | SNP, | MS-275, | Combination Effect of Silver Nanoparticles and Histone Deacetylases Inhibitor in Human Alveolar Basal Epithelial Cells |
| - | in-vitro, | Lung, | A549 |
| 328- | SNP, | Rad, | Silver nanoparticles outperform gold nanoparticles in radiosensitizing U251 cells in vitro and in an intracranial mouse model of glioma |
| - | vitro+vivo, | GBM, | U251 |
| 329- | SNP, | Rad, | Enhancement of radiotherapy efficacy by silver nanoparticles in hypoxic glioma cells |
| - | in-vitro, | GBM, | U251 |
| 330- | SNP, | Rad, | Reactive oxygen species acts as executor in radiation enhancement and autophagy inducing by AgNPs |
| - | in-vitro, | GBM, | U251 |
| 331- | SNP, | Rad, | Silver nanoparticles: a novel radiation sensitizer for glioma? |
| - | vitro+vivo, | GBM, | NA |
| 332- | SNP, | Rad, | Enhancement of Radiosensitization by Silver Nanoparticles Functionalized with Polyethylene Glycol and Aptamer As1411 for Glioma Irradiation Therapy |
| - | in-vivo, | GBM, | NA |
| 386- | SNP, | Tam, | Synergistic anticancer effects and reduced genotoxicity of silver nanoparticles and tamoxifen in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 396- | SNP, | Systemic Evaluation of Mechanism of Cytotoxicity in Human Colon Cancer HCT-116 Cells of Silver Nanoparticles Synthesized Using Marine Algae Ulva lactuca Extract |
| - | in-vitro, | Colon, | HCT116 |
| 380- | SNP, | QC, | CA, | Chit, | Quercetin- and caffeic acid-functionalized chitosan-capped colloidal silver nanoparticles: one-pot synthesis, characterization, and anticancer and antibacterial activities |
| - | in-vitro, | MG, | U118MG |
| 381- | SNP, | Silver Nanoparticles Exert Apoptotic Activity in Bladder Cancer 5637 Cells Through Alteration of Bax/Bcl-2 Genes Expression |
| - | in-vitro, | Bladder, | 5637 |
| 382- | SNP, | Investigation the apoptotic effect of silver nanoparticles (Ag-NPs) on MDA-MB 231 breast cancer epithelial cells via signaling pathways |
| - | in-vitro, | BC, | MDA-MB-231 |
| 383- | SNP, | In vitro and in vivo evaluation of anti-tumorigenesis potential of nano silver for gastric cancer cells |
| - | in-vitro, | GC, | MKN45 |
| 384- | SNP, | Dual functions of silver nanoparticles in F9 teratocarcinoma stem cells, a suitable model for evaluating cytotoxicity- and differentiation-mediated cancer therapy |
| - | in-vitro, | Testi, | F9 |
| 403- | SNP, | RF, | Synergetic effects of silver and gold nanoparticles in the presence of radiofrequency radiation on human kidney cells |
| - | in-vitro, | NA, | HNK |
| - | in-vitro, | BC, | MCF-7 |
| 400- | SNP, | MF, | Polyvinyl Alcohol Capped Silver Nanostructures for Fortified Apoptotic Potential Against Human Laryngeal Carcinoma Cells Hep-2 Using Extremely-Low Frequency Electromagnetic Field |
| - | in-vitro, | Laryn, | HEp2 |
| 399- | SNP, | SIL, | Cytotoxic potentials of silibinin assisted silver nanoparticles on human colorectal HT-29 cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 398- | SNP, | Silver nanoparticles induced testicular damage targeting NQO1 and APE1 dysregulation, apoptosis via Bax/Bcl-2 pathway, fibrosis via TGF-β/α-SMA upregulation in rats |
| - | in-vivo, | Testi, | NA |
| 397- | SNP, | GEM, | Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment |
| - | in-vitro, | Ovarian, | A2780S |
| 358- | SNP, | Preparation of triangular silver nanoparticles and their biological effects in the treatment of ovarian cancer |
| - | vitro+vivo, | Ovarian, | SKOV3 |
| 395- | SNP, | The apoptotic and genomic studies on A549 cell line induced by silver nitrate |
| - | in-vitro, | Lung, | A549 |
| 394- | SNP, | Anticancer activity of Moringa oleifera mediated silver nanoparticles on human cervical carcinoma cells by apoptosis induction |
| - | in-vitro, | Cerv, | HeLa |
| 393- | SNP, | Green synthesized plant-based silver nanoparticles: therapeutic prospective for anticancer and antiviral activity |
| - | in-vitro, | NA, | HCT116 |
| 392- | SNP, | Biogenic silver nanoparticles synthesized from Piper longum fruit extract inhibit HIF-1α/VEGF mediated angiogenesis in prostate cancer cells |
| 391- | SNP, | Silver nanoparticles inhibit VEGF-and IL-1β-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells |
| 390- | SNP, | Anti-cancerous effect of albumin coated silver nanoparticles on MDA-MB 231 human breast cancer cell line |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | BC, | NA |
| 389- | SNP, | Citrate, | Silver Citrate Nanoparticles Inhibit PMA-Induced TNFα Expression via Deactivation of NF-κB Activity in Human Cancer Cell-Lines, MCF-7 |
| - | in-vitro, | BC, | MCF-7 |
| 388- | SNP, | Apoptotic efficacy of multifaceted biosynthesized silver nanoparticles on human adenocarcinoma cells |
| - | in-vitro, | BC, | MCF-7 |
| 387- | SNP, | Silver nanoparticles induce mitochondria-dependent apoptosis and late non-canonical autophagy in HT-29 colon cancer cells |
| - | in-vitro, | Colon, | HT-29 |
| 385- | SNP, | Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment |
| - | in-vitro, | Hepat, | HepG2 | - | in-vitro, | Hepat, | WI38 |
| 378- | SNP, | Antitumor efficacy of silver nanoparticles reduced with β-D-glucose as neoadjuvant therapy to prevent tumor relapse in a mouse model of breast cancer |
| - | ex-vivo, | BC, | 4T1 |
| 357- | SNP, | Hypoxia-mediated autophagic flux inhibits silver nanoparticle-triggered apoptosis in human lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | L132 |
| 359- | SNP, | Anti-cancer & anti-metastasis properties of bioorganic-capped silver nanoparticles fabricated from Juniperus chinensis extract against lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 |
| 360- | SNP, | Moringa, | Cytotoxic and Genotoxic Evaluation of Biosynthesized Silver Nanoparticles Using Moringa oleifera on MCF-7 and HUVEC Cell Lines |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | HUVECs |
| 361- | SNP, | Annona muricata assisted biogenic synthesis of silver nanoparticles regulates cell cycle arrest in NSCLC cell lines |
| - | in-vitro, | Lung, | A549 |
| 362- | SNP, | Comparative and Mechanistic Study on the Anticancer Activity of Quinacrine-Based Silver and Gold Hybrid Nanoparticles in Head and Neck Cancer |
| - | vitro+vivo, | SCC, | SCC9 |
| 363- | SNP, | Silver nanoparticles induce oxidative cell damage in human liver cells through inhibition of reduced glutathione and induction of mitochondria-involved apoptosis |
| 364- | SNP, | Differential Action of Silver Nanoparticles on ABCB1 (MDR1) and ABCC1 (MRP1) Activity in Mammalian Cell Lines |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Hepat, | HepG2 | - | in-vitro, | CRC, | SW-620 |
| 365- | SNP, | Silver nanoparticles affect glucose metabolism in hepatoma cells through production of reactive oxygen species |
| - | in-vitro, | Hepat, | HepG2 |
| 366- | SNP, | Silver nanoparticles inhibit the function of hypoxia-inducible factor-1 and target genes: insight into the cytotoxicity and antiangiogenesis |
| - | in-vitro, | BC, | MCF-7 |
| 367- | SNP, | Presence of an Immune System Increases Anti-Tumor Effect of Ag Nanoparticle Treated Mice |
| - | in-vivo, | NA, | NA |
| 368- | SNP, | In vitro evaluation of silver nanoparticles on human tumoral and normal cells |
| - | in-vitro, | Var, | NA |
| 369- | SNP, | Silver nanoparticles induce oxidative cell damage in human liver cells through inhibition of reduced glutathione and induction of mitochondria-involved apoptosis |
| - | in-vitro, | Liver, | NA |
| 370- | SNP, | Differential genotoxicity mechanisms of silver nanoparticles and silver ions |
| - | in-vitro, | lymphoma, | TK6 |
| 371- | SNP, | Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549 |
| - | in-vitro, | Lung, | A549 |
| - | in-vitro, | Hepat, | HepG2 |
| 373- | SNP, | Cytotoxic Potential and Molecular Pathway Analysis of Silver Nanoparticles in Human Colon Cancer Cells HCT116 |
| - | in-vitro, | Colon, | HCT116 |
| 374- | SNP, | Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 375- | SNP, | ALA, | Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vivo, | NA, | NA |
| 376- | SNP, | Antitumor activity of colloidal silver on MCF-7 human breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 377- | SNP, | Anticancer Action of Silver Nanoparticles in SKBR3 Breast Cancer Cells through Promotion of Oxidative Stress and Apoptosis |
| - | in-vitro, | BC, | SkBr3 |
| 379- | SNP, | Effects of green-synthesized silver nanoparticles on lung cancer cells in vitro and grown as xenograft tumors in vivo |
| - | in-vivo, | Lung, | H1299 |
| 2288- | SNP, | Silver Nanoparticle-Mediated Cellular Responses in Various Cell Lines: An in Vitro Model |
| - | Review, | Var, | NA |
| 2287- | SNP, | Silver nanoparticles induce endothelial cytotoxicity through ROS-mediated mitochondria-lysosome damage and autophagy perturbation: The protective role of N-acetylcysteine |
| - | in-vitro, | Nor, | HUVECs |
| 2286- | SNP, | Short-term changes in intracellular ROS localisation after the silver nanoparticles exposure depending on particle size |
| - | in-vitro, | Nor, | 3T3 |
| 2834- | SNP, | Gluc, | Electrochemical oxidation of glucose on silver nanoparticle-modified composite electrodes |
| - | Study, | NA, | NA |
| 2835- | SNP, | Gluc, | Carbohydrate functionalization of silver nanoparticles modulates cytotoxicity and cellular uptake |
| - | in-vitro, | Liver, | HepG2 |
| 2836- | SNP, | Gluc, | Glucose capped silver nanoparticles induce cell cycle arrest in HeLa cells |
| - | in-vitro, | Cerv, | HeLa |
| 2837- | SNP, | Trojan-Horse Mechanism in the Cellular Uptake of Silver Nanoparticles Verified by Direct Intra- and Extracellular Silver Speciation Analysis |
| - | in-vitro, | NA, | NA |
| 2539- | SNP, | SDT, | Combined effect of silver nanoparticles and therapeutical ultrasound on ovarian carcinoma cells A2780 |
| - | in-vitro, | Melanoma, | A2780S |
| 2538- | SNP, | SDT, | Z, | Dual-functional silver nanoparticle-enhanced ZnO nanorods for improved reactive oxygen species generation and cancer treatment |
| - | Study, | Var, | NA | - | vitro+vivo, | NA, | NA |
| 4421- | SNP, | Effect of Biologically Synthesized Silver Nanoparticles on Human Cancer Cells |
| - | in-vitro, | Cerv, | NA |
| 4555- | SNP, | Silver nanoparticles from Dendropanax morbifera Léveille inhibit cell migration, induce apoptosis, and increase generation of reactive oxygen species in A549 lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HepG2 |
| 4554- | SNP, | Involvement of telomerase activity inhibition and telomere dysfunction in silver nanoparticles anticancer effects |
| - | in-vitro, | Cerv, | HeLa |
| 4556- | SNP, | Biofilm Impeding AgNPs Target Skin Carcinoma by Inducing Mitochondrial Membrane Depolarization Mediated through ROS Production |
| - | in-vitro, | Melanoma, | A431 |
| 4553- | SNP, | Cytotoxicity induced by engineered silver nanocrystallites is dependent on surface coatings and cell types |
| - | in-vitro, | Nor, | RAW264.7 |
| 4552- | SNP, | ART/DHA, | Green synthesis of silver nanoparticles using Artemisia turcomanica leaf extract and the study of anti-cancer effect and apoptosis induction on gastric cancer cell line (AGS) |
| - | in-vitro, | GC, | AGS |
| 4551- | SNP, | Fenb, | Ångstrom-Scale Silver Particles as a Promising Agent for Low-Toxicity Broad-Spectrum Potent Anticancer Therapy |
| - | in-vivo, | Lung, | NA |
| 4550- | SNP, | The Effect of Charge at the Surface of Silver Nanoparticles on Antimicrobial Activity against Gram-Positive and Gram-Negative Bacteria: A Preliminary Study |
| - | Study, | Nor, | NA |
| 4549- | SNP, | Silver nanoparticles: Synthesis, medical applications and biosafety |
| - | Review, | Var, | NA | - | Review, | Diabetic, | NA |
| - | in-vitro, | BC, | MCF-7 |
| 4547- | SNP, | GoldNP, | VitC, | Exploration of Biocompatible Ascorbic Acid Reduced and Stabilized Gold Nanoparticles, as Sensitive and Selective Detection Nanoplatform for Silver Ion in Solution |
| - | Study, | NA, | NA |
| 4546- | SNP, | Chapter 2 - Silver nanoparticles in cancer therapy |
| - | Study, | Var, | NA |
| 4545- | SNP, | VitC, | Citrate, | Ascorbic Acid-assisted Green Synthesis of Silver Nanoparticles: pH and Stability Study |
| - | Study, | NA, | NA |
| 4544- | SNP, | VitC, | Current Research on Silver Nanoparticles: Synthesis, Characterization, and Applications |
| - | Review, | Nor, | NA |
| 4543- | SNP, | Biogenic synthesis of silver nanoparticles using Zaleya pentandra and investigation of their biological activities |
| - | Study, | Nor, | NA |
| 4542- | SNP, | Silver Nanoparticles (AgNPs): Comprehensive Insights into Bio/Synthesis, Key Influencing Factors, Multifaceted Applications, and Toxicity─A 2024 Update |
| - | Review, | NA, | NA |
| 4541- | SNP, | RosA, | Eco-friendly synthesis of silver nanoparticles: multifaceted antioxidant, antidiabetic, anticancer, and antimicrobial activities |
| - | in-vitro, | Nor, | WI38 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | PC, | PANC1 |
| 4540- | SNP, | VitC, | Silver nanoparticles from ascorbic acid: Biosynthesis, characterization, in vitro safety profile, antimicrobial activity and phytotoxicity |
| - | in-vitro, | Nor, | NA |
| 4539- | SNP, | VitC, | Citrate, | Investigating the Anti-cancer Potential of Silver Nanoparticles Synthesized by Chemical Reduction of AgNO3 Using Trisodium Citrate and Ascorbic Acid |
| - | in-vitro, | Nor, | L929 | - | in-vitro, | Ovarian, | SKOV3 |
| 4432- | SNP, | Emerging nanostructure-based strategies for breast cancer therapy: innovations, challenges, and future directions |
| - | Review, | NA, | NA |
| 4422- | SNP, | Bioengineering of Piper longum L. extract mediated silver nanoparticles and their potential biomedical applications |
| - | in-vitro, | Cerv, | HeLa |
| 4423- | SNP, | Pongamia pinnata seed extract-mediated green synthesis of silver nanoparticle loaded nanogel for estimation of their antipsoriatic properties |
| - | in-vivo, | PSA, | NA |
| 4424- | SNP, | Understanding the prospective of nano-formulations towards the treatment of psoriasis |
| - | in-vivo, | PSA, | NA |
| 4426- | SNP, | Antiangiogenic properties of silver nanoparticles |
| - | Study, | NA, | NA |
| 4427- | SNP, | Silver nanoparticles induce apoptosis and G2/M arrest via PKCζ-dependent signaling in A549 lung cells |
| - | in-vitro, | Lung, | A549 |
| 4428- | SNP, | p38 MAPK Activation, DNA Damage, Cell Cycle Arrest and Apoptosis As Mechanisms of Toxicity of Silver Nanoparticles in Jurkat T Cells |
| - | in-vitro, | AML, | Jurkat |
| 4429- | SNP, | Comparative proteomic analysis reveals the different hepatotoxic mechanisms of human hepatocytes exposed to silver nanoparticles |
| - | in-vitro, | Liver, | HepG2 |
| 4430- | SNP, | Evaluation of the Genotoxic and Oxidative Damage Potential of Silver Nanoparticles in Human NCM460 and HCT116 Cells |
| - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Nor, | NCM460 |
| 4431- | SNP, | doxoR, | Oxidative Stress-Induced Silver Nano-Carriers for Chemotherapy |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | BC, | 4T1 | - | in-vitro, | Nor, | 3T3 |
| 4433- | SNP, | Advancements in metal and metal oxide nanoparticles for targeted cancer therapy and imaging: Mechanisms, applications, and safety concerns |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Nor, | L02 |
| - | vitro+vivo, | Nor, | NA |
| 4435- | SNP, | Gluc, | Glucose-Functionalized Silver Nanoparticles as a Potential New Therapy Agent Targeting Hormone-Resistant Prostate Cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 4436- | SNP, | Silver Nanoparticles (AgNPs) as Enhancers of Everolimus and Radiotherapy Sensitivity on Clear Cell Renal Cell Carcinoma |
| - | in-vitro, | Kidney, | 786-O |
| 4437- | SNP, | Green Fabrication of silver nanoparticles by leaf extract of Byttneria Herbacea Roxb and their promising therapeutic applications and its interesting insightful observations in oral cancer |
| - | in-vitro, | Oral, | NA |
| 4438- | SNP, | ART/DHA, | Biogenic synthesis of AgNPs using Artemisia oliveriana extract and their biological activities for an effective treatment of lung cancer |
| - | in-vitro, | Lung, | A549 |
| 4439- | SNP, | Anticancer Potential of Green Synthesized Silver Nanoparticles Using Extract of Nepeta deflersiana against Human Cervical Cancer Cells (HeLA) |
| - | in-vitro, | Cerv, | HeLa |
| 4447- | SNP, | Anti-inflammatory action of silver nanoparticles in vivo: systematic review and meta-analysis |
| - | Review, | Nor, | NA |
| 4581- | SNP, | Antimicrobial, anticoagulant and antiplatelet activities of green synthesized silver nanoparticles using Selaginella (Sanjeevini) plant extract |
| 4580- | SNP, | Biogenic Synthesis of Antibacterial, Hemocompatible, and Antiplatelets Lysozyme Functionalized Silver Nanoparticles through the One-Step Process for Therapeutic Applications |
| - | in-vitro, | NA, | NA |
| 4579- | SNP, | Response of platelets to silver nanoparticles designed with different surface functionalization |
| 4562- | SNP, | VitC, | Eco-friendly Synthesis of Silver Nanoparticles using Ascorbic Acid and its Optical Characterization |
| - | Study, | NA, | NA |
| 4578- | SNP, | Green synthesized novel silver nanoparticles and their application as anticoagulant and thrombolytic agents: A perspective |
| - | Review, | NA, | NA |
| 4577- | SNP, | Characterization of Antiplatelet Properties of Silver Nanoparticles |
| - | vitro+vivo, | Stroke, | NA |
| 4576- | SNP, | Nanosilver, Next-Generation Antithrombotic Agent |
| - | Study, | NA, | NA |
| 4574- | SNP, | Advances in nano silver-based biomaterials and their biomedical applications |
| - | Review, | NA, | NA |
| 4573- | SNP, | Bioactive silver nanoparticles derived from Carica papaya floral extract and its dual-functioning biomedical application |
| - | in-vitro, | Var, | MCF-7 | - | NA, | NA, | HEK293 |
| 4564- | SNP, | GoldNP, | Cu, | Chemo, | PDT | Cytotoxicity and targeted drug delivery of green synthesized metallic nanoparticles against oral Cancer: A review |
| - | Review, | Var, | NA |
| 4563- | SNP, | Rad, | Silver nanoparticles enhance neutron radiation sensitivity in cancer cells: An in vitro study |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | Melanoma, | A431 |
| 4585- | SNP, | Tyndall-effect-based colorimetric assay with colloidal silver nanoparticles for quantitative point-of-care detection of creatinine using a laser pointer pen and a smartphone |
| 4561- | SNP, | VitC, | Cellular Effects Nanosilver on Cancer and Non-cancer Cells: Potential Environmental and Human Health Impacts |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | HEK293 |
| 4560- | SNP, | Exploiting antidiabetic activity of silver nanoparticles synthesized using Punica granatum leaves and anticancer potential against human liver cancer cells (HepG2) |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Diabetic, | NA |
| 4559- | SNP, | Anticancer activity of biogenerated silver nanoparticles: an integrated proteomic investigation |
| - | in-vitro, | BC, | SkBr3 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Colon, | Caco-2 |
| 4558- | SNP, | Role of Oxidative and Nitro-Oxidative Damage in Silver Nanoparticles Cytotoxic Effect against Human Pancreatic Ductal Adenocarcinoma Cells |
| - | in-vitro, | PC, | PANC1 |
| 4557- | SNP, | The apoptotic effect of nanosilver is mediated by a ROS- and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells |
| - | in-vitro, | NA, | NIH-3T3 | - | in-vitro, | CRC, | HCT116 |
| 4661- | SNP, | Silver nanoparticles induces apoptosis of cancer stem cells in head and neck cancer |
| - | in-vitro, | HNSCC, | NA |
| 4600- | SNP, | Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model |
| - | in-vivo, | Nor, | NA |
| 4599- | SNP, | ProBio, | Impacts of dietary silver nanoparticles and probiotic administration on the microbiota of an in-vitro gut model |
| - | in-vivo, | Nor, | NA |
| 4598- | SNP, | In vivo human time-exposure study of orally dosed commercial silver nanoparticles |
| - | in-vivo, | Nor, | NA |
| 4596- | SNP, | Oral administration of silver nanomaterials affects the gut microbiota and metabolic profile altering the secretion of 5-HT in mice |
| - | in-vivo, | NA, | NA |
| 4595- | SNP, | ORAL DELIVERY OF SILVER NANOPARTICLES – A REVIEW |
| - | Review, | NA, | NA |
| 4594- | SNP, | Citrate, | Bioavailability and Toxicokinetics of citrate-coated silver nanoparticles in rats |
| - | in-vivo, | Nor, | NA |
| 4593- | SNP, | Chit, | Chitosan-coated silver nanoparticles promoted antibacterial, antibiofilm, wound-healing of murine macrophages and antiproliferation of human breast cancer MCF 7 cells |
| - | in-vitro, | BC, | MCF-7 |
| 4592- | SNP, | Chit, | Chitosan conjugated silver nanoparticles: the versatile antibacterial agents |
| - | in-vitro, | NA, | NA |
| 4591- | SNP, | Chit, | Synthesis and Characterization of Multifunctional Chitosan–Silver Nanoparticles: An In-Vitro Approach for Biomedical Applications |
| - | in-vitro, | NA, | NA |
| 4590- | SNP, | Chit, | Silver nanochitosan: a sustainable approach for enhanced antimicrobial, antioxidant, and anticancer applications |
| - | in-vitro, | NA, | NA |
| 4589- | SNP, | Chit, | Synthesis and Characterization of Chitosan–Silver Nanocomposite Film: Antibacterial and Cytotoxicity Study |
| - | in-vitro, | NA, | NA |
| 4588- | SNP, | Chit, | Solid-state tailored silver nanocomposites from chitosan: Synthesis, antimicrobial evaluation and molecular docking |
| - | in-vitro, | NA, | NA |
| 4587- | SNP, | Chit, | Multifunctional Silver Nanoparticles Based on Chitosan: Antibacterial, Antibiofilm, Antifungal, Antioxidant, and Wound-Healing Activities |
| - | in-vitro, | NA, | NA |
| 4586- | SNP, | Tyndall-effect-enhanced supersensitive naked-eye determination of mercury (II) ions with silver nanoparticles |
| 4584- | SNP, | Silver Nanoparticles Synthesized Using Carica papaya Leaf Extract (AgNPs-PLE) Causes Cell Cycle Arrest and Apoptosis in Human Prostate (DU145) Cancer Cells |
| - | in-vitro, | Pca, | DU145 |
| 4583- | SNP, | Metal-Based Nanoparticles for Cardiovascular Diseases |
| - | Review, | NA, | NA |
| 4582- | SNP, | Silver CASRN 7440-22-4 | DTXSID4024305 |
| 4378- | SNP, | Exploring silver nanoparticles for cancer therapy and diagnosis |
| - | Review, | Var, | NA |
| 4386- | SNP, | Evaluation of hepatic cancer stem cells (CD73+, CD44+, and CD90+) induced by diethylnitrosamine in male rats and treatment with biologically synthesized silver nanoparticles |
| 4385- | SNP, | Hepatoprotective effect of engineered silver nanoparticles coated bioactive compounds against diethylnitrosamine induced hepatocarcinogenesis in experimental mice |
| - | in-vitro, | Liver, | NA |
| 4383- | SNP, | Exploring the Potentials of Silver Nanoparticles in Overcoming Cisplatin Resistance in Lung Adenocarcinoma: Insights from Proteomic and Xenograft Mice Studies |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | Lung, | A549 |
| 4382- | SNP, | Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism |
| - | in-vitro, | Nor, | RAW264.7 |
| 4381- | SNP, | Oxidative stress-dependent toxicity of silver nanoparticles in human hepatoma cells |
| - | in-vitro, | Liver, | HepG2 |
| 4380- | SNP, | Silver nanoparticles induce toxicity in A549 cells via ROS-dependent and ROS-independent pathways |
| - | in-vitro, | Lung, | A549 |
| 4379- | SNP, | Exposure to silver nanoparticles induces size- and dose-dependent oxidative stress and cytotoxicity in human colon carcinoma cells |
| - | in-vitro, | CRC, | LoVo |
| 4387- | SNP, | Attenuation of diethylnitrosamine (DEN) - Induced hepatic cancer in experimental model of Wistar rats by Carissa carandas embedded silver nanoparticles |
| - | in-vitro, | Liver, | NA |
| 4377- | SNP, | Interaction between silver nanoparticles of 20 nm (AgNP20 ) and human neutrophils: induction of apoptosis and inhibition of de novo protein synthesis by AgNP20 aggregates |
| - | in-vitro, | NA, | NA |
| 4376- | SNP, | Interaction of multi-functional silver nanoparticles with living cells |
| - | in-vitro, | Nor, | L929 | - | in-vitro, | Lung, | A549 |
| 4375- | SNP, | The cellular uptake and cytotoxic effect of silver nanoparticles on chronic myeloid leukemia cells |
| - | in-vitro, | AML, | K562 |
| 4374- | SNP, | Enhancing antitumor activity of silver nanoparticles by modification with cell-penetrating peptides |
| - | in-vitro, | BC, | MCF-7 |
| 4373- | SNP, | In vitro toxicity of silver nanoparticles at noncytotoxic doses to HepG2 human hepatoma cells |
| - | in-vitro, | Liver, | HepG2 |
| 4372- | SNP, | Negligible particle-specific toxicity mechanism of silver nanoparticles: the role of Ag+ ion release in the cytosol |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | A549 |
| 4371- | SNP, | Effects of Green Silver Nanoparticles on Apoptosis and Oxidative Stress in Normal and Cancerous Human Hepatic Cells in vitro |
| - | in-vitro, | Liver, | HUH7 |
| 4370- | SNP, | Effect of silver nanoparticles in the induction of apoptosis on human hepatocellular carcinoma (HepG2) cell line |
| - | in-vitro, | Liver, | HepG2 |
| - | in-vitro, | OS, | MG63 |
| 4404- | SNP, | Rad, | Main Approaches to Enhance Radiosensitization in Cancer Cells by Nanoparticles: A Systematic Review |
| - | Review, | Var, | NA |
| 4403- | SNP, | Silver Nanoparticles Decorated UiO-66-NH2 Metal-Organic Framework for Combination Therapy in Cancer Treatment |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | GL26 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | CRC, | RKO |
| 4402- | SNP, | Enhancement of Triple-Negative Breast Cancer-Specific Induction of Cell Death by Silver Nanoparticles by Combined Treatment with Proteotoxic Stress Response Inhibitors |
| - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 4401- | SNP, | Rad, | Metformin-loaded chitosan nanoparticles augment silver nanoparticle-induced radiosensitization in breast cancer cells during radiation therapy |
| - | in-vitro, | BC, | NA |
| 4400- | SNP, | Rad, | Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | BC, | MDA-MB-231 |
| 4399- | SNP, | Chit, | Silver nanoparticles impregnated alginate-chitosan-blended nanocarrier induces apoptosis in human glioblastoma cells |
| - | in-vitro, | GBM, | U87MG |
| 4398- | SNP, | Induction of apoptosis in cancer cells at low silver nanoparticle concentrations using chitosan nanocarrier |
| - | in-vitro, | Colon, | HT29 |
| 4397- | SNP, | Synthesis and Characterization of Silver Nanoparticles from Rhizophora apiculata and Studies on Their Wound Healing, Antioxidant, Anti-Inflammatory, and Cytotoxic Activity |
| - | NA, | Wounds, | NA |
| 4369- | SNP, | Silver nanoparticles induce p53-mediated apoptosis in human bronchial epithelial (BEAS-2B) cells |
| - | in-vitro, | Nor, | BEAS-2B |
| 4395- | SNP, | Hepatoprotective effect of silver nanoparticles synthesized using aqueous leaf extract of Rhizophora apiculata |
| - | in-vivo, | LiverDam, | NA |
| 4394- | SNP, | Silver nanoparticles provoke apoptosis of Dalton's ascites lymphoma in vivo by mitochondria dependent and independent pathways |
| - | in-vivo, | lymphoma, | NA |
| 4393- | SNP, | Nanotoxic Effects of Silver Nanoparticles on Normal HEK-293 Cells in Comparison to Cancerous HeLa Cell Line |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HEK293 |
| 4392- | SNP, | Hepatocurative activity of biosynthesized silver nanoparticles fabricated using Andrographis paniculata |
| - | in-vivo, | LiverDam, | NA |
| 4391- | SNP, | Silver Nanoparticles Induce Apoptosis in HepG2 Cells through Particle-Specific Effects on Mitochondria |
| - | NA, | Liver, | HepG2 |
| 4390- | SNP, | Therapeutic Potential of Cucumis melo (L.) Fruit Extract and Its Silver Nanopartciles Against DEN-Induced Hepatocellular Cancer in Rats |
| - | in-vivo, | Liver, | NA |
| 4389- | SNP, | Graphene Oxide-Silver Nanocomposite Enhances Cytotoxic and Apoptotic Potential of Salinomycin in Human Ovarian Cancer Stem Cells (OvCSCs): A Novel Approach for Cancer Therapy |
| - | in-vitro, | Ovarian, | NA |
| 4388- | SNP, | Differential Cytotoxic Potential of Silver Nanoparticles in Human Ovarian Cancer Cells and Ovarian Cancer Stem Cells |
| - | in-vitro, | Cerv, | NA |
| 4368- | SNP, | Silver nanoparticles crossing through and distribution in the blood-brain barrier in vitro |
| - | NA, | Nor, | NA |
| 4419- | SNP, | Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis |
| - | NA, | PSA, | NA |
| 4418- | SNP, | Nanocarriers for the topical treatment of psoriasis - pathophysiology, conventional treatments, nanotechnology, regulatory and toxicology |
| - | Human, | PSA, | NA |
| 4417- | SNP, | Caffeine-boosted silver nanoparticles target breast cancer cells by triggering oxidative stress, inflammation, and apoptotic pathways |
| - | in-vitro, | BC, | MDA-MB-231 |
| 4416- | SNP, | Efficacy of curcumin-synthesized silver nanoparticles on MCF-7 breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 4415- | SNP, | SDT, | CUR, | Examining the Impact of Sonodynamic Therapy With Ultrasound Wave in the Presence of Curcumin-Coated Silver Nanoparticles on the Apoptosis of MCF7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 |
| 4414- | SNP, | Silver nanoparticles: Forging a new frontline in lung cancer therapy |
| - | Review, | Lung, | NA |
| 4413- | SNP, | Anzaroot, | Green synthesis of silver nanoparticles from plant Astragalus fasciculifolius Bioss and evaluating cytotoxic effects on MCF7 human breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 4412- | SNP, | Biosynthesis and characterization of silver nanoparticles from Asplenium dalhousiae and their potential biological properties |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Melanoma, | A2780S |
| 4411- | SNP, | Eco-friendly synthesis of silver nanoparticles using Anemone coronaria bulb extract and their potent anticancer and antibacterial activities |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | HEK293 |
| 4410- | SNP, | Green-synthesized silver nanoparticles: a sustainable nanoplatform for targeted colon cancer therapy |
| - | Review, | Colon, | NA |
| 4409- | SNP, | Plant-based synthesis of gold and silver nanoparticles using Artocarpus heterophyllus aqueous leaf extract and its anticancer activities |
| - | in-vitro, | BC, | MCF-7 |
| 4408- | SNP, | Chitosan-coated silver nanoparticles synthesized using Moringa oleifera flower extract: A potential therapeutic approach against triple-negative breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 |
| 4407- | SNP, | Green Synthesis and Characterization of Silver Nanoparticles from Eclipta alba and Its Activity Against Triple-Negative Breast Cancer Cell Line (MDA-MB-231) |
| - | in-vitro, | BC, | MDA-MB-231 |
| 4406- | SNP, | Silver nanoparticles achieve cytotoxicity against breast cancer by regulating long-chain noncoding RNA XLOC_006390-mediated pathway |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 |
| 4405- | SNP, | Silver nanoparticles defeat p53-positive and p53-negative osteosarcoma cells by triggering mitochondrial stress and apoptosis |
| - | in-vitro, | OS, | NA |
| 4359- | SNP, | Antimicrobial Silver Nanoparticles for Wound Healing Application: Progress and Future Trends |
| - | NA, | Wounds, | NA |
| 4366- | SNP, | Gut Dysbiosis and Neurobehavioral Alterations in Rats Exposed to Silver Nanoparticles |
| - | in-vivo, | Nor, | NA |
| 4365- | SNP, | Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview |
| - | Review, | Var, | NA |
| 4364- | SNP, | Selective cytotoxicity of green synthesized silver nanoparticles against the MCF-7 tumor cell line and their enhanced antioxidant and antimicrobial properties |
| - | in-vitro, | BC, | MCF-7 |
| 4363- | SNP, | Immunomodulatory properties of silver nanoparticles contribute to anticancer strategy for murine fibrosarcoma |
| - | in-vivo, | fibroS, | NA |
| 4362- | SNP, | Enhancing Colorectal Cancer Radiation Therapy Efficacy using Silver Nanoprisms Decorated with Graphene as Radiosensitizers |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vivo, | NA, | NA |
| 4361- | SNP, | GoldNP, | Biocompatible silver, gold and silver/gold alloy nanoparticles for enhanced cancer therapy: in vitro and in vivo perspectives |
| - | in-vivo, | Liver, | HepG2 |
| 4360- | SNP, | Silver Nanoparticles as Real Topical Bullets for Wound Healing |
| - | Study, | Nor, | NA |
| 4358- | SNP, | HPT, | Rad, | Silver nanocrystals mediated combination therapy of radiation with magnetic hyperthermia on glioma cells |
| - | in-vitro, | GBM, | U251 |
| 4367- | SNP, | Effects of Prolonged Silver Nanoparticle Exposure on the Contextual Cognition and Behavior of Mammals |
| - | in-vivo, | Nor, | NA |
| 2205- | SNP, | Potential protective efficacy of biogenic silver nanoparticles synthesised from earthworm extract in a septic mice model |
| - | in-vivo, | Nor, | NA |
| 2208- | SNP, | Sepsis diagnosis and treatment using nanomaterials |
| - | Review, | NA, | NA |
| 2207- | SNP, | TQ, | Protective effects of Nigella sativa L. seeds aqueous extract-based silver nanoparticles on sepsis-induced damages in rats |
| - | in-vivo, | Nor, | NA |
| 2206- | SNP, | RES, | ENHANCED EFFICACY OF RESVERATROL-LOADED SILVER NANOPARTICLE IN ATTENUATING SEPSIS-INDUCED ACUTE LIVER INJURY: MODULATION OF INFLAMMATION, OXIDATIVE STRESS, AND SIRT1 ACTIVATION |
| - | in-vivo, | Nor, | NA |
| 1406- | SNP, | The antioxidant effects of silver, gold, and zinc oxide nanoparticles on male mice in in vivo condition |
| - | in-vivo, | Nor, | NA |
| 1903- | SNP, | Novel Silver Complexes Based on Phosphanes and Ester Derivatives of Bis(pyrazol-1-yl)acetate Ligands Targeting TrxR: New Promising Chemotherapeutic Tools Relevant to SCLC Managemen |
| - | in-vitro, | Lung, | U1285 |
| 1906- | SNP, | GoldNP, | Cu, | Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors |
| - | Review, | Var, | NA |
| 1905- | SNP, | Evaluation of the effect of silver and silver nanoparticles on the function of selenoproteins using an in-vitro model of the fish intestine: The cell line RTgutGC |
| - | in-vivo, | Nor, | NA |
| 1902- | SNP, | Modulation of the mechanism of action of antibacterial silver N-heterocyclic carbene complexes by variation of the halide ligand |
| - | in-vitro, | NA, | NA |
| 1907- | SNP, | GoldNP, | Cu, | In vitro antitumour activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Colon, | HCT15 | - | in-vitro, | Cerv, | HeLa |
| 1908- | SNP, | Exposure to Silver Nanoparticles Inhibits Selenoprotein Synthesis and the Activity of Thioredoxin Reductase |
| - | in-vitro, | Lung, | A549 |
| 1909- | SNP, | The Antibacterial Drug Candidate SBC3 is a Potent Inhibitor of Bacterial Thioredoxin Reductase |
| - | in-vivo, | Nor, | NA |
| 1594- | SNP, | Citrate, | Silver Citrate Nanoparticles Inhibit PMA-Induced TNFα Expression via Deactivation of NF-κB Activity in Human Cancer Cell-Lines, MCF-7 |
| - | in-vitro, | BC, | MCF-7 |
| 1512- | Squ, | Combination therapy in combating cancer |
| - | Review, | NA, | NA |
| 107- | SS, | Saikosaponin B1 and Saikosaponin D inhibit tumor growth in medulloblastoma allograft mice via inhibiting the Hedgehog signaling pathway |
| - | vitro+vivo, | MB, | NA |
| - | in-vitro, | NSCLC, | A549 |
| 112- | SuD, | Inhibition of Gli/hedgehog signaling in prostate cancer cells by “cancer bush” Sutherlandia frutescens extract |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP |
| 3853- | Sulfas, | Sulfur-containing therapeutics in the treatment of Alzheimer's disease |
| - | Review, | AD, | NA |
| 4215- | SY, | Safflower yellow alleviates cognitive impairment in mice by modulating cholinergic system function, oxidative stress, and CREB/BDNF/TrkB signaling pathway |
| - | in-vivo, | NA, | NA |
| 4157- | Taur, | Antidepressant dose of taurine increases mRNA expression of GABAA receptor α2 subunit and BDNF in the hippocampus of diabetic rats |
| - | in-vivo, | AD, | NA |
| 4151- | Taur, | Gins, | Taurine and Ginsenoside Rf Induce BDNF Expression in SH-SY5Y Cells: A Potential Role of BDNF in Corticosterone-Triggered Cellular Damage |
| - | in-vitro, | AD, | NA |
| 3954- | Taur, | Mode of action of taurine as a neuroprotector |
| - | in-vitro, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 3950- | Taur, | Taurine Supplementation as a Neuroprotective Strategy upon Brain Dysfunction in Metabolic Syndrome and Diabetes |
| - | Review, | Diabetic, | NA | - | Review, | Stroke, | NA | - | Review, | AD, | NA |
| 3951- | Taur, | Taurine Supplementation Alleviates Blood Pressure via Gut–Brain Communication in Spontaneously Hypertensive Rats |
| - | in-vivo, | NA, | NA |
| 3952- | Taur, | Taurine and Astrocytes: A Homeostatic and Neuroprotective Relationship |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3953- | Taur, | Role of taurine in regulation of intracellular calcium level and neuroprotective function in cultured neurons |
| - | in-vitro, | AD, | NA |
| 3964- | Taur, | Comparison of Urinary Excretion of Taurine Between Elderly with Dementia and Normal Elderly |
| - | Human, | AD, | NA |
| 3955- | Taur, | Mechanism of neuroprotective function of taurine |
| - | in-vitro, | NA, | NA |
| 3956- | Taur, | Mechanisms underlying taurine protection against glutamate-induced neurotoxicity |
| - | Review, | AD, | NA |
| 3957- | Taur, | Expedition into Taurine Biology: Structural Insights and Therapeutic Perspective of Taurine in Neurodegenerative Diseases |
| 3958- | Taur, | Evaluation of the neuroprotective effect of taurine in Alzheimer’s disease using functional molecular imaging |
| - | in-vivo, | AD, | NA |
| 3959- | Taur, | Taurine Directly Binds to Oligomeric Amyloid-β and Recovers Cognitive Deficits in Alzheimer Model Mice |
| - | in-vivo, | AD, | NA |
| 3960- | Taur, | Versatile Triad Alliance: Bile Acid, Taurine and Microbiota |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3961- | Taur, | Effects of Dietary Taurine Supplementation on Blood and Urine Taurine Concentrations in the Elderly Women with Dementia |
| - | Human, | AD, | NA |
| 3962- | Taur, | The Development of Taurine Supplementary Menus for the Prevention of Dementia and Their Positive Effect on the Cognitive Function in the Elderly with Dementia |
| - | Human, | AD, | NA |
| 3963- | Taur, | Past Taurine Intake Has a Positive Effect on Present Cognitive Function in the Elderly |
| - | Human, | AD, | NA |
| 3967- | Taur, | The Effects of Oral Taurine on Resting Blood Pressure in Humans: a Meta-Analysis |
| - | Review, | Nor, | NA |
| 3966- | Taur, | The Effects of Dietary Taurine-Containing Jelly Supplementation on Cognitive Function and Memory Ability of the Elderly with Subjective Cognitive Decline |
| - | Human, | AD, | NA |
| 3965- | Taur, | Taurine-Related Nutritional Knowledge Has a Positive Effect on Intake of Taurine and Cognitive Function in the Elderly |
| - | Human, | AD, | NA |
| 1137- | Taur, | Taurine Attenuates Epithelial-Mesenchymal Transition-Related Genes in Human Prostate Cancer Cells |
| - | in-vitro, | Pca, | NA |
| 1051- | Taur, | immuno, | Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8+ T cell function |
| - | in-vivo, | Lung, | NA |
| 1202- | Tb, | The influence of theobromine on angiogenic activity and proangiogenic cytokines production of human ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA |
| 2373- | TMZ, | The role of pyruvate kinase M2 in anticancer therapeutic treatments |
| - | Review, | Var, | NA |
| 139- | Tomatine, | CUR, | Combination of α-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells |
| - | in-vitro, | Pca, | PC3 |
| 113- | TQ, | Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer |
| - | vitro+vivo, | Pca, | C4-2B |
| 1138- | TQ, | Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 1019- | TQ, | Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation |
| - | vitro+vivo, | CRC, | LoVo |
| 962- | TQ, | Thymoquinone affects hypoxia-inducible factor-1α expression in pancreatic cancer cells via HSP90 and PI3K/AKT/mTOR pathways |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | Nor, | hTERT-HPNE | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | Bxpc-3 |
| 1052- | TQ, | Thymoquinone Anticancer Effects Through the Upregulation of NRF2 and the Downregulation of PD-L1 in MDA-MB-231 Triple-Negative Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 2353- | TQ, | The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies |
| - | Review, | PC, | NA |
| 3553- | TQ, | Study Effectiveness and Stability Formulation Nanoemulsion of Black Cumin Seed (Nigella sativa L.) Essential Oil: A Review |
| - | Review, | Nor, | NA |
| 3554- | TQ, | Neuroprotective efficacy of thymoquinone against amyloid beta-induced neurotoxicity in human induced pluripotent stem cell-derived cholinergic neurons |
| - | in-vitro, | AD, | NA |
| 3570- | TQ, | Thymoquinone alleviates the experimentally induced Alzheimer's disease inflammation by modulation of TLRs signaling |
| - | in-vivo, | AD, | NA |
| 3571- | TQ, | The Role of Thymoquinone in Inflammatory Response in Chronic Diseases |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA |
| 3572- | TQ, | Enhanced oral bioavailability and hepatoprotective activity of thymoquinone in the form of phospholipidic nano-constructs |
| - | in-vivo, | Nor, | NA |
| 3573- | TQ, | Chronic diseases, inflammation, and spices: how are they linked? |
| - | Review, | Var, | NA |
| 3555- | TQ, | Thymoquinone administration ameliorates Alzheimer's disease-like phenotype by promoting cell survival in the hippocampus of amyloid beta1-42 infused rat model |
| - | in-vivo, | AD, | NA |
| 3556- | TQ, | Thymoquinone alleviates the experimentally induced Alzheimer’s disease inflammation by modulation of TLRs signaling |
| - | in-vivo, | AD, | NA |
| 3557- | TQ, | Thymoquinone protects against lipopolysaccharides-induced neurodegeneration and Alzheimer-like model in mice. |
| - | in-vivo, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 3559- | TQ, | Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 3560- | TQ, | Protective effects of thymoquinone on D-galactose and aluminum chloride induced neurotoxicity in rats: biochemical, histological and behavioral changes |
| - | in-vivo, | AD, | NA |
| 3561- | TQ, | Studi In Silico Potensi Piperine, Piperlongumine, dan Thymoquinone Sebagai Obat Alzheimer |
| - | NA, | AD, | NA |
| 3562- | TQ, | ACETYLCHOLINESTERASE AND GROWTH INHIBITORY EFFECTS–VARIOUS GRADES OF N. SATIVA OILS |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 3563- | TQ, | Thymoquinone (TQ) demonstrates its neuroprotective effect via an anti-inflammatory action on the Aβ(1–42)-infused rat model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3564- | TQ, | The Potential Neuroprotective Effect of Thymoquinone on Scopolamine-Induced In Vivo Alzheimer's Disease-like Condition: Mechanistic Insights |
| - | in-vivo, | AD, | NA |
| 3565- | TQ, | Thymoquinone as a potential therapeutic for Alzheimer’s disease in transgenic Drosophila melanogaster model |
| 3417- | TQ, | Antiproliferative Effects of Thymoquinone in MCF-7 Breast and HepG2 Liver Cancer Cells: Possible Role of Ceramide and ER Stress |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Liver, | HepG2 |
| 3418- | TQ, | Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome |
| - | in-vitro, | Melanoma, | A375 | - | in-vivo, | NA, | NA |
| 3419- | TQ, | Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients |
| - | in-vitro, | BC, | NA |
| 3420- | TQ, | Thymoquinone alleviates the accumulation of ROS and pyroptosis and promotes perforator skin flap survival through SIRT1/NF-κB pathway |
| - | in-vitro, | Nor, | HUVECs | - | in-vitro, | NA, | NA |
| 3416- | TQ, | Thymoquinone induces apoptosis in bladder cancer cell via endoplasmic reticulum stress-dependent mitochondrial pathway |
| - | in-vitro, | Bladder, | T24 | - | in-vitro, | Bladder, | 253J | - | in-vitro, | Nor, | SV-HUC-1 |
| 3421- | TQ, | Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer |
| - | Analysis, | Nor, | NA | - | in-vivo, | Nor, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HaCaT |
| 3432- | TQ, | Thymoquinone: Review of Its Potential in the Treatment of Neurological Diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3431- | TQ, | PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| 3430- | TQ, | Targeting microRNAs with thymoquinone: a new approach for cancer therapy |
| - | Review, | Var, | NA |
| 3429- | TQ, | Thymoquinone exerts potent growth-suppressive activity on leukemia through DNA hypermethylation reversal in leukemia cells |
| - | in-vitro, | AML, | NA | - | in-vivo, | NA, | NA |
| 3427- | TQ, | Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets |
| 3426- | TQ, | Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | AML, | JK |
| 3397- | TQ, | Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer |
| - | Review, | CRC, | NA |
| 3425- | TQ, | Advances in research on the relationship between thymoquinone and pancreatic cancer |
| 3424- | TQ, | Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex |
| - | Review, | Var, | NA |
| 3423- | TQ, | Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics |
| - | Review, | Var, | NA |
| 3406- | TQ, | Se, | A study to determine the effect of nano-selenium and thymoquinone on the Nrf2 gene expression in Alzheimer’s disease |
| - | in-vivo, | AD, | NA |
| 3422- | TQ, | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
| - | Review, | Var, | NA |
| 3398- | TQ, | 5-FU, | Impact of thymoquinone on the Nrf2/HO-1 and MAPK/NF-κB axis in mitigating 5-fluorouracil-induced acute kidney injury in vivo |
| - | in-vivo, | Nor, | NA |
| 3399- | TQ, | Anticancer Effects of Thymoquinone through the Antioxidant Activity, Upregulation of Nrf2, and Downregulation of PD-L1 in Triple-Negative Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | NA, | BC, | MDA-MB-468 |
| 3400- | TQ, | Chemo, | Thymoquinone Ameliorates Carfilzomib-Induced Renal Impairment by Modulating Oxidative Stress Markers, Inflammatory/Apoptotic Mediators, and Augmenting Nrf2 in Rats |
| - | in-vitro, | Nor, | NA |
| 3401- | TQ, | Molecular mechanisms and signaling pathways of black cumin (Nigella sativa) and its active constituent, thymoquinone: a review |
| - | Review, | Var, | NA |
| 3402- | TQ, | Enhanced Apoptosis in Pancreatic Cancer Cells through Thymoquinone-rich Nigella sativa L. Methanol Extract: Targeting NRF2/HO-1 and TNF-α Pathways |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 |
| 3403- | TQ, | A multiple endpoint approach reveals potential in vitro anticancer properties of thymoquinone in human renal carcinoma cells |
| - | in-vitro, | RCC, | 786-O |
| 3404- | TQ, | The Neuroprotective Effects of Thymoquinone: A Review |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 3405- | TQ, | doxoR, | Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity and the underlying mechanism |
| - | vitro+vivo, | NA, | NA |
| 3415- | TQ, | The anti-neoplastic impact of thymoquinone from Nigella sativa on small cell lung cancer: In vitro and in vivo investigations |
| - | in-vitro, | Lung, | H446 |
| 3407- | TQ, | Thymoquinone and its pharmacological perspective: A review |
| - | Review, | NA, | NA |
| 3408- | TQ, | Thymoquinone: A small molecule from nature with high therapeutic potential |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3409- | TQ, | Thymoquinone therapy remediates elevated brain tissue inflammatory mediators induced by chronic administration of food preservatives |
| - | in-vivo, | Nor, | NA |
| 3410- | TQ, | Anti-inflammatory effects of thymoquinone and its protective effects against several diseases |
| - | Review, | Arthritis, | NA |
| 3411- | TQ, | Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone |
| - | Review, | Var, | NA |
| 3412- | TQ, | Thymoquinone induces oxidative stress-mediated apoptosis through downregulation of Jak2/STAT3 signaling pathway in human melanoma cells |
| - | in-vitro, | Melanoma, | SK-MEL-28 | - | in-vivo, | NA, | NA |
| 3413- | TQ, | Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src‑mediated phosphorylation of EGF receptor tyrosine kinase |
| - | in-vitro, | CRC, | HCT116 |
| 3414- | TQ, | Thymoquinone induces apoptosis through inhibition of JAK2/STAT3 signaling via production of ROS in human renal cancer Caki cells |
| - | in-vitro, | RCC, | Caki-1 |
| 4172- | TQ, | Chronic Administration of Thymoquinone Enhances Adult Hippocampal Neurogenesis and Improves Memory in Rats Via Regulating the BDNF Signaling Pathway |
| - | in-vivo, | AD, | NA |
| 4173- | TQ, | Thymoquinone Can Improve Neuronal Survival and Promote Neurogenesis in Rat Hippocampal Neurons |
| - | in-vivo, | NA, | NA |
| 1932- | TQ, | Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis |
| - | Review, | Var, | NA |
| 1937- | TQ, | Migration and Proliferation Effects of Thymoquinone-Loaded Nanostructured Lipid Carrier (TQ-NLC) and Thymoquinone (TQ) on In Vitro Wound Healing Models |
| - | NA, | Nor, | 3T3 |
| 1936- | TQ, | Thymoquinone induces apoptosis and increase ROS in ovarian cancer cell line |
| - | in-vitro, | Ovarian, | CaOV3 | - | in-vitro, | Nor, | WRL68 |
| 1935- | TQ, | Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis |
| - | Review, | OS, | NA |
| 1934- | TQ, | Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | C4-2B |
| 1933- | TQ, | Thymoquinone: potential cure for inflammatory disorders and cancer |
| - | Review, | Var, | NA |
| 1308- | TQ, | Thymoquinone induces apoptosis via targeting the Bax/BAD and Bcl-2 pathway in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 1309- | TQ, | QC, | Thymoquinone and quercetin induce enhanced apoptosis in non-small cell lung cancer in combination through the Bax/Bcl2 cascade |
| - | in-vitro, | Lung, | NA |
| 2129- | TQ, | doxoR, | Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 2126- | TQ, | Biological and therapeutic activities of thymoquinone: Focus on the Nrf2 signaling pathway |
| - | Review, | Nor, | NA |
| 2130- | TQ, | Thymoquinone Attenuates Brain Injury via an Anti-oxidative Pathway in a Status Epilepticus Rat Model |
| - | in-vivo, | Nor, | NA |
| 2131- | TQ, | Therapeutic impact of thymoquninone to alleviate ischemic brain injury via Nrf2/HO-1 pathway |
| - | in-vitro, | Stroke, | NA | - | in-vivo, | Nor, | NA |
| 2132- | TQ, | Thymoquinone treatment modulates the Nrf2/HO-1 signaling pathway and abrogates the inflammatory response in an animal model of lung fibrosis |
| - | in-vivo, | Nor, | NA |
| 2133- | TQ, | CUR, | Cisplatin, | Thymoquinone and curcumin combination protects cisplatin-induced kidney injury, nephrotoxicity by attenuating NFκB, KIM-1 and ameliorating Nrf2/HO-1 signalling |
| - | in-vitro, | Nor, | HEK293 | - | in-vivo, | NA, | NA |
| 2134- | TQ, | Modulation of Nrf2/HO1 Pathway by Thymoquinone to Exert Protection Against Diazinon-induced Myocardial Infarction in Rats |
| - | in-vivo, | Nor, | NA |
| 2135- | TQ, | Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and AMPKα as upstream targets |
| - | in-vitro, | Nor, | HaCaT |
| 2136- | TQ, | Nigella sativa and thymoquinone suppress cyclooxygenase-2 and oxidative stress in pancreatic tissue of streptozotocin-induced diabetic rats |
| - | in-vivo, | Nor, | NA |
| 2137- | TQ, | Gastroprotective activity of Nigella sativa L oil and its constituent, thymoquinone against acute alcohol-induced gastric mucosal injury in rats |
| - | in-vivo, | Nor, | NA |
| 2138- | TQ, | Thymoquinone has a synergistic effect with PHD inhibitors to ameliorate ischemic brain damage in mice |
| - | in-vivo, | Nor, | NA |
| 2139- | TQ, | Thymoquinone regulates microglial M1/M2 polarization after cerebral ischemia-reperfusion injury via the TLR4 signaling pathway |
| - | in-vivo, | Nor, | NA |
| 2115- | TQ, | Protective effects of Nigella sativa on gamma radiation-induced jejunal mucosal damage in rats |
| - | in-vivo, | Nor, | NA |
| 2114- | TQ, | Anti-Aging Effect of Nigella Sativa Fixed Oil on D-Galactose-Induced Aging in Mice |
| - | in-vivo, | Nor, | NA |
| 2128- | TQ, | Thymoquinone inhibits phorbol ester-induced activation of NF-κB and expression of COX-2, and induces expression of cytoprotective enzymes in mouse skin in vivo |
| - | in-vivo, | NA, | NA |
| 2127- | TQ, | Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways |
| - | Review, | GBM, | NA |
| 2113- | TQ, | Potential role of Nigella sativa (NS) in abating oxidative stress-induced toxicity in rats: a possible protection mechanism |
| - | in-vivo, | Nor, | NA |
| 2125- | TQ, | Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1α-Mediated Glycolysis |
| - | in-vitro, | RCC, | RCC4 | - | in-vitro, | RCC, | Caki-1 |
| 2124- | TQ, | Thymoquinone: an emerging natural drug with a wide range of medical applications |
| - | Review, | Var, | NA |
| 2123- | TQ, | Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma |
| - | in-vitro, | lymphoma, | PEL |
| 2122- | TQ, | Review on Molecular and Therapeutic Potential of Thymoquinone in Cancer |
| - | Review, | Var, | NA |
| 2121- | TQ, | Thymoquinone Inhibits Tumor Growth and Induces Apoptosis in a Breast Cancer Xenograft Mouse Model: The Role of p38 MAPK and ROS |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 2120- | TQ, | Thymoquinone induces apoptosis of human epidermoid carcinoma A431 cells through ROS-mediated suppression of STAT3 |
| - | in-vitro, | Melanoma, | A431 |
| 2119- | TQ, | Dual properties of Nigella Sativa: anti-oxidant and pro-oxidant |
| - | Review, | Var, | NA |
| 2118- | TQ, | Rad, | In vivo radioprotective effects of Nigella sativa L oil and reduced glutathione against irradiation-induced oxidative injury and number of peripheral blood lymphocytes in rats |
| - | in-vivo, | Nor, | NA |
| 2117- | TQ, | Effects of Nigella sativa L. on Lipid Peroxidation and Reduced Glutathione Levels in Erythrocytes of Broiler Chickens |
| - | in-vivo, | Nor, | NA |
| 2116- | TQ, | Cisplatin, | Oral administration of Nigella sativa oil ameliorates the effect of cisplatin on membrane enzymes, carbohydrate metabolism and oxidative damage in rat liver |
| - | in-vivo, | Nor, | NA |
| 2092- | TQ, | Dissecting the Potential Roles of Nigella sativa and Its Constituent Thymoquinone on the Prevention and on the Progression of Alzheimer's Disease |
| - | Review, | AD, | NA |
| 2103- | TQ, | Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells |
| - | in-vitro, | PC, | Hs766t | - | in-vitro, | PC, | MIA PaCa-2 |
| 2102- | TQ, | A review on therapeutic potential of Nigella sativa: A miracle herb |
| - | Review, | Var, | NA |
| 2101- | TQ, | HDAC inhibition by Nigella sativa L. sprouts extract in hepatocellular carcinoma: an approach to study anti-cancer potential |
| - | Study, | HCC, | NA |
| 2100- | TQ, | Dual properties of Nigella Sative: Anti-oxidant and Pro-oxidant |
| - | Review, | NA, | NA |
| 2099- | TQ, | Cisplatin, | Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo |
| - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | H146 | - | in-vivo, | NA, | NA |
| 2098- | TQ, | Anticancer activity of Nigella sativa (black seed) and its relationship with the thermal processing and quinone composition of the seed |
| - | in-vitro, | Colon, | MC38 | - | in-vitro, | lymphoma, | L428 |
| 2097- | TQ, | Crude extract of Nigella sativa inhibits proliferation and induces apoptosis in human cervical carcinoma HeLa cells |
| - | in-vitro, | Cerv, | HeLa |
| 2096- | TQ, | Effect of total hydroalcholic extract of Nigella sativa and its n-hexane and ethyl acetate fractions on ACHN and GP-293 cell lines |
| - | in-vitro, | Nor, | GP-293 | - | in-vitro, | Kidney, | ACHN |
| 2095- | TQ, | Review on the Potential Therapeutic Roles of Nigella sativa in the Treatment of Patients with Cancer: Involvement of Apoptosis |
| - | Review, | Var, | NA |
| 2105- | TQ, | Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined Inhibition of Histone Deacetylation and Induction of Histone Acetylation |
| - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | Hs766t | - | in-vivo, | NA, | NA |
| 2094- | TQ, | Cytotoxicity of Nigella sativa Extracts Against Cancer Cells: A Review of In Vitro and In Vivo Studies |
| - | Review, | Var, | NA |
| 2106- | TQ, | Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy |
| - | Review, | Var, | NA |
| 2107- | TQ, | Cytotoxicity of Nigella sativa seed oil and extract against human lung cancer cell line |
| - | in-vitro, | Lung, | A549 |
| 2108- | TQ, | Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa |
| - | Review, | Var, | NA |
| 2093- | TQ, | Regulation of NF-κB Expression by Thymoquinone; A Role in Regulating Pro-Inflammatory Cytokines and Programmed Cell Death in Hepatic Cancer Cells |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Nor, | NA |
| 2104- | TQ, | The Potential Role of Nigella sativa Seed Oil as Epigenetic Therapy of Cancer |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Cerv, | HeLa |
| 2091- | TQ, | Determination of anti-cancer effects of Nigella sativa seed oil on MCF7 breast and AGS gastric cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | GC, | AGS |
| 2090- | TQ, | Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies |
| - | Review, | Var, | NA |
| - | in-vitro, | Nor, | SH-SY5Y |
| 2088- | TQ, | Nigella sativa L. and Its Bioactive Constituents as Hepatoprotectant: A Review |
| - | Review, | Nor, | NA |
| 2087- | TQ, | Nigella sativa thymoquinone-rich fraction greatly improves plasma antioxidant capacity and expression of antioxidant genes in hypercholesterolemic rats |
| - | in-vivo, | Nor, | NA |
| 2086- | TQ, | Cardioprotective effects of Nigella sativa oil on cyclosporine A-induced cardiotoxicity in rats |
| - | in-vivo, | Nor, | NA |
| 2085- | TQ, | Anticancer Activities of Nigella Sativa (Black Cumin) |
| - | Review, | Var, | NA |
| 2084- | TQ, | Thymoquinone, as an anticancer molecule: from basic research to clinical investigation |
| - | Review, | Var, | NA |
| 2083- | TQ, | Thymoquinone inhibits proliferation in gastric cancer via the STAT3 pathway in vivo and in vitro |
| - | in-vitro, | GC, | HGC27 | - | in-vitro, | GC, | BGC-823 | - | in-vitro, | GC, | SGC-7901 | - | in-vivo, | NA, | NA |
| 2109- | TQ, | Thymoquinone Induces Mitochondria-Mediated Apoptosis in Acute Lymphoblastic Leukaemia in Vitro |
| - | in-vitro, | AML, | CEM |
| 2110- | TQ, | Nigella sativa seed oil suppresses cell proliferation and induces ROS dependent mitochondrial apoptosis through p53 pathway in hepatocellular carcinoma cells |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 |
| 2111- | TQ, | MTX, | Effect of Nigella sativa (black seeds) against methotrexate-induced nephrotoxicity in mice |
| - | in-vivo, | Nor, | NA |
| 2112- | TQ, | Crude flavonoid extract of the medicinal herb Nigella sativa inhibits proliferation and induces apoptosis in breastcancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 1928- | TQ, | Thymoquinone Crosstalks with DR5 to Sensitize TRAIL Resistance and Stimulate ROS-Mediated Cancer Apoptosis |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 1929- | TQ, | Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells |
| - | in-vitro, | Bladder, | 5637 | - | in-vitro, | Bladder, | T24 |
| 1930- | TQ, | Therapeutic implications and clinical manifestations of thymoquinone |
| - | Review, | Var, | NA |
| 1931- | TQ, | doxoR, | Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms |
| - | in-vivo, | AML, | NA |
| 4538- | TQ, | Thymoquinone Anticancer Effects Through the Upregulation of NRF2 and the Downregulation of PD‐L1 in MDA‐MB‐231 Triple‐Negative Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 4565- | TQ, | Thymoquinone in the clinical treatment of cancer: Fact or fiction? |
| - | Review, | BC, | NA |
| 2454- | Trip, | Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ |
| - | in-vitro, | HNSCC, | HaCaT | - | in-vivo, | NA, | NA |
| 2413- | TTT, | Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [18F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression |
| - | in-vitro, | GBM, | U87MG |
| 2412- | TTT, | A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights |
| - | Review, | GBM, | NA |
| 3747- | TTT, | Tumor treating induced fields: a new treatment option for patients with glioblastoma |
| - | in-vitro, | GBM, | U87MG |
| 3788- | UA, | RosA, | Ursolic acid and rosmarinic acid ameliorate alterations in hippocampal neurogenesis and social memory induced by amyloid beta in mouse model of Alzheimer’s disease |
| - | in-vivo, | AD, | NA |
| 3790- | UA, | Therapeutic applications of ursolic acid: a comprehensive review and utilization of predictive tools |
| 3789- | UA, | Ex, | Combined Ursolic Acid and Resistance/Endurance Training Improve Type 3 Diabetes Biomarkers-Related Memory Deficits in Hippocampus of Aged Male Wistar Rats |
| - | in-vivo, | AD, | NA |
| 2411- | UA, | Ursolic acid in health and disease |
| - | Review, | Var, | NA |
| 2350- | UA, | Ursolic acid-mediated changes in glycolytic pathway promote cytotoxic autophagy and apoptosis in phenotypically different breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 1020- | UA, | Root Bark of Morus alba L. and Its Bioactive Ingredient, Ursolic Acid, Suppress the Proliferation of Multiple Myeloma Cells by Inhibiting Wnt/β-Catenin Pathway |
| - | in-vitro, | Melanoma, | RPMI-8226 |
| 1058- | UA, | Ursolic acid, an antagonist for transforming growth factor (TGF)-beta1 |
| - | in-vivo, | NA, | NA |
| 119- | UA, | CUR, | RES, | Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 1139- | UA, | Ursolic acid inhibits epithelial-mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cells |
| - | in-vitro, | Lung, | A549 |
| 942- | UA, | Ursolic Acid Inhibits Breast Cancer Metastasis by Suppressing Glycolytic Metabolism via Activating SP1/Caveolin-1 Signaling |
| - | vitro+vivo, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 1310- | UA, | Ursolic acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 4846- | Uro, | Urolithin A exerts anti-tumor effects on gastric cancer via activating autophagy-Hippo axis and modulating the gut microbiota |
| - | in-vivo, | GC, | NA |
| 4858- | Uro, | The Metabolite Urolithin-A Ameliorates Oxidative Stress in Neuro-2a Cells, Becoming a Potential Neuroprotective Agent |
| - | in-vitro, | Nor, | NA |
| 4847- | Uro, | Metabolite of ellagitannins, urolithin A induces autophagy and inhibits metastasis in human sw620 colorectal cancer cells |
| - | in-vitro, | CRC, | SW-620 |
| 4848- | Uro, | OXA, | Urolithin A gains in antiproliferative capacity by reducing the glycolytic potential via the p53/TIGAR axis in colon cancer cells |
| - | in-vitro, | Colon, | HCT116 |
| 4849- | Uro, | Urolithin A suppresses tumor progression and induces autophagy in gastric cancer via the PI3K/Akt/mTOR pathway |
| - | vitro+vivo, | GC, | NA |
| 4850- | Uro, | Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population |
| - | Review, | Var, | NA |
| 4851- | Uro, | Urolithin A suppressed osteosarcoma cell migration and invasion via targeting MMPs and AKT1 |
| - | in-vitro, | OS, | MG63 |
| 4852- | Uro, | Dietary Urolithin B Suppresses Lung Tumorigenesis Correlating with Autophagy Induction and Gut Microbiota Remodeling |
| - | vitro+vivo, | Lung, | NA |
| 4853- | Uro, | Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer |
| - | vitro+vivo, | PC, | MIA PaCa-2 | - | in-vitro, | NA, | PANC1 |
| 4854- | Uro, | Urolithins: Emerging natural compound targeting castration-resistant prostate cancer (CRPC) |
| - | Review, | Pca, | NA |
| 4855- | Uro, | Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells |
| - | in-vitro, | Bladder, | UMUC3 |
| 4856- | Uro, | Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro |
| - | in-vitro, | NPC, | CNE1 | - | in-vitro, | NPC, | CNE2 |
| 4857- | Uro, | Evaluation and comparison of the anti-proliferative and anti-metastatic effects of urolithin A and urolithin B against esophageal cancer cells: an in vitro and in silico study |
| - | in-vitro, | ESCC, | KYSE-30 |
| 4845- | Uro, | The gut microbiota metabolite urolithin A, but not other relevant urolithins, induces p53-dependent cellular senescence in human colon cancer cells |
| - | in-vitro, | Colon, | HCT116 |
| 4844- | Uro, | Urolithin A Inhibits Epithelial–Mesenchymal Transition in Lung Cancer Cells via P53-Mdm2-Snail Pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 4843- | Uro, | The effects of urolithins on the response of prostate cancer cells to non-steroidal antiandrogen bicalutamide |
| - | in-vitro, | Pca, | LNCaP |
| 4842- | Uro, | Urolithin A inhibits breast cancer progression via activating TFEB-mediated mitophagy in tumor macrophages |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | 4T1 |
| 4841- | Uro, | Urolithin A induces cell cycle arrest and apoptosis by inhibiting Bcl-2, increasing p53-p21 proteins and reactive oxygen species production in colorectal cancer cells |
| - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | SW-620 |
| 4840- | Uro, | Urolithin A: A promising selective estrogen receptor modulator and 27-hydroxycholesterol attenuator in breast cancer |
| - | vitro+vivo, | BC, | NA |
| 4839- | Uro, | Urolithin A induces prostate cancer cell death in p53-dependent and in p53-independent manner |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | LNCaP |
| 4838- | Uro, | The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention |
| - | Review, | Var, | NA |
| 4837- | Uro, | Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review |
| - | Review, | Var, | NA |
| 4836- | Uro, | Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation |
| - | in-vitro, | Var, | NA |
| 4835- | Uro, | Urolithin A, induces apoptosis and autophagy crosstalk in Oral Squamous Cell Carcinoma via mTOR /AKT/ERK1/2 pathway |
| - | in-vitro, | SCC, | NA |
| 4834- | Uro, | Urolithin A increases the natural killer activity of PBMCs in patients with prostate cancer |
| - | Human, | Pca, | NA |
| 4833- | Uro, | Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | IBD, | NA |
| 4313- | VitA,RetA, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4616- | VitA,RetA, | VitC, | VitD3, | VitE, | Rad | Vitamins and Radioprotective Effect: A Review |
| - | Review, | NA, | NA |
| 4311- | VitB1/Thiamine, | Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy |
| - | in-vivo, | AD, | NA |
| 4312- | VitB1/Thiamine, | Pharmacological thiamine levels as a therapeutic approach in Alzheimer's disease |
| - | Review, | AD, | NA |
| 4327- | VitB1/Thiamine, | Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease |
| - | Study, | AD, | NA |
| 4310- | VitB1/Thiamine, | Pharmacological thiamine (Vitamin B1) as a treatment for alzheimer’s disease |
| - | Review, | AD, | NA |
| 4314- | VitB1/Thiamine, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 1888- | VitB1/Thiamine, | DCA, | High Dose Vitamin B1 Reduces Proliferation in Cancer Cell Lines Analogous to Dichloroacetate |
| - | in-vitro, | PC, | SK-N-BE | - | NA, | PC, | PANC1 |
| 4049- | VitB1/Thiamine, | Vitamin B1 (thiamine) and dementia |
| - | Review, | AD, | NA |
| 4048- | VitB12, | Plasma Homocysteine and Serum Folate and Vitamin B12 Levels in Mild Cognitive Impairment and Alzheimer’s Disease: A Case-Control Study |
| - | Study, | AD, | NA |
| 4056- | VitB12, | VitB6, | FA, | Vitamin B12, B6, or Folate and Cognitive Function in Community-Dwelling Older Adults: A Systematic Review and Meta-Analysis |
| - | Review, | AD, | NA |
| 4058- | VitB12, | VitB6, | FA, | The preventive efficacy of vitamin B supplements on the cognitive decline of elderly adults: a systematic review and meta-analysis |
| - | Review, | AD, | NA |
| 4054- | VitB12, | VitB6, | FA, | Role of B vitamins in modulating homocysteine and metabolic pathways linked to brain atrophy: Metabolomics insights from the VITACOG trial |
| - | Study, | AD, | NA |
| 4053- | VitB12, | VitB6, | FA, | Vitamins in Alzheimer’s Disease—Review of the Latest Reports |
| - | Review, | AD, | NA |
| 4038- | VitB12, | Vitamin B12 and Age-Related Cognitive Decline—Dementia and “Alzheimer’s Disease” |
| - | Review, | AD, | NA |
| 4066- | VitB12, | VitB6, | FA, | Vitamin B6, B12, and Folate’s Influence on Neural Networks in the UK Biobank Cohort |
| - | Study, | AD, | NA |
| 4067- | VitB12, | VitB6, | VitD3, | Plants, Plants, and More Plants: Plant-Derived Nutrients and Their Protective Roles in Cognitive Function, Alzheimer's Disease, and Other Dementias |
| - | Review, | AD, | NA |
| 4050- | VitB12, | VitD3, | VitE, | Nutrient intake, nutritional status, and cognitive function with aging |
| - | Review, | AD, | NA |
| 4047- | VitB12, | Cognitive impairment and vitamin B12: a review |
| - | Review, | AD, | NA |
| 4046- | VitB12, | Plasma Vitamin B-12 Levels and Risk of Alzheimer’s Disease: A Case-Control Study |
| - | Study, | AD, | NA |
| 4045- | VitB12, | FA, | Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial |
| - | Trial, | AD, | NA |
| 4043- | VitB12, | FA, | Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment |
| - | Trial, | AD, | NA |
| 4042- | VitB12, | Genetic determinants of low vitamin B12 levels in Alzheimer's disease risk |
| - | Review, | AD, | NA |
| 4040- | VitB12, | FA, | Role of vitamin B12 and folic acid in treatment of Alzheimer’s disease: a meta-analysis of randomized control trials |
| - | Review, | AD, | NA |
| 4041- | VitB12, | Thoughts on B-vitamins and dementia |
| - | Review, | AD, | NA |
| 4037- | VitB12, | FA, | Mechanistic Link between Vitamin B12 and Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4318- | VitB12, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4315- | VitB2, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| 4316- | VitB3, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 4033- | VitB3, | Can nicotinamide riboside protect against cognitive impairment? |
| - | in-vivo, | AD, | NA |
| 4032- | VitB3, | Modulation of cGAS-STING Pathway by Nicotinamide Riboside in Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 4031- | VitB3, | Nicotinamide Riboside-The Current State of Research and Therapeutic Uses |
| - | Review, | NA, | NA |
| 4334- | VitB5, | Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model |
| - | in-vivo, | AD, | NA |
| 4317- | VitB5, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4323- | VitB5, | Cerebral deficiency of vitamin B5 (d-pantothenic acid; pantothenate) as a potentially-reversible cause of neurodegeneration and dementia in sporadic Alzheimer's disease |
| - | Study, | AD, | NA |
| 4324- | VitB5, | Substantively Lowered Levels of Pantothenic Acid (Vitamin B5) in Several Regions of the Human Brain in Parkinson’s Disease Dementia |
| - | Study, | AD, | NA | - | Study, | Park, | NA |
| 4325- | VitB5, | Localized Pantothenic Acid (Vitamin B5) Reductions Present Throughout the Dementia with Lewy Bodies Brain |
| - | Study, | AD, | NA | - | Study, | Park, | NA |
| 4326- | VitB5, | Cerebral Vitamin B5 (D-Pantothenic Acid) Deficiency as a Potential Cause of Metabolic Perturbation and Neurodegeneration in Huntington’s Disease |
| - | in-vivo, | HD, | NA |
| 4328- | VitB5, | Pantethine |
| - | Review, | AD, | NA |
| 4329- | VitB5, | Long-Term Pantethine Treatment Counteracts Pathologic Gene Dysregulation and Decreases Alzheimer's Disease Pathogenesis in a Transgenic Mouse Model |
| - | in-vivo, | AD, | NA |
| 4336- | VitB5, | Effectiveness of long-term treatment with pantethine in patients with dyslipidemia |
| - | Trial, | NA, | NA |
| - | Trial, | NA, | NA |
| 4330- | VitB5, | Metabolic changes and inflammation in cultured astrocytes from the 5xFAD mouse model of Alzheimer’s disease: Alleviation by pantethine |
| - | in-vivo, | AD, | NA |
| 4077- | VitB6, | FA, | VitB12, | VitD3, | VitE | Vitamin Supplementation as an Adjuvant Treatment for Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4065- | VitB6, | VitB12, | FA, | Vitamin B6, B12, and Folic Acid Supplementation and Cognitive Function |
| - | Review, | AD, | NA |
| 4052- | VitB6, | B-Vitamin Intake and Biomarker Status in Relation to Cognitive Decline in Healthy Older Adults in a 4-Year Follow-Up Study |
| - | Study, | AD, | NA |
| 4062- | VitB6, | FA, | VitB12, | Vitamin B6, B9, and B12 Intakes and Cognitive Performance in Elders: National Health and Nutrition Examination Survey, 2011–2014 |
| - | Study, | AD, | NA |
| 4055- | VitB6, | VitD3, | Vitamin B6 and vitamin D deficiency co-occurrence in geriatric memory patients |
| - | Study, | AD, | NA |
| 4057- | VitB6, | VitB12, | FA, | Folate, Vitamin B6 and Vitamin B12 Intake and Mild Cognitive Impairment and Probable Dementia in the Women’s Health Initiative Memory Study |
| - | Study, | AD, | NA |
| 4181- | VitB6, | Vitamin B6 prevents cognitive impairment in experimental pneumococcal meningitis |
| - | in-vivo, | NA, | NA |
| 4319- | VitC, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4468- | VitC, | Se, | Selenium modulates cancer cell response to pharmacologic ascorbate |
| - | in-vivo, | GBM, | U87MG | - | in-vitro, | CRC, | HCT116 |
| 1836- | VitC, | VitK3, | Chemo, | Vitamins C and K3: A Powerful Redox System for Sensitizing Leukemia Lymphocytes to Everolimus and Barasertib |
| - | in-vitro, | AML, | NA |
| 1819- | VitC, | VitK3, | The association of vitamins C and K3 kills cancer cells mainly by autoschizis, a novel form of cell death. Basis for their potential use as coadjuvants in anticancer therapy |
| - | Review, | Var, | NA |
| 2485- | VitC, | TACE, | High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma |
| - | Case Report, | HCC, | NA |
| - | in-vitro, | Nor, | RAW264.7 | - | in-vitro, | AML, | PLB-985 |
| 3102- | VitC, | Two Faces of Vitamin C—Antioxidative and Pro-Oxidative Agent |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA |
| 3103- | VitC, | Effect of Vitamin C on Reactive Oxygen Species Formation in Erythrocytes of Sickle Cell Anemia Patients |
| - | Human, | Nor, | NA |
| 3116- | VitC, | Vitamin C Inhibits NF-kB Activation by TNF Via the Activation of p38 Mitogen-Activated Protein Kinase |
| - | in-vitro, | Nor, | ECV304 | - | in-vitro, | Nor, | HUVECs |
| 3117- | VitC, | Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells |
| - | in-vitro, | Nor, | mESC |
| 3118- | VitC, | Vitamin C boosts DNA demethylation in TET2 germline mutation carriers |
| - | Trial, | Nor, | NA |
| 3119- | VitC, | Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma |
| - | in-vitro, | RCC, | NA |
| 3120- | VitC, | Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells |
| - | in-vitro, | lymphoma, | NA |
| 3121- | VitC, | immuno, | Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma |
| - | in-vivo, | RCC, | A498 | - | in-vitro, | RCC, | 786-O |
| 3122- | VitC, | Ascorbic Acid Promotes Plasma Cell Differentiation through Enhancing TET2/3-Mediated DNA Demethylation |
| 3123- | VitC, | Ascorbic Acid Enhances Tet-Mediated 5-Methylcytosine Oxidation and Promotes DNA Demethylation in Mammals |
| - | in-vitro, | Nor, | mESC |
| 3124- | VitC, | Ascorbic acid improves parthenogenetic embryo development through TET proteins in mice |
| - | in-vivo, | Nor, | NA |
| 3125- | VitC, | Vitamin C inhibits NLRP3 inflammasome activation and delays the development of age-related hearing loss in male C57BL/6 mice |
| - | in-vivo, | Nor, | NA |
| 3126- | VitC, | Safety of High-Dose Vitamin C in Non-Intensive Care Hospitalized Patients with COVID-19: An Open-Label Clinical Study |
| - | Study, | NA, | NA |
| 3104- | VitC, | Pro- and Antioxidant Effects of Vitamin C in Cancer in correspondence to Its Dietary and Pharmacological Concentrations |
| 3127- | VitC, | Vitamin C inhibits the activation of the NLRP3 inflammasome by scavenging mitochondrial ROS |
| - | in-vitro, | Nor, | NA | - | in-vivo, | Nor, | NA |
| 3115- | VitC, | The NF-κB Transcriptional Network Is a High-Dose Vitamin C-Targetable Vulnerability in Breast Cancer |
| - | in-vitro, | BC, | NA |
| 3114- | VitC, | Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression |
| - | in-vitro, | AML, | NA |
| 3113- | VitC, | Vitamin C enhances NF-κB-driven epigenomic reprogramming and boosts the immunogenic properties of dendritic cells |
| - | in-vitro, | Nor, | NA |
| 3112- | VitC, | Antioxidative and Anti-Inflammatory Activity of Ascorbic Acid |
| - | Review, | Nor, | NA |
| 3111- | VitC, | https://pmc.ncbi.nlm.nih.gov/articles/PMC4492638/ |
| - | Trial, | Nor, | NA |
| 3110- | VitC, | Vitamin C Attenuates Oxidative Stress, Inflammation, and Apoptosis Induced by Acute Hypoxia through the Nrf2/Keap1 Signaling Pathway in Gibel Carp (Carassius gibelio) |
| - | in-vivo, | Nor, | NA |
| 3109- | VitC, | Vitamin C Inhibited Pulmonary Metastasis through Activating Nrf2/HO-1 Pathway |
| - | in-vitro, | Lung, | H1299 |
| 3108- | VitC, | QC, | The role of quercetin and vitamin C in Nrf2-dependent oxidative stress production in breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Lung, | A549 |
| 3107- | VitC, | Repurposing Vitamin C for Cancer Treatment: Focus on Targeting the Tumor Microenvironment |
| - | Review, | Var, | NA |
| 3106- | VitC, | Protective effect of vitamin C on oxidative stress: a randomized controlled trial |
| - | Trial, | Nor, | NA |
| 3105- | VitC, | ROS-lowering doses of vitamins C and A accelerate malignant melanoma metastasis |
| - | Review, | Var, | NA |
| 3153- | VitC, | Vitamin C Status and Cognitive Function: A Systematic Review |
| - | Review, | AD, | NA |
| 3140- | VitC, | Vitamin-C-dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrest |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Nor, | HEK293 |
| 3151- | VitC, | Role of Vitamin C in the Function of the Vascular Endothelium |
| - | Review, | Nor, | NA |
| 3150- | VitC, | Vitamin C: A Review on its Role in the Management of Metabolic Syndrome |
| - | Review, | Obesity, | NA |
| 3149- | VitC, | Hepatoprotective benefits of vitamin C against perfluorooctane sulfonate-induced liver damage in mice through suppressing inflammatory reaction and ER stress |
| - | in-vivo, | Nor, | NA |
| 3148- | VitC, | Antioxidants in brain tumors: current therapeutic significance and future prospects |
| - | Review, | Var, | NA |
| 3147- | VitC, | Vitamin C modulates the metabolic and cytokine profiles, alleviates hepatic endoplasmic reticulum stress, and increases the life span of Gulo−/− mice |
| - | in-vivo, | Nor, | NA |
| 3146- | VitC, | Vitamin C protects against hypoxia, inflammation, and ER stress in primary human preadipocytes and adipocytes |
| - | in-vivo, | Nor, | NA |
| 3145- | VitC, | Vitamin C inhibits the growth of colorectal cancer cell HCT116 and reverses the glucose‐induced oncogenic effect by downregulating the Warburg effect |
| - | in-vitro, | CRC, | HCT116 |
| 3144- | VitC, | Some characteristics of Rabbit muscle phosphofructokinase-1 inhibition by ascorbate |
| - | in-vitro, | Nor, | NA |
| 3143- | VitC, | ATO, | Vitamin C enhances the sensitivity of osteosarcoma to arsenic trioxide via inhibiting aerobic glycolysis |
| - | in-vitro, | OS, | NA |
| 3142- | VitC, | Vitamin C promotes apoptosis in breast cancer cells by increasing TRAIL expression |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF12A |
| 3141- | VitC, | High-dose Vitamin C inhibits PD-L1 expression by activating AMPK in colorectal cancer |
| - | in-vitro, | CRC, | HCT116 |
| 3128- | VitC, | Vitamin C Mitigates Oxidative Stress and Tumor Necrosis Factor-Alpha in Severe Community-Acquired Pneumonia and LPS-Induced Macrophages |
| - | in-vitro, | Nor, | NA |
| 3139- | VitC, | Vitamin C and sodium bicarbonate enhance the antioxidant ability of H9C2 cells and induce HSPs to relieve heat stress |
| - | in-vitro, | Nor, | H9c2 |
| 3138- | VitC, | The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity |
| - | in-vitro, | RCC, | RCC4 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Colon, | SW48 | - | in-vitro, | GBM, | U251 |
| 3137- | VitC, | Vitamin C inhibits the growth of colorectal cancer cell HCT116 and reverses the glucose-induced oncogenic effect by downregulating the Warburg effect |
| - | in-vitro, | CRC, | HCT116 |
| 3136- | VitC, | Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer |
| - | in-vitro, | Colon, | SW48 | - | in-vitro, | Colon, | LoVo |
| 3135- | VitC, | The interplay between vitamin C and thyroid |
| - | Review, | Thyroid, | NA |
| 3134- | VitC, | Vitamin C promotes human endothelial cell growth via the ERK-signaling pathway |
| - | in-vitro, | Nor, | HUVECs |
| 3133- | VitC, | Vitamin C supplementation had no side effect in non-cancer, but had anticancer properties in ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA |
| 3132- | VitC, | Vitamin C affects G0/G1 cell cycle and autophagy by downregulating of cyclin D1 in gastric carcinoma cells |
| - | in-vitro, | GC, | MKN45 |
| 3131- | VitC, | Antioxidant Vitamin C attenuates experimental abdominal aortic aneurysm development in an elastase-induced rat model |
| - | in-vivo, | Nor, | NA |
| 3130- | VitC, | Effect of high-dose vitamin C on MMP2 expression and invasive ability in human pancreatic cancer cell line PANC-1 |
| - | in-vitro, | PC, | PANC1 |
| 3129- | VitC, | Therapeutic treatment with vitamin C reduces focal cerebral ischemia-induced brain infarction in rats by attenuating disruptions of blood brain barrier and cerebral neuronal apoptosis |
| - | in-vivo, | Stroke, | NA |
| 2592- | VitC, | Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line |
| - | in-vitro, | CLL, | NA |
| 636- | VitC, | Acute Effects of Vitamin C Exposure On Colonic Crypts: Direct Modulation of pH Regulation |
| - | in-vivo, | NA, | NA |
| 635- | VitC, | VitK3, | The combination of ascorbate and menadione causes cancer cell death by oxidative stress and replicative stress |
| - | in-vitro, | NA, | NA |
| 634- | VitC, | Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? |
| - | Analysis, | NA, | NA |
| 633- | VitC, | Diverse antitumor effects of ascorbic acid on cancer cells and the tumor microenvironment |
| - | Analysis, | NA, | NA |
| 632- | VitC, | High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients |
| - | Review, | NA, | NA |
| 631- | VitC, | Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2 |
| - | vitro+vivo, | Liver, | NA |
| 114- | VitC, | QC, | Chemoprevention of prostate cancer cells by vitamin C plus quercetin: role of Nrf2 in inducing oxidative stress |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | NA, | DU145 |
| 1067- | VitC, | Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer |
| - | in-vivo, | CRC, | NA |
| 614- | VitC, | Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use |
| 612- | VitC, | VitK3, | Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. I. Synergism of combined vitamin C and K3 action |
| 615- | VitC, | High Dose IV Vitamin C and Metastatic Breast Cancer: A Case Report |
| - | Case Report, | NA, | NA |
| 616- | VitC, | Suppression of alkaline phosphatase in prostate cancer patients by high dose intravenous Vitamin C Treatment: Three cases |
| - | Case Report, | NA, | NA |
| 617- | VitC, | Chemo, | The Use of Vitamin C with Chemotherapy in Cancer Treatment: An Annotated Bibliography |
| - | Review, | NA, | NA |
| 618- | VitC, | Low levels of catalase enzyme make cancer cells vulnerable to high-dose ascorbate |
| 619- | VitC, | Natural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stress |
| 620- | VitC, | Case Study: High-Dose Intravenous Vitamin C in the Treatment of a Patient with Adenocarcinoma of the Kidney |
| - | Case Report, | NA, | NA |
| 621- | VitC, | Sixteen-Year History with High Dose Intravenous Vitamin C Treatment for Various Types of Cancer and Other Diseases |
| 622- | VitC, | Treatment of Pancreatic Cancer with Pharmacological Ascorbate |
| - | vitro+vivo, | PC, | NA |
| 623- | VitC, | The Involvement of Ascorbic Acid in Cancer Treatment |
| - | Review, | NA, | NA |
| 624- | VitC, | Ascorbic Acid in Colon Cancer: From the Basic to the Clinical Applications |
| - | Review, | NA, | NA |
| 625- | VitC, | The Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review |
| 626- | VitC, | Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials |
| - | Review, | NA, | NA |
| 627- | VitC, | High-Dose Vitamin C for Cancer Therapy |
| - | Review, | NA, | NA |
| 628- | VitC, | Mg, | Enhanced Anticancer Effect of Adding Magnesium to Vitamin C Therapy: Inhibition of Hormetic Response by SVCT-2 Activation |
| - | in-vivo, | Colon, | CT26 | - | in-vitro, | NA, | MCF-7 | - | in-vitro, | NA, | SkBr3 |
| 629- | VitC, | Cu, | Fe, | The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer |
| - | in-vitro, | NA, | NA |
| 630- | VitC, | Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | HT-29 |
| 593- | VitC, | MF, | Protective Effect of Ascorbic Acid on Molecular Behavior Changes of Hemoglobin Induced by Magnetic Field Induced by Magnetic Field |
| 588- | VitC, | MF, | Preparation of magnetic nanoparticle integrated nanostructured lipid carriers for controlled delivery of ascorbyl palmitate |
| 596- | VitC, | High-Dose Vitamin C in Advanced-Stage Cancer Patients |
| - | Review, | NA, | NA |
| 597- | VitC, | dietSTF, | GlucDep, | The Result of Vitamin C Treatment of Patients with Cancer: Conditions Influencing the Effectiveness |
| 598- | VitC, | Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly |
| - | Review, | NA, | NA |
| 599- | VitC, | Generation of Hydrogen Peroxide in Cancer Cells: Advancing Therapeutic Approaches for Cancer Treatment |
| - | Review, | NA, | NA |
| 600- | VitC, | VitK3, | Serum markers variation consistent with autoschizis induced by ascorbic acid-menadione in patients with prostate cancer |
| - | in-vitro, | NA, | NA |
| 580- | VitC, | MF, | Extremely low frequency magnetic field induces oxidative stress in mouse cerebellum |
| - | in-vivo, | Nor, | NA |
| 579- | VitC, | MF, | Effect of Magnetic Field on Ascorbic Acid Oxidase Activity, I |
| - | in-vitro, | NA, | NA |
| 605- | VitC, | Therapeutic Use of Vitamin C in Cancer: Physiological Considerations |
| - | Review, | NA, | NA |
| 606- | VitC, | Understanding the Therapeutic Potential of Ascorbic Acid in the Battle to Overcome Cancer |
| - | Review, | NA, | NA |
| 607- | VitC, | Intravenously administered vitamin C as cancer therapy: three cases |
| - | Case Report, | NA, | NA |
| 609- | VitC, | ALA, | VitK3, | Se, | Vitamin C and Cancer: Is There A Use For Oral Vitamin C? |
| 610- | VitC, | Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues |
| - | in-vitro, | lymphoma, | JPL119 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vitro, | Nor, | NA |
| 611- | VitC, | Characterization of a new malignant human T-cell line (PFI-285) sensitive to ascorbic acid |
| - | in-vitro, | NA, | NA |
| 613- | VitC, | High-dose Vitamin C (Ascorbic Acid) Therapy in the Treatment of Patients with Advanced Cancer |
| - | Review, | NA, | NA |
| 300- | VitC, | ALA, | Combination of High-Dose Parenteral Ascorbate (Vitamin C) and Alpha-Lipoic Acid Failed to Enhance Tumor-Inhibitory Effect But Increased Toxicity in Preclinical Cancer Models |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Ovarian, | PANC1 | - | in-vitro, | Pca, | PC3 |
| 1215- | VitC, | immuno, | Metabolomics reveals ascorbic acid inhibits ferroptosis in hepatocytes and boosts the effectiveness of anti-PD1 immunotherapy in hepatocellular carcinoma |
| - | ex-vivo, | HCC, | NA | - | in-vivo, | HCC, | NA |
| 1216- | VitC, | Ascorbic acid induces ferroptosis via STAT3/GPX4 signaling in oropharyngeal cancer |
| - | in-vitro, | Laryn, | FaDu | - | in-vitro, | SCC, | SCC-154 |
| 1217- | VitC, | High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition |
| - | in-vitro, | BC, | Bcap37 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 1218- | VitC, | ASA, | Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E2 production |
| - | in-vitro, | GBM, | SK-N-SH |
| 1219- | VitC, | Ascorbic acid and ascorbate-2-phosphate decrease HIF activity and malignant properties of human melanoma cells |
| - | in-vitro, | Melanoma, | NA |
| - | Trial, | Sepsis, | NA |
| 1223- | VitD3, | Vitamin D3 Treatment Influences PGE2 and TGFβ in Normal and Increased Breast Cancer Risk Women |
| - | Trial, | NA, | NA |
| - | in-vivo, | RCC, | NA | - | in-vivo, | BCC, | NA |
| 1313- | VitD3, | MEL, | The effects of melatonin and vitamin D3 on the gene expression of BCl-2 and BAX in MCF-7 breast cancer cell line |
| - | in-vitro, | BC, | MCF-7 |
| 1738- | VitD3, | VITAL study: an incomplete picture? |
| - | Trial, | Var, | NA |
| 1739- | VitD3, | Effect of Vitamin D3 Supplements on Development of Advanced Cancer |
| - | Trial, | Var, | NA |
| 1741- | VitD3, | Vitamin D Deficiency: Effects on Oxidative Stress, Epigenetics, Gene Regulation, and Aging |
| - | Review, | Var, | NA |
| 1740- | VitD3, | Vitamin D and Cancer: An Historical Overview of the Epidemiology and Mechanisms |
| - | Review, | Var, | NA |
| 2171- | VitD3, | Vitamin D and the Immune System |
| - | Analysis, | Nor, | NA |
| 4185- | VitD3, | Effects of vitamin D supplementation on neuroplasticity in older adults: a double-blinded, placebo-controlled randomised trial |
| - | Study, | NA, | NA |
| 4184- | VitD3, | Neuroplasticity-related effects of vitamin D relevant to its neuroprotective effects: A narrative review |
| - | Review, | NA, | NA |
| 4182- | VitD3, | The association between vitamin D and BDNF on cognition in older adults in Southern Brazil |
| - | Study, | AD, | NA |
| 4183- | VitD3, | Ex, | Combined Exercise and Vitamin D on Brain-Derived Neurotrophic Factor |
| - | Review, | NA, | NA |
| 4187- | VitD3, | Protective effects of vitamin D on neurophysiologic alterations in brain aging: role of brain-derived neurotrophic factor (BDNF) |
| - | in-vivo, | NA, | NA |
| 4186- | VitD3, | The Association of Vitamin D, Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF), and Glial Cell-Derived Neurotrophic Factor (GDNF) with Development in Children |
| - | Study, | NA, | NA |
| 4086- | VitD3, | The beneficial role of vitamin D in Alzheimer's disease |
| - | Review, | AD, | NA |
| 3921- | VitD3, | RES, | Vitamin D Combined with Resveratrol Prevents Cognitive Decline in SAMP8 Mice |
| - | in-vivo, | AD, | NA |
| 4350- | VitD3, | Vitamin D: Evidence-Based Health Benefits and Recommendations for Population Guidelines |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4320- | VitD3, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4618- | VitD3, | Vitamin D sensitizes cervical cancer to radiation-induced apoptosis by inhibiting autophagy through degradation of Ambra1 |
| - | in-vivo, | Cerv, | NA |
| 4617- | VitD3, | Vitamin D3 and its Potential to Ameliorate Chemical and Radiation-Induced Skin Injury During Cancer Therapy |
| - | Case Report, | NA, | NA |
| 2369- | VitD3, | Long Non-coding RNA MEG3 Activated by Vitamin D Suppresses Glycolysis in Colorectal Cancer via Promoting c-Myc Degradation |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | CRC, | RKO |
| 2368- | VitD3, | Vitamin D3 supplementation shapes the composition of gut microbiota and improves some obesity parameters induced by high-fat diet in mice |
| - | in-vivo, | Obesity, | NA |
| 2367- | VitD3, | Vitamin D activates FBP1 to block the Warburg effect and modulate blast metabolism in acute myeloid leukemia |
| - | in-vivo, | AML, | NA |
| 2366- | VitD3, | Vitamin D3 decreases glycolysis and invasiveness, and increases cellular stiffness in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 2365- | VitD3, | Vitamin D Affects the Warburg Effect and Stemness Maintenance of Non- Small-Cell Lung Cancer Cells by Regulating the PI3K/AKT/mTOR Signaling Pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1975 | - | in-vivo, | NA, | NA |
| 4089- | VitE, | Cognitive function in elderly people is influenced by vitamin E status |
| - | Study, | AD, | NA |
| 4088- | VitE, | Vitamin E and Alzheimer’s Disease—Is It Time for Personalized Medicine? |
| - | Review, | AD, | NA |
| 4087- | VitE, | Vitamin E and Alzheimer's disease: what do we know so far? |
| - | Review, | AD, | NA |
| 4079- | VitE, | VitC, | Effects of fruits and vegetables on levels of vitamins E and C in the brain and their association with cognitive performance |
| - | Review, | AD, | NA |
| 4179- | VitE, | Vitamin E protects against oxidative damage and learning disability after mild traumatic brain injury in rats |
| - | in-vivo, | NA, | NA |
| 4321- | VitE, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4322- | VitK2, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4309- | VitK2, | Vitamins in the Prevention and Support Therapy of Neurodegenerative Diseases |
| - | Review, | NA, | NA |
| 1816- | VitK2, | Role of Vitamin K in Selected Malignant Neoplasms in Women |
| - | Review, | Var, | NA |
| 1840- | VitK2, | The mechanisms of vitamin K2-induced apoptosis of myeloma cells |
| - | in-vitro, | Melanoma, | NA |
| 1833- | VitK2, | Divergent effects of vitamins K1 and K2 on triple negative breast cancer cells |
| - | in-vitro, | BC, | HS587T | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | SUM159 |
| 1830- | VitK2, | Vitamin K Intake and Risk of Lung Cancer: The Japan Collaborative Cohort Study |
| - | Study, | Lung, | NA |
| 1829- | VitK2, | Vitamin K: New insights related to senescence and cancer metastasis |
| - | Review, | Var, | NA |
| 1825- | VitK2, | Vitamin K intake and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial |
| - | Analysis, | Pca, | NA |
| 1824- | VitK2, | Vitamin K and its analogs: Potential avenues for prostate cancer management |
| - | Review, | Pca, | NA |
| 1822- | VitK2, | Vitamin K: A novel cancer chemosensitizer |
| - | Review, | Var, | NA |
| 1817- | VitK2, | Research progress on the anticancer effects of vitamin K2 |
| - | Review, | Var, | NA |
| 1823- | VitK2, | VitK3, | Vitamins K2, K3 and K5 exert antitumor effects on established colorectal cancer in mice by inducing apoptotic death of tumor cells |
| - | in-vitro, | CRC, | NA | - | in-vivo, | NA, | NA |
| 1818- | VitK2, | New insights on vitamin K biology with relevance to cancer |
| - | Review, | Var, | NA |
| 2282- | VitK2, | Vitamin K prevents oxidative cell death by inhibiting activation of 12-lipoxygenase in developing oligodendrocytes |
| - | in-vitro, | Nor, | NA |
| 2285- | VitK2, | New insights into vitamin K biology with relevance to cancer |
| - | Review, | Var, | NA |
| 2284- | VitK2, | Menadione-induced DNA damage in a human tumor cell line |
| - | in-vitro, | BC, | MCF-7 |
| 2283- | VitK2, | Vitamin K Contribution to DNA Damage—Advantage or Disadvantage? A Human Health Response |
| - | Review, | Var, | NA |
| 2274- | VitK2, | Vitamin K2 Modulates Mitochondrial Dysfunction Induced by 6-Hydroxydopamine in SH-SY5Y Cells via Mitochondrial Quality-Control Loop |
| - | in-vitro, | Nor, | SH-SY5Y |
| 2281- | VitK2, | The biological responses of vitamin K2: A comprehensive review |
| - | Review, | Var, | NA |
| 2280- | VitK2, | Vitamin K2 induces non-apoptotic cell death along with autophagosome formation in breast cancer cell lines |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | AML, | HL-60 |
| 2279- | VitK2, | Vitamin K2 Induces Mitochondria-Related Apoptosis in Human Bladder Cancer Cells via ROS and JNK/p38 MAPK Signal Pathways |
| - | in-vitro, | Bladder, | T24 | - | in-vitro, | Bladder, | J82 | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | Nor, | L02 | - | in-vivo, | NA, | NA |
| 2278- | VitK2, | VitK3, | VitC, | Vitamin K: Redox-modulation, prevention of mitochondrial dysfunction and anticancer effect |
| - | Review, | Var, | NA |
| 2277- | VitK2, | Vitamin K2 suppresses rotenone-induced microglial activation in vitro |
| - | in-vitro, | Nor, | BV2 | - | NA, | AD, | NA | - | NA, | Park, | NA |
| 2276- | VitK2, | Vitamin K2 (MK-7) Intercepts Keap-1/Nrf-2/HO-1 Pathway and Hinders Inflammatory/Apoptotic Signaling and Liver Aging in Naturally Aging Rat |
| - | in-vivo, | Nor, | NA |
| 2275- | VitK2, | Delivery of the reduced form of vitamin K2(20) to NIH/3T3 cells partially protects against rotenone induced cell death |
| - | in-vitro, | Nor, | NIH-3T3 |
| 1213- | VitK2, | Vitamin K2 Inhibits Hepatocellular Carcinoma Cell Proliferation by Binding to 17β-Hydroxysteroid Dehydrogenase 4 |
| - | in-vitro, | HCC, | HepG2 |
| 1214- | VitK2, | Vitamin K2 promotes PI3K/AKT/HIF-1α-mediated glycolysis that leads to AMPK-dependent autophagic cell death in bladder cancer cells |
| - | in-vitro, | Bladder, | T24 | - | in-vitro, | Bladder, | J82 |
| 1212- | VitK2, | Vitamin K2 stimulates osteoblastogenesis and suppresses osteoclastogenesis by suppressing NF-κB activation |
| - | in-vitro, | ostP, | NA |
| 1211- | VitK2, | Mechanisms of PKC-Mediated Enhancement of HIF-1α Activity and its Inhibition by Vitamin K2 in Hepatocellular Carcinoma Cells |
| - | in-vitro, | HCC, | HUH7 |
| 4188- | VitK2, | Vitamin K2 protects against aluminium chloride-mediated neurodegeneration |
| - | in-vivo, | NA, | NA |
| 4091- | VitK2, | The possible role of vitamin K deficiency in the pathogenesis of Alzheimer's disease and in augmenting brain damage associated with cardiovascular disease |
| - | Review, | AD, | NA |
| 4090- | VitK2, | ProBio, | Vitamin K2 Holds Promise for Alzheimer's Prevention and Treatment |
| - | Review, | AD, | NA |
| 2428- | VitK3, | Vitamin K3 and K5 are inhibitors of tumor pyruvate kinase M2 |
| - | Study, | Var, | NA |
| 2372- | VitK3, | The role of pyruvate kinase M2 in anticancer therapeutic treatments |
| - | Review, | Var, | NA |
| 1832- | VitK3, | VitC, | Vitamin K3 and vitamin C alone or in combination induced apoptosis in leukemia cells by a similar oxidative stress signalling mechanism |
| - | in-vitro, | AML, | K562 |
| 1815- | VitK3, | VitK2, | Vitamin K |
| - | Review, | Nor, | NA |
| 1839- | VitK3, | Vitamin K3 derivative inhibits androgen receptor signaling in targeting aggressive prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 1838- | VitK3, | PDT, | Photodynamic Effects of Vitamin K3 on Cervical Carcinoma Cells Activating Mitochondrial Apoptosis Pathways |
| - | in-vitro, | Cerv, | NA |
| 1837- | VitK3, | VitC, | Alpha-Tocopheryl Succinate Inhibits Autophagic Survival of Prostate Cancer Cells Induced by Vitamin K3 and Ascorbate to Trigger Cell Death |
| - | in-vivo, | Pca, | NA |
| 1835- | VitK3, | VitC, | Potential therapeutic application of the association of vitamins C and K3 in cancer treatment |
| - | Review, | Var, | NA |
| 1834- | VitK3, | PDT, | Effects of Vitamin K3 Combined with UVB on the Proliferation and Apoptosis of Cutaneous Squamous Cell Carcinoma A431 Cells |
| - | in-vitro, | Melanoma, | A431 |
| 1831- | VitK3, | VitK2, | The anticancer effects of vitamin K |
| - | Review, | Var, | NA |
| 1820- | VitK3, | Vitamin K3 (menadione) suppresses epithelial-mesenchymal-transition and Wnt signaling pathway in human colorectal cancer cells |
| - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | SW-620 |
| - | in-vitro, | Oral, | NA | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | Nor, | HaCaT |
| 1828- | VitK3, | VitC, | Pankiller effect of prolonged exposure to menadione on glioma cells: potentiation by vitamin C |
| - | in-vivo, | GBM, | NA |
| 1827- | VitK3, | A biophysical approach to menadione membrane interactions: relevance for menadione-induced mitochondria dysfunction and related deleterious/therapeutic effects |
| - | Analysis, | Var, | NA |
| 1826- | VitK3, | PRX1 knockdown potentiates vitamin K3 toxicity in cancer cells: a potential new therapeutic perspective for an old drug |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | A549 |
| 1755- | WBV, | Reduction of breast cancer extravasation via vibration activated osteocyte regulation |
| 1756- | WBV, | Low-frequency mechanical vibration induces apoptosis of A431 epidermoid carcinoma cells |
| - | in-vitro, | MB, | A431 |
| 1757- | WBV, | The Impact of Vibration Therapy Interventions on Skin Condition and Skin Temperature Changes in Young Women with Lipodystrophy: A Pilot Study |
| - | Human, | Nor, | NA |
| 1758- | WBV, | Whole-body vibration in breast cancer survivors: a pilot study exploring its effects on muscle activity and subjectively perceived exertion |
| - | Human, | BC, | NA |
| 1759- | WBV, | Prostate cancer and occupational exposure to whole-body vibration in a national population-based cohort study |
| - | Study, | Pca, | NA |
| 1760- | WBV, | Molecular jackhammers eradicate cancer cells by vibronic-driven action |
| - | in-vitro, | Melanoma, | NA |
| 1761- | WBV, | Low Intensity Vibration Mitigates Tumor Progression and Protect Bone Quantity and Quality in a Murine Model of Myeloma |
| - | in-vivo, | Melanoma, | NA |
| 1753- | WBV, | Ex, | Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor—Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study |
| - | Trial, | BC, | NA |
| 1752- | WBV, | Chemo, | Feasibility of whole body vibration during intensive chemotherapy in patients with hematological malignancies – a randomized controlled pilot study |
| - | Trial, | Var, | NA |
| 1751- | WBV, | Yoda1 Enhanced Low-Magnitude High-Frequency Vibration on Osteocytes in Regulation of MDA-MB-231 Breast Cancer Cell Migration |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | AML, | RAW264.7 |
| 1754- | WBV, | Vibration Therapy for Cancer-Related Bone Diseases |
| - | Review, | Var, | NA |
| 1750- | WBV, | Whole body vibration exercise in the management of cancer therapy-related morbidities: A systematic review |
| - | Review, | Var, | NA |
| 2427- | Wog, | Anti-cancer natural products isolated from chinese medicinal herbs |
| - | Review, | Var, | NA |
| 2621- | Wog, | Natural compounds targeting glycolysis as promising therapeutics for gastric cancer: A review |
| - | Review, | Var, | NA |
| 2301- | Wog, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2397- | Wor, | Phytochemicals targeting glycolysis in colorectal cancer therapy: effects and mechanisms of action |
| - | Review, | Var, | NA |
| 1913- | Xyl, | Partial Substitution of Glucose with Xylitol Prolongs Survival and Suppresses Cell Proliferation and Glycolysis of Mice Bearing Orthotopic Xenograft of Oral Cancer |
| - | in-vivo, | Oral, | NA |
| 4084- | Z, | Role of micronutrients in Alzheimer's disease: Review of available evidence |
| - | Review, | AD, | NA |
| 4165- | Z, | Antidepressant-like activity of zinc: further behavioral and molecular evidence |
| - | in-vivo, | AD, | NA |
| 4164- | Z, | Zinc treatment induces cortical brain-derived neurotrophic factor gene expression |
| - | Review, | AD, | NA |
| 4196- | Z, | The effect of zinc supplementation on brain derived neurotrophic factor: A meta-analysis |
| - | Review, | NA, | NA |
| - | Trial, | Obesity, | NA |
| 4197- | Z, | The Effect of Zinc Supplementation on Circulating Levels of Brain-Derived Neurotrophic Factor (BDNF): A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| - | Review, | NA, | NA |
| 1221- | Z, | Unexpected zinc dependency of ferroptosis: what is in a name? |
| - | Analysis, | Nor, | NA |
| 1222- | Z, | Zinc regulates primary ovarian tumor growth and metastasis through the epithelial to mesenchymal transition |
| - | in-vitro, | Ovarian, | NA |
| 961- | Z, | Zinc Downregulates HIF-1α and Inhibits Its Activity in Tumor Cells In Vitro and In Vivo |
| - | in-vitro, | RCC, | RCC4 | - | vitro+vivo, | GBM, | U373MG | - | in-vitro, | Nor, | HUVECs |
| 4191- | Zeax, | Lut, | Effects of macular xanthophyll supplementation on brain-derived neurotrophic factor, pro-inflammatory cytokines, and cognitive performance |
| - | Trial, | AD, | NA |
| 604- | ZO, | Plant-Mediated Zinc Oxide Nanoparticles: Advances in the New Millennium towards Understanding Their Therapeutic Role in Biomedical Applications |
| - | Review, | NA, | NA |
| 2414- | β‐Ele, | Beta‐elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vivo, | NA, | NA |
| 2425- | γ-Toc, | Anticancer Effects of γ-Tocotrienol Are Associated with a Suppression in Aerobic Glycolysis |
| - | in-vitro, | NA, | MCF-7 | - | in-vivo, | NA, | NA |
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rpid,rpid2